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Abstract 
G protein coupled receptors (GPCRs) are the largest family of transmembrane receptors in the 
genome and are activated by a multitude of ligands including neuropeptides, hormones and sensory 
signals. The paraventricular nucleus (PVN) and supraoptic nucleus (SON) of the hypothalamus are 
important mediators in homeostatic control. Many modulators of PVN/SON activity, including 
neurotransmitters and hormones act via GPCRs - in fact over 100 non-chemosensory GPCRs have 
been detected in either the PVN or SON. The introduction to this thesis begins with a comprehensive 
summary of GPCR expression within the PVN/SON, with a critique of the detection techniques used 
within the literature. Also discussed are some aspects of the regulation and known roles of GPCRs in 
the PVN/SON, as well the possible functional significance of orphan GPCRs. Particular interest is 
paid to the recently 'deorphanised' G protein-coupled oestrogen (E2) receptor, GPER, which is the 
first receptor to be acknowledged as a steroid binding GPCR (although there are conflicting studies 
regarding its affinity for E2) and is expressed in the PVN and SON. Steroids are known to have fast 
non-genomic effects that are thought to be mediated in-part by membrane-associated forms of the 
traditional steroid receptors (members of a family of transcription factors). However, the possible 
discovery of a fast E2 GPCR has raised speculation regarding the existence of other steroid binding 
GPCRs. Thus the experimental Chapters were undertaken to explore the concept of fast steroid 
receptors, with particular emphasis on their possible roles in neuroendocrine systems. Firstly, the 
distribution of the putative E2 receptor was investigated to give further insight into its possible in vivo 
roles. In the rodent, high levels of GPER gene and protein expression were detected in the oxytocin 
and vasopressin neurones in the PVN and SON, the anterior and intermediate lobe of the pituitary, 
adrenal medulla and renal medulla and pelvis, suggesting roles for GPER in multiple functions 
including hormone release. To clarify the controversy surrounding GPER as an E2 receptor, we 
investigated GPER function in vitro using a series of cell signalling assays. However, E2 did not 
stimulate GPER-mediated signalling, suggesting that either GPER remains an orphan GPCR, or the 
cell lines used in this study lacked a vital component for E2 activation of GPER. As the rapid effects 
of glucocorticoid have been reported in numerous brain regions (including the PVN and SON), 
endocrine, and other tissues, the second part of this thesis focussed on the search for a possible fast 
glucocorticoid receptor. We compared the tissue distribution gene expression profiles of 
approximately 125 orphan GPCRs common to human and rodent with tissues that are known to 
exhibit fast effects of steroids (e.g., hippocampus, PVN, SON, thymus, kidney, etc.). Of the 125 
orphans, 3 GPCRs (GPR108, GPRI46, and TMEM87B) had distribution profiles that closely matched 
the regions/tissues of interest. These orphans were tested for glucocorticoid activation using a 
universal deorphanisation assay. However, the identity of the fast glucocorticoid receptor remains 
unknown, as none of the candidate orphan GPCRs responded to glucocorticoids. 
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Adenine 
Adrenocorticotrophin releasing honnone 
Arbitrary fluorescence units 
Abbreviations 





Adenosine 5' -triphosphate 
Beta-galactosidase 
N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid, N,N-Bis(2 
hydroxyethyl)taurine 
Base pairs 
Bovine serum albumin 
Cytosine 
Cyclic adenosine monophosphate 
Cellular proto-oncogene 
Chinese hamster ovary cells 
Chloroform/isoamyl alcohol 
Central nervous system 
Cortisol in humans, corticosterone in rodents 
Transfonned kidney fibroblast cells of the African green monkey 
Counts per minute 
cAMP response element binding protein 
Corticotrophin releasing factor 
Counts per minute 
3,3' -diaminobenzidine 
4' ,6-diamidino-2-phenylindole 
DNS binding domain 
Diethylpyrocarbonate 
Dulbecco's modified Eagle's medium 




Oestrogen or 17p-oestradiol 
Oestrogen covalently linked to BSA 
Escherichia coli. 
Half-maximal effector concentration 
Extracellular loop 
Ethylenediaminetetraacetic acid 
Epidermal growth factor 
Epidermal growth factor receptor 
Oestrogen receptor alpha 
Oestrogen receptor beta 
Oestrogen response elements 
Extracellular signal-regulated kinases 





























































Growth hormone-releasing hormone 
Gonadotrophin-releasing hormone 
G protein-coupled receptor 




Influenza hemagglutinin epitope tag 
Human embryonic kidney 293 cells 










In situ hybridization histochemistry 
Knock out (mouse) 
Lysogeny broth 
Ligand binding domain 
Molar 
Mitogen-activated protein kinase 




Magnocellular portion of the PVN 









Polymerase chain reaction 
Paraformaldehyde 
Phosphatidylinositol 4,S-bisphosphate 
Protein kinase A 
Protein kinase C 
Phospholipase C 
Phosphorylated extracellular signal-regulated kinases 
Proopiomelanocortin 
Progesterone receptor 




























Paraventricular nucleus of the hypothalamus 




Rotations per minute 
3SS labelled uri dine triphosphate 
Second(s) 
Suprachiasmatic nucleus 
Sodium dodecyl sulphate 
Small hairpin RNA 
Small interfering RNA 
Human breast carcinoma cells 






Triton-X 100/ t-Octylphenoxypolyethoxyethanol 
Uracil 
Vasoactive intestinal peptide 
(Arginine) Vasopressin 




Note: Abbreviations for non-chemosensory GPCRs are the standard nomenclature for these receptors 
as advocated by NC-IUPHAR (the International Union of Basic and Clinical Pharmacology 
Committee on Receptor Nomenclature and Drug Classification). Please note that generic family 
names are used rather than the individual receptor gene names given to each species (e.g., as in the 
case of the oestrogen receptor GPER (family name), it has been assigned the human gene name 
GPER, rat gene name Gper, and the mouse gene name Gpr30). For simplicity, nuclear receptors will 
be referred to once by their official names agreed by NC-IUPHAR and the Nuclear Receptor 
Nomenclature Committee, 1999, and from then on by their trivial names (e.g., oestrogen receptor 
alpha's official nomenclature is NR3Al and trivial name is ERa). Abbreviations for the endogenous 
ligands of the non-chemosensory GPCRs and steroid receptors will be in keeping with the family 
names or trivial names, respectively. 
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Chapter 1: General Introduction 
The hypothalamo-neurohypophseal system (HNS) responds to dehydration by increasing vasopressin 
(VP) and oxytocin (OT) gene transcription and translation, and releasing large amounts ofVP and OT 
into the systemic circulation. Similarly, acute and chronic stress, pregnancy, and lactation are all 
associated with phenotypic changes in the paraventricular (PVN) and/or supraoptic (SON) nuclei of 
the hypothalamus that include elevations in VP, OT and/or corticotropin-releasing factor (CRF) gene 
expression (Aguilera et al., 2008; Burbach et al., 200 I). Alterations in the pattern and/or level of 
modulating inputs (e.g., receptor-driven signals) that impinge on the PVN and SON have important 
functional implications in the control of the HNS and the hypothalamic-pituitary-adrenal (HP A) axis 
response to stress. The activity of such inputs may drive changes in the PVN/SON VP and OT 
signature associated with a number of neuroendocrinological disturbances (Swaab, 1998), and 
contribute to the dysregulation of the HPA axis implicated in many conditions including the classical 
psychosomatic disorders, cardiovascular disease, diabetes and affective disorders such as depression. 
Receptor function in the PVN/SON may also be altered in immunologically-related disturbances such 
as immunosuppression and autoimmune, allergic, and inflammatory states (Channandari et al., 2005; 
Raison and Miller, 2003). 
By virtue of their expression in the PVN and SON, many receptors are key targets for regulating 
hypothalamic-HNS and -HPA axis activity. There are four major classes of receptors in the central 
nervous system (CNS) - (1) the ionotropic receptors such as the excitatory glutamate (e.g., N-methyl-
D-aspartate (NMDA» or inhibitory GABAA receptors that create a membrane pore to allow the flow 
of ions, and have a very rapid response time; (2) receptor tyrosine kinases such as tyrosine kinase 
receptor type B (TrkB) and the epidennal growth factor receptor (EGFR), which upon stimulation 
activate intracellular signalling networks like the extracellular signal-regulated kinase (ERK) pathway; 
(3) nuclear receptors including glucocorticoid, sex steroid and thyroid honnone receptors that regulate 
transcriptional activation; and (4) G protein-coupled receptors (GPCRs), or seven transmembrane 
(TM) receptors, occasionally tenned heptahelical or 'serpentine' receptors. GPCRs constitute the 
largest superfamily of transmembrane signalling molecules, estimated to comprise about 1,900 
members (not including pseudogenes) in the rat and mouse genomes, and at least 800 members in the 
human genome (Gloriam et al., 2007). The proportion of one-to-one GPCR orthologues is 
approximately 60% between rats and humans, primarily due to divergence in chemosensory receptors 
that are activated by sensory signals of external origin such as odors, pheromones or tastes. Olfactory 
receptors make up about 60% of all GPCRs in the rat and mouse genome and 50% in the human 
genome (Gloriam et al., 2007). Most other GPCRs are activated by a diverse array of endogenous, 
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extracellular (and perhaps intracellular) signals that include photons, biogenic amines, neuropeptides, 
amino acids, ions, hormones, chemokines, lipid-derived mediators and proteases. Upon ligand binding, 
GPCRs primarily transduce these signals via the heterotrimeric G proteins into rapid intracellular 
responses that regulate cell function (e.g., increases in protein kinase C (PKC) and/or protein kinase A 
(PKA) activity, intracellular calcium and cyclic adenosine monophosphate (cAMP». It is estimated 
that 80% of all known hormones and neurotransmitters activate cellular signal transduction 
mechanisms via GPCRs (Birnbaumer et al., 1990), and a substantial portion (estimates vary between 
30 and 60%) of current pharmaceutical agents directly or indirectly act on these receptors (Hopkins 
and Groom, 2002; Lundstrom, 2006) - angiotensin II and aminergic (adrenoceptor, dopamine, 5-
hydroxytryptamine (5-HT» receptor subtypes feature as prominent drug targets (Insel et al., 2007). 
There are still 120-130 non-chemosensory 'orphan' GPCRs for which the corresponding ligands have 
not yet been identified (Gloriam et al., 2007; Harmar et al., 2009). 
The current Chapter will highlight efforts to examine GPCR expression and regulation in the rat PVN 
and SON by receptor autoradiography (ARG), immunohistochemistry (IHC) and in situ hybridization 
histochemistry (ISHH) methods, in conjunction with more recent transcriptomic approaches (e.g., 
DNA microarrays) to present an overall estimate of the GPCR repertoire expressed in the PVN and 
SON. Data has been collated on all of the known non-chemosensory GPCRs documented in the on-
line International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature 
and Drug Classification database (NC-IUPHAR; http://www.iuphar-db.orgl) (Harmar et al., 2009) 
including orphan GPCRs. These data will be discussed in the context of the regulation and function 
(and possible redundancy) of GPCRs in the PVN and SON as revealed by current 
pharmacologicaVphysiological approaches in rats, the species in which the vast majority of studies on 
the HNS and HP A axis have been conducted. With respect to GPCR localisation in the PVN and SON 
efforts have been made to cite as many of the original reference sources as possible - apologies are 
made in advance if some citations have inadvertently been omitted. The architecture of the PVN/SON, 
GPCR structure/function studies, and the function of many neurotransmitters/neurohormones in the 
PVN and/or SON have been extensively reviewed and we shall refer to these papers throughout. The 
GPCR subfamily nomenclature will be used thoughout this Chapter (e.g., 5-HT1A; rather than rat gene 
name (e.g., Htrla» as per NC-IUPHAR recommendations (Harmar et al., 2009). 
1.1 Anatomy and function of the rat PVN and SON 
The hypothalamus is essential for maintaining homeostatic equilibrium, integrating signals from other 
brain regions to regulate an assortment of functions including temperature regulation, appetite and 
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fertility. Within the hypothalamus the PVN and SON are two of the most exhaustively studied nuclei 
and are fundamental in the control of fluid homeostasis. lactation. cardiovascular regulation. feeding 
behaviour. nociception. behaviour and the response to stress. The PVN is located either side of the 
third ventricle. and can be subdivided into five parvocellular (pPVN) (peri ventricular. anterior. medial. 
dorsal and lateral parts) and three magnocellular (mPVN) (anterior. medial and posterior parts) 
divisions (Simmons and Swanson. 2009; Swanson and Sawchenko. 1983). The main neuronal 
populations in the mPVN and pPVN subdivisions are intermingled with interneurons and supporting 
cells such as glia. The SON straddles the lateral border of the optic chiasm and contains a 
'homogeneous' population of magnocellular neurons (Poulain and Wakerley. 1982). The large 
magnocellular neurons in the PVN and SON secrete mainly VP and OT as part of the HNS whereas 
the smaller parvocellular neurons elaborate primarily CRF. VP and OT as part of the HP A axis and/or 
regulate autonomic activity. Elegant. detailed studies on the mapping of the spatial organization of 
major neuroendocrine and non-neuroendocrine neurons in the rat PVN have revealed that although 
neuroendocrine neuron clusters display a unique distribution pattern. there is extensive overlap 
between different phenotypes (Simmons and Swanson. 2009). For instance. there is some intermixing 
of magnocellular and parvocellular neurons particularly at the mPVN/pPVN border (Simmons and 
Swanson. 2009). and isolated magnocellular cells in the pPVN have been noted (Engelmann et al .• 
2004). Moreover. there is evidence that the HNS and HPA axis may functionally overlap but the extent 
of this interaction is not fully understood (Engelmann et al., 2004). 
Magnocellular neurons of both the PVN and SON project via the internal zone of the median eminence 
to the posterior pituitary, and upon appropriate stimulation secrete VP and/or OT into the peripheral 
blood. Magnocellular VP is released mainly in response to dehydration, hypovolemia and hypotension, 
while magnocellular OT is primarily involved in the milk ejection reflex during lactation, and uterine 
contraction at the later stages of parturition (Gimpl and Fahrenholz, 2001; Poulain and Wakerley, 
1982; Renaud and Bourque, 1991; Stricker and Sved, 2002). Parvocellular neurons project from the 
periventricular, anterior, and medial (dorsal portion) parts of the PVN to the external zone of the 
median eminence, and release their peptides into the hypophysial portal system, a series of blood 
vessels that bathe the anterior lobe of the pituitary. In response to stressful stimuli, CRF and VP from 
the dorsomedial pPVN stimulate the release of adrenocorticotrophin releasing hormone (ACTH) from 
the corticotrope cells of the anterior pituitary, which in tum induces the secretion of cortisol 
(corticosterone (CORT) in rodents) from the adrenal glands. CORT exerts a negative feedback action 
on the pituitary. PVN and other brain regions such as the hippocampus to restrict the dramatic initial 
release of ACTH and CORT (Antoni, 1988). OT can either potentiate or inhibit ACTH and/or CORT 
responses by binding to the pituitary VP V IB receptor or by an action on central OT receptors, 
respectively (Roper et al., 201l; Windle et al., 2006). In addition, OT stimulates the release of 
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luteinising hormone from gonadotropes, and prolactin from lactotropes in the anterior pituitary (Gimpl 
and Fahrenholz, 2001). Other parvocellular neuroendocrine cells include those that express growth 
hormone-releasing hormone (GHRH), somatostatin, dopamine and thyrotropin-releasing hormone 
(TRH) (Simmons and Swanson, 2009). Parvocellular neurons from the dorsal, lateral, and medial 
(ventral portion) regions of the PVN also project to other regions of the brain, in particular to the brain 
stem and spinal cord (Swanson and Sawchenko, 1983). Here the parvocellular 
neurotransmitters/neuropeptides modulate somatomotor-behavioural and autonomic circuitry; for 
example, CRFaxons terminate in regions such as the locus coeruleus, where the peptide is reported to 
interact with noradrenergic neurons (Dunn et aI., 2004; Valentino et al., 1992), VP neurons project to 
autonomic nuclei in the brainstem and spinal cord, and are involved in cardiovascular control 
(Benarroch, 2005; Pyner, 2009; Sofroniew, 1980), while parvocellular OT released in the 
hindbrain/spinal cord influences nociception, gastric reflexes, cardiovascular responses, yawning and 
penile erection (Gimpl and Fahrenholz, 2001; Kita et al., 2006; Ludwig and Leng 2006; Pyner, 2009). 
Moreover, dendritically released neuropeptides from magnocellular perikarya may act locally or 
diffuse away from the PVN/SON, contributing to the central OT and VP pool (Ludwig and Leng 
2006). It has been proposed that centrally released OT and VP from dendrites and/or parvocellular 
projections modulates behaviour e.g., maternal and affiliative behaviour, sexual behaviour, and social 
recognition (Guastella et al., 2010; Ludwig and Leng 2006, Strom and Tecott, 2005). 
The PVN and SON are subject to regulation by many brain regions including the hindbrainlbrainstem, 
limbic regions, lamina terminalis system, and other hypothalamic nuclei, and also from 
chemicalslhormones such as oestrogen (E2) and CORT that can pass the blood brain barrier 
(Cunningham and Sawchenko, 1991; Hatton, 1990; Michael, 1965; Sladek, 2000; Swanson and 
Sawchenko, 1983). As such the PVN/SON is modulated by a considerable array of neurotransmitters 
and hormones. For example, neurons of the PVN/SON are immersed in glutamatergic and GABAergic 
terminals that provide major stimulatory and inhibitory tone, respectively. Input from the hindbrain to 
the PVN and SON includes catecholamine and serotonergic afferents from the ventral medulla, and 
catecholamine projections from the nucleus of the solitary tract and locus coeruleus, all of which may 
co-express additional neurotransmitters or neuropeptides (Sladek, 2000; Swanson and Sawchenko, 
1983; Ulrich-Lai and Herman, 2009). The PVN and SON also receive efferents from the subfomical 
organ, and those projecting to the PVN have been shown to contain angiotensin II (Ferguson, 2009), 
while neuropeptide Y (NPY)- and proopiomelanocortin (POMC)-expressing neurons projecting to the 
PVN from the arcuate nucleus (Sawchenko, 1998) are essential for the complex control of feeding 
behaviour (Schwartz et al., 2000). Further, parvocellular and magnocellular neurons of the PVN/SON 
coexpress many neuroactive substances (e.g., CRF, galanin, cholecystokinin, enkephalin, and 
vasoactive intestinal peptide (VIP) that may have a paracrine/autocrine action on PVN/SON neurons 
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(Bundzikova et ai., 2008, Ceccatelli et ai., 1989). Importantly, in response to various physiological 
conditions the PVN and SON exhibit a considerable degree of morphological (e.g., glial cell 
remodeling (Hatton, 2002» and functional plasticity. This can manifest itself by changes in neuronal 
excitability (Flak et ai., 2009; Tasker et ai., 2002) that may be accompanied by enhanced co-
expression of certain neuropeptides (e.g., VP in CRF pPVN neurons after stress exposure (Aguilera et 
ai., 2008; Bundzikova et ai., 2008) and/or altered neuro-transmitter/peptide release (Burbach et ai., 
200 I; Ludwig, 2002). 
The defined cytoarchitecture of the rat PVN and SON and the features of the neurons contained within 
and projecting from these nuclei (e.g., large size of magnocellular cells; accessibility to experimental 
manipUlation with reference to the SON in particular; physiologically defined outputs) make these 
brain regions excellent models to investigate GPCR function. As shown in Figure 1.1, GPCRs can 
modulate PVN/SON activity at a number of levels. 
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Figure 1. 1. Schematic diagra m represe nti ng the possible roles of G PC Rs in mod ulati ng PVNI ON activity. 
I) Hormonal signals from peripheral blood may regulate PVN/SON activity directly (substances such as neuropeptide Y and 
orexin A (Kastin and Akerstrom, I 999a,b) that can pass through the blood brain barrier activating GPCRs), or indirectly (e.g., 
activation of GPCRs in the circum ventricular organs by humoral factors like cytokines, or neuropeptides such as angiotensin 
II (Ganong, 2000) can regulatc neurotransmitter/neuropeptide-expressing neurons projecting to the PVNI 0 ). 2) Local 
release of neurotransmitters from within PVNI 0 (e.g., from dendrites) that act on GPCRs may have potential 
autocrine/paracrine effects on PVN/SON neurons e.g., priming of OT neurons by dendritically released OT in 
parturition/lactation (Ludwig and Leng, 2006). In addition, neurotransmitters (e.g., melatonin, gonadotrophin releasing 
hormone (Veening and Barendregt. 2010)) released from alternate (ventricular bordering) brain regions may reach the PVN 
via the ventricular system. and act to regulate neuronal activity via GPCRs. Similarly. dendritically released OT and VP from 
PVN neurons may permeate into the cerebrospinal nuid of the third ventricle and diffuse to, and act on. GPCRs in distant 
brain regions (Veening and Barendregt, 20 I 0). 3) GPCRs may modulate the activity of neurons that project away from the 
PVN/SON (e.g., parvocellular PVN projections to the hindbrain), acting directly on perikarya within the PVN/SON and/or at 
the nerve terminals in different brain regions. 4) GPCRs may be present on/or near the nerve terminals of interneurons (e.g., 
GABAergic and glutamatergic) within the PVNI ON and/or neurons originating from other regions (e.g., alternate areas of 
the hypothalamus, hippocampu . amygdala, brainstem). that synapse with PV ISO soma, possibly regulating postsynaptic 
neurotransmitter release or acting directly to stimulate/ inhibit PVN/ 0 neuronal activity. 5) GPCRs present in the external 
zone of the median eminence could modulate the secretion of CRF/OTNP from parvocellular neurons into the portal blood 
stream, and GPCRs in the pituitary could have a direct effect on hormone relcase e.g .. regulate VP/OT release from the neural 
lobe (6) and ACTII (amongst other neuroendocrine hormones) from the anterior lobe (7). PVN. paraventricular nucleus; 
SO , supraoptic nucleus; ME, median eminence; L. neural lobe; fL, intermediate lobe; AP, anterior pituitary; opt, optic 
tract; 3V, third ventricle. 
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1.2 Structure and function of GPCRs 
In the CNS, GPCR ligands function mainly as slow neuromodulators rather than the fast, small 
molecule neurotransmitters such as glutamate and GABA acting on ionotropic receptors. Traditionally 
GPCRs are regarded as plasma membrane-bound receptors, although some are not highly expressed on 
the cell surface (e.g., human gonadotrophin releasing hormone (GnRH) receptor (Finch et al., 2008) 
and the putative E2 receptor GPER (Revankar et al., 2005», and increasing evidence suggests that 
functional GPCRs may be found in intracellular compartments such as the endoplasmic reticulum, 
golgi apparatus, nuclear membrane and even inside the nucleus itself (Boivin et al., 2008; Calebiro et 
al., 2010; Cheng et al., 2011; Re et al., 2010; Revankar et al., 2005). The structure/function 
relationship of GPCRs has been covered extensively and we refer the reader to a number of excellent 
recent reviews (e.g., (Costanzi et al., 2009; Hofmann et al., 2009; Rosenbaum et al., 2009). At a basic 
level all GPCRs have a common structure of seven membrane-spanning domains, flanked by an 
extracellular amino terminus and an intracellular carboxyl terminus. The transmembrane (TM) 
domains are formed by seven hydrophobic a-helices linked by alternating extracellular and 
intracellular loops. Much of what we know about GPCR ligand-binding pockets and G protein-
coupling domains comes from site-directed mutagenesis and chimeric receptor studies assisted on 
occasions by computational modelling (e.g., (Gearing et al., 2003; Wess, 1993; Wheatley et al., 2003). 
In general, this large body of work has revealed that the extracellular and TM domains are responsible 
for ligand binding, while intracellular domains dock and activate G proteins, and anchor the receptor 
to the membrane. The intracellular domains are also targets for post-translational modification such as 
phosphorylation which playa critical role in GPCR 'memory' resulting in reduced (desensitization) or 
augmented (sensitization) responses (Gainetdinov et al., 2004). GPCR desensitization in response to 
agonist stimulation is common to nearly all GPCRs, and typically involves GPCR kinase (GRK) - or 
other kinase-induced phosphorylation of the activated GPCR, and recruitment of J3-arrestins to 
uncouple the receptor from its associated G protein (s), and target the' GPCR for endocytosis by 
linking it to 'adaptor' molecules such as clathrin (Gainetdinov et al., 2004; Tobin et al., 2008a). The 
amino terminus invariably contains N-linked glycosylation sites involved in intracellular receptor 
trafficking, membrane expression and ligand binding (Wheatley and Hawtin, 1999), and the carboxyl 
terminus hosts sites for palmitoylation to facilitate interaction with the membrane, and together with 
phosphorylation sites have roles in receptor dimerisation and internalisation, and intracellular 
signalling (Huynh et al., 2009). 
GPCRs can be grouped into four main classes based on shared sequence motifs: (I) Class A 
(rhodopsin-like), the largest GPCR class that includes the earliest GPCRs c1o~ed (J32-adrenoceptor 
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(Dixon et al., 1986), acetylcholine Ml (Kubo et al., 1986» and the aminergic, olfactory and majority 
of neuropeptide GPCRs; (2) Class B (secretin-like), comprising calcitonin, glucagon, CRF and 
parathyroid hormone receptors that have a characteristic long amino-terminus tail containing three 
conserved disulphide bonds; (3) Class C (metabotropic glutamate-like) with an amino terminus 
consisting of two lobe-like structures that resemble that of a 'venus flytrap' (e.g., metabotropic 
glutamate, calcium-sensing, and GABAB receptors); and (4) Frizzled/Smoothened receptors, which are 
the sole members of the fourth group. Frizzled receptors have a large amino terminus, and are 
important in embryonic development and adult tissue homeostasis, while Smoothened receptors 
contribute to the hedgehog signalling system, and are involved in embryogenesis and tumorigenesis 
(Harmar et al., 2009; Oldham and Hamm, 2008). 
For many years the prototypical reference for GPCR organization in the lipid bilayer has been based 
on rhodopsin and its high-resolution X-ray crystallographic structure (Palczewski et al., 2000). The 
successful crystallography of hormone-binding GPCRs is a significant breakthrough in GPCR research 
that has required the recombinant generation of high levels of GPCR protein, enhancing their stability 
(e.g., using stabilizing ligands) and structural modifications to encourage crystal formation. The 
structures of a number of Class A GPCRs (e.g., 131- and 13radrenoceptors (Cherezov et al., 2007; 
Rasmussen et al., 2007); adenosine A2A receptor (Jaakola et al., 2008) and the minimally active 
conformation of opsin (the ligand-free form of rhodopsin) (Park et al., 2008) have now been 
elucidated, confirming that essentially all Class A (and by extension Classes B and C) GPCRs possess 
seven membrane-spanning helical domains arranged in a bundle with a cytoplasmic eighth helix 
immediately following TM7. One insight from the small number of X-ray crystallography studies to 
date is that each subfamily of GPCRs possesses its own unique mode of natural ligand binding 
reflecting their unique structure. In the rat genome there are a total of 356 non-chemosensory GPCRs 
of which 132 are classified as orphans (Harmar et al., 2009). 
GPCRs are coupled to G proteins that are comprised of three subunits: Ga., GP and Gy. Stimulation 
from physiological, environmental or experimental signals provokes a conformational change in the 
receptor-7TM structure, catalysing the replacement of GDP for GTP on the Go. subunit. Subsequently, 
Go. detaches from GJty to create two separate components that can activate a multitude of intracellular 
signalling pathways e.g., Go. may increase adenylyl cyclase activity, whilst GPy can independently act 
to stimulate phospholipases and ERKs, and activate ion channels. Heterotrimeric G proteins are 
encoded by a family of related genes that comprises 21 Go., 5 GP and 12 Gy mammalian genes, giving 
rise to a variety of G protein combinations (Downes and Gautam, 1999). They are categorised into 
four main groups according to the structure and function of the a. subunit: Ga., G<lqtl It G«i, and Go.12113 
(Oldham and Hamm, 2008). Ga. typically activates adenylate cyclases that catalyse the production of 
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cAMP from ATP, stimulating PKA activity. G<1q/11 couples to and activate phospholipase Cp (PLCP), 
and increases intracellular calcium and PKC activity. Gai often inhibits adenylate cyclase activity, 
impeding cAMP synthesis, as well as activating G protein-coupled potassium channels. The remaining 
group of G proteins is the Ga121l3 family that regulate the small G protein Rho through Rho-specific 
guanine nucleotide exchange factors (Pierce et al., 2002). 
A typical feature of GPCR signalling is that by activating a cascade of signal transduction mediators 
the signals can be amplified. Cross-talk between GPCRs, or GPCRs and other proteins at the cell 
surface (e.g., via oligomerization) and in the cytoplasm (e.g., via convergent signalling pathways such 
as GJGc/Gi-and receptor tyrosine kinase-activation of ERKs) can modify GPCR-mediated signalling. 
In addition, GPCRs vary in their specificity for activating/coupling to the G protein subtypes with 
some activating only one Ga subtype while others are more promiscuous and couple to a number of 
Ga proteins to activate mUltiple intracellular signalling cascades. The ability of GPCRs to activate 
more than one class of G proteins can depend on receptor density, the nature of the ligand (different 
responses to two ligands can confer 'functional selectivity'), tissue distribution, and on its localisation 
within specialized compartments of the plasma membrane which may depend on whether the GPCR is 
active in a monomeric or oligomeric form (Kenakin and Miller, 2010; Maudsley et al., 2005; Woehler 
and Ponimaskin, 2009; Zheng et al., 201 Oa). One facet of GPCR intracellular signalling that should 
not be overlooked is that some GPCRs can activate both G protein-dependent and G protein-
independent pathways. For example, angiotensin II ATIA receptor-triggered transactivation of the 
EGFR, and J3-arrestin-dependent and -independent ATIA receptor internalization can take place 
independently of G protein activation (Feng et al., 2005). In addition, ATIA-mediated activation of 
ERK features both Gq- and J3-arrestin-dependent pathways (Lefkowitz and Shenoy, 2005), while J3r 
adrenoceptor stimulation of the ERK pathway is Gs-coupled and Ga-independentltyrosine kinase Src-
dependent at low and high concentrations of stimulating agonist, respectively (Sun et al., 2007). 
Overall it is apparent that GPCRs dynamically interact with numerous associated proteins as part of a 
tightly regulated signalling network, and this interaction in different tissues reflects the types of 
signalling components within a given cell and the receptor's physiological role. 
1.3 GPCR expression in the PVN and SON 
Over 90% of non-chemosensory GPCRs are expressed in the mouse brain with a large proportion 
(82% of those examined by RT-PCR) expressed in the hypothalamus (Vassilatis et al., 2003). The 
profiles of the vast majority of GPCRs are unique, and when combined with brain region-specific 
intracellular signalling component expression (see Section 1.3.1), yield thousands of GPCR signalling 
combinations for the modulation of physiological processes. Some GPCRs even appear to be relatively 
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confined to the CNS, although it is rare to find evidence of CNS exclusivity if techniques such as 
reverse-transcription (RT)-PCR or EST profiling (e.g., see http://www.ncbi.nlm.nih.govlUniGeneD are 
used. 
After a flourish of research in the 1980's/early 1990's localizing GPCRs by receptor ARG, more 
recent developments in IHC, ISHH, transcriptome approaches such as DNA microarrays, and ex 
vivo/in vivo electrophysiological methods have greatly contributed to our understanding of the 
regulation of the PVN/SON activity by GPCR-based signalling. The PVN and SON are highly 
vascularized and blood vessel elements and 'supporting' cells such as glial cells express GPCRs. In 
the following sections we focus on the expression of GPCRs in neurons of the rat PVN and SON, 
although it should be emphasized that this has not been conclusively demonstrated in all studies, e.g., 
receptor ARG and DNA microarray experiments. 
1.3.1. Intr~cellular signalling components in the PVN/SON 
We would expect that cells in the PVN and SON are equipped with the appropriate sets of receptors 
and various intracellular signalling components to sense and respond to perturbations in homeostasis. 
Regulation of both GPCR signalling molecules and GPCRs themselves (see Section 1.4) will 
contribute to the adaptive responses of the PVN and SON. The distribution of various GPCR 
cytoplasmic signalling components in the PVN/SON has not been extensively studied, although the 
function of various G proteins and other intracellular signal transduction mediators involved in GPCR-
mediated effects has been implicated in a number of studies. Immunoreactive (ir)-GJ31-5 and y3 are 
expressed at low levels in the rat PVN and the expression of the various J3 subunits is increased by 
repeated restraint (Lee et al., 2006; Liang et al., 1998). While ISHH studies suggest that there are very 
low levels of PKC subunit mRNAs in the rat PVN and SON (Brandt et al., 1987), other studies point 
to the expression of ir-PKC-o in neuronal cell bodies in the PVN/SON, and ir-PKC-~ in PVN fibres 
(Irani et al., 2010), and phosphatidylcholine specific phospholipase C-mediated VP release from the 
hypothalamus in vitro appears to involve PKC activation (Wayte et al., 1997). Osmotic stimulation 
increases Gaj and Gas mRNAs in the magnocellular PVN and SON, and cAMP in the SON (Young et 
al., 1987), while Gaq appears to participate in high-salt induced VP secretion in Dahl salt-sensitive rats 
(Wainford and Kapusta, 2010). Of the nine adenylate cyclase isofoims only type 2 appears to be 
strongly expressed in the PVN and SON (Mons and Cooper, 1994). Elevated cAMP within PVN/SON 
neurons may stimulate cAMP response elements in gene promoters to alter neuropeptide (or GPCR) 
gene transcription, exemplified by studies showing cAMP-driven CRF and VP gene expression in the 
PVN (Arima et al., 2001; Burbach et al., 2001; Itoi et aI., 1996; Wong et al., 2003). The PVN and 
SON also express mRNAs for numerous members of the regulators for G protein signalling (RGS) 
family including RGS4, 5, 7, 8 and 9 (Gold et al., 1997) - these proteins modulate the function of the 
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Go. and GI3 subunits, and the gene expression of at least one member (RGS4) in the PVN has been 
shown to be downregulated by repeated stress (Ni et al., 1999). Other studies suggest that the spatial 
distribution of some signalling molecules within the PVN may be functionally relevant, e.g., RGS4 
and Ga.q/\\ mRNAs are found in both pPVN and mPVN neurons while RGS7 gene expression is 
confined to the mPVN (Shuey et al., 1998). 
Gene expression profiling (Hindmarch et al., 2006) considerably extends early studies (Lightman, 
1988) cataloguing some GPCR-related signalling molecules in the PVN and SON. A plethora of gene 
transcripts relevant to GPCR signal transduction has been revealed (see Supplementary Tables I and 
2), including those encoding the relatively abundantly expressed calcium-binding calmodulins, 
endocytosis adaptor molecules dynamin and clathrin, various RGS and G proteins, and a number of 
PKC, phospholipase C and D, and cAMP isoforms. While the presence and anatomical distribution of 
the majority of these transcripts has not been validated by other criteria (e.g., IHC, ISHH, RT-PCR), 
the data indicates that the PVN and SON express a considerable network of intracellular signalling 
proteins that could potentially be enlisted upon GPCR activation. 
1.3.2. Detection of GPCR proteins by receptor autoradiography (ARG) 
The advent of molecular biological techniques that resolved the genetic fingerprint of GPCRs led to 
the popular use of GPCR antibodies - generated from predicted protein sequences of cloned GPCR 
DNA sequences - to visualize GPCR protein expression by techniques such as IHC. Prior to this 
receptor ARG was a popular tool to delineate GPCR binding sites in brain and peripheral tissues since 
it provided the ability to anatomically resolve receptor protein expression and to quantitate receptor 
levels. The method can give higher (cellular) resolution if tissue sections are apposed against 
emulsion-coated covers lips (Young and Kuhar, 1979) rather than against X-ray film. A major 
consideration when using receptor ARG is that not all pharmacologically defined . binding sites 
necessarily represent physiologically active receptors - in a famous 'caveat' to those undertaking 
receptor studies, Cuatrecasas and Hollenberg described how iodinated insulin appears to bind with 
high affinity to non-biological surfaces like talc with characteristics - except 'biological activity' - that 
are commonly attributed to specific hormone-receptor interactions (Cuatrecasas and Hollenberg, 
1975). Moreover, while radio labelled ligands may bind 'functional' (capable of binding an agonist) 
GPCRs they may not bind to the entire receptor pool. For example, they may only bind to high affinity 
binding sites, receptor-G protein interactions critical for agonist binding may be disrupted during the 
receptor ARG procedure, and 'immature' GPCRs that have not been post-translationally modified 
andlor possess the requisite tertiary structure, or degraded GPCRs may not bind the ligand. Other 
limitations of the technique include the masking of binding sites by endogenous ligand, although this 
is usually minimized by buffer pre-washes prior to ligand incubation. Receptor binding studies on 
11 
Chaptcr I: Gcncral Introduction 
tissue homogenates (infrequently if ever used for GPCR expression in the PVN/SON) or receptor 
ARG are critically dependent on the specificity and selectivity of the radiolabelled ligand employed -
high affinity radioligands selective for a particular GPCR subclass are not always available. Specific 
binding is defined as for receptor binding assays on tissue homogenates, and includes diminution of 
bound radioactivity by the addition of excess cold ligand and establishing a pharmacological profile 
using c1osely- and distantly- related compounds. Knockout (KO) mice (providing the distribution of 
GPCRs in rat and mouse are the same) are an invaluable addition in validating radioligands for a 
specific receptor. Detection of low amounts of protein also depends on the sensitivity and specific 
activity of the radioIigand, e.g., iodinated versus tritiated ligands can be used for shorter exposure 
times against film but offer lower resolution. 
The list of the 25 GPCR subfamilies detected in the PVN/SON by receptor ARG is shown in 
Supplementary Table 3. The number is likely incomplete since not all the literature covering GPCR 
receptor ARG in the brain encompasses the pertinent hypothalamic levels, and even when the relevant 
brain levels have been included in some studies it is often difficult to ascertain if binding is above 
background levels. Critically receptor ARG (and other receptor protein or RNA detection techniques) 
does not directly inform about GPCR function. This can be addressed in part by 'functional' ARG 
with eSS]GTPyS to map region-specific, GPCR ligand-dependent activation of G proteins (Harrison 
and Traynor, 2003; S6vlig6 et al., 2001). Although it has not used extensively in the PVN and SON, 
eSS]GTPyS binding ARG has demonstrated 'active' neuropeptide YI and Y2 (Shaw et al., 2003), and 
cannabinoid CBI (Hesketh et al., 2008) binding sites in the PVN. Positron emission topography (PET) 
is an alternative imaging technique to visualize GPCRs non-invasively in the PVN and SON in vivo; 
while the technique is relatively low resolution and there is a dearth of suitable GPCR ligands for such 
studies, there are a few publications (e.g., 5-HTIA receptors in the rat PVN (Aznavour el al., 2009) 
indicating that this approach may be a useful adjunct to receptor ARG studies in the future. Receptor 
ARG rarely has the sensitivity or resolution of IHC. Moreover, in the absence of selective ligands to 
define a GPCR family in the PVN/SON, IHC and/or ISHH with subtype-selective antibodies and 
DNAIRNA probes, respectively, can elaborate a specific GPCR receptor subtype. 
1.3.3. Immunohistochemistry (IHC) to visualize GPCR expression 
Since GPCR-specific and -selective ligands are not available for all GPCRs, antibodies have been a 
popular option to detect many GPCRs. IHC employing primary GPCR antibodies traced with 
secondary antibodies to permit fluorescent or chromogenic detection of ir- proteins is a valuable 
technique to localise GPCR expression in sections of the PVN and SON, offering a far greater lateral 
and axial resolution than receptor ARG. A major consideration in all GPCR protein and mRNA 
detection techniques is specificity. The GPCR field is awash with reports of GPCR antibodies that 
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don't 'work' between laboratories, those that have stopped working after new batches were purchased, 
and those that give no staining. For antibodies in particular and the IHC method in general, the 
evaluation of specificity has provoked numerous comments in the past with many concluding that 
antibody specificity is a difficult criterion to fulfil (Swaab et ai., 1977). There are well-established 
controls for IHC procedures, including the absence of staining when the antibody is pre-absorbed with 
the immunizing antigen (although this only proves that the antibody bound the added antigen and not 
that the antibody is 'specific' for the GPCR), and the presence by Western blotting of the appropriate 
GPCR molecular sizes which may correspond to post-translationally modified and/or oligomeric 
forms. However, other points related to antibody use and storage (e.g., possibility of 'carrier' 
antibodies contributing to staining patterns; tendency of antibodies to form aggregates at 4°C; potential 
instability of immunoglobulin fractions or affinity-purified antisera; prolonged storage times between 
fixation, sectioning and staining; inefficient blocking of immunoglobulin Fc receptors (which are 
present in the PVN/SON (Hindmarch et ai., 2006) - e.g., see (Wendelboe and Bisgaard, 2009) tend to 
be under-appreciated and often overlooked, and can lead to increased non-specific, or variable or 
complete absence of specific staining. Alterations in IHC staining patterns between different antibody 
batches (either from different animals or different bleeds from the same animal) can often be explained 
by the inherent characteristics of the normal immune response, e.g., decreasing antibodies titres, or 
high-affinity antibodies present in an early bleed may be replaced by high-avidity antibodies (perhaps 
with a lower relative concentrations of specific versus 'less-specific' immunoglobulins) as the immune 
response proceeds. The majority of GPCR antibodies for IHC are raised to short, synthetic GPCR 
peptides ('haptens') usually coupled to a carrier (e.g., keyhole limpet hemocyanin or sometimes 
bovine serum albumin (BSA» to enhance the anti-hapten antibody response, or less frequently to 
partially purified native or recombinant GPCRs. Invariably the antibodies are a polyclonal mixture 
(monoclonal antibodies have only been used occasionally (e.g., see (Rosin et ai., 1998; Shi et ai., 
1999; Zhang et ai., 2004) and directed to regions that are most divergent between different GPCR 
subclasses, N- or C-terminus moieties being the most attractive targets. Most GPCRs are post-
translationally modified (Chini and Parenti, 2009; Tobin et al., 2008a; Wheatley and Hawtin, 1999), a 
crucial point in GPCR antibody production since regions that can be potentially glycosylated, 
phosphorylated or acylated in vivo may mask an epitope to hinder antibody recognition. On the flip 
side, phosphospecific GPCR antibodies can be made (e.g., (Tran et al., 2004». Antibodies can also 
conceivably differentially react to ligand-activated versus unoccupied GPCR conformations, and 
antibodies raised against denatured GPCR proteins may not recognize the 'native' (usually fixed) 
GPCR in tissue sections. 
For GPCRs, serious specificity concerns have been raised in a number of articles contesting the 
reliability of many GPCR antibodies for mc (e.g., (Michel et ai., 2009». In contrast the specificity of 
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antibodies to neuropeptides and other cellular constituents are rarely indicted to the same degree, 
commensurate with the diverse, largely structurally non-conserved nature of GPCR ligands compared 
with the often, high amino acid homology between different GPCR subtypes. A recent review of 
studies using antibodies against 19 a,1- and J31-adrenoceptor, acetylcholine, dopamine and galanin 
receptor subtypes for immunoblotting and IHC concluded that apparent lack of specificity of GPCR 
antibodies appears to be the rule rather than the exception (Michel et al., 2009). Some sensible 
suggestions for improving GPCR antibody validation have been made (Jositsch et al., 2009; Michel et 
al., 2009). These include the reduction of immunostaining following GPCR knockdown using RNA 
interference (although a lack of knowledge of GPCR mRNA and protein turnover may make this 
problematic - see Section 1.4) and obtaining similar staining patterns with antibodies against different 
GPCR epitopes, although it is rare to find studies using two or more antibodies to detect GPCRs by 
IHC in the PVN and SON (exceptions include the dopamine D4 (Defagot et al., 1997) and glutamate 
mGlul (Kiss et al., 1996) GPCRs). Similarly, the absence of GPCR immunostaining in GPCR KOs has 
also been advocated as a desired IHC control (Michel et al., 2009). Assuming that an antibody is truly 
GPCR-specific in both rats and mice, and there are no species differences in the GPCR distribution 
between those animals, the absence of immunostaining in tissues from a KO animal in which the entire 
GPCR protein coding sequence has been eliminated should serve as an excellent 'negative' control in 
IHC on rat tissues. However, if the KO targeting construct does not include the relevant protein region 
to which the antibody was raised, it is possible that the antibody could react to a protein translated in-
frame from the targeting construct in vivo, and lack of staining is not a foregone conclusion. While we 
do not necessarily share the outlook that the specificity of most GPCRs is suspect, a review of the 
literature emphasizes that caution is warranted, especially when using some commercially prepared 
antibodies (Grimsey et al., 2008; Pradidarcheep et al., 2008). We have not endeavoured to evaluate the 
specificity of antibodies used to detect GPCRs in the PVN and SON. However the expression of many 
GPCRs detected by IHC (see Supplementary Table 4) has been validated by other methods (which 
also have their own specificity issues). 
Individual GPCR numbers per cell are usually quite low in the brain, with lower estimates ranging 
from 100-300 receptors per cell (very low copy number) to upwards of 2,000-6,000 receptors per cell 
(around physiological levels for many GPCRs - e.g., see (Kasai et al., 2011) and refs therein». By way 
of comparison, cells engineered to express recombinant GPCRs can achieve levels of greater than 
100,000 receptors in each cell. The threshold of detection for a 'good' antibody in IHC is probably in 
the order of 10-1,000 receptors per cell depending on the staining and microscopical method used 
(e.g., see (Chung et al., 2005; Eberwine and Bartfai, 2011». The detection ofir-GPCRs in cell bodies, 
axons, dendrites and terminals, and in intracellular organelles such as endosomes, endoplasmic 
reticulum and the nucleus by IHC with conventional light microscopy can be facilitated by the use of 
14 
Chapt~r I: General Introdul.:tion 
high-resolution optical imaging techniques like confocal microscopy. GPCRs are highly mobile and 
traffic between different subcellular compartments in the PVN and SON, and are probably 
dendritic ally sorted as in other brain regions (Ritter and Hall, 2009). For example, IHC has revealed 
that the tachykinin NK3 receptor trans locates to the nucleus of VP and non-VP PVN neurons in a 
stimulus-dependent manner, where it may playa role in transcriptional regulation (Haley and Flynn, 
2006; Howe et ai., 2004). 
CNS GPCRs are not particularly abundant proteins and their signals (and non-specific staining) can be 
enhanced by using modified IHC protocols incorporating tyramide signal amplification (TSA) 
(Bobrow et ai., 1989). Even with improvements in IHC detection, however, it is often difficult to 
discern whether GPCR staining is associated with the cell surface in detergent (e.g., Triton X-I00)-
treated sections of fixed tissue, although there are some examples of uniform or punctate staining 
closely apposed to the plasma membrane (e.g., tachykinin NK3 (Howe et ai., 2004); PTH2 parathyroid 
hormone (Wang et ai., 2000) receptors). In most cases in the PVN and SON GPCR-ir staining is quite 
nondescript and apparently found mainly intracellularly, which has important functional implications 
for some GPCRs that are thought to be active inside the cell (Revankar el ai., 2005). For the majority 
of GPCRs, an intracellular versus plasma membrane distinction may 'simply' reflect the detection of 
mature GPCRs in the endocytic pathway and/or immature GPCR pools (presumably functionally 
inactive) yet to be presented to the plasma membrane. In a few instances light microscopic studies 
have been reinforced by higher magnification immuno-electron microcopy, e.g., in the PVN and SON 
ir-GABAB! is mainly associated with the endoplasmic reticulum, golgi apparatus and large membrane-
bound vesicles, while a small amount of staining is found close to the plasma membrane (Richards el 
ai., 2005). The possible functional relevance of ir-GPCR localisation in PVN and SON neurons is 
supported by other studies, e.g., staining for the CBI cannabinoid receptor, a GPCR that inhibits the 
release of excitatory and inhibitory neurotransmitters in the brain (Pertwee et ai., 2010), is clearly 
present in GABAergic terminals and fibres surrounding OTergic PVN neurons (Castelli et ai., 2007). 
The CBI receptor appears to be synthesized in the PVN and SON (Matsuda et ai., 1993) but other 
GPCRs such as the prostanoid EP3 receptor (Nakamura et ai., 2000) appear to be confined to fibre 
terminals presumably as part of afferent projections to the PVN/SON. So IHC can give some idea of 
the pre/post-synapticallocalisation of GPCRs in the PVN and SON. 
Strong indirect evidence that GPCRs in the PVN and SON may be functionally important also comes 
from studies where ir-GPCRs have been localised to phenotypically-identified neurons. For example, 
<lID-adrenoceptor (Sands et ai., 1990) and angiotensin ATIA (Oldfield et ai., 2001) receptors are both 
located in pPVN CRF-expressing neurons, the 5-HTIA/2A (Zhang et al., 2004), apelin APJ (Tobin et al., 
2008b), chemokine CXCR4 (Callewaere et ai., 2006), GABAsds2 (Richards et aI., 2005), 1C opioid 
(Smith and Wise, 2001) and tachykinin NK3 (Haley and Flynn, 2006) receptors are expressed in VP 
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and/or OT neurons, whereas the glutamate mGlul receptor has been identified in both CRF and VP 
neurons (Kocsis et al., 1998). VP, OT and CRF (and TRH, dopamine, GHRH and somatostatin) 
neurons in the PVN and SON also express additional neuropeptides that could be co-regulated 
(Bundzikova et al., 2008). The presence ofVP VIA receptors on VP neurons (Howe et al., 2004) and 
OT receptors on OT neurons (Marroni et aI., 2007) suggests that these receptors may act in an 
autocrine fashion to regulate the release of their own cognate ligands. Moreover, the demonstration 
that some GPCRs (e.g., apelin APJ (Tobin et al., 2008b), E2 GPER (see Chapter 3), and parathyroid 
hormone PTH2 (Wang et aI., 2000) receptors) are present on both PVN and SON neuronal cell bodies, 
fibres and terminals (e.g., in the median eminence or in the posterior pituitary) suggests that GPCRs 
may act at different locations to alter neuropeptide or neurotransmitter synthesis and/or release. Based 
on its intracellular, and to a minor degree cell surface localisation, the E2 GPER receptor is an 
example of a GPCR that may be functionally active on or in neuronal cell bodies in the PVN and SON, 
dendrites, and axonal projections through the internal zone of the median eminence and posterior 
pituitary nerve terminals (see Chapter 3). Given the breadth of ir-GPCR distributions in the PVN and 
SON, and the estimated number of neurons in the PVN and SON (e.g., there are about 1,000 and 3,000 
VP neurons in the rat PVN and SON, respectively, and approximately 1,250 OT neurons in both nuclei 
- (Rhodes et al., 1981), it would be extremely likely that many GPCRs are co-expressed in individual 
neurons. In fact, the possible co-existence of two (or more) different GPCRs in the same neuron would 
support the concept that GPCRs may physically interact (see Section 1.5) in the PVN and SON. 
However, demonstrating co-expression of two or more proteins in a cell is difficult, although not 
impossible (see (Brouns et al., 2002; Negoescu et al., 1994) using antibodies raised in the same 
species to detect non-abundant proteins. In the SON and elsewhere in the brain GPCR co-expression 
appears to be the case for the two subunits (each a 7TM 'receptor') of the GABAB receptor, GABAB1 
and GABAB2 (Richards et al., 2005), which must heterodimerize for functional GABAB responses 
(Marshall and Foord, 2010). 
There are a number of mismatches between GPCR protein and mRNA as determined by receptor ARG 
and/or IHC and ISHH, respectively. For example, binding studies with an iodinated glucagon GLP-l 
receptor agonist detect dense labelling in the median eminence and posterior pituitary where there is 
no GLP-l receptor mRNA (Goke et al., 1995; Shughrue et al., 1996). Conversely, GLP-I receptor 
mRNA is concentrated in the PVN where only weak binding is observed and where ir-GLP-l fibre 
terminals are closely associated with OT - and CRF-expressing neurons (Tauchi et al., 2008). The 
apparent discrepancies between GPCR protein and mRNA localisations may highlight technical issues 
(e.g., sensitivity). Alternative it may be a product of transportation e.g., GPCR transcript from cell 
bodies is translated (either in the cell bodies themselves or perhaps in the axons and/or dendrites), and 
is transported along the axonal and dendritic fibres of the PVN and SON. 
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1.3.4. In situ hybridization histochemistry (ISHH) localisation of GPCR mRNA 
ISHH was introduced in 1969 (Buongiorno-Nardelli and Amaldi, 1970; Gall and Pardue, 1969; John et 
ai., 1969) as a method to detect specific mRNAs within cells by hybridizing labelled RNA, cDNA, or 
short oligonucleotide DNA probes to target sequences in tissue samples. Employing IHC in concert 
with ISHH can provide converging anatomical evidence to form testable hypotheses and support data 
on GPCR function in the PVN and SON. High throughput ISHH as advocated for mapping high-
resolution gene expression in the brain «Lein et ai., 2007) - see Allen Brain Atlas at http:lbrain-
map.org) is usually satisfactory for abundant genes. Apart from a few notable exceptions such as the 
cannabinoid CB) receptor gene that is highly expressed in many brain regions (Matsuda et al., 1993), 
most GPCR mRNA(s) are not as abundant as those encoding ionotropic receptors and are visualized 
usually after a short exposure (weeks-months) against X-ray film or photographic emulsion. However, 
refinements in the ISHH method permit the detection of as few as 10-20 mRNA copies per cell (Siegel 
and Young, 1985), sensitive enough to visualize the majority of the rarest GPCR transcripts, and to 
compare changes in GPCR gene expression at the cellular level by counting silver grains or at the 
macroscopic level by image analysis and densitometry with reference to the appropriate 
autoradiographic standards (as for receptor ARG). ISHH detection sensitivity can also be enhanced by 
using multiple oligonucleotide probes to different regions of the designated mRNA, or by a number of 
amplification methods such as TSA (see Section 1.3.3). 
Cloning of the mammalian GPCR cDNAs, or identification of GPCR DNA sequences using 
homology-based searching tools, has provided the platform to map GPCR transcript expression in the 
brain by ISHH. More often than not 3sS-labelled antisense RNA probes targeting a large part of the 
GPCR mRNA (e.g., approx. 300-600 base pairs (bp) RNA probes (riboprobes) for proteins whose 
coding regions average about 1,000-1,500bp in length) are used for optimal GPCR transcript 
detection: these can be labelled to a higher specific activity, and bind more strongly to target mRNA 
sequences, than oligonucleotide probes. The use of long riboprobes and even short oligonucelotides 
(typically 40-48bp) introduces its own set of problems since hybridization to closely related GPCR 
subtypes may occur if probes are designed to a relatively well-conserved part of the GPCR mRNA 
sequence. GPCR-subtype specificity is usually increased if regions such as the 3' -untranslated (UTR) 
of GPCRs are targeted (providing the G/C content of the probe is not so low to preclude high 
stringency washes). However, specificity concerns may also be compounded if sense probes used as 
negative controls for antisense probe binding label the tissue of interest (one definition of 'non-
specific' hybridization), which is not implausible since over 50% of the mammalian genome can 
produce transcripts from both DNA strands (Katayama et al., 2005). Evidence that the complementary 
DNA strand of a GPCR gene can code for another gene is provided by the study of Foletta and 
coworkers (Foletta et al., 2002), where a sense VP V2 receptor probe which does not hybridize to the 
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V2 receptor-expressing kidney (Ostrowski et al., 1993), detected transcripts for a Rho GTPase 
activating protein in the brain. It is generally advised to use well-characterized probes (e.g., ones that 
has been validated by Northern blots, and gives appropriate hybridization patterns in control tissues), 
or more than one probe (and corresponding sense 'control') against a target sequence to minimize 
erroneous interpretations of ISHH labelling patterns. Our experience and that of many other 
laboratories using ISHH is that, as in the case of antibodies and IHC, there is often significant 
variability in the signaVnoise ratios for different probes directed to the same GPCR mRNA target. 
As outlined in Supplementary Table 4, a large number of GPCR mRNAs have been detected in the cell 
bodies of PVN and SON neurons. By and large there is general agreement on steady-state GPCR gene 
expression in the PVN and SON between laboratories but some exceptions are apparent in the 
literature. For example, while Hurbin and coworkers (Hurbin et al., 1998; Hurbin et al., 2002) detected 
VP V IB receptor mRNA and protein expression in the mPVN and SON using short oliognucleotide 
probes and receptor antibodies, respectively, others found only occasional V IB receptor mRNA-
expressing cells in the pPVN using riboprobes directed against the 3'UTR of the receptor (Young et 
al., 2006). Studies such as these emphasize the importance of probe specificity and the limits of ISHH, 
and raise questions of mRNA and protein turnover (see Section 1.5). 
Like IHC, ISHH is also amenable to' co-expression studies, whether combined with IHC or 
alternatively used alone to investigate the expression of two distinct transcripts in neuronal cell bodies. 
For example, 5-HT2C (Heisler et al., 2007), adrenoceptor <lIB (Day et al., 1999), CRFI (Imaki et al., 
2001) and melanocortin MC4 (Lu et al., 2003) receptor mRNAs are predominantly found in CRF 
neurons, neuromedin U NMU2 receptor mRNA is mainly present in OT neurons (Qiu et al., 2005), 
and neuropeptide Y Y 1 receptor transcripts are co-expressed with TRH mRNA in pPVN cells (Kishi et 
al., 2005). Of the 52 GPCRs with known ligands detected in the PVN by IHC, 34 ofthe corresponding 
mRNAs have also been detected in the same or independent studies (see Supplementary Table 4). The 
great majority of GPCRs are expressed in both the pPVN and mPVN (e.g., 5-HTIN2A (Zhang et al., 
2004); <lm-adrenoceptor (Sands and Morilak,- 1999); ape lin APJ (O'Carroll, et al., 2000; Tobin et al., 
2008b); calcium-sensing CaS (Rogers et al., 1997); CRF, (Imaki et al., 2001); melanocortin MC4 (Lu 
et al., 2003); prostanoid EP1I4 (Oka et al., 2000) receptors). Some GPCRs appear to be preferentially 
expressed in the pPVN (e.g., consistent with regulating stress or autonomic responses), or mPVN (e.g., 
compatible with regulating water homeostasis or reproductive status) by either IHC and/or ISHH 
(pPVN: 5-HT2C (Heisler et al., 2007); angiotensin AT'A (Oldfield et 01., 2001); prolactin-releasing 
peptide PRRP (Lin et 01., 2002) receptors; mPVN: chemokine CXCR4 (Callewaere et 01., 2006); 
neuromedin U NMU2 (Qiu et 01., 2005); K opioid (Smith and Wise, 2001) receptors). One GPCR 
(neuropeptide FF/neuropeptide AF NPFF1) seems to be PVN-specific in rats (Goncharuk et al., 2002), 
although ir-NPFFI fibres found just dorsal to the SON, as in humans (Goncharuk et 01.,2004), may 
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project to the SON (Jhamandas et 01., 1989) and be responsible for the inhibitory effects of centrally 
administered NPFF on hypovolemia-induced VP secretion into the blood (Arima et 01., 1996). 
1.3.5. Transcriptomic analysis olGPeR expression in the PVN/SON 
RT-PCR-based methods have been used to delineate a partial GPCR transcriptome in a number of 
tissues including mouse heart (Moore-Morris et 01., 2009) and brain (Vassilatis et 01., 2003). Only the 
odd study has used PCR to detect the expression of an individual GPCR gene in dissected PVN/SON 
(Coppola et 01., 2004; Lu et 01., 2009; Shrestha et 01., 2009; Stotkova et 01., 2009). Large-scale 
transcriptome analysis of enriched genes, including some GPCR transcripts, has been performed in a 
number of mouse brain regions including striatum, frontal cortex, hippocampus and amygdala (Becker 
et 01., 2008; Ghate et 01., 2007; Lein et 01., 2004). Recently DNA microarray-based transcriptomal 
analysis of the rat PVN, SON, subfomical organ and area postrema, and mouse SON was reported 
from our laboratories (Hindmarch et 01., 2006; Hindmarch et 01., 2008; Hindmarch et 01., 2011; 
Stewart et 01., 2011). There are some limitations associated with such 'global' studies in rats as 
highlighted previously (Hindmarch et 01., 2006). For example, manual rather than laser dissection of 
PVN and SON was used so a small amount of surrounding tissue such as the third ventricle could have 
been included in the samples. In addition, most but not all GPCRs with known ligands, or orphan 
GPCRs are represented on the Affymetrix 230 2.0 rat genome chip interrogated - examples of some 
'missing' GPCRs include the bombesin BB3 receptor and the orphan GPCRs GPRIOI and GPRI65. 
Furthermore, some rare GPCR transcripts in the PVN and SON may escape detection, or some probe 
sets may have failed in some or all of the replicates, thus excluding them from the analysis - examples 
of this are the ape lin APJ, E2 GPER, and VP VIA receptors which are readily detected by receptor 
ARG, IHC and/or ISHH in the PVN and SON. Bearing these points in mind, we have constructed a list 
of the GPCRs genes considered present by DNA microarrays in the PVN and SON (Supplementary 
Tables 4, 5, 6). The relative abundance of GPCR transcripts in both hypothalamic nuclei varies from 
those that are highly expressed such as various GABAB subunits, and neurotensin NTS2 and endothelin 
ET B receptors, to the less highly expressed purinergic P2Y \3, adenosine A3, and metabotropic 
glutamate mGI14 and mGlu7 receptors. 
About 80% of GPCR transcripts in the PVN are also present in the SON, and approximately 70% and 
50% of transcripts for GPCRs with known ligands in the PVN and SON, respectively, has been 
validated by receptor ARG, IHC and/or ISHH. This includes some GPCR transcripts (e.g., parathyroid 
hormone PTH1 and neuropeptide Y Y s in the PVN/SON) that are towards the lower limits of detection. 
The GPCR gene lists include 14-16 'new' GPCRs with known ligands, such as adenosine A2B, 
chemokine CXCR3 and CXCR7, Iysophospholipid LPA1 and SIPh metabotropic glutamate mGI14, 
purinergic P2Y\3 and protease-activated PARI receptors, and 17-21 'new' orphan GPCRs (see 
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Supplementary Table 7) whose localisation in the PVN and SON is unvalidated on review of the 
literature, and which may represent novel targets for future physiological studies. Another interesting 
feature of the transcriptomic data is that by virtue of multiple oligonucleotide probe sets representing 
some genes on the array chip, a number of GPCR splice variants appear to be present in the PVN and 
SON. Alternate splicing of pre-mRNAs is one mechanism for increasing diversity in the 
transcriptome. Although approximately half of GPCR genes are devoid of introns within their coding 
sequence, those that possess introns can theoretically undergo alternative splicing and this may have 
consequences on GPCR functions such as altered pharmacological profiles, constitutive activity and 
subcellular localisation (Markovic and Challiss, 2004). Examples of GPCRs that exhibit varying 
degrees of alternate splicing include the GABAB1 subunit (Wei et al., 2001), NOP opioid (Xie et al., 
1999), metabotropic glutamate (Niswender and Conn, 2010) endothelin ETA (Hatae et al., 2007) and 
parathyroid hormone PTHI (Joun et ai., 1997) receptors, all of which have potential isoforms 
identified by DNA microarrays in the PVN and SON. Transcriptome analysis of the PVN and SON 
also reveals four GABAB1 subunit isoforms (a, f, g, j) - and IHC and ISHH studies indicate that at least 
two GABAB1 subunits (Bla and Bib) are expressed in the PVN and SON (Fritschy et ai., 1999; 
Bischoff et al., 1999). There are twelve GABAB1 variants (a-k including c-a and c-b) in total, the 
majority of which are secreted forms that may confer functional differences to the GABAB11B2 
heterodimer (Tiao et al., 2008). 
It is very likely that the number of GPCR genes expressed in the PVN and SON in the DNA 
microarray studies outlined above is an underestimate, and would be expanded further by 
transcriptomic experiments on single neurons. High throughput, deep/next generation sequencing (e.g., 
RNASeq (Wang et al., 2009a) of single cell cDNA libraries from pPVN, mPVN and SON neurons, 
similar to that reported for electrophysiologically identified warm sensitive neurons from the anterior 
hypothalamic pre-optic area (Eberwine and Bartfai, 2011), would reveal GPCR splicing complexity, 
rare GPCR transcripts and also those GPCR genes that are co-expressed (and thus are candidates for 
heterodimerization) in PVN/SON neurons. 
1.3.6. Numbers ofGPCRs in the PVN and SON: an overview 
Embracing the data from the various detection methods outlined above we have arrived at a 
conservative estimate of the number of GPCRs expressed in the PVN and SON (Table 1.1). Of the 
224 known non-chemosensory GPCRs in the rat genome 101 are present in the PVN (with a further 14 
from unvalidated DNA microarrays), and 80 are present in the SON (excluding another 16 from 
un validated DNA microarrays). Interestingly, of the 132 orphan non-chemosensory GPCRs in the rat 
genome 22 (9 validated) and 24 (9 validated) are present in the PVN and SON, respectively. The 
GPCRs encompass the vast majority (33 that are activated by different peptide classes from 46 GPCR 
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families in total) of GPCR families excluding chemosensory and orphan GPCRs present in the rat 
genome (Table 1.2). The estimate includes a few instances where GPCR ligands appear to have 
functional effects (e.g. , anaphylatoxin, formyl peptide, kisspeptin , leukotriene, melatonin, motilin, 
platelet-activating factor and trace amine receptors; see Supplementary Table 9) in the PVN/SON but 
their presence has not been confirmed by any of the detection criteria reviewed . It should also be 
emphasized that, as far as we are aware, none of the GPCR cDNAs/genes in the PVN and SON have 
been sequenced. Variations in GPCR sequences and/or potential splicing patterns may have an impact 
on the function of PVN/SON GPCRs. 
GPCRs e\pn.'ssed ill the PVN and SON 
Total number of known GPCRs' 
Number of orphan GPCRs' 
Known GPCRs in rat PVN 
Orphan G PCRs in rat PVN 
Known GPCRs in rat SON 
o han GPCRs in rat SON 
224 
96 (class A), 29 (class 8) & 7 (class C) = 132 
94 + 7 based on functional criteria + 14 unvalidated arrays 
9 by ISHH + 17 unvalidated arrays 
74 + 6 based on functional criteria + 16 unvalidated arrays 
9 b rSHH + 21 unvalidated arra s 
Table 1.1. Summary of GPCRs expressed in the rat PVN and SON. 
'Numbers based on lists in the on-line IUPHAR Database of Receptors and Ion Channels (http://www.iuphar-
db.orglindex. jsp) (Harmar el al., 2009) excluding chemosensory (e.g. , olfactory, vomeronasal , taste) receptors 
and possible spliced (see Supplementary Tables 5 and 6) GPCR variants. 
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Vaso ressill and ox tocin 
There are 46 GPCR families expressed in the PVN, including 33 different peptide classes (ill bold italics). 
Notably absent are lipid-like GPCRs (e.g., Iysophospholipids) which were detected in DNA microarrays but 
whose presence in the PVN (or SON) has not been validated, and the anaphylatoxin, formyl peptide, kisspeptin, 
leukotriene, melatonin, motilin, platelet-activating factor, and trace amine GPCRs for which there are functional 
responses in the PVN following central or peripheral administration of agonists, or in HNS cultures in vitro. The 
vast majority of GPCRs expressed in the PVN are also present in the SON- the exceptions are members of 
anaphylatoxin, formyl peptide, leukotriene, platelet-activating factor, and trace amine GPCRs which have not 
been demonstrated in the SON to our knowledge. To date members of the bile acid, free fatty acid, glycoprotein 
hormone, gonadotrophin-releasing hormone and hydroxyl acid GPCRs families do not appear to be expressed in 
either the PVN or SON. 
1.4 Regulation of GPCR expression in the PVN and SON 
There is ample evidence that GPCR expression can be regulated by, and contribute to changes in PVN 
and SON neuronal plasticity. Levels of GPCRs are determined in part by the rate of receptor protein 
synthesis, which can be regulated by either transcriptional or post-transcriptional mechanisms. Unless 
a reserve of "spare" receptors exists, alterations in cell surface or cytoplasmic GPCR levels can 
significantly influence receptor signalling capacity. GPCR signalling components (e.g., G proteins) 
themse lves are also dynamically regulated (Kohout and Lefkowitz, 2003 ; Morris and Malbon, 1999), 
and ultimately GPCR expression and function is dependent on a host of factors that influence GPCR 
desensitization (e.g. , following chronic activation of many GPCRs), redistribution and degradation. 
The role of many intracellular signalling molecules (such as GRKs and arrestins) is critical in 
22 
Chapter I: General Introduction 
regulating these processes. RNA regulation is also very complex, with small RNA molecules like 
microRNAs (miRs) and piwi-interacting RNAs linked to transcriptional silencing, and long non-
coding RNAs involved in transcriptional, post-transcriptional (e.g., RNA alternate splicing, 
translation) and epigenetic regulation (Licatalosi et al., 2010). 
The apparent absence, or low levels of GPCR expression does not preclude the possibility that some 
GPCRs may be induced by perturbations of PVN and/or SON neuronal function (e.g., change in 
osmolality, lactation, stress) as in the case of the CRFI receptor (Luo et al., 1994). Changes in mRNA 
levels are usually easier to detect by ISHH compared to changes in protein as measured by IHC, but 
this obviously depends on when the mRNA is assayed after experimental manipulations, since GPCR 
mRNA turnover may vary considerably. GPCR mRNA and protein turnover has been primarily 
established in cell lines expressing native or cloned GPCRs and could be quite different in the 
PVN/SON microenvironment. Half-lives are highly variable and often cell context-dependent, ranging 
from around 2-20 hours for both GPCR mRNA (e.g., acetylcholine ml (Lee et al., 1994), UI-
adrenoceptor (Izzo et al., 1990), ul-adrenoceptor (Sakaue and Hoffman, 1991), J32-adrenoceptor 
(Hadcock et al., 1989), 1eukotriene BLTI (Stankova et al., 2002) receptors) and GPCR protein at the 
cell surface (adenosine AI/2A12B/3 (Klaasse et al., 2008), U2A12Bl2c-adrenoceptor (Saunders and Limbird, 
1997; Wilson and Limbird, 2000), J32-adrenoceptor (Drake et al., 2006), calcium-sensing CaS 
(Cavanaugh et al., 2010), cannabinoid CBI (McIntosh et aI., 1998) receptors). The mRNA turnover for 
a number of GPCRs is also decreased by agonist stimulation (Coon et al., 1997; Hadcock et al., 1989; 
Izzo et al., 1990; Lee et al., 1994), emphasizing the importance of local agonist levels in the PVN and 
SON in regulating both GPCR mRNA and protein levels. In a few of these studies, in contrast to 
research on GPCR mRNA expression in the PVN and SON, nuclear run-on experiments (requiring a 
million cell nuclei or more) were used to confirm that changes in mRNA levels were the result of 
changes in GPCR gene transcription. Nuclear run on experiments provide a measure of the frequency 
of transcription initiation and are largely independent of the effects of RNA stability. Interestingly, 
other studies using hybridization of DNA microarrays with steady-state mRNA versus newly 
transcribed (nuclear run on) RNA have shown that approximately half of stress-regulated genes in 
H 1299 lung carcinoma cells are due to changes in gene transcription with a similar fraction due to 
changes in mRNA turnover (Fan et al., 2002). A point that may be relevant to possible GPCR co-
expression and cross-talk in the PVN and SON is that the angiotensin AT I receptor induces bradykinin 
B2 receptor transcription activation via the phosphorylation of cAMP response element binding protein 
(CREB) and assembly of p-CREB on the B2 receptor promoter in kidney collecting duct cells (Shen et 
al., 2007). 
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An alternative method to look at gene transcription rates, and one that is particularly amenable to 
tissue sections of PVN and SON, is to examine heteronuclear (hn)RNA levels. The binding of probes 
specific for introns in RNA-coding region of genes can be used to quantify hnRNA levels as an 
indirect measurement of the transcription rate of genes in response to a particular stimulus. For GPCR 
genes that contain multiple introns care must be exercised in choosing which introns to target because 
they can be excised from the nascent pre-mRNA at different rates (Lang and Spritz, 1987). ISSH with 
intron-specific probes has been successfully used to measure hnRNA changes for relatively abundant 
neuropeptide (e.g., VP, OT and to a lesser extent CRF (Herman et al .. , 1991; Kovacs and Sawchenko, 
1996; Vue et al., 2008» mRNAs, but has not proved particularly useful to assess GPCR transcriptional 
activity. One exception is the dopamine D2 mRNA distribution in the brain where hnRNA levels are 
(as expected) a fraction of steady-state mRNA levels (Fox et al., 1993). 
There are numerous studies showing that the expression of PVN/SON neuropeptides, in particular VP, 
or and CRF, are developmentally regulated (Altstein et al., 1988; Baram and Lerner, 1991; Szarek et 
al., 2010), and that their expression can be altered by experimental manipulations (Burbach et al., 
2001; Aguilera et al., 2008). In comparison, reports of ontogenetic variations in GPCR expression in 
the PVN/SON are scarce, with the transcript or protein level, and/or function of a few GPCRs 
including the angiotensin II ATla (mRNA present in PVN E19 onwards (Nuyt et al., 2001», 
neuropeptide Y I (mRNA present in PVN P2 onwards coincident with a significant increase in NPY-
containing fibres innervating the nucleus (Grove et al., 2003», and melanocortin MC4 (mRNA present 
in PVN and SON at E18 and P27, respectively, approximating the appearance ofmelanocortin binding 
sites (Kistler-Heer et al., 1998; Lichtensteiger et al., 1996» changing developmentally. At least one 
GPCR in the PVN and SON is also diurnally regulated - (l2-adrenoceptor expression in the PVN peaks 
at the onset of dark (when CORT levels are highest) whereas in the SON the reverse diurnal pattern is 
observed (Jhanwar-Uniyal et al., 1986). 
There have been many studies using receptor ARG, IHC or ISHH to demonstrate alterations in GPCR 
expression by pharmacological or physiological manipulations. More recently, transcriptome 
approaches have established that dehydration alters the levels of transcripts encoding the cannabinoid 
CB), GABABlj, melanocortin MC4, protease-activated PARI and somatostatin sst3 receptors in the rat 
SON (Hindmarch et al., 2006). Changes in GPCR protein and mRNA levels in the PVN/SON in 
response to agonist or antagonist administration, or physiological perturbations such as adrenalectomy, 
salt-loading, dehydration, lactation, gestation and stress are commonly less than two-fold, but 8-10-
fold or higher increases in GPCR mRNA have been reported in some instances - e.g., for the apelin 
APJ receptor (O'Carroll el al., 2003) (see Supplementary Table 8). Invariably gene or protein 
expression has been imaged over the entire PVN and/or SON, so any change in cell-to-cell GPCR 
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expression is often obscured. Importantly, since the vast majority of studies investigate a single 
experimental time point, it is surprising to note how often it is assumed that changes in GPCR mRNA 
reflect changes in GPCR protein levels and perhaps receptor function. That this may not always be the 
case is emphasized in studies where the correlation between mRNA and protein levels has been 
investigated using transcriptomic- in conjunction with proteomic- approaches. For example, in kidney 
inner medullary duct cells a large number (approx.1I3) of proteins that showed significant changes in 
abundance in kidney inner medullary collecting duct cells following challenge with dDAVP 
(desmopressin; a VP V2 receptor agonist) did not show any changes in the corresponding mRNA 
species (measured by interrogating DNA microarrays) (Khositseth et al., 2011). While this result relies 
heavily on the quantitative accuracy of the methods used, it conceivably highlights an important role in 
post-transcriptional regulation of protein abundance, and also obviously reflects the dynamics of 
mRNA versus protein turnover. Impressively, given that the half-life of GPCR mRNA or protein is 
usually not known, a number of studies have combined receptor ARG (or in some cases IHC) with 
ISHH to show that alterations in GPCR mRNA levels in the PVN/SON are associated with changes in 
the corresponding GPCR protein. A few examples of this are the increases in angiotensin ATIA 
receptor after antagonist administration (Macova et al., 2009; Wei et al., 2009), and cholecystokinin 
CCKI and CCK2 (Hinks et al., 1995; Meister et al., 1994), and galanin GALl (Burazin et al., 2001) 
receptors following osmotic perturbations. 
There are other, largely unexplored and speCUlative ways in which GPCRs in the PVN and SON could 
possibly be regulated. One such mechanism is miR-mediated post-transcriptional regulation. There is 
substantial evidence that the 3' -UTR of proteins can affect mRNA stability and is involved in 
regulating gene expression at the post-transcriptional level, and in the case of some GPCRs such as the 
opioid receptors the length of the 3'-UTR influences receptor protein level (Wu et al., 2008). MiRs are 
short, single-stranded non-protein coding RNAs that tend to suppress target gene expression by 
binding to their complementary mRNA sequences usually in introns or exons of the 3'-UTR, and have 
emerged as crucial modulators of gene expression especially in synaptic plasticity. The feasibility of 
mIR-mediated GPCR mRNA regulation has been demonstrated by miR-23b inhibition of opioid J.1 
receptor expression (Wu et al., 2008). Conversely, opioid J.l receptor agonists regulate miR-190 
activity (Zheng et al., 2010b). Scanning individual GPCRs for consensus miR binding sites that are 
conserved between species would be a starting point for studies on the potential role of miRs in 
regulating PVN/SON GPCRs. It is also becoming increasingly clear that epigenetic control of gene 
(especially CRF and VP) expression in the PVN is important in the HP A axis response to stress (e.g., 
see (Elliott et al., 2010; Murgatroyd et al., 2009). DNA methylation and histone modifications have 
been shown to coincide with the differential expression of the opioid J.1 receptors in the brain (Hwang 
et al., 2007). 
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As noted previously, some GPCRs have very low expression levels (e.g., <1000 receptor copies/cell) 
and ultimately the demonstration of a ligand-specific function is paramount. For those GPCRs 
investigated, a functional response has generally been observed where GPCR binding sites, ir-protein 
and/or mRNA have been detected in the PVN/SON. 
1.5 Functions of GPCRs in the PVN and SON 
The actions of numerous neurotransmitters, neuropeptides and hormones in the PVN and SON have 
been well documented (e.g., (Bealer et al., 2010; Cunningham and Sawchenko, 1991; Hatton, 1990; 
Ludwig, 1998; Ludwig and Leng, 2006; Renaud and Bourque, 1991; Sladek, 2000; Swanson and 
Sawchenko, 1983) and only some salient features will be described here. The tonic and stimulated 
activity of the PVN and SON is regulated by a number of excitatory and inhibitory neurotransmitters 
and neuromodulators, including glutamate and GABA, the main excitatory and inhibitory 
neurotransmitters, respectively, as well as a host of other effectors including angiotensin II, 
catecholamines, histamine and numerous other neuropeptides that activate GPCRs, and mediators such 
as humoral factors and nitric oxide (e.g., (Brunton et al., 2008a; Brunton et al., 2008b; Engelmann and 
Ludwig, 2004; Itoi et al., 2004; . Kalra and Kalra, 2004; Li et al., 2010; Sladek, 2000; Ulrich-Lai and 
Herman, 2009). This regulation can occur directly in the PVN or SON via the effects of 
neurotransmitterslneuropeptides synthesized within the two nuclei and/or indirectly by interactions 
with glutamatergic or GABAergic intemeurons or afferent projections from other hypothalamic or 
extrahypothalamic areas that innervate the PVN or SON (Ferguson, 2009; Joels and Baram, 2009; 
Sladek, 2000). Apparent mismatches between neurotransmitterslneuropeptides and their receptors that 
are prevalent in the brain (Herkenham et al., 1987) may not be such an issue in the PVN and SON 
where GPCR ligands are available from a number of sources within the nuclei or extra-PVN/SON 
locations. 
In addition to their peptidergic or neurotransmitter phenotypes, neurons in the pPVN, and mPVN and 
SON have defined electrophysiological characteristics. Classically, under basal conditions OT 
magnocellular cells are continuously active, whereas the activity of VP magnocellular cells ranges 
from continuously active to robust phasic to relatively silent (Brown et al., 2007; Ludwig and Leng, 
2006). Early studies indicated that mPVN and SON neurons have similar electrophysiological 
properties (Armstrong et al., 1994; McKenzie et al., 1995; Tasker and Dudek, 1991) whereas pPVN 
cells exhibited electrophysiological heterogeneity (Tasker and Dudek, 1991). Neurosecretory neurons 
concentrated in the medial pPVN have no low threshold spike (L TS) and small T -type calcium 
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et ai., 2002). In magnocellular cells bursts of activity often characterize periods of enhanced 
neuropeptide release. For example, during suckling in the lactating rat and in pregnant animals OT 
magnocellular neurons discharge synchronously to release large amounts of OT into the systemic 
circulation which is dependent on dendritic OT release (Lincoln and Wakerley, 1974; Ludwig and 
Leng, 2006), and VP magnocellular cells increase their firing (and may switch to phasic activity) to 
release VP following dehydration (Leng et ai., 2008; Wakerley et ai., 1978) and hemorrhage 
(Wakerley et ai., 1975). 
The effects of GPCR ligands on PVN and SON neuronal function can be direct or indirect depending 
upon whether they are administered peripherally, centrally via the circumventricular organs, or intra-
nuclei by injection or iontophoretic application. It should be borne in mind that high doses of GPCR 
agonists may give 'pharmacological' rather than physiological responses, especially when compounds 
are applied in the vicinity of their presumed site of action. GPCR activation in the PVN/SON has been 
demonstrated in a number of ways. These include increases in neuronal immediate early gene (e.g., c-
Fos) activation, changes in electrophysiological characteristics or neuropeptide mRNA or protein 
levels (e.g., by ISHH, IHC or content of push-pull perfusates or microdialysates), and alterations in 
any number of physiological end-points such as plasma VP, OT, CRF and ACTH release, water and 
energy homeostasis, cardiovascular parameters, nociception and behaviour (see Supplementary Table 
9 for some examples). The specificity of the ligand-GPCR interaction is usually demonstrated by the 
inhibition of responses with GPCR-selective antagonists or, as in a few cases, by 
immunoneutralization with neuropeptide/GPCR antibodies (e.g., for NPFF effects on VP release 
(Yokoi et al., 1998», and more recently by RNA interference-driven gene silencing that has the added 
advantage over acute administration of synthetic small interfering (si)RNAs of long-term (days-
months) GPCR knockdown if viral, GPCR-specific small hairpin (sh)RNA constructs are employed. 
The sustainable expression of such constructs obviates some of the problems that may be encountered 
with long GPCR mRNA turnover rates. 
1.5.1. Generalfeatures o/GPCR/unction in the PVN and SON 
With amplification procedures used in various GPCR detection techniques, an important question is 
what level of GPCR mRNA or protein is physiologically relevant? Radioligand- or fluorescent-ligand 
binding assays can detect as few as about 50-100 GPCRs per cell (e.g., see Mahan and Insel, 1986) 
which is sufficient to elicit (although higher levels are probably required to sustain) a signal 
transduction response in some in vitro systems (Sklar et al., 1985). In PVN and SON neurons in vivo 
some GPCRs may be clustered to concentrate their levels at pre- or post-synaptic sites. A number of 
studies underscore the differences in the sensitivity/specificity of detection techniques used between 
laboratories, and highlight the importance of obtaining (specific) functional GPCR responses. For 
example, while VP V2 receptor mRNA was not detected in the PVN or SON by nested PCR in one 
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study (Hurbin et al., 1998), V2 receptor mRNA (by PCR on RNA obtained from 20 neurons), and V2 
receptor protein and apparent functional responses have recently been reported in isolated cells from 
the SON (Sato et al., 2011). Similarly, the lack of angiotensin II AT IA receptor gene expression in the 
mPVN by ISHH in some studies (e.g., (Lenkei et al., 1998) appears at odds with the AT I-type 
pharmacological responses observed by electrophysiology in PVN slices (Latchford and Ferguson, 
2004. Furthermore, prostanoid EP3 receptor electrophysiological responses have been observed in the 
SON (Shibuya et al., 2002) where no ir-EP3 receptor cell bodies or fibres have been found (Nakamura 
et at., 2000). 
It is possible that some of the GPCR effects in the PVN or SON are spurious or redundant in nature, 
since it is difficult to envisage that every GPCR we have listed (see Tables 1.1 and 1.2) has an 
important role in co-ordinating control of PVN and/or SON function. We are reminded of a comment 
attributed to Alfred Gilman a number of years ago: "A typical cell has perhaps 50 different receptors, 
and the cell doesn't pay attention to just one receptor at a time. How does it know how to interpret the 
signal from one hormone when it's listening to 45 other ones at the same time? How does the whole 
signalling system work as a network? That's what we want to find out" (Lemonick et al., 2001). 
Functional studies of GPCRs indicate that they do have individual roles in the PVN and SON and are 
probably key to neurones intergrating multiple functions as outline below (see Supplementary Table 
9). 
Change in the levels of intracellular signal transduction molecules (see Section 1.3.1) and immediate 
early gene activation (Ho et al., 2009; Hoffman et al., 1993) are frequently used as indices of neuronal 
activity in the PVN and SON, and are particularly amenable to cell imaging techniques. For example, 
agonist-induced increases in intracellular calcium or ERK activation have been shown for S-HT IA 
(Crane et al., 2007), <lIA-adrenoceptor (Song et al., 2010), dopamine D4 (Bitner et al., 2006), 
melanocortin MC4 (Sabatier and Leng, 2006), purinergic P2Y I (Song et al., 2007), OT (Blume et al., 
2008; Lambert et al., 1994; Sabatier and Leng, 2006), VIPIPACAP (Oayanithi et al., 2000) and VP 
VIA (Gouzenes et al., 1999) receptors. These are often accompanied by increases in PVN or SON c-
Fos expression, as demonstrated for many GPCRs such as the S-HT2A12c (Lee et al., 2009), CRFI 
(Parkes et al., 1993), dopamine 0 4 (Bitner et al., 2006), glucagon GLP-I (Larsen et al., 1997), 
melanocortin MC4 (Kawasaki et al., 2009), motilin (Wu et al .• 2005). neuropeptide FF/neuropeptide 
AF NPFFI (Jjamandas and MacTavish, 2003), prolactin-releasing peptide PRRP (Matsumoto et al .• 
2000; Yamada et al .• 2009) and tachykinin NK3 (Kawasaki et al .• 2009) receptors. One of the most 
extensively studied functional aspects of GPCRs in pPVN presympathetic. mPVN and SON neurons, 
is their often profound affects on neuronal excitability. examples of which are shown in 
Supplementary Table 9. and include presynaptic effects mediated via metabotropic glutamate receptors 
(Boudaba et al .• 2003a,2003b; Schrader and Tasker. 1997) andendocannabinoids (acting through 
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cannabinoid CB I receptors) (Di et ai, 2005; Sabatier and Leng, 2006) in the SON, and GABA release 
in pre sympathetic pPVN neurons (Chen et al., 2006; Li et al., 2005). 
GPCR activation in the PVN/SON can alter neuropeptide or GPCR gene synthesis (e.g., see (AI-
Barazanji et al., 2001; Fekete et al., 2001, 2002; Konishi et al., 2003; Morris el al., 2000; Wei et al., 
2001» andlor the release of neurotransmitters/neuropeptides from dendrites andlor axon terminals. 
Local dendritic release of neuropeptides acting in an autocrine or paracrine fashion are likely to be 
important factors in determining the sensitivity and plasticity of PVN and SON neurons to their 
multitude of inputs (Landgraf and Neumann, 2004; Ludwig, 1998; Ludwig and Leng, 2006; Morris el 
aI., 2000). Dendritic peptides may also regulate local blood flow (Alonso el al., 2008) and have local 
(e.g., OT is anxiolytic via the PVN OT receptor (van den Burg and Neumann, 2011) and distant effects 
on behaviour (Ludwig and Leng, 2006). Examples of GPCRs that modulate neuropeptide release, 
typically performed in studies measuring VP andlor OT release from large magnocellular cells, rather 
than CRF release from the smaller pPVN neurons, include the a.1-adrenoceptors (inhibit intra-PVN 
hypoxia-induced CRF release) (Chen el al., 2004», apelin APJ (increases firing rate of VP neurons 
and VP dendritic release) (Tobin el al., 2008b», histamine H1I2 (increases dendritic release of OT via 
stimulating noradrenaline release) (Bealer and Crowley, 1999), melanocortin MC4 (increases calcium 
in OT neurons; stimulation of dendritic, and inhibition of terminal OT release) (Ludwig and Leng, 
2006; Sabatier el al., 2003), 1C opioid (locally released dynorphin inhibits VP neurons and is essential 
for expression ofVP neuron phasic activity; inhibits VP terminal release) (Brown and Bourque, 2004; 
Brown et al., 2007), VIPIPACAP (stimulates somatodendritic and terminal VP release (Lutz-Bucher et 
al., 1996; Shibuya et al., 2008», VP VIA (acting on autoreceptors to excite and inhibit quiescent and 
phasic VP neurons, respectively (Brown et al., 2004; Ludwig and Leng, 1997, 2006», and OT 
(stimulates dendritic OT release via OT receptor; inhibits OT neurons by increasing endocannabionoid 
inhibition of glutamate release (Ludwig and Leng, 2006» receptors. 
The release of neurohypophysial hormones from posterior pituitary nerve terminals, and CRF and 
other pPVN products from the median eminence into the anterior pituitary portal circulation is often 
reflected by increased circulating levels ofVP and OT, ACTH (due to the action ofCRF, VP and other 
ACTH secretagogues) and CORT, and thyroid hormones, and in changes in water homeostasis 
(principally brought about by altered VP secretion) (Supplementary Table 9 gives some examples). 
GPCRs can also modulate autonomic functions by activating secretory and non-secretory pPVN 
neurons. For example, central or intra-PVN administration of a number of GPCR ligands results in 
orexigenic (e.g., ghrelin (Shrestha et al., 2009), galanin (Kyrkouli et al., 1990), and NPV agonists via 
VI and Vs (Kalra and Kalra, 2004) receptors) or anorexigenic (e.g., via CRFI (Heinrichs et al., 1993), 
melanocortin MC4 (Garza et al., 2008), neuropeptide S NPS (Fedelli et al., 2009), and neuromedin U 
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(Bains et al., 1992), CRF2 (Li et al., 20 I 0), tachykinin NK3 (Takano et al., 1993), and urotensin II UT 
(Watson et al., 2008) receptors), nociception (e.g., a-adrenoceptors (Zhou et al., 2010», body 
temperature (e.g., acetylcholine muscarinic receptors (Takahashi et al., 2001), and penile erection 
(e.g., dopamine receptors (Succu et al., 2007). 
1.5.2. Possible GPCR co-expression in the PVN and SON 
We do not know how many GPCRs are co-expressed in PVN/SON neurons, and different 
complements of GPCRs may be expressed in subsets of neurons such as magnocellular VP cells with 
different basal electrical activity, magnocellular neurons with different neuropeptidergic phenotypes, 
mPVN versus pPVN neurons, or pPVN endocrine versus non-endocrine neurons. However, 
extrapolating from the study on single warm-sensitive neurons (transciptomic analysis gave 168 non-
olfactory GPCRs of which 27 are orphans (Eberwine and Bartfai, 2011) suggests that the number of 
co-expressed GPCRs is likely to be larger than the number of co-expressed neuropeptides. At least 20 
different neuropeptides are co-expressed in magnocellular VP or OT neurons (Bundzikova et al., 
2008) but the extent of the total overlap is unknown. The co-expression of GPCRs raises the question 
of possible functional consequences of receptor oligomerization in the PVN and SON. The formation 
of functional GABAB receptors from two GABAB subunits is an example of GPCR heterodimerization 
that we know occurs in the PVN and SON (Zhong et al., 2008). Of the GPCRs listed in Supplementary 
Table 4, there is also a high degree of co localisation of SHT1A and SHT2A in OT and CRF neurons in 
the PVN where activation of one receptor subtype may induce the desensitization of the other (Zhang 
et al., 2004). There are many examples of apparent GPCR homodimerization and heterodimerization 
in the literature (Milligan, 2009), and a number of consequences of GPCR oligomerization such as 
changes in receptor expression, compartmentalization, recycling, turnover and degradation have been 
noted mainly in in vitro studies (Franco et al., 2009; Springael et al., 2007). Assuming that 
oligomerization is relatively stable, co-expressed GPCRs may allow graded regulation of a population 
of functionally equivalent neurons in the PVN and SON, as receptor ratios and the levels of their 
corresponding ligands vary as a function of the physiological and pharmacological state. This could 
mean that with oligomerization between GPCRs of the same subclass it is possible that the 
heterodimer acts as a 'concentration-dependent switch' where one GPCR is activated by low agonist 
concentrations whereas the other is activated by higher agonist concentrations (e.g., see co-expressed 
adenosine AI/2A receptors (Ciruela et al., 2006); note that the four adenosine receptor subtypes are all 
possibly expressed in the PVN (see Supplementary Table 4». The signalling of one GPCR could be 
shut down while the other is active, e.g., by internalization of the 'inactive' GPCR. Moreover, the 
heterodimer may have new signalling modalities e.g., switching to coupling to a new G protein to 
activate a new signalling pathway (e.g., see co-expressed dopamine receptors (Lee et al., 2004). To 
add to the complexity, GPCRs may also physically associate with non-GPCRs e.g., the dopamine Ds 
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receptor and the GABAA y2 ligand-gated ion channel subunit appear to complex leading to an 
attenuation in Ds receptor-mediated cAMP accumulation and GABAA-mediated current (Liu et aJ., 
2000). 
1.5.3. Possible/unction %rphan GPCRs 
Some orphan GPCRs, or indeed some GPCRs with known endogenous ligands, may be constitutively 
active in the PVN and SON. This is not as far-fetched as it may seem since constitutive activity in 
GPCRs is a relatively well-known phenomenon that can be signalling pathway-dependent, and can 
result from the overexpression of receptors in native tissue or heterologous systems, and/or by changes 
in the DNA (introduced or somatic mutations) or RNA (visa vi RNA editing as in the 5-HT2c receptor 
(Marion et aJ., 2004) sequence of GPCRs. For example, isoforms of the histamine H3 receptor are 
constitutively active pre- and post-synaptically in native brain cortical tissue (Morisset et aJ., 2000), 
and in cell lines (lIA- and (l\B-adrenoceptors (which can heterodimerize) (Cotecchia, 2010), bradykinin 
B2 (Quitterer et aJ., 1996), ghrelin (Holst et aJ., 2004), melanocortin MC4 (Nijenhuis et aJ., 2001) and 
neurotensin NTS2 (Holst et aJ., 2004) receptors exhibit constitutive activity, and co-expression of the 
constitutively active histamine HI receptor with the 5-HTIB receptor confers constitutive activity on 
the latter receptor (Bakker et al., 2004). All these GPCRs are expressed in the PVN and SON. The 
orphan GPCRs GPR3, 6, 12, 20, 26 (present in SON by DNA microarrays), 39,61 (present in PVN 
and SON by DNA microarrays) and 78 also alter basal signal transduction activity when expressed in 
vitro (Holst et al., 2004; Jones et al., 2007; Tanaka et al., 2007; Toyooka et al., 2009). Although we 
may be able to predict changes in GPCR activity based on altered GPCR sequences, the demonstration 
of constitutive activity in the PVN and SON needs to be functionally-based. A component of the high, 
basal eSS]GTPyS labelling in the rat PVN (Aaltonen et al., 2008) may reflect constitutive basal 
activity of known and/or orphan GPCRs. Highly expressed, constitutively active GPCRs may account 
in part for the molecular mechanisms regulating signal transduction effectors in PVN/SON neurons. 
Some of these molecules e.g., cAMP, calcium, have key roles in axonal growth of developing or 
regenerating neurons (e.g., (Ming et al., 1997». Constitutive activity may also underlie ligand-
independent functions of orphan GPCRs such as involvement in GPCR heterodimerization and 
altering target GPCR function - an example of this is the orphan GPCR GPR50 heterodimerizing with 
the melatonin MTI receptor to inhibit its activity (see (Levoye et aJ., 2006». In fact, constitutive 
activity is observed in the PVN and SON. For example, nitric oxide (whose generation is enhanced by 
many GPCR agonists, and is generally considered to be an inhibitor of PVN and SON activity (Stem 
et aJ., 2004», constitutively restrains ongoing firing in SON neurons (Stem and Zhang, 2005). As to 
GPCR-'specific' effects, very recently the melanocortin MC4 receptor was shown to be constitutively 
active in the mouse PVN (Ghamari-Langroudi et aJ., 2011). 
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There are a number of candidate substances that may be ligands for orphan GPCRs expressed within 
the PVN and SON. These include peptides that modulate PVN/SON function and/or are perhaps 
expressed in mPVN and SON, or pPVN neurons. Various peptides derived from larger precursor 
molecules (and isolated by proteomic methods) are expressed in the PVN/SON, such as: (I) the 
neuroendocrine regulatory peptides (NERPS-1I2), which are products ofthe VGF gene that colocalise 
with VP in the storage granules of the PVN and SON of both rats and humans, and suppress basal, 
hypertonic saline- or angiotensin II-induced VP release (Toshinai et al., 2009; Yamaguchi et al., 
2007); (2) neuronostatin, a product of the somatosatin gene that depolarizes or hyperpolarizes PVN 
magnocellular, parvocellular or preautonomic neurons and administered centrally increases blood 
pressure and decreases food intake and water drinking (Samson et al., 2008); (3) nesfatin-I, an amino-
terminal fragment derived from NEFAInucleobindin 2 (NUCB2) (Garcia-Galiano et al., 2010) that is 
present in VP and OT neurons (Brailoiu et al., 2007), elevates intracellular calcium in dissociated 
hypothalamic (Brailoiu et al., 2007) and isolated PVN (Maejima et al., 2009) neurons, alters the 
electrophysiological properties of PVN neurons (Price et al., 2008a), increases OT release from PVN 
tissue slices (Maejima et al., 2009) and administered centrally increases c-Fos in the PVN/SON and 
decreases food intake via an OT -dependent, leptin-independent melanocortin pathway (Maejima et al., 
2009; Garcia-Galiano et al., 2010) (note that it has been reported that nesfatin activates GPR12 (Mori 
and Eguchi, 2009), an orphan GPCR which exhibits constitutive activity (Tanaka et al., 2007»; and 
(4) augurin, a product of the c2orf40 gene which encodes the oesophageal cancer-related gene 4 
(ECRG4) protein) (Tadross et al., 2010) that is present in PVN and SON OT and VP neurons 
(Robertson et al., 2009), increases VP and CRF release from hypothalamic explants and elevates 
plasma ACTH levels when administered centrally or intra-PVN (Tadross et 01., 2010). It is interesting 
to note that peptidomics of the rat SON has identified 20 unique peptides from known pro-hormones 
(Bora et aI., 2008). Candidate orphan GPCR ligands are not restricted to peptides and their by-
products and post-translationally modified counterparts, but could also include compounds such as 
steroids (e.g., glucocorticoids) that are known to interact with the PVN/SON. There are a number of 
'fast', apparently non-genomic effects of steroids (Losel et al., 2003) and their metabolites (e.g., see 
(Neuhaus et al., 2009» that may be mediated by GPCRs, including chemosensory receptors, in the 
PVN/SON and other brain regions. 
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1.6 Steroids 
1.6.1 Steroids, nuclear receptors, and genomic interactions 
Steroids are hormones derived from a common cholesterol backbone. There are two major classes of 
steroid hormones: the sex steroids (progestogens, E2s, androgens) and adrenal steroids 
(glucocorticoids, and mineralocorticoids). Sex steroids reaching the circulation are mainly synthesised 
and released from the gonads (progestogens and E2s from the ovaries, and androgens from the testis), 
but they (particularly androgens) and/or their precursors (which are converted into active forms in 
central and peripheral tissues) are also excreted by the adrenal glands (de Ronde, 2003; Feder et ai., 
1967; Beato and Klug, 2000). Sex steroids are imperative in the differentiation of the embryonic 
reproduction system, and brain gender assignment at birth, and dictate adult secondary sexual 
characteristics, and control reproduction and reproductive behaviour (Evans, 1988). The adrenal 
steroids are synthesised and released from the adrenal cortex and are heavily implicated in 
maintaining homeostasis, regulating for example, the neuroendocrine stress response, metabolism, 
water and solute secretion, and the immune system (Evans, 1988). 
The effects of steroid are mediated by nuclear receptors which are part of a family of evolutionary-
related, DNA-binding transcription factors that also respond to other signalling molecules including 
vitamin 03, retinoids, and thyroid hormones (Germain et ai., 2006; Huang et ai., 2010). The structure 
of nuclear receptors are characterised by an N-terminal which contains the ligand-independent 
activation function (AF-l; a transcriptional activation surface), a highly conserved DNA binding 
domain (DB D), followed by a hinge region, and then a moderately conserved ligand binding domain 
(LBO) which contains the C-terminus and the ligand-dependent transactivation function (AF-2; a 
second transcriptional activation region) (Beato and Klug, 2000; Wierman, 2007). The receptors are 
also split up into seven regions (A-F) which is reminiscent of the original nomenclature assigned 
following comparisons between the first cloned nuclear receptors (the human E2 receptor a 
(ERalNR3Al), human glucocorticoid receptor (GRlNR3Cl), and chicken ERa) - subsequent 
functional and structural analysis revealed that these regions were components of the functional 
domains described above (see Figure 1.2) (Beato and Klug, 2000; Wierman, 2007). 
Nuclear receptors have been classified into six evolutionary groups of which steroid receptors are 
members of the third group - hence each official receptor name (as annotated by NC-IUPHAR and 
the Nuclear Receptor Nomenclature Committee, 1999) begins with nuclear receptor 3 (NR3) e.g., 
androgen receptor's official name is NR3C4 (trivial name AR) (note: for simplicity, nuclear receptor 
will be referred to by their trivial names henceforth in this dissertation). The remaining nomenclature 
is representative of the three subgroups within the nuclear receptor 3 group: (A), NR3AI (ERa) and 
NR3A2 (E2 receptor P (ERP»; (B), NR3Bl (E2-related receptor alpha (ERRa) and NR3B2 (E2-
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related receptor alpha (ERRP); and (C) NR3C 1 (GR), NR3C2 (mineralocorticoid receptor (MR)), 
NR3C3 (progesterone receptor (PR)), and NR3C4 (AR). 
In their inactive state, the steroid receptors are associated with a multimeric complex of proteins that 
include heat shock proteins (e.g., heat shock protein 90) and immunophilins (e.g. , Hsp56) (Pratt and 
Toft, 1999). Subsequent to ligand interaction, steroid receptors typically form homodimers (although 
the orphan receptors ERRa./p also bind DNA as monomers, ERa and ERP possibly form 
heterodimers, and GR has been shown to form heterodimers with unrelated transcription factors e.g. , 
nuclear factor kappa B), and translocate to the nucleus where they bind to two specific palindromic 
genomic sequences (hormone response elements) within the promoters of target genes (Beato and 
Klug, 2000; Falkenstein et al., 2000). Whether steroid receptors activate or silence gene transcription 
is dependent on the recruitment of co-activators (e.g. , steroid receptor co-activator-I (SRC-I), and 
CREB) or co-repressors (e.g. , nuclear receptor co-repressor 1 (NCOR I), and silencing mediator for 
retinoid and thyroid hormone receptors (SMRTINCOR2)) (Beato and Klug, 2000). 
AF-I AF-2 
A B c D E F 
OBO LBO 
Figure 1.2. Schematic diagram representing the modular structure of steroid receptors. 
The structure of nuclear receptors are characterised by: I) an N-terminal which contains the ligand-independent 
activation function (AF-I; a transcriptional activation surface); 2) a highly conserved DNA binding domain 
(OBO); 3) followed by a hinge region (D); 4) and then a moderately conserved ligand binding domain (LBO) 
which contains the C-terminus and the ligand-dependent transactivation function (AF-2; a second transcriptional 
activation region) . The LBO may bind ligands, co-activators and co-repressors, and along with the OBO and 
hinge region, dock to the multimeric complex of proteins such as heat shock proteins etc, when in the 
inactivated state. The receptors are also split into seven regions (A-F) which is reminiscent of the original 
nomenclature assigned following comparisons between the first cloned nuclear receptors. 
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1.6.2 Fast effects of steroids 
In addition to their genomic effects, it is well recognised that steroids also have rapid non-genomic 
actions (Falkenstein et al., 2000). Non-genomic effects are typically characterised by a rapid onset, 
insensitivity to inhibitors of transcription (e.g., actinomycin D) and translation (e.g., cycloheximide), 
and interaction with transduction cascades e.g., mobilisation of intracellular calcium, increase in 
adenylyl cyclase activity, and stimulation of the ERIOI2, phosphoinositide 3-kinase (P13K), and PLC 
pathways. Fast non-genomic effects have been described for all of the main steroid groups, for 
example: progesterone induces a rapid increase in intracellular calcium in frog oocytes, E2 
hyperpolarises the postsynaptic membranes of rat medial amygdala neurones, testosterone increases 
ERKI/2 phosphorylation in rat muscle fibres within 5 min of administration, aldosterone (ALD) 
rapidly stimulates inositol triphosphate (IP3) generation in human leukocytes, and CORT rapidly 
reduces mouse leydig cell cAMP content (Wasserman et al., 1980; Nabekura et al., 1986; Estrada et 
al., 2003; Christ et al., 1993; Dong et al., 2004). 
There are numerous reports of steroid binding sites on the plasma membrane e.g., eH]-testosterone 
binds to synaptic plasma membranes prepared from rat brain, and eH]-E2 binding sites are found on 
hepatocyte membranes (Towle and Sze, 1983; Pietras and Szego, 1980). The notion that steroids may 
mediate their fast effects from the plasma membrane is supported by studies that show that membrane 
impermeable steroids are able to elicit fast effects e.g., the membrane impermeable BSA-CORT 
conjugate activates ERKI/2 in rat embryonic hippocampal neurons (Xiao et al., 2005). Indeed some 
of the fast effects have been attributed to membrane-associated forms of the traditional receptors, for 
example ERP agonists increase cAMP production in immortalized GnRH neuronal cells (Hu et al., 
2008). These extranuclear receptors are thought to be localised to isolated caveolae rafts which are 
also part of a much larger signalsome complex consisting of many other signal proteins including G 
proteins, growth factor receptors (EGFR, Insulin-like growth factor 1 receptor), non-growth factor 
tyrosine kinases (Src, Ras), linker proteins (modulator of non-genomic actions of steroid receptors, 
striatin), and GPCRs (Hammes and Levin, 2007). On the other hand, there are also instances where 
fast effects of steroids appear to occur independently of the nuclear receptors. For example, the MR 
antagonist spironolactone does not inhibit an ALD-mediated increase in cAMP in rat inner medullary 
collecting ducts (Sheader et al., 2002). This suggests that there may be other non-nuclear, membrane-
bound steroid receptors. 
The fast effects of steroids are often dependent on G protein activation e.g., the CORT-mediated 
suppression of nicotine-induced calcium influx in PC-12 adrenal chromaffin tumour cells, is inhibited 
by pertussis toxin, a GUj inhibitor (Qiu et al., 1998). Therefore, it is unsurprising that GPCRs have 
been implicated in steroid signalling. Recent developments in steroid research have revealed three 
putative G protein-coupled steroid receptors: the once orphan GPER has been shown to bind E2 with 
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high (nanomolar) affinity, the odorant receptor PSGR has been reported to be activated by 
testosterone metabolites, and the calcium sensing receptor GPRC6 has also been implicated in 
testosterone signalling (Thomas et al., 2005; Revankar et al., 2005; Neuhaus et aI., 2009; Pi et al., 
20 I 0). While little is known regarding the role of PSGR and GPRC6 in rapid testosterone signalling, 
there has been a considerable amount of research on GPER, since its deorphanisation in 2005. 
Officially regarded as an E2 receptor, GPER marks a new age in steroid research. 
1.6.3 The G protein-coupled oestrogen (E2) receptor 
In 1996 a GPCR with low homology to the chemokine family of receptors was first cloned by Dr 
Stephen Lolait and colleagues from a human B-cell lymphoblast cDNA library (Owman et al., 1996). 
Subsequently named G protein-coupled E2 receptor 1 (GPER), the endogenous ligand for the GPCR 
was not initially identified although Northern blot analysis revealed high expression in both central 
and peripheral tissues (O'Dowd et al., 1998; Owman et al., 1996). In 2000, Filardo and co-workers 
identified a link between GPER and E2 signalling. They demonstrated that: (1) E2 activates ERK1I2 
in SKBRJ cancer cells that do not express ERa and ERP, yet express GPER (Filardo et al., 2000); and 
(2) MDA-MB-231 breast cancer cells (ERa-IERp+/GPER-) that are generally unresponsive to E2-
mediated ERK 112 phosphorylation, become E2-responsive following transfection with GPER (Filardo 
et al., 2000). In addition, the (EGFR) kinase inhibitor, tyrphostin AG-1478, blocks E2-induced ERK-
112 phosphorylation, suggesting that GPER requires EGFR to activate ERK 112 signalling in MDA-
MB-231 breast cancer cells (Filardo et al., 2000). Further studies revealed that E2 stimulation of 
GPER activates a modest increase in adenylyl cyclase and cAMP mediated signalling, and early c-Fos 
expression in SKBRJ cancer cells (Filardo et al., 2002; Maggiolini et al., 2004). 
In 2005, two studies provided direct evidence for E2 activation of GPER. Thomas and colleagues 
demonstrated high affinity binding of radiolabelled E2 ([3H] E2) to membranes of SKBRJ cancer 
cells and human embryonic kidney 293 (HEK293) cells transfected with human GPER, with a 
dissociation constant of approximately 3nM; an effect abolished in cells pre-treated with GPER 
siRNA (Thomas et al., 2005). Revankar and co-workers performed competition binding assays using 
fluorescent E2 derivatives along with E2 in COS-7 monkey kidney fibroblast cells transfected with 
human GPER, and obtained an inhibitory constant for E2 of approximately 6.6 nM for the receptor 
(Revankar et al., 2005). They further demonstrated that flourescent E2 binding to GPER occurred 
predominantly in the endoplasmic reticulum, a finding confirmed using an antibody directed against 
GPER (Revankar et al., 2005). The same group later found that only membrane-permeable E2 
derivatives are capable of stimulating GPER and activating rapid calcium mobilisation and PI3K 
signalling in transfected COS-7 cells, indicating that the GPCR functions intracellularly (Revankar et 
al., 2007). While this is a controversial finding considering that many GPCRs are localised and 
function on the plasma membrane, the cellular compartmentalisation is not unique amongst GPCRs 
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e.g., the proportion of human GnRH receptors at the cell surface in some cells is less than 1 % (Finch 
et al., 2008). In addition, studies on GPER have revealed that the partial and pure ER antagonists, 
tamoxifen and ICI 182,780 respectively, are capable of binding and activating the receptor (Revankar 
et al., 2005; Thomas et al., 2005). Tamoxifen is often used to treat breast cancer patients to block the 
proliferative actions of ERa and ER~ on tumour growth, and hence GPER provides a potential target 
for therapeutic intervention (Filardo and Thomas, 2005). 
1.7 Aims 
The main aim of this thesis was to investigate the concept of whether GPCRs act as fast steroid 
receptors, focussing on steroids that have prominent roles in neuroendocrine systems (e.g., E2s and 
glucocorticoids). This is initially addressed in results Chapters 3 and 4 by examining the first GPCR 
to be identified as a putative steroid receptor, the E2 receptor GPER. Chapter 3 attempts to map 
GPER mRNA and protein distribution throughout central and peripheral rodent tissue, to provide 
insight into the roles of GPER as a fast E2 receptor - with particular interest paid to GPER distribution 
in the OT and VP neuroendocrine systems. Amidst controversy surrounding the E2 binding 
capabilities of GPER (with some arguing that GPER still remains an orphan receptor) and its unusual 
intracellular localisation, Chapter 4 attempts to characterise GPER (and verify the activation of GPER 
by E2) in vitro. 
Results Chapters 5 and 6 address the possibility that there may be other steroid-binding GPCRs, with 
emphasis on a fast glucocorticoid receptor. Chapter 5 endeavours to identify some orphan GPCRs as 
candidates for fast glucocorticoid receptors, by matching the distribution of candidate orphan 
receptors with tissues that have been implicated in rapid glucocorticoid responses (hypothalamus, 
hippocampus, heart, thymus, etc.). Orphans with transcripts detected in the majority of target tissues 
were further investigated in Chapter 6, in an attempt to uncover a faSt acting CORT receptor. 
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Chapter 2: General Methods 
2.1 In vivo procedures 
2.1.1 Animals 
Adult male and female Sprague-Dawley rats, weighing 200-250g (Harlan), and adult (10-12 week) 
male and female wildtype mice (2S-30g) from our VP V 1B receptor KO colony (Wersinger et ai., 
2002), were used in this studies. Animals were housed under a constant temperature (21± 2°C), light 
(lights on from 0700 to 1900 h) and humidity (45-50%) regimens with food and water ad libitum. 
Animal care, maintenance and surgery were performed in accordance with the Animal Scientific 
Procedures Act (1986) United Kingdom and the appropriate University of Bristol ethical review 
process. 
2.1.2 Collection of tissue/or ISHH 
Animals were sacrificed by decapitation rather than cervical dislocation to avoid damage to the brain 
and pituitary. Removal of tissues from head-to-toe took approximately 15-20 min. 
Brain 
Following tissue removal, a shallow midline cut was made with fine micro-dissecting scissors from 
the back of the skull to an approximate point of bregma, with care taken not to damage the brain. Two 
cuts were performed at the back of the skull either side of the first midline, allowing the caudal part of 
the skull to be prised back with fine micro-dissecting forceps. Another shallow cut was made from 
bregma to the rostral side of the skull, and both sides of this cut were peeled back to reveal the 
complete brain. With a fine micro-dissecting spatula, the brain was gently detached from surrounding 
membranes, with close attention paid when removing the olfactory bulb. The brain was lifted from 
skull and the optic nerves severed to liberate the brain. 
Pituitary gland 
Surrounding membranes were removed from the pituitary gland with fine micro-dissecting forceps. 
The pituitary gland was then lifted from the base of the skull. 
Peripheral tissues. 
Skin was removed from rodent thoracic and abdominal region and a midline incision made though the 
muscle layers to expose the underlying organs. All peripheral organs were dissected using micro-
dissecting scissors and forceps, with care taken to remove excess connective tissue and fat. Skeletal 
muscle was removed from the hind leg, and fat from the abdominal regiof.l following hair and skin 
removal using a scalpel. 
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Freezing 
All above tissues were wrapped in aluminium foil apart from the pituitary gland, adrenal gland and 
ovary which were submerged in tissue freezing medium-filled (Leica Microsystems, Germany) 
aluminium foil boats (mounting for sectioning). Tissues were snap frozen on dry ice and stored at -
80°C until processing for ISHH. 
2.1.3 Perfusion flXllt;on and collection of tissue for IHC 
Perfusion of rodents with 4% paraformaldehyde (PF A) was performed prior to IHC, to preserve cells 
and tissue structure, and provide mechanical strength to sections during the subsequent processing: a 
failure to properly fix tissue can lead to fragile sections and an increase in background staining. The 
method is essentially the same for both rat and mouse, although slight modifications were made to 
accommodate for the differences in animal size. 
Animals received a lethal injection of sodium pentobarbital (1 OOmglkg i.p.). Once reflexes (check eye 
and pain reflexes by touching the eye and taiVpaw pinching, respectively) were absent, rodents were 
transferred to a fume-hood and paws pinned to a polystyrene base to keep the animal in place during 
the procedure. A midline cut was made from neck to abdomen, from which skin and muscle were 
pulled back to expose the ribcage. A surgical cut was made along the diaphragm with blunt micro-
dissecting scissors avoiding the heart and lungs. Lateral edges of the ribcage were cut with blunt 
micro-dissecting scissors, allowing the ribcage to be pulled upwards and away (and clamped/pinned) 
exposing the heart and lungs. Firstly, to reduce clotting, heparin (100 units/300g) (Sigma, UK) was 
injected into the left ventricle. A surgical needle attached to a peristaltic pump (Harvard Apparatus, 
UK) (for rats), or an AutoMate In Vivo Perfusion System (AutoMate Scientific, USA; for mice), was 
inserted into the left ventricle (and positioned up into the aorta in rats, and positioned into left 
ventricle in mice) and clamped. Pumps were turned on/valve turned to 'on' position and the right 
atrium was nicked with sharp micro-dissecting scissors. 300ml (rats) or 30ml (mice) of Ix phosphate-
buffered saline (PBS) was infused into the cardiovascular system followed by an equal volume of 4% 
PFA in Ix PBS (see Appendix II for preparation of 4% PFA in Ix PBS). The peristaltic pump infused 
at a rate of 10-15ml per min whereas the AutoMate In Vivo Perfusion System relied on gravity 
(perfusate was placed into large 140ml syringes which were attached to the surgical needle by plastic 
tubing- the force of gravity pushed the perfusate through the mouse cardiovascular system). 
If successfully perfused (as determined by blanching of tissues), tissues were removed as in section 
2.1.2 and were post fixed overnight in 20% sucrose/4% PFA in Ix PBS solution at 4°C. Tissues were 
then frozen rapidly over liquid nitrogen in plastic weigh boats, wrapped in aluminium foil (apart from 
pituitary glands, adrenal glands and ovaries, which were placed in tissue freezing medium-filled 
aluminium foil boats) and stored at -80°C until sectioning for IHC. 
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2.2 Analysis of receptor mRNA distribution by ISHH 
ISHH is a method of mRNA detection that allows insight into tissue (and cellular) specific gene 
expression. The use of riboprobes rather than oligonucleotide probes offers greater sensitivity (RNA: 
RNA hybrids are more stable that DNA: RNA hybrids, allowing for greater stringency washes and 
potentially higher signal: noise ratio). This ISHH protocol used in this thesis is described at: 
http://intramural.nimh.nih.gov/lcmr/snge/Protocols/ISHH/ISHH.html 
2.2.1 Tissue sectioning 
l2J11ll sections of brain and peripheral tissues were cut using a cryostat (Leica, Germany) and thaw-
mounted onto polylysine slides (VWR International, UK). Slides were rapidly dried on a heat mat 
warmed to approximately 37°C, and stored at -80°C until use. 
2.2.2 Riboprobe design 
Probes of approximately 300-600bp in length were designed against the genes of interest. As GPCRs 
are part of a highly homologous family of receptors, every attempts were made to either direct the 
riboprobes towards the 3' -untranslated region (as the non-translated regions tend to have less 
sequence homology with other mRNA strands) or to non-conserved sequences within the translated 
region of the gene. For each mRNA of interest, antisense and sense riboprobes were synthesised to 
correspond to the sense strand of mRNA and antisense strand of mRNA (as a control), respectively. 
Riboprobes were checked for sequence homology against other mRNA sequences in the NCBI blast 
search engine (http://blast.ncbi.nlm.nih.gov/Blast.cgi) to verify that the riboprobes only potentially 
recognised the target transcript. 
Melting temperature (Tm) is the temperature at which 50% of the duplexes have dissociated, and a 
measure of the stability of hybrids. The optimum hybridisation temperature is approximately l5-25°C 
below Tm, while the high stringency wash temperature is approximately 5-l5°C below Tm 
(Wilkinson, 1999). Therefore, to predict whether the riboprobes could withstand the 55°C 
hybridisation incubation and the stringent low salt 65°C wash (see section 2.2.6 and 2.2.7 for 
hybridisation and wash steps), the Tm of each probe was calculated. If the Tm for a riboprobe was 
unavoidably low, the hybridisation and wash temperatures were adjusted accordingly (for each 
riboprobe, the Tm and corresponding hybridisation and wash temperatures are given in Chapters 3 
and 5). The following formula was used to calculate Tm for RNA: RNA hybrids: 
Tm = 79.8 + 18.5Iog(Na' + 58(% G+C)/1OO + 11.8(% G+C/1OO)1-1.1(% mismatched pairs) 
- 810/ribonucleotide length - 0.35(% formamide). 
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("Ai G+C), represents the total guanine-cytosine content of the riboprobe; Na+, incorporates the molarity of 
monovalent cations within the hybridisation buffer; ("/6 mismatched pairs, takes into consideration any 
unmatched nucleotides within the hybrid duplex (all of the riboprobes in this chapter were designed to match 
the target mRNA sequence); % formam ide, is the amount offormamide in the hybridisation buffer. 
As the fonnula highlights Tm is proportional to G+C content. This is a product of three hydrogen 
bonds fonned between guanine and cytosine (as opposed to the two hydrogen bonds fonn between 
adenine (A) and uracil «U) or thymine (T) for DNA probes». Hence, riboprobes with a high (% G+C) 
are more stable and fonn a much stronger bond within the RNA:RNA duplexes. As a result probes 
with high (% G+C) have higher Tms and those with low (% G+C) have reduced Tms. However, it is 
important that (% G+C) is not too high as it increases the possibility that nonspecifically bound 
riboprobes may remain bound throughout the stringent wash steps, thus increasing background signal. 
For this reason, riboprobes were not directed to the 5' untranslated region of the gene as it has a 
tendency to be G/C rich. Within this protocol it was found that a probe G+C content of approximately 
50 % was optimal. As previously explained, if (% G+C)/Tm was unavoidably low for certain 
riboprobes (e.g., if a 3'untranslated region was too Aff rich) then the hybridisationlwash temperatures 
were reduced. 
2.2.3 Riboprobe templates 
Rat probe templates were generated by PCR from 125-150ng rat genomic DNA. The genomic DNA 
template for the rat orphan probes was extracted from rat testis, while genomic DNA for the GPER 
probe was purchased from Promega, UK (Promega no. G3l3A). The mouse GPER probe was 
generated by PCR from 20ng mouse GPER cDNA from an AtT -20 pituitary tumour cDNA library. 
PCR reactants included 5Jll lOx HotStar buffer (Qiagen, UK), Sfll deoxyribonucleotides (dNTPs) 
(final concentration 200J.1M) (Applied Biosystems, UK), lOfll 'Q' solution (a liquid of unknown 
composition that according to the manufacturers reduces non-specific primer annealing - we suspect 
'Q' is a DMSO solution) (Qiagen, UK), 0.5fll 2.5 U ampJitaq DNA polymerase (Applied Biosystems, 
UK), 2Jll 20J.1M primers (final concentration 200nM) (Invitrogen, UK), and made up to 50fll with 
distilled H20. The standard PCR run consisted of an initialization step for 45 seconds (s)-l minute 
(min) at 95°C; 45s denaturation step at 94°C, 1 min annealing step at 45-50°C, 30s elongation step 
for at noc, for 20-40 cycles; followed by a 10 min final elongation at noc and a 4°C soak. 
However, not all primers amplified a product of threshold size, and changes to annealing temperature 
were made accordingly (see Appendix I for PCR conditions). Primers contained recognition 
sequences for restriction endonucleases, details of which are outlined in experimental Chapters 3 and 
5. 
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To check the PCR product was the correct size IOll1 of the reaction was run on a 1.6% ethidium 
bromide agarose gel, and then the ends of the remaining product were filled in to ensure that the 5'-
and 3'- terminal bp were 'flushed' (no overhangs so that restriction endonuclease recognition 
sequences were intact (see Appendix I). Riboprobes were digested with restriction endonucleases 
(see the experimental Chapters 3 and 5) and run on a 1.6% ethidium bromide agarose gel. Bands 
corresponding to riboprobes were removed from the gel, and the DNA extracted using a Qiagen gel 
extraction kit (see Appendix I for gel extraction protocol). Riboprobes were digested with restriction 
endonucleases (see Chapters 3 and 5 for details) and subcloned into the RNA expression vector 
pGEM4z (see Appendix I for ligation protocol). Vectors were transformed into DH5a Escherichia 
coli (E. coli; Invitrogen, UK) and spread onto lysogeny broth (LB)-agar plates containing SOIlg/ml 
ampicillin (AMP) (Sigma, UK) and left to grow overnight at 37°C (pGEM4z contains an AMP 
resistant gene) (see Appendix I). Colonies were picked, grown overnight in LB-AMP, and DNA 
extracted using a DNA miniprep protocol (see Appendix I). IOIlI of DNA was digested with 
corresponding restriction enzymes and run on a 3% agarose (microsieve; Severn Biotech Ltd, UK) gel 
to check the vector contained the correct insert. A colony containing the appropriate construct was 
grown overnight in 100m 1 AMP-LB at 37°C (rocked at 22Srpm), and plasmid DNA obtained from 
lysed bacteria cells using a Qiagen plasmid maxi prep protocol (Qiagen, UK; see Appendix I for 
protocol). DNA concentration was measured using a spectrophotometer (at a 260nm wavelength). 
2.2.4 Radioactive labelling and synthesis of riboprobe 
The pGEM4z vector contains SP6 and T7 RNA polymerase promoters flanking the mUltiple cloning 
sites, thus enabling the use of RNA polymerases SP6 or T7 to transcribe the antisense and sense probe 
(Chapters 3 and S outline the polymerases used to transcribe each probe). Prior to transcription 
vectors were linearised (see Appendix I for linearising vectors protocol) using the restriction 
endonuclease which recognised the incorporated restriction enzyme sequence 3' downstream of the 
insert (details of which restriction endonucleases were used are summarised in Chapters 3 and 5). 
SOOng DNA starting template was labelled with S3S -UTP using the Ambion MAXIscript® 
transcription kit (Ambion, UK; see Appendix I for protocol). 
The synthesised probe was precipitated overnight at -20°C, and centrifuged (16,000xg) for 10-15 min 
at 4°C. Supernatant was removed and pellet washed with 70% ethanol and resuspended in 97111 tris-
ethylenediaminetetraacetic acid (Tris-EDT A or TE), 2111 10% sodium dodecyl sulphate (SDS) and llli 
SM dithiothreitol (OTT) (all performed on ice). llli of riboprobe was placed into Sml scintillation 
fluid and radioactivity measured in a scintillation counter (Wallac model 1410). to give the counts per 
minute (cpm). Throughout the ISSH procedure, all aqueous radioactive waste was disposed of into an 
appointed radioactive sink. Solid waste with radioactivity above background (>2 counts per second 
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determined by a beta counter) was collected and stored with the departmental radioactive waste, until 
deemed no longer radioactive. 
2.2.5 Preparing tissue sections/or hybridisation 
The ISHH protocol was carried out in a RNase-free environment in an attempt to minimise 
degradation of riboprobes/tissue mRNA. All buffers were diluted in diethylpyrocarbonate (DEPC)-
treated water (see Appendix II), cylinders and tanks were pre-treated with RNase-AWAyTM 
(Invitrogen, UK) prior to autoclaving, and pipette tips were filter plugged and RNaselDNase free. The 
prehybridisation steps were as follows: 
1) Slides were removed from -80°C storage and allowed to equilibrate to room temperature 
for 10-20 min. 
2) Slides were placed into coplin jars and immediately submerged in 4% formaldehyde in 
Ix PBS for 5 min. 
3) 2 x brief washes with Ix PBS 
4) Slides were immersed in 0.25% acetic anhydride/0.42% concentrated hydrochloric acid! 
1.5 % triethanolamine in Ix PBS. Acetic anhydride acetylates positive charge residues to 
help reduce nonspecific binding of the negatively charged riboprobes. 
5) Sections were dehydrated with ascending alcohol washes: 70%/80%/95%11 00% each for 
1 min. 
6) Chloroform for 5 min to de-fat and permeabilise sections. 
7) Sections rehydrated with descending alcohol washes: 100%/95% each for 1 min. 
8) Slides air dried for approximately 20 min. 
9) And finally sections were placed on top of 3M paper (that had been pre-soaked in 50% 
formamide/4x SSPE) within a paper container. 
2.2.6 Hybridisation o/sections 
Hybridisation of sections was performed behind a Perspex shield to protect from beta radiation 
emitted from 3sS_UTP. 50J.1i of hybrid is at ion solution, containing approximately 1-2 cpm of 3SS-probe, 
was applied to each section and covered with a 22 x 22mm cover slip (light pressure was applied to 
each cover slip to remove any residual air bubbles that could mask the tissue from hybridisation 
buffer). 
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50J.11 Hybridisation solution consisted of: 
1) 35S-probe + DEPC-H20, 4J.11 total. 
2) 2J.11 ribonucleic acid mixt (reduces nonspecific binding. N.B., ribonucleic acid mix was a 
mixture of 35S_probe and OEPC-H20 which was then melted at 65°C for 5 min to 
denature the probe. This was cooled on ice, prior to adding it to the rest of the 
hybridisation solution). 
3) 42J.11 Hybridisation buffert (constituents in this buffer amongst other things aid probe 
dispersion, and control the stringency and efficiency of the hybridisation). 
4) IJ.11 SM DTI (is a reducing agent and protects 35S from oxidation, as well as reduce 
background). 
5) 0.SJ.11 10% sodium thiosulphate (aids probe dispersion and reduces nonspecific ionic and 
non-ionic absorption ofthe probe). 
6) 0.5J.11 10% SDS (permeabilises tissue and increases signal: noise ratio). 
t Reagent composition described in Appendix II 
7) Sections complete with hybridisation solution were incubated at 55°C overnight 
(however, this temperature was altered depending on the riboprobe Tm - see Chapters 3 
and 5 for hybridisation temperatures for each probe). 
2.2.7 Post hybridisation processing of sections 
Sections underwent a variety of descending salt (SSPE) washes to remove 'nonspecific' and weakly 
bound 35S-probe (mismatched hybrids are more stable at high salt concentrations), and reduce 
background signal. The most stringent ofthese is the O.1x SSPE wash performed at 65°C (see below). 
OTI was included in washes to protect the 3SS from oxidation. 
1) Cover slips were gently removed from sections by dipping 4x SSPEllmM orr in OEPC-
H20. Slides were transferred to a slide rack and placed into a dish containing 4x 
SSPE/I mM OTI in DEPC-H20. 
2) 4 x 5 min wash in 4x SSPEIl mM OTT in DEPC-H20 at room temperature with gentle 
rocking. 
3) 30 min incubation in RNase A solution (see Appendix II) for 30 min at 37°C. This step 
degrades single stranded mRNA (i.e., unbound probe). 
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4} 2 x 5 min wash in 2x SSPEllmM OTT in OEPC-H20 at room temperature with gentle 
rocking. 
5} I x 5 min wash in O.lx SSPE/lmM OTT in OEPC-H20 at room temperature with gentle 
rocking. 
6} 2 x 30 min wash in O.lx SSPE/1mM OTT in OEPC-H20 at 65°C without agitation 
(depending on the riboprobe Tm this temperature may have been changed - see 
experimental Chapters 3 and 5 for hybridisation temperatures for each probe). 
7} I x 5 min wash in O.1x SSPE/lmM OTT in OEPC-H20 at room temperature with gentle 
rocking. 
8} Finally sections are dehydrated with ascending ethanol washes that contain 300mM 
ammonium acetate: 70%/80%/90%/95%/100%, each for one min. Ammonium acetate 
was included in the ethanol washes to reduce the denaturation of hybrids. 
9} Sections are air dried before exposure to film (Amersham Hyper film MP) or emulsion 
dipped (see Appendix I for protocol). 
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2.3 Analysis of protein distribution by IHC 
IHC is the localisation of a protein of interest within ex vivo tissue, using antibodies that are directed 
towards that protein (such as a GPCR). The following protocols were used to investigate the 
distribution of GPER in rat and mouse tissue, and possible co-localisation of GPER with OT and VP 
neurones (Yao et al., 2000; Yao et al., 2001). The GPER antibody was a kind gift from Professor Eric 
Prossnitz from the University of New Mexico, and was a rabbit polyclonal antibody directed against 
the last 18 amino acids of the human C-terminus GPER (AVIPDSTEQSDVRFSSA V). The specificity 
of this antibody has previously been confirmed in human cancer cell lines that endogenously express 
the receptor, and COS-7 cells transfected with GPER-GFP, and has also been used to determine the 
central protein distribution of the rat GPER (Revankar et al., 2005; Brailoiu et al., 2007). The use of 
the human antibody in rodent tissue is only made possible by the high sequence homology between 
the human and rodent C-terminals (see Figure 4.29). 
2.3.1 Tissue sectioning 
Free floating brain sections 
Rat and mouse brains were sectioned on a cryostat to a thickness of 40JUD for rat or 35JUD for mouse 
(as the mouse brain is smaller, thinner sectioning produces more slices per region of interest). Using a 
fine paint brush (slightly dampened with I x PBS (see Appendix II for PBS recipe)) each brain slice 
was transferred from cryostat to a 12-well tissue culture dish. A maximum of 4 sections/well for rat 
brain and 8 mouse sections/well were used. 
Peripheral tissues 
12JUD sections of rat and mouse peripheral tissues were cut and thaw-mounted onto Superfrost Plus 
slides (VWR International, UK). Slides were allowed to dry on a heat mat and sections were drawn 
around using an ImmEdge™ Pen (Vector, UK). Slides were then placed into slide mailers containing 
Ix PBS. 
2.3.2 Single staining with 3,3'-diaminobenzidine (DAB) 
This protocol was used for both free-floating mouse brain and slide-mounted peripheral sections to 
detect GPER-immunoreactivity (ir). The optimum dilution of GPER antibody was determined in 
preliminary experiments. For all steps (excluding PBS washes) sections were incubated in 400Jil of 
solution/well and 20011V slide, and were subject to light agitation on a rocking platform. Slides 
underwent Ix PBS washes within slide mailers (this was not agitated), and free-floating sections were 
washed in approximately 500111 Ix PBS with agitation. Unless otherwise stated, each step was 
performed at room temperature. 
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I} I x 5 min wash in Ix PBS. 
2} Endogenous peroxidase activity was quenched with 3% hydrogen peroxide in Ix PBS for 
10 min. 
3) 3 x 10 min wash with Ix PBS. 
4) Incubation in 10% normal goat serum (NGS}/O.3% t-Octylphenoxypolyethoxyethanol 
(Triton-X 100 or TX-IOO; Sigma, UK) in Ix PBS for IS min to reduce non-specific 
antibody binding and permeabilise tissue sections. 
5} 3 x 10 min wash with I x PBS. 
6} Sections were incubated overnight in an affinity-purified rabbit antiserum against GPER 
diluted (1:1000 for rat tissue; 1:2000 for mouse) in 1% NGS/0.3% TX-IOO in Ix PBS at 
4°C (not on a plate rocker). Normal rabbit immunoglobulin G (IgG) serum (Vector 
Laboratories) was used as a control at the same concentration as the antibody. 
7) 3 x 10 min wash with 1 x PBS. 
8) 1 hour incubation at room temperature in secondary biotinylated affinity purified goat 
anti-rabbit (1:500, Vector laboratories), in 1% NGS/O.3% TX-I00 in Ix PBS. 
9} 3 x 10 min wash with Ix PBS. 
10) 1 hour incubation in horseradish peroxidise streptavadin (1 :500, Vector laboratories) in 
1 % NGS/O.3% TX-IOO in Ix PBS for a further hour. 
II} The GPER signal was visualised with 3,3'-diaminobenzidine (DAB) in peroxidase buffer 
(10 min at 1:10, Roche Diagnostics). 
12) Mouse brain sections were mounted onto Superfrost Plus slides with 0.5% gelatin 
solution, and left to air-dry. 
13} Slides were coverslipped with DPX mounting medium (VWR, UK). 
14} Sections were viewed under a light microscope (Leica DM IRB, Germany), and 
permanently stored at room temperature. 
2.3.3 Double immunofluorescence 
For double immunofluorescence staining, hypothalamic free floating sections (40JUD for rats; 35JUD 
for mice) were processed to either detect GPER-ir and OT-ir localisation, or GPER-ir and VP-ir 
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localisation, see below points 1-10. Unless otherwise stated, each step was performed at room 
temperature on a rocking platform. The optimum dilution of GPERlOTNP antiserum was determined 
in preliminary experiments. 
1) 1 x 5 min wash in Ix PBS. 
2) Nonspecific ir blocked with 10% NGS/0.3% TX-I00 in Ix PBS for 15 min. 
3) 3 x 10 min wash in Ix PBS. 
4) Sections were incubated overnight at 4°C (not on a plate rocker) with rabbit antiserum 
against GPER (diluted I: 1000) and guinea pig antiserum against OT or VP (diluted 
1:2000 (OT), 1:500 (VP); Peninsula Laboratories). 
5) 3 x 10 min wash in Ix PBS. 
6) I hour incubation at room temperature in biotinylated goat anti-rabbit antibody (to detect 
GPER protein), and Alexa Fluor 488 goat anti-guinea pig antibody (diluted 1:500, 
Invitrogen) to detect OT or VP protein. 
7) 3 x 10 min wash in Ix PBS. 
8) Sections are incubated for an hour in streptavadin-conjugated Alexa Fluro 594 (diluted 
1 :500, Vector Laboratories) to fluorescently label the biotinylated goat anti-rabbit 
secondary antibody. 
9) Sections were mounted onto Superfrost Plus slides, coverslipped with an antifade 
mounting medium (Vectashield Hard Set, Vector Laboratories, UK) and stored at 4°C (or 
at -20°C for long term-term storage). 
10) Sections were viewed under a confocal laser-scanning microscope (Leica TCS-NT 
microscope housing a Leica OM IRBE inverted epifluorescence with a two-line 
krypton/argon laser) and processed with Adobe Photoshop CS3 extended computer 
software. 
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2.4 Molecular cloning of receptors and enzymes 
2.4.1. Rodent GPER 
Tagged and untagged rat GPER 
Epitope tagged and untagged rat GPER receptors were generated by PCR using 250ng rat genomic 
DNA as a template. PCR reagents included 10J.l1 5x Herculase II Fusion DNA buffer (Agilent 
Technologies, UK), 200J.1M dNTPs, IJ.l1 Herculase II fusion DNA polymerase (Agilent Technologies, 
UK), 2J.lI 10mM primers, and the reaction volume was made up to 50J.lI with distilled H20. Each PCR 
cycle consisted of 95°C for 2 min; then 45 s at 94°C, I min at 65°C, and 1 min at noc for 40 cycles; 
followed by 10 min at noc, and a 4°C soak. 
For the untagged receptor, primers were directed to 5' and 3'-untranslated regions of the receptor 
(upstream: 5'- AGCTTAAGCT7UAAGCCATGGCTGCAACTACT -3'; downstream: 5'-
AGAGCCTCGAGGTGGTITGTTAAAGGGCC -3') and corresponded to 15718643-15720408bp of 
the rat GPER gene (Genbank Accession number NC_005111), generating a 1765bp product. Primers 
for the tagged receptor were again directed to 5' and 3'-untranslated regions of the receptor, but the 5' 
primer contained an additional 27 bp which coded for the Influenza hemagglutinin (HA) epitope tag 
(upstream: 5'-
AAGCTTAAGCT7UAAGCCATGTATCCATATGATGTTCCAGATTATGCTGCTGCAACTAC 
TCCAGC -3' (bold underlined letters highlight the additional HA tag sequence); downstream: 5'-
AGAGCCTCGAGGTGGTITGTTAAAGGGCC -3'), and gave rise to a 1793bp product 
corresponding to 15718642-15718643bp of the rat GPER gene. Primers for both tagged/untagged 
receptors contained recognition sequences for the restriction endonucleases HindIII and XhoI 
(represented by underlined italics). Primer restriction endonuclease sites allowed subcloning into the 
vector pcDNA3.1(+) (containing AMP and neomycin resistance genes) for expression in mammalian 
cells. 
Untagged mouse GPER 
The untagged mouse GPER receptor was generated by PCR using 7.5ng mouse GPER cDNA (cloned 
from a mouse AtT-20 pituitary tumour cDNA library; Dr Lolait unpublished data) as a template. PCR 
reaction mix contained 10J.lI 5x Herculase II Fusion DNA buffer, 200J.1M dNTPs, IJ.lI Herculase II 
fusion DNA polymerase, 2J.lI 10mM primers, and the reaction volume was made up to 50J.lI with 
distilled H20. PCR cycling comprised of 95°C 2min; 94°C 45sec, 65°C Imin, nOc Imin for 30 cycles; 
72"C 10min; 4°C soak. Primers were directed to 5' and 3'-untranslated regions of the receptor 
(upstream: 5'- ACTGGGATCCGAAGCCATGGATGCGACTACC -3'; downstream: 5'-
GCATCCTCGAGCAGGAAGGCGTTITGTTA -3') and corresponded to 595-2323bp of the mouse 
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GPER gene (Genbank Accession number NM_029771), generating a 1728bp product, and contained 
recognition sequences for the restriction endonucleases BamHI and XhoI (represented by underlined 
italics). Incorporation of restriction endonuclease sites into primers allowed subcloning into the vector 
pcDNA3.1(+) (containing AMP and neomycin resistance genes) for expression in mammalian cells. 
2.4.2. Mouse E2 sulphotransferase 
A mouse E2 sulphotransferase cDNA clone was purchased from Geneservice (IMAGE clone: 
1479883; SourceBioscience, UK), and supplied as pre-streaked bacterial colonies on a LB-agar slope. 
The mEST clone had been subcloned into pT7T3D-Pac vector which contains an AMP resistant gene. 
Bacterial colonies were re-spread on LB-agar plates containing SOJ.1g/ml AMP and grown overnight at 
37°C. Colonies were picked and grown overnight in LB-AMP and bacteria were lysed and DNA 
extracted using the DNA miniprep protocol. 10...,1 of DNA was digested with EcoRI and Notl 
restriction endonucleases, and the product run on a 1% ethidium bromide agarose gel to check the 
insert was the correct size. A colony containing the correct insert was grown overnight in 100ml 
AMP-LB at 37°C (rocked at 22Srpm), and plasmid DNA obtained using the Qiagen plasmid maxiprep 
protocol (Appendix I). 
For transfection of the mEST cDNA into a mammalian cell line, it was necessary to subclone the 
mEST cDNA into a mammalian expression vector. In this instance the vector pcDNA3.1 Hygromycin 
(Hygro) (+) was preferred as it contained a Hygro B resistance gene (as well as AMP resistance gene). 
Hygro resistance enabled mEST to be stably transfected into an already established stable line that 
had been selected with an alternative antibiotic (i.e., mGPER-expressing HEK293 cells that had been 
selected with the ·antibiotic Geneticin® (G418». However, as there is an absence of an EcoRI site 
from the pcDNA3.1(+)Hygro multiple cloning sites, the mEST clone could not be directly inserted 
into the vector. The mouse E2 sulphotransferase plasmid DNA was therefore used as a template in 
PCR to amplify mouse E2 sulphotransferase DNA with the appropriate linkers for subcloning. 
A new mEST clone with suitable restriction enzyme linkers was generated by PCR using 20ng of 
eDNA retrieved from the previous plasmid maxi prep as a template. PCR reaction mix contained 10J.1l 
Sx Herculase II Fusion DNA buffer, 200J.1M dNTPs, 1 J.11 Herculase II fusion DNA polymerase, 2J.11 
10mM primers, and the reaction volume was made up to 50...,1 with distilled H20. PCR cycling 
comprised of 95°C 2min; 94°C 4Ssec, 60°C Imin, 7fc Imin for 30 cycles; n'c lOmin; 4'C soak. 
Primers were directed to the 5' and 3'untranslated of the enzyme (upstream: 5'-
ACAGTGGATCCITIGAGATGGAGACTTCTATGCC -3'; downstream: 5'-
CAGGCCTCGAGTTATTTTTACTAGAAATC -3'), and corresponded to 97-1212bp of the mEST 
gene (Genbank Accession number NM _ 023135.1), generating alII Sbp product. Primers contained 
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recognition sequences for the restriction endonucleases BamHI and Xhol (represented by underlined 
italics). 
2.4.3. Human orphan receptors GPR108, GPRU6, TMEM87B 
Orphan GPCR cDNA clones were purchased from Geneservice, and supplied as pre-streaked bacterial 
colonies, on LB-agar slopes. The GPRI08 cDNA was subcloned into a pCR4-TOPO vector (IMAGE 
clone: 9056837; vector contained kanamycin and AMP resistance genes); GPRI46 cDNA was 
inserted into a pOTB7 vector (IMAGE clone: 4563636; vector had a chloramphenicol resistance 
gene); and TMEM87B cDNA was inserted into a pCR-BluntlI-Topo vector (IMAGE clone: 
40026807; vector contained a kanamycin resistance gene). For each orphan, bacterial colonies were 
re-spread onto LB-agar plates containing the appropriate antibiotic (30llglml kanamycin sulphate 
(Sigma, UK) or 341lg/ml chloramphenicol (Sigma, UK» and grown overnight at 37°C. Colonies were 
picked and grown overnight at 37°C in LB containing antibiotics (30Ilg/ml kanamycin sulphate or 
341lg/ml chloramphenicol), and DNA extracted using the DNA miniprep protocol (see Appendix I). 
lO1l1 of DNA was digested with restriction endonucleases and the product run on a 0.8% ethidium 
bromide agarose gel (GPR108/pCR4-TOPO vector was digested with the restriction endonucleases 
SpeI and Not I; GPR146/pOTB7 vector was digested with EcoRi and XhoI; and TMEM87B/pCR-
BluntII-Topo vector was digested with BamHI and XhoI). Bands corresponding to the inserts were 
removed from the gel and the DNA extracted (see Appendix I for gel extraction). 
To allow transfection into mammalian cells, the orphans were subcloned into the mammalian 
expression vector pcDNA3.1(+). Following gel extraction GPR146 cDNA was ligated into 
pcDNA3.1(+) that had previously been digested with EcoRi and XhoI (see Appendix I). Unlike the 
GPRI46 cDNA, the GPRI08 and TMEM87B cDNAs could not be directly subcloned into 
pcDNA3.1(+) as both clones were originally inserted into their Geneservice expression vectors by 
blunt-end ligation. Instead, the DNAs extracted from the previous DNA minipreps were used as PCR 
DNA templates to re-amplify the orphan GPCRs by PCR. For both GPRI08 and TMEM87B the PCR 
reactants included 10111 Herculase II Fusion DNA buffer, 200J.1M dNTPs, 1 III Herculase II fusion 
DNA polymerase, 1111 miniprep DNA (diluted 1:10 to give a DNA concentration of -15-20ng), 2111 
10mM primers, and the reaction volume made up to 50111 with distilled H20. For GPRI08 each PCR 
cycle consisted of 95°C for 2 min; then 45 s at 95°C, 1 min at 62°C, and 1 min at noc for 25 cycles; 
followed by 10 min at noc, and a 4°C soak. PCR conditions remained the same for TMEM87B apart 
from the annealing temperature which was at 60°C. 
For GPRI08 primers were also directed to the 5' and 3' untranslated regions of the receptor 
(upstream: 5'- GGAGGGATCCCCAGAGATGGCAGTGAGC- 3'; downstream: 5'-
CTGGCTCGAGGAAGGGACTCTTCTTCC- 3 '), and corresponded to 5-1828bp of the human 
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GPR10S gene (Genbank Accession number BC146909), generating a 1823bp product. For 
TMEMS7B primers were directed to the 5' and 3-untranslated regions of the receptor (upstream: 5'-
CAGCGGATCCATCAAGATGGTCGCCGCC- 3'; downstream: 5'-
AAACCTCGAGGCCTGCCACCTA TCAGCT - 3 '), giving rise to a 1969bp product corresponding to 
15S-2127bp of the human TMEMS7B gene (Genbank Accession number BCl15373). Primers for 
both receptors contained recognition sequences for restriction endonucleases BamHI and XhoI 
(shown with bold italics). Primer restriction endonucleases sites allowed subcloning into 
pcDNA3.l(+) (containing AMP and neomycin resistance genes) in a 5'--.3' direction. 
2.4.4. Amplifying eDNA clones 
The ends of the PCR products were filled-in (see Appendix I), digested with appropriate restriction 
endonucleases (see previous sections 2.4.1-2.4.3 for individual digests), and run on 0.8-1.2% agarose 
gels. Bands corresponding to the cDNAs were gel extracted and ligated into vector that had 
previously been digested with restriction enzymes corresponding to the insert (all cDNAs were 
inserted into the pcDNA3.1(+) vector (containing a neomycin resistance gene) except for mEST 
which was inserted into pcDNA3.1(+)Hygro vector) (see Appendix I for vector restriction 
endonucleases digests). 
Following the subcloning of cDNA inserts into pcDNA3.l(+)/pcDNA3.1(+)Hygro, vectors were 
transformed into DH5a. E.coli, spread onto LB-agar plates containing 50J.lglml AMP (both vectors 
contain the AMP resistance gene), and left to grown overnight at 37°C (see Appendix I). Colonies 
were picked, grown overnight and the DNA extracted (as per section 2.2.3). 10J.ll of DNA was 
digested with corresponding restriction enzymes and run on a 0.S-I.2% ethidium bromide agarose gel 
to check the vector contained the correct sized insert. DNA from a colony containing the appropriate 
construct was amplified and extracted as described in section 2.2.3. 
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2.5 Cell culture techniques 
2.5.1 Cell lines 
A variety of cells types were used during the in vitro studies including African green monkey 
transformed kidney fibroblast cells (COS-7), Chinese hamster ovary cells (CHO-K 1), Human 
embryonic kidney 293 cells (HEK293), Human cervical adenocarcinoma cells (HeLa), endometrial 
adenocarcinoma cells (Ishikawa cells), and Human breast carcinoma cells (SKBRJ). 
2.5.2 Cell maintenance 
All cell lines were grown in 10cm diameter culture dishes (Appleton Woods, UK). COS-7, HEK293, 
HeLa, Ishikawa and SKBRJ cells were maintained in high glucose Dulbecco's Modified Eagle's 
Medium (DMEM; Sigma, UK) supplemented with 10% inactivated foetal calf serum (FCS; 
Invitrogen, UK), SOO unitslml Penicillin (Sigma, UK), O.Smg/ml Streptomycin (Sigma, UK) 
(collectively abbreviated to PIS) and 2mM L-glutamate (Q; Sigma, UK), and maintained at 37°C in a 
S% CO2 atmosphere. CHO-Kl cells were cultured in Minimum Essential Medium (MEM), a Medium 
(Ix) (aMEM, Invitrogen, UK), supplemented with 10% FCS and PIS, and kept at 37°C in S% CO2• 
Cells were passaged (see Appendix I for passaging cells) approximately 1:40 once a week (excluding 
COS-7 and SKBRJ cells which were passages 1:20 twice a week), and media was changed every 3-4 
days (see Appendix II for media change). Earlier passages were frozen down in freezing-down media, 
for long-term storage in liquid nitrogen (see Appendix I for freezing down and thawing cells». 
2.5.3 Transiently transfecting cells 
COS-7 and HeLa cells were seeded at 10,000 or IS,OOO cells per well, respectively, in Costar plain 
black-wall 96-well plates (Coming, UK) for 24 hours. Cells were transiently transfected with cDNA 
and Nanofectin (PAA: The Cell Culture Company, UK) as shown: 
1) Media was changed 2 hours prior to transfection with 200p.1 DMEM, 10% FCS, 
PIS and Q. 
2) For each well of a 96-well plate, 0.2Sp.g DNA was made up to a total volume of 
10p.1 with Nanofectin diluent (P AA, UK), and mixed with gentle vortexing. 
3) Nanofectin solution was prepared by diluting 0.8p.1 Nanofectin in 9.2p.1 
Nanofectin diluent (for each well), with gentle vortexing. 
4) Nanofectin solution was combined with the DNA solution, mixed immediately by 
vortexing, and incubated at room temperature for 30 min. 
53 
(,hapt~r ') . General Method" 
5) 20~1 DNA-Nanofectin solution was added dropwise to each well (with gentle 
rocking backwards and forwards of the plate), and plate incubated at 37°C/5% 
CO2 for 3.5 hours. 
6) Cells were washed with \OO~I I x PBS and replaced with 200~1 DMEM with 10% 
FCS, PIS and Q and incubated at 37°C/5% CO2 overnight. 
Alongside each transfection, transfection efficiency was estimated using a 5-bromo-4-chloro-3-
indolyl-p-D-galactopyranoside (X-gal) staining assay. Control cells were transfected with a 
mammalian vector inserted with a LacZ gene (pSV-p-Galacto idase control vector; Promega, UK), 
and subsequent beta-galactosidase (p-gal) activity estimated from the percentage of blue cells (as 
shown in Figure 2. I ; see Appendix I for detailed protocol). 
Figure 2.1. X-gal staining assay. 
COS-7 (A), HeLa (8), and HEK293(C) cells were transiently transfected with pSV-~-Galactosidase control 
vector using Nanofectin transfection reagent. Transfection efficiency was estimated using the Xgal staining 
assay: cells successfully transfected with the LacZ gene developed a blue colour (red arrows highlight a few, out 
of many positive cells in A and 8, but out of few in C). Scale bars, 200~m in (A); I OO~m in (8); 50~m in (C). 
2.5.4 Constructing stable eel/lines 
HEK293 cells were seeded at approximately 5 x 105 cells per well of a 6-well plate (or such that on 
day of transfection cells were no more than 50% confluent), and incubated for 18-24 hours in 2ml 
DMEM supplemented with 10% FCS, PIS and Q and maintained at 37°C/5% CO2. Media was 
changed two hours prior to transfection. Cells were transfected with cDNA using a calcium phosphate 
protocol (Chen et ai., 1988) and a range of DNA concentrations were evaluated to achieve optimal 
transfection efficiency. 
I) I -6~g DNA was made up to 54~1 with sterile H20. 
2) 6~1 O.25M calcium chloride dihydrate (Sigma, UK; Appendix II) was mixed into each 
DNA solution, followed by dropwise addition of 60~1 2x BES (Appendix II), 
accompanied by gentle vortexing. The solution was left for 20 min at room temperature. 
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DNA-calcium phosphate solutions were added dropwise to the wells, and the plate was 
slightly agitated to facilitate mixing. 
3) Plates were incubated overnight at 35°C in a 3% CO2 atmosphere. 
Grains of DNA-calcium phosphate precipitate were observed in each well. These DNA-calcium 
phosphate complexes (grains) form slowly under conditions of low pH, and precipitate gradually onto 
cells when in a low CO2 atmosphere. Grains ranged from course to fine depending on the DNA 
concentration used (see Figure 2.2). Optimal transfection is usually obtained where a transition is 
observed between coarse and fine grains (usually occurred between 2-4Jlg). Wells were washed twice 
with media and left in media for 24 hours at 37°C/5% CO2. Media was removed and replaced with 
media containing antibiotics for selection (DMEM plus 10% FCS, PIS, Q and supplemented with 
800Jlg/ml G418 (Invitrogen, UK) for cells transfected with vectors containing a neomycin resistance 
gene, or 500Jlg/ml Hygro 8 (Invitrogen, UK) for cells transfected with vectors containing a Hygro 8 
resistance gene (cells transfected with both vectors were exposed to both antibiotics for selection». 
Cells were maintained in selection media for 17-18 days before creation of clonal cell lines. 
1If, .. . 
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Figure 2.2. DNA-calcium phosphate precipitate. 
.. -
Example of the transition between coarse and fine grains following the transfection of mEST cDNA 
into HEK293 cells with calcium phosphate. In this instance the transition occurred between 4Jlg 
cDNNwell (A; coarse grains shown with arrow heads) and 5Jlg cDNNwell (8; fine grains shown 
with thin arrows). Pictures appear pink due to phenol red in the DMEM medium. Scale bars, 100Jlm 
in (A) and (8). 
To create clonal lines, cells were plated by limiting dilution to approximately I celliwell into 96-well 
plates and grown to near conf1uency in 200JlI selection media. During thi period (approximately 4-5 
days) plates were not moved to ensure that any dividing cells did not set up separate colonies. Only 
wells with one colony were chosen for subsequent study - any wells with colonies with an ambiguous 
shape, which may have suggested two independent colonies had expanded, were not included in the 
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study. Clones were then trypsinised, and split, with 1:10 cells remaining on the master plate (and 
replenished with new selection media) and 1:4 transferred to a sister 96-well plate and grown in 200",,1 
selection media. The sister plate was grown to 80-90% confluency ready for Northern blotting (see 
section 2.6), whilst the clones on the master plate were maintained in selective media and passaged if 
confluency was reached. 
Clones that expressed high levels of mRNA of interest, as identified by Northern blotting (see section 
2.6), were transferred to a 6-well plate and grown-up in maintenance media (DMEM, 10% FCS, PIS, 
Q and supplemented with 400J.1g/ml G418 and/or 250J.1g/ml Hygro). Once confluent, clones were 
further cultured in 10cm diameter petri dishes containing 10mi maintenance media (early passages 
were frozen down in DMSO as liquid nitrogen stocks (see Appendix I». 
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2.6 Analysis of mRNA expression in cultured cells by Northern 'dot' blot 
hybridisation 
2.6.1 Designing and labelling oligonucleotide probes 
To determine the endogenous transcript expression of some genes of interest or cDNAs introduced 
into cells by transfection we performed northern 'dot' blot hybridisation. Two oligonucleotides 
approximately 48bp in length were designed against individual target genes. As some genes code for 
more than one transcript splice variant (that may be physiologically active) oligonucleotides were 
designed against regions of the gene common to all known variants. This also included homologues 
(and variants) from other species (e.g., human, hamster, and monkey) as expression was investigated 
in a variety of cells lines (human (HEK293IHeLa), hamster (CHO-K 1), or monkey (COS-7) cells». 
To reduce potential hybridisation to other mRNA sequences, attempts were made to direct the 
oligonucleotides to the 5' - or 3' -untranslated regions (as the non translated regions tend to be less well 
conserved than protein-coding regions). As with designing riboprobes the Tm of each oligonucleotide 
was calculated to estimate whether the probe would remain bound during the high temperature/low 
salt washes. Optimum hybridisation temperature for oligonucleotides is between 37-45°C in a 
hybridisation solution containing 50% formamide, while the high stringency wash temperature is 
approximately 5-20°C below Tm (Wilkinson, 1999). Below is the formula used to calculate the Tm of 
oligonucleotides in Chapters 4 and 6: 
To calculate the Tm of DNA: RNA hybrids: 
Tm = 81.5 - 820/oligonucleotide length + 16.6Iog(Na J + 41(% G+C) - 1.2(% mismatched 
pairs) - 0.38(% formamide) 
("/6 G+C), represents the total guanine/cytosine content of the riboprobe; Na +, incorporates the molarity of 
monovalent cations within the hybridisation buffer; % mismatched pairs, talces into consideration any 
unmatched nucleotides within the hybrid duplex (all of the probes in Chapters 4 and 6 were designed to exactly 
match the target mRNA sequence); %formamide, is the percentage offormamide in the hybridisation buffer. 
As highlighted in section 2.2.2 Tm is related to probe (% G+C). At times it was difficult to achieve. an 
optimum G+C content (Within this protocol it was found that a probe G+C content of approximately 
50-70% was optimal) in the 5' and 3' untranslated regions (as often is the case that the 3' untranslated 
region of a gene has a low (% G+C) and the 5' untranslated region has high (% G+C». In instances 
where untranslated regions had inadequate G+C content, or where the transcript splice variants of the 
gene were only homologous in the translated region, the oligonucleotides were directed to the 
translated region of the mRNA, with maximum effort made to aim for non-conserved regio~s of the 
gene. Similarly, in instances where the (% G+C) could not be increased (e.g., when an oligonucleotide 
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had to be directed to an A!f rich region of the gene) the temperatures of the hybridisation and wash 
steps were reduced. To check that the oligonucleotides only potentially recognised the target 
transcript(s), each oligonucleotide was checked for sequence homology against other mRNA 
sequences in the NCBI blast search engine (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Individual 
oligonucleotide sequences used in this thesis are summarised in Chapters 4 and 6. 
Oligonucleotides were purchased from Invitrogen, UK and -3.SJIM was end labelled with a_p32_ATP 
using the Roche Terminal Transferase tailing method (see Appendix I for protocol). Following tailing 
the reaction was made up to 200J.lI with TE with the addition of I J.11 tRNA, and cleaned up by P/CII 
(200J.11 P/CII; see Appendix II) and C/I (200J.lI; see Appendix II) extraction. 10J.l1 4N NaCI and SSOJ.l1 
absolute ethanol were added to the top phase of the CII extraction and the labelled probe was 
precipitated on dry ice for 10-15 min, and centrifuged (l6,OOOxg) at 4°C for 10-15 min. The pellet 
was washed with ice cold absolute ethanol and resuspended in 12.SJ.lI TE. IJ.11 of labelled 
oligonucleotide was placed into Sml scintillation fluid and radioactivity measured in a scintillation 
counter, to give the cpm. Throughout the northern blot procedure, all radioactive waste was disposed 
of as described in section 2.2.4. 
2.6.2 Blotting cells 
Once the sister plate (from section 2.5.4), or a plate containing other cells of interest, had reached 80-
90% confluency, the medium was removed and cells washed with 100J.l1 Ix PBS at room temperature, 
and trypsinised with S0J.11 trypsin (Appendix I) for 10-15 min at 5% C02/37°C. After the addition of 
SOJ.ll media, cells were transferred to a 96-well vacuum manifold lined with a nitrocellulose 
membrane (WHATMAN, Germany) pre-soaked in lOx sse buffer (Invitrogen, UK». Wells were 
washed through with 100J.11 lOx sse and the nitrocellulose membrane removed and exposed to 
ultraviolet light (UV;1200 joules) in a Stratalinker~ 1800 UV crosslinker (Agilent Technologies UK 
Ltd), for I min, to cross-link the RNA to the nitrocellulose membrane. The membrane was air dried 
for IS min, baked for 2 hours at 800 e (to maximise RNA binding to the membrane), and stored at 
room temperature until hybridisation. 
2.6.3 Northern 'dot blot' hybridisation 
Pre-hybridisation: The nitrocellulose membrane was placed into a tub pre-treated with RNase-
AWAyTM and washed with 4x SSPE for 10 min at room temperature. To pre-hybridise, the 
membrane was put into a plastic bag and filled with S-IOml pre-hybridisation buffer (see Appendix 
II). The bag was sealed with a foot operated heat sealer (Hulme Martin, UK) and placed at 37°e for 
approximately 4 hours. 
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Hybridisation: The blot was transferred to a new plastic bag and filled with 3-10ml hybridisation 
buffer containing two a_32P_A TP labelled oligonucleotide probes (1-2 x 10-6 cpmlml per probe), and 
incubated at 37°C overnight. 
Wash: Blot was washed twice (2-3 min wash) in Ix SSPE/O.2% SDS in DEPC-H20 with gentle 
agitation, at room temperature, then 4 times at 54-56°C (temperature was altered for oligonucleotides 
with lower Tm's, see Chapter 4 and 6 for individual temperatures) for 15 min in a shaking water bath 
(45rpm). The blot was then briefly blotted on 3M paper, wrapped in cling-film, exposed to film 
(Amersham Hyper film MP) (in a cassette sandwiched between two enhancing screens), and stored at 
-80°C for 4-10 days. 
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2.7 Visualising HA-tagged receptor protein expression in transfected cell lines 
2.7.1 Immunocytochemistry 
Localisation of HA-tagged rat GPER receptors in stably transfected HEK293 was detected by an 
immunocytochemistry protocol using an anti-HA antibody, and visualised in a semi-automated 
system for image acquisition (IN CELL Analyser 1000, GE Healthcare, UK; Finch et al., 2008). HA-
tagged and untagged GPER HEK293 stables were cultured in poly-I-Iysine-coated Costar plain black-
wall 96-well plates at 10,000-15,000 cells per well (poly-I-Iysine was necessary to maximise cell 
adherence during wash procedures: the coating of plates is described in (Appendix I). Percentage of 
cell surface vs whole cell HA-tagged-GPER expression was determined as follows: 
Cell Surface imaging 
I) Media was removed by pipetting and washed with 100J.1I/well of ice cold 1% BSA 
(Sigma, UK) in Ix PBS. 
2) 1% BSAlI x PBS was replaced with 40J.1l/well I :200 dilution of mouse monoclonal anti-
HA.11 (Cambridge Bioscience, UK) in ice cold 1% BSA in Ix PBS and incubated at 4°C 
for one hour on a plate rocker. 
3) I wash with 100J.1l/well ice cold Ix PBS. 
4) Cells were fixed with ice cold 2% PFA in Ix PBS for 30 min at room temperature. 
5) PFA was removed and cells permeabilised with 100J.1l1well 0.1% TX-lOO in Ix PBS for 
10 min at 4°C (binding of anti-HA.ll in step 2 may have caused receptor intemalisation; 
therefore, the cells were permeabiJised to allow penetration by the secondary antibody). 
6) 3 x washes with 100J.1l1welllx PBS for 1-2 min on a rocker. 
7) Non-specific secondary antibody binding blocked with 100J.1l1well 0.1% TX-l 0011 % BSA 
in I x PBS, and placed on a rocker for I hour at room temperature. 
8) Cells were incubated in 40J.1l1well I :500 dilution of Alexa Fluor 488 goat anti-mouse IgG 
(H+L) secondary antibody (Invitrogen, UK) in 0.1% TX-IOO/O.1% BSAllx PBS, for 1 
hour at room temperature with constant agitation. 
9) 2 x washes with 100J.1l1welllx PBS for 1-2 min on a rocker. 
10) Nuclei were fluorescently labelled with 100J.1l1well 300nM 4',6-diamidino-2-
phenylindole (DAPI; Sigma, UK) in Ix PBS for 15 min at room temperature. 
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II} 1 wash with IOOJ.ll/wellIx PBS. 
I2} Finally 100J.ll Ix PBS was added to each well, and plates were either imaged 
immediately, or were wrapped in tin foil and stored at 4°C until imaging (in the latter case 
the plate was left for at least 20 min at room temperature before acquiring images). 
Whole cell imaging 
I} Media was removed by pipetting and washed with I00J.ll/well of ice cold 1 x PBS. 
2} Cells were fixed with ice cold 2% PF A in 1 x PBS for 30 min at room temperature. 
3} PF A was removed and cells permeabilised with 100J.ll/well 0.1 % TX-IOO in Ix PBS for 
10 min at 4°C. 
4} 3 x washes with 100J.ll/welllx PBS for 1-2 min on a rocker. 
S} Nonspecific primary antibody binding blocked with 100J.ll/well 0.1 % TX-l 0011 % BSA in 
Ix PBS, and placed on a rocker for I hour at room temperature'. 
6} Cells were incubated in 40J.lllwell 1 :200 dilution of mouse monoclonal anti-HA.ll in 
0.1% TX-IOO/I% BSA in Ix PBS and incubated for one hour at 4°C on a plate rocker. 
7} 3 x washes with 100J.ll/welllx PBS for 1-2 min on a rocker. 
8} 40J.l1 of Alexa Fluor 488 goat anti-mouse IgO (H+L) secondary antibody (I :500) in 0.1 % 
TX-I00/0.l% BSAllx PBS was added to each well and rocked for I hour at room 
temperature. 
9} 2 x washes with 100J.ll/well Ix PBS for 1-2 min on a rocker. 
10} Cells were incubated in 100J.lllwell of 300nM DAPI in I x PBS on rocker for 15 mins. 
II) I x wash with 100J.lllwellIx PBS 
12) Finally IOOJ.l1 Ix PBS was added to each well, and plates were either imaged 
immediately, or were wrapped in tin foil and stored at 4°C until imaging. 
, It was possible to reprocess the cell surface plate to achieve whole cell HA staining. In this instance 
the whole cell s.taining began at stage 5 as the cells had already been fIXed and permeabi!ised in the 
previous cell surface protocol. 
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2.7.2 Acquiring images 
Cell surface and whole cell HA-GPER expression were measured by the IN CELL Analyser 1000. In 
brief, each plate was placed into the IN CELL Analyser microscope, and fluorescent images were 
taken using a lOx objective, excitation filters 475-nm (HA) and 360-nm (DAPI), and monitored 
through emission filters 535-nm (detecting Alexa 488, green fluorescence: HA signal) and 460-nm 
(detecting blue fluorescence: DAPI signal), with a 61002 trichroic mirror (GE Healthcare, UK). 2-3 
fields were acquired per well (each field capturing a O.602mm2 area with a lOx objective), obtaining 
digital images of approximately 150-2500 cells per well. 
2. 7.3 Image analysis 
Analysis of HA-GPER localisation was performed using the IN Cell 1000 Analysis Software (GE 
Healthcare, UK). Within each cell the software used green channel images (535-nm emission filter) to 
measure HA fluorescence intensity and defined the cytoplasm; while blue channel images (460-nm 
emission filter) measured DAPI intensity and defined the nucleus. For each field the average total 
amount of HA fluorescence in the cytoplasm was calculated. This value, following the subtraction of 
background florescence (normally measured in regions of the field absent of cells), was expressed as 
arbitrary fluorescence units (AFU). As HEK293 cells grow in epithelioid sheaths, a background 
reading was often difficult to obtain; as such, AFU was calculated from the fluorescence intensity in 
green channel images for each field, minus the average fluorescence intensity in green channel images 
from wells without primary antibody. 
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2.8 In vitro calcium stimulation assay 
2.8.1 Live cell imaging 
Calcium activation was detennined using the green-fluorescent calcium indicator. fluo-4 AM (fluo-4; 
Invitrogen. UK). and measured in the IN CELL Analyser 1000 (Annstrong et al .• 2009). Cells were 
plated out at varying concentrations in Costar plain back-wall 96-well plates: CHO-K 1 cells were 
seeded at 9.000 cells/well; SKBR3 cells 15.000 cells/well; and HEK293 cells 12.500-15.000 
cells/well (into previously poly-I-Iysine-coated plates). The following day. cells that were to be treated 
with steroids in the calcium stimulation assay were serum-starved overnight with phenol-red free 
DMEM with PIS. Q. 0.44mM calcium chloride dihydrate and 100J.lg/,.ti BSA (HEK293 cells). or 
phenol red/serum free Dulbecco's Modified Eagle's Medium: Nutrient Mixture F-12 (DMEMlFI2) 
with PIS (SKBR3 cells). 
Prior to stimulation cells were loaded with 80J.lVwe1l2.5J.LM (HEK293) - 5J.LM (CHO-Kl and SKBR3) 
Fluo-4 and 0.5J.LM Hoechst nuclear stain (GE Healthcare. UK) in the same media used for serum 
starving (as above) or PSS for CHO-KI cells (see Appendix II for PSS recipe) and incubated at 
37°C/5% CO2 for 1 hour (SKBR3) - 1.5 hours (CHO-Kl and HEK293 cells). Cells were stimulated 
and imaged in the IN CELL Analyser 1000 environmental control chamber. at 37°C in a 5% CO2 
humidified atmosphere. Treatment was loaded into an equivalent compound plate and inserted into 
the IN CELL Analyser 1000. The automated sampling system stimulated each well in tum with 20J.lI 
of 5x ligand/treatment at 12000 milliseconds (ms) (final volume in well is 100J.lI. as such 
ligands/treatments underwent a 1:5 dilution). Fluorescence images of one field per well were acquired 
every 12000ms ranging from Oms to 72000ms using a lOx objective. excitation filters 475-nm (fluo-4) 
and 360-nm (Hoechst). and monitored through emission filters 535-nm (detecting green fluorescence; 
fluo-4 signal) and 460-nm (detecting blue fluorescence; Hoechst signal) with a 61002 trichroic mirror. 
Each field captured approximately 50-1500 cells over a 0.602mm2 area. 
2.8.2 Image analysis 
Analysis was perfonned using the IN Cell 1000 Analysis Software. Within each cell the software used 
green channel images (535-nm emission filter) to measure fluo-4 fluorescence intensity to define 
staining in the cytoplasm. while blue channel images (460-nm emission filter) measured Hoechst 
intensity to define the nucleus. For each field the average total amount of flu0-4 in the cytoplasm was 
calculated. This value. following the subtraction of background florescence (measured in regions of 
the field absent of cells). was expressed as AFU. For sheathing HEK293 cells. a background reading 
was difficult to obtain. as such. AFU was calculated from the fluorescence intensity from the green 
channel images for each field, minus the fluorescence intensity from a manually selected background 
reading (free of cells). Data was presented as fold change over time point Oms. 
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2.9 In vitro ERK phosphorylation assay 
2.9.1 Immunocytochemistry 
Cell expression of total (tERK) and phosphorylated ERK (ppERK) was detected by an 
immunocytochemistry protocol using antibodies against tERK and ppERK, and imaged in the IN 
CELL Analyser 1000 (Caunt et al., 2008). Cells were seeded in Costar plain black-wall 96-well plates 
in varying concentrations overnight (which as previously determined reached approximately SO% 
confluency on the day of stimulation): CHO-Kl and Ishikawa cells were seeded at 10,000 cells/well; 
HEK293 cells 1O,000-IS,000 cells/well (HEK293 cells were seeded into poly-I-Iysine-coated wells); 
SKBR3 cells IS,000-20,000 cells/well; and transiently transfected COS-7 and HeLa cells were set up 
as in section 2.S.3. The next day, cells were serum starved in either 90J11 phenol-free DMEM with 
0.1 % charcoal stripped FCS, PIS and Q (HEK292, HeLa, COS-7, Ishikawa cells), 90J1l phenol free 
aMEM with 0.1% FCS and PIS (CHO-Kl cells), or 90J11 phenol- and serum-free DMEMlF12 and PIS 
(SKBR3), and left overnight at 37°C/S% CO2• Cells were stimulated with 10).l1 of lOx desired 
agonist/antagonist concentration (agonist/antagonist undergo a 1: 10 dilution when 10J1l is added to the 
90J11 of media) for the required incubation period. Stimulation was quenched with IS0J1Vwell ice cold 
1 x PBS and incubated on ice for 3-S min. tERK and ppERK expression was visualised using the 
subsequent protocol: 
1) 1 x PBS was removed by pipetting and cells fixed with ice cold 4% PF A in 1 x PBS and 
placed on a rocking platform for 10 min at room temperature. 
2) The fixative was discarded and cells permeabilised by adding SOJ1l/well of absolute 
methanol (pre-cooled to -20°C) and incubated for S min at -20°C. 
3) 1 x wash with IS0J11 Ix PBS 
4) To block for immunostaining 40J11 of S% normal goat serum in Ix PBS was added to each 
well and plates were incubated at room temperature on a rocking platform for 2 h. 
S) 1 x wash with IS0J11 Ix PBS. 
6) 40J11 Primary mouse anti-ppERKl/2 antibody (Sigma, UK) and primary rabbit anti-
ERK1/2 in 1% normal goat serum (Cell Signalling Technology, UK)/lx PBS were added 
to each well (each primary antibody was titrated to give the optimal antibody 
concentration for each cell type: CHO-KI, COS-7 and HeLa cells 1:800 dilution mouse 
anti-ppERK 1/2 antibody, 1 :400 primarY rabbit anti-ERK 112; HEK293 and Ishikawa cells 
1: 1600 dilution mouse anti-ppERK 112 antibody, 1 :800 primary rabbit anti-ERK 1/2; 
SKBRJ cells 1:6400-12000 dilution mouse anti-ppERKlI2 antibody, 1:3200 primary 
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rabbit anti-ERK1I2). 40lll 1% normal goat serum/ice cold Ix PBS was added to the no 
primary antibody control wells. The plate was incubated overnight on a rocking platform 
at 4°C. 
7) 3 x washes with 150111 I x PBS. 
8) 40111 of I :500 dilution of Alexa labelled 488 goat anti-mouse (Invitrogen, UK) and 1:500 
Alexa labelled 546 goat anti-rabbit secondary antibody (Invitrogen, UK) in I % normal 
goat serum/Ix PBS was added to each well, and placed on a rocking platform at room 
temperature for 90 min. 
9) 2 x washes with I 5 o III Ix PBS. 
10) 100111 of300nM OAPI in Ix PBS was added to each well and incubated on rocker for 15 
mins. 
II) 1 x wash with 150111 Ix PBS. 
12) Finally 100111 Ix PBS was added to each well, and plates were either imaged 
immediately, or were wrapped in tin foil and stored at 4°C until imaging (if the latter the 
plate was left for at least 20 min at room temperature before acquiring images). 
13) Images were obtained by the IN CELL Analyser 1000. Immunofluorescence was detected 
using a lOx objective, excitation filters 535-nm (tERK), 475-nm (ppERK) and 360-nm 
(OAPI), and emission filters 620-nm (detecting Alexa 546, red fluorescence: total ERK 
signal), 535-nm (detecting Alexa 488, green fluorescence: ppERK signal) and 460-nm 
(detecting blue fluorescence: OAPI signal) with a 61002 trichroic mirror. 2-4 fields were 
acquired per well (each field capturing a 0.602mm2 area), obtaining digital images of 
approximately 150-3000 cells per well. 
2.9.2 In cell image analysis 
Analysis of total ERK and ppERK activity was performed using the IN Cell 1000 Analysis Software. 
Within each cell the software used red channel images (620-nm emission filter) to measure tERK 
fluorescence intensity and define the cytoplasm perimeter; green channel images (535-nm emission 
filter) to measure ppERK fluorescence intensity and also define the cytoplasm perimeter; while the 
blue channel images (460-nm emission filter) measured OAPI intensity and defined the nucleus. For 
each field the average total amount of tERK and ppERK in the whole cell was calculated. These 
values following the subtraction of background florescence (measured in regions of the field absent of 
cells) were expressed as AFU. In the case of sheathing HEK293 cells and confluent COS-7 and HeLa 
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cells (that had been transiently transfected), the IN Cell 1000 Analysis Software was unable to 
accurately measure background fluorescence (see Figure 2.3) - thus the background reading was 
taken from wells without primary antibody. Data was normalised to vehicle to allow pooling of 
independent experiments (fluorescence intensity can vary between experimental plates/purchased 
antibodyaliquots). 
(B) 
Figure 2.3. Examples of segmentation by the IN Cell 1000 Analysis Software. 
(A) CHO-KI cells stably transfected with V IB receptor cDNA were treated with VP (IOOnM) for 10 
min and processed for the ERK phosphorylation assay. Image of tERK, ppERK and DAPI 
fluorescence were obtained in the IN CELL Analyser 1000. An example image of ppERK 
fluorescence that has been analysed using the IN Cell 1000 Analysi Software is shown. Cytoplasmic 
and nuclear compartments are clearly demarcated. Cells outlined in green are deemed responsive as 
the ppERK fluorescence is above background threshold (background threshold is set for each cell type 
and/or antibody concentration by using a cell/background intensity filter) , and cell outlined in red are 
unresponsive (ppERK is similar to background levels). (8) ppERK fluorescence in HEK293 cells 
treated with 0.0 I % ethanol for 5 min. As HEK293 cells grow in sheaths, the IN Cell 1000 Analysis 
Software is unable to clearly define the cell perimeter - therefore the oftware cannot obtain a 
background reading adjacent to each cell. Instead background is taken as the ppERK fluorescence 
measure in well absent of primary antibody. Scale bar, 100fl.m. 
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Chapter 3: Localisation of GPER, a novel G protein-coupled E2 receptor, suggests 
multiple functions in rodent brain and peripheral tissues 
3.1 Introduction 
3.1.1. E2 
E2 (17~-oestradiol) is the primary female sex honnone in women of a reproductive age and is 
essential for feminisation, menstruation and reproduction. E2 also affects a variety of physiological 
processes in both men and women including fertility, immune function, the cardiovascular system, 
locomotion, neuroprotection, mood and cognition (de Ronde et al., 2003; McEwen, 2002; Watson and 
Gametchu, 2001). The ovary is the main site of E2 production in premenopausal women, and in men 
the majority of E2 (a product of testosterone aromatisation) is excreted from the testis. In both 
genders, the zona reticularis of the adrenal glands is also a source of E2 precursors (e.g., androgens 
and oestrone) which are converted into E2 locally in brain, fat, and skeletal muscle by aromatase or 
17f3-hydroxysteroid dehydrogenase (17~-HSD) enzyme action (de Ronde et al., 2003). It should be 
emphasised that E2s are also fonned by the action of steroid sulphatases acting for example, on 
dehydroepiandrosterone sulphate or oestrone sulphate (Reed et al., 2005), and these processes may 
also contribute to the E2 pool. Furthermore, testosterone and E2 metabolites and other derivatives, 
some of which may be biologically active (e.g., 5a~dihydrotestosterone, 3a-diol or 3~-diol bind E2 
receptors (Pak et al., 2007», may dramatically influence the biology ofE2 at the local tissue level. 
E2s effects are typically mediated by two structurally related receptors, the alpha and beta subtypes 
(ERa and ER~), that belong to the steroid/retinoid receptor gene superfamily (Weihua et 01., 2003). 
Within the cell the inactivated ERs bind to heat shock proteins within the cytoplasm. Upon ligand 
activation, the ERs trans locate to the nucleus and bind to E2 response elements (ERE) present in the 
promoter region of a target gene, where they modulate transcription. The genomic actions of the ERs 
generally occur slowly (hours-days). ERa is found in the brain - predominantly in the bed nucleus of 
the stria terminalis, hypothalamus, and amygdala (Merchenthaler et 01.,2004), and also in bone (Lee 
et al., 2003), uterus and mammary gland (Pelletier and EI-Alfy, 2000). ER~ is most abundant in 
tissues such as the brain - e.g., bed nucleus stria terminalis and hypothalamus (Merchenthaler et al., 
2004), lung (Morani et al., 2006), prostate, testis, mammary gland, and ovary (Pelletier and EI-Alfy, 
2000). Transgenic models clearly illustrate the contrasting roles of the individual ERs. For example, 
the ERa KO mouse is typically infertile, displays disrupted mating behaviour, and stunted bone 
growth. The ER~ KO is fertile although it exhibits reduced litter sizes, and adult females have 
increased bone density, while adult males are prone to prostatic hyperplasia (pettersson and 
Gustafsson, 2001; Walker and Korach, 2004). 
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Besides the 'slow' genomic effect of E2 it is well documented that E2 can also evoke fast non-
genomic effects in variety of tissues e.g., rapid release of intracellular calcium in granulosa cells of 
the ovary, and stimulation of uterine intracellular cyclic AMP (Morley et al., 1992; Szego and Davis, 
1967). These effects may be mediated by the ERs, as a subpopulation of the receptors can be found 
near the cell membrane and on activation stimulate second messenger pathways (Levin, 2005; Zhang 
and Trudeau, 2006). However several lines of evidence indicate the existence of a novel ER - e.g., E2 
rapidly stimulates c-Fos protein accumulation in area 2 of cingulate cortex and the olivary pretectal 
nucleus in brains of ERap KO mice (Dominguez-Salazar et al., 2006), and the ER antagonist leI 
182,780 potentiates, rather than attenuates, the stimulatory effects of E2 on ERK 1 12 signalling in 
human neuroblastoma cells (Watters et ai., 1997) 
3.1.2. Fast E2 receptor and possible presence in the hypothalamo-neuTohypophseal 
system 
GPER a GPCR, specifically binds E2 with high (nanomolar) affinity and evokes rapid effects 
(Revankar et al., 2005; Thomas et al. 2005), including stimulating calcium mobilisation from 
intracellular stores directly or via EGFR transactivation, c-Fos expression, adenylyl cyclase and 
cAMP mediated signalling and ERK-1/2 in a variety of cell types (Prossnitz el ai., 2008). Intriguingly, 
only a small fraction of total cellular GPER appears to be expressed on the cell surface with most of 
the receptor is located intracellularly in the endoplasmic reticulum (Revankar et al., 2007). GPER acts 
as an atypical GPCR, in that it is activated intracellularly by E2 which readily diffuses across cell 
membranes (Revankar el al., 2007). 
Transgenic models have enabled further insight into possible roles for GPER in vivo. Martensson and 
colleagues have shown that the female GPER KO mouse has decreased insulin expression with 
associated hyperglycemia, and impaired glucose tolerance. The females also exhibit reduced skeletal 
development, lower serum insulin-like growth factor-1 levels and elevated blood pressure 
(Martensson el al., 2009). Additional KO models have revealed that both male and female GPER KOs 
have increased body weight and visceral obesity, but remain fertile and reproduce normally (Haas et 
al., 2009; Otto et al., 2009). In fact, the development of the female reproductive organs (mammary 
gland, uterus and ovary) in the GPER KO are unimpaired and remain E2 responsive (Otto el al., 
2009). 
Only a few studies have investigated the distribution of GPER. Northern blot analysis has revealed 
wide GPER transcript distribution in human and rat central and peripheral tissues (Owman el aI., 
1996; Bonini et al., 1997; Carmeci el al., 1997; Fung & Gregor, 1997; Kvingedal & Smeland, 1997). 
An immunohistochemical study of GPER in the rat brain revealed high protein expression in regions 
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such as the Islands of Calleja, striatum, olfactory tubercle, and the hypothalamic PVN and SON 
(Brailoiu et al., 2007). 
Other studies have also detected GPER-ir in the rat PVN/SON, with reports that GPER is expressed in 
OT neurones, implicating a role for GPER in the fast, non-genomic actions of E2 on OT release 
(Wang et al., 1995; Brailoiu et al., 2007). It is interesting to note that stimulation of the ERK1I2 (as is 
associated with GPER activation) pathway has been shown to modulate OT gene transcription (Koohi 
et al., 2005). Whether or not GPER is expressed in vasopressin (VP) neurones remains unclear. One 
recent study found co-expression of GPER with VP (Brailoiu et al., 2007), while another did not 
(Sakamoto et al., 2007), even though both studies used the same GPER primary antibody. A role for 
E2 in regulating OT and/or VP release is supported by studies showing that administration of E2 to 
post menopausal women increases circulating levels of OT and VP (Bossmar et al., 1995), and E2 
rapidly stimulates intrahypothalamic and peripheral OT and possibly VP release (Wang et al., 1995; 
Burbach et al., 2001). 
As GPER provides an alternative model for E2 signalling, and possibly E2-stimulated release of OT 
and VP, the present study was undertaken to clarify the distribution of GPER in the rodent. The aims 
within this chapter were to 1) clarify whether or not GPER is co-expressed in rat and mouse OTNP 
neurones; 2) map the distribution of GPER in the mouse brain to determine whether there are 
differences to that shown in the rat; and 3) identify and highlight regions that express high levels of 
GPER mRNA and protein in the rodent periphery providing additional insights into the role of GPER. 
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3.2 Materials and Methods 
3.2.1 Animals 
Adult male and female Sprague-Dawley rats, weighing 200-250g (Harlan), and adult (10-12 week) 
male and female wildtype mice (25-30g) from our VP VIS receptor KO colony (Wersinger et al., 
2002) were used in this study. For each separate experiment (lHC, double immunofluorescence, or 
ISHH) three mice or rats of each gender were used. Animals were anaesthetised with sodium 
pentobarbital (lOOmg/kg Lp.) and intracardially perfused as outlined in section 2.1.3 for IHC, and 
sacrificed by decapitated for ISSH. 
3.2.2 111<7 
Tissues were post-fixed overnight in 20% sucrose/4% PF A in Ix PBS solution. Following overnight 
fixation the tissues were rapidly frozen over liquid nitrogen and stored at -80°C until processed. In 
single staining, rat and mouse peripheral cryostat sections (12 pm) were cut and thaw-mounted onto 
Superfrost Plus slides, or free-floating (40 pm) mouse brain sections were cut and processed for 
GPER-ir. Tissues were first washed in Ix PBS, endogenous peroxidase activity was quenched with 
3% H20 2 for 10 min, washed (3 x 10 min with Ix PBS), and then blocked with 10% normal goat 
serum (NGS)/O.3% Triton-X 100 (TX-I00) in Ix PBS for 15 min. After washing (3 x 10 min with Ix 
PBS) sections were incubated overnight in an affinity-purified rabbit antiserum against GPER diluted 
(1:1000-1:2000) in 1% NGS/0.3% TX-I00 in O.IM PBS at 4°C. The specificity of GPER antiserum 
has previously been confirmed (Revankar et al., 2005; Brailoiu el al., 2007), and normal rabbit IgG 
serum was used as a control at the same concentration as the antibody. After washing (3 x 10 min 
with Ix PBS), sections were incubated at room temperature in secondary biotinylated affmity purified 
goat anti-rabbit (1:500), in 1% NGS/O.3% TX-I00 in O.1M PBS for I hour, washed (3 x 10 min with 
Ix PBS) and incubated in horseradish peroxidise streptavadin (1:500) in 1% NGS/O.3% TX-IOO in 
0.1 M PBS for a further hour. The GPER signal was visualised with DAB in peroxidase buffer (10 min 
at 1: 10). Mouse brain sections were mounted onto Superfrost Plus slides with 0.5% gelatin solution, 
and along with the pre-mounted peripheral sections were cover-slipped and viewed under a light 
microscope. 
For double immunofluorescence staining, hypothalamic free-floating sections (40J,UD) were rinsed in 
Ix PBS, and then blocked with 10 % NGS/0.3% TX-IOO in Ix PBS for 15 min. After washing (3 x 10 
min in Ix PBS) sections were incubated overnight at 4°C with rabbit antiserum against GPER (diluted 
I: 1000) and guinea pig antiserum against OT or VP (diluted 1:2000 (OT), 1:500 (VP». Sections were 
washed and incubated for an hour at room temperature in biotinylated goat anti-rabbit antibody (as 
above), and Alexa Fluor 488 goat anti-guinea pig antibody (diluted I :500) to detect OT or VP protein. 
Sections were further washed and incubated for an hour in streptavadin-conjugated Alexa Fluro 594 
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(diluted 1:500). Sections were mounted onto Superfrost Plus slides, coverslipped with an antifade 
mounting medium and viewed under a confocal laser-scanning microscope and processed with Adobe 
Photoshop CS3 extended computer software. 
3.2.3 1~~1l 
Coronal cryostat sections (l2JUl1) were cut, thaw-mounted onto polylysine-coated slides and stored at 
-80°C until use. The mouse GPER riboprobe was generated by PCR using approximately 20ng mouse 
GPER cDNA (cloned from a mouse AtT-20 pituitary tumour cDNA library; SJL unpublished data) as 
a template. Primers (upstream: 5'-GAGAGGATCCGGTCAGGGGCGCAGGC-3'; downstream 5'-
AAACAAGCTTTGTGAGAGGAGCA TC-3') corresponding to bp 1739-2344 of a mouse GPER 
mRNA (Genbank Accession number NM_029771) were used to generate a 606bp product. The 
primers contain the recognition sequences for the restriction endonucleases BamHl and HindIII. The 
rat GPER riboprobe was generated using approximately 150ng rat genomic DNA (Promega #G313A, 
UK) as a template. PCR primers (upstream: 5'-GAGAGGATCCTCCTAGAGGAAAACGGA-3'; 
downstream 5'-AAACAAGCTTTGTGAGAGGAGCATC-3') corresponding to bpI5718722-
15718072 of a rat GPER gene (Genbank Accession numbers NM_133573 and NC_005111) were 
used to generate a 651 bp product. The primers contain the recognition sequences for the restriction 
endonucleases BamHl and HindIII. Primer restriction endonuclease sites allowed subcloning into the 
RNA generating vector pGEM4Z (Promega, WI, USA), and sense and antisense probes were 
generated using T7 and SP6 polymerases (mouse and rat antisense: linearised with BamHI and 
generated with T7 polymerase; sense: linearised with HindIII and generated with SP6 polymerase) 
with 3sS_UTP and the MAXIscript in vitro transcription kit. The integrity of each probe was verified 
by DNA sequencing (Geneservice, UK). All ISHH experiments were performed as explained in 
section 2.2. Hybridised sections were exposed to film (Amersham HyperfilmTM MP) for 8 weeks, or 
emulsion dipped (Ilford K5) for 24 weeks and then counterstained with toluidine blue. 
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3.3 Results 
3.3.1 Distribution olGPER-immunoreactivity (ir) in the adult mouse brain 
The data presented here are semi-quantitative assessments based on subjective judgement of three 
independent observers. No apparent gender differences were observed in the distribution of GPER in 
the adult mouse brain. In most brain regions GPER-ir was expressed in cell bodies and fibres; in some 
regions mostly cell bodies (e.g., paraventricular nucleus of the thalamus, hypothalamic ventromedial 
nucleus) or fibres (e.g., lateral mammillary nucleus) expressed GPER-ir (see Table 3.1 and Figures 
3.1-3.3). 
In the forebrain GPER-ir expression was high in the cingulate, motor (Figure 3.1A) and 
somatosensory regions of the isocortex, piriform cortex (Figure 3.1 B), entorhinal cortex, the dentate 
gyrus hilus (Figure 3.2A), and subiculum of the dorsal hippocampus formation, and the zona incerta 
(Figure 3.2B). Moderate to high expression was identified in the mitral layer of the olfactory bulb, 
dorsal endopiriform nucleus, CA 1-3 of the ventral hippocampal formation, the medial habenular 
nucleus of the thalamus, and anteroventral periventricular nucleus, and the medial preoptic nucleus. 
The retrosplenial granular region of the isocortex, the lateral nucleus of the septal complex, the 
nucleus of the horizontal limb of the diagonal band of broca, the olfactory tubercle, the anterior 
amygdaloid area of the amygdala, and the paraventricular nucleus of the thalamus (Figure 3.10), all 
demonstrated moderate expression of GPER. Low to moderate staining was noted in the granular 
insular, perirhinal and retrosplenial agranular regions of the isocortex, medial nucleus of the septal 
complex, and the CA2 of the dorsal hippocampal formation. Expression of GPER was low in many 
areas including the glomerular layer of the olfactory bulb, islands of Calleja, claustrum, caudate 
putamen of the striatum, shell of the accumbens nucleus, subfomical organ, CA 1 and CA3 of the 
dorsal hippocampal formation, bed nucleus of the stria terminalis, and amygdalohippocampal nucleus 
and medial nucleus ofthe amygdala. The data are summarised in Table 3.1. 
In the hypothalamus intense GPER expression was found in the arcuate nucleus, PVN (Figure 3.1 E), 
periventricular hypothalamic nucleus, SON (Figure 3.lC), dorsomedial, central and ventrolateral 
divisions of the ventromedial hypothalamic nucleus with moderate to high expression in the 
suprachiasmatic nucleus (SCN), and lateral mammillary nucleus. GPER-ir was low in the dorsal 
medial nucleus, medial mammillary nucleus and ventral tuberomammillary nucleus and GPER 
expression was sparse in the lateral hypothalamic area, posterior hypothalamic nucleus, subthalamic 
nucleus, and supramammillary nucleus. 
In the midbrain and pons distinct GPER-ir could be seen in the pontine nuclei, anterior tegmental 
nucleus, medioventral periolivary nucleus and superior paraolivary nucleus of the superior olive, and 
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the locus coeruleus (Figure 3.3B). A moderate to high expression was noted in the interpeduncular 
nucleus, compact region of the substantia nigra (Figure 3.2E) and the reticulotegmental nucleus of 
pons. The dorsal medial periaqueductal gray, inferior colliculus, caudal linear raphe nuclei, oral 
pontine reticular nucleus, the rostal, dorsal, caudal periolivary regions and the lateral superior olivary 
nucleus of the superior olive, nucleus of trapezoid body, lateral nucleus of the parabrachial region and 
the medial vestibular nucleus all expressed moderate levels of GPER. On the other hand, low levels 
were found in areas such as the lateral and reticular regions of the substantia nigra, superior colliculus, 
dorsal raphe, and the lateral vestibular nucleus. 
In the hindbrain high expression of GPER was found in the oral and dorsomedial region of the spinal 
trigeminal nucleus (Figure 3.3C-D). GPER-ir was also high in the Purkinje cells of the cerebellum. 
Moderate .expression was seen in the facial motor nucleus, principal nucleus of the inferior olive and 
the dorsal motor nucleus of vagus with low to moderate expression in the middle cerebellar peduncle, 
nucleus ambiguous and nucleus of the solitary tract. Low to moderate to staining was also found in 
the internal granule layer and molecular layers of the cerebellum. Low expression was detected in 
other regions including the posterodorsal tegmental nucleus, supratrigeminal, parapyramidal, 
intermediate reticular, gigantocellular, lateral reticular and the rosteroventrolateral reticular nuclei and 
the area postrema. 
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Brain Reg/on GPER Brain region GPER 
Forebrain Rhomboid nucleus 
Olfactory bulb Medial habenular nucleus ++/+++/c 
Glomerular layer +/c Precommisural nucleus 
Mitral layer ++/+++/c Pretectal nucleus 
External plexiform layer Lateral posterior thalamic nucleus 
Granule layer Ventral medial thalamic nucleus 
Islands of Calleja +/c Zona incerta +++ 
Cortex Subincertal nucleus +/c 
Allocortex Preoptic area 
Piriform +++/c Anteroventral periventricular nucleus ++/+++/c 
Dorsal endopiriform nucleus ++/+++/f Lateral preoptic nucleus +/c 
Isocortex Medial preoptic nucleus ++/+++/c 
Agranular insular Magnocellular preoptic area 
Cingulate +++/c Hypothalamus 
Dorsal peduncular -I+/c Anterior commissural nucleus 
Granular insular +/++/c Anterior hypothalamic nucleus 
Infra-limbic -/+/c Arcuate nucleus +++ 
Prelimbic -/+/c Dorsomedial nucleus 
Motor +++/c Lateral hypothalamic area -/+/c 
Somatosensory +++/c Paraventricular hypothalamic nucleus +++ 
Perirhinal +/++/c Periventricular hypothalamic nucleus +++/c 
Retrosplenial agranular +/++/c Posterior hypothalamic nucleus -/+ 
Retrosplenial granular ++/c Subthalamic nucleus -/+ 
Visual -/+/c Suprachiasmatic nucleus ++/+++ 
Dorsal tenia tecta Supraoptic nucleus +++ 
Claustrum +/f Ventromedial hypothalamic nucleus 
Striatum Dorsomedial +++/c 
Caudate putamen +/f Cental +++/c 
Globus Pallidus Ventrolateral +++/c 
Septal complex Lateral mammillary nucleus ++/+++ 
Lateral nucleus ++/c Medial mammillary nucleus + 
Medial nucleus +/++ Supramammillary nucleus -/+ 
Septohippocampal nucleus Ventral tuberomammillary nucleus + 
Diagonal band of broca 
Horizontal limb diagonal band ++ Midbrallll poDI 
Vertical limb diagonal band +/c Deep mesencephalic nucleus 
Accumbens nucleus Edinger-Westphal nucleus -/+ 
Shell +/c Interfascicular nucleus -/+ 
Core -/+/c Interpeduncular nucleus ++/+++ 
Ventral Pallidum -/+/c Suprageniculate thalamic nucleus -/+ 
Subfomical organ +/c Substantia nigra (caudal) 
Hippocampal formation- dorsal Compact ++/+++ 
CAl + Lateral +/c 
CA2 +/++ Reticular +/c 
CAJ + Ventral tegmental area 
Dentate gyrus hilus +++ Nucleus brachium inferior colliculus -/+ 
Subiculum +++/c Parabrachial pigmented nucleus -/+/c 
Hippocampal formation-ventral Periaqueductal gray 
CAI-CA3 ++/+++ Dorsal medial ++/c 
Entorhinal cortex +++/c Superior colliculus + 
Intemal capsule Inferior colliculus ++ 
Bed nucleus of the stria terminalis + Raphe nuclei 
Interstitial nucleus post limb anterior commisure + Rostallinear -1+ 
Olfactory tubercle ++/c Caudal Linear ++ 
Substantia innominata + Mediallparamedian -1+ 
Amygdala Dorsal raphe + 
Anterior amygdaloid area ++ Pontine nuclei +++/c 
Amygdalohippocampal nucleus +/c Pontine reticular nucleus 
Basolateral nucleus Oral ++/c 
Basomedial nucleus Caudal 
Cortical amygdaloid nucleus Intercollicular nucleus 
Central nucleus Lateral lemniscus -/+ 
Medial nucleus + Parabigeminal nucleus 
Thalamus Dorsal tegmental nucleus +1++ 
Anterodorsal nucleus Pedunculopontine tegemental nucleus 
Mediodorsal nucleus Reticulotegmental nucleus pons ++/+++ 
Central medial nucleus -I+/c Anterior tegmental nucleus +++ 
Paraventricular nucleus ++/c Superior Olive 
Table 3.1. GPER distribution in the adult mouse brain. 
Summary of GPER-ir distribution in the adult mouse brain, determined using three males and three females. Data presented 
here are of semi-quantitative assessments and the intensity of staining is based on the subjective judgement of three 
observers. No apparent gender differences were detected. Intensity of label: +++ intense; ++ moderate; + low; - absent; cells 
(c); fibres (t)- al1 other regions contain both immunoreactive cells and fibres. 
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Medioventral periolivary nucleus 
Rostral peri olivary region 
Dorsal periolivary region 
Superior paraolivary nucleus 
Caudal periolivary nucleus 
Lateral superior olivary nucleus 






Medial Vestibular nucleus 






Middle cerebellar peduncle 
Posterodorsal tegmental nucleus 
Supratrigeminal nucleus 
Facial motor nucleus 
Parapyrarn idal nucleus 
Intermediate reticular nucleus 
Gigantocellular reticular nucleus 
Lateral reticular nucleus 
Paragigantocelluar reticular nucleus 
Rostoventrolateral reticular nucleus 
Nucleus ambiguus 
Prepositus nucleus 
Nucleus solitary tract 
Area postrema 
Inferior olive, principal nucleus 
Dorsal motor nucleus of vagus 
Trigeminal nucleus, sensory 
Spinal trigeminal nucleus 
Spinal trigeminal nucleus, oral 
Cerebellum 
Molecular layer 
Purkinje cell layer 
Internal granule layer 








































I~ 0 c a lis a t ion 0 f C; PER 
Summary of GPER-ir distribution in the adult mouse brain. Intensity of label: +++ intense; ++ moderate; + low; 
- absent; cells (c); fibres (f)- all other regions contain both immunoreactive cells and fibres. 
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Figure 3.1. Immunoreactivity for GPER in the adult male or female mouse brain. 
Labelled cells in the supplementary motor cortex (A), piriform cortex (B), labelled cells and fibres in the SON 
(C), with moderate labelling of cells in the paraventricular nucleus of the thalamus (D), labelled cells and fibres 
in the PVN (E) with an absence of labelling in the PVN with a section incubated with IgG in place of GPER 
antiserum (F). M2, supplementary motor cortex; PIR, piriform cortex; PVT, paraventricular nucleus of the 
thalamus; OC, optic chiasm; 3V, third ventricle. Scale bars, 100 11m in (A-B,E-F); 50 11m in (C-D). A lower 
magnification of the PVT is inserted in (D) (Scale bar = 100Ilm). 03V, dorsal third ventricle. 
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Figure 3.2. Immunoreactivity for GPER in the adult male or female mou e brain. 
Labelled cells and fibres in the dentate gyrus of the hippocampus (A), zona incerta (8), arcuate nucleus and cell 
bodies of the ventromedial hypothalamic nucleus (C), GPER-ir in cells and fibre of the lateral mamillary 
nucleus of the hypothalamus (D), labelled cells and fibres of the pars compacta of the substantia nigra (E) and 
labelled cel ls of the pontine nuclei (F). DG, dentate gyrus of the hippocampus; ZI, zona incerta; Are, arcuate 
nucleus of the hypothalamus; VMH, ventromedial hypothalamic nucleu ; LM, lateral mamillary nucleus of the 
hypothalamus; SNC, pars compacta of the substantia nigra; Pn, pontine nuclei; 3V, third ventricle. cale bars, 
100 11m in (A-D); 50 11m in (E-F). In E and F, lower magnifications of the NC and Pn, repectively, are shown 
(scale bars = 200l1m). 
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Figure 3.3. Immunoreactivity for GPER in the adult male or female mou e brain. 
Labelled cells of the Purkinje cell layer of the cerbellum (A), locus coeruleus (8), and sensory trigeminal 
nucleus (C) enlarged in (D). pcL, Purkinje cell layer of the cerbellum; Ie, locus coeru leus; Pr5. sensory 
trigeminal nucleus; 4V, fourth ventrcle. Scale bars, 100 f.lm in (A-C); 50 ~lm in (D). In (C). a lower 
magnification of Pr5 is shown (scale bar = 200f.ltn). 
78 
ilaptcr 3: Locali"ation or JP[R 
3.3.2 GPER co-localises witll oxytocin (01) and vasopressin (VP) neurones 
The results for this part of the study were obtained from three male and three female rat and mouse 
brains, double labelled with antibodies to GPER and either OT or YP. Pictures of GPER 
immunofluorescence were acquired and merged with the corresponding immunofluorescence pictures 
of OT or YP. Neurones containing both GPER-ir (red) and OT-ir or YP-ir (green) appeared yellow 
(merged) and were counted, and a co-expression percentage was calcu lated against the total number 
ofOT-ir or YP-ir neurones. 
In the rat PYN, GPER-ir is prominent in the magnocellular PYN with low level labelling in the 
parvocellular PYN (Figure 3.4). Dual labelling of hypothalamic ections revealed that GPER-ir was 
present in both OT and YP magnocellular neurones and 40-60% of OT neurones and 50-70% of YP 
neurones co-expressed GPER-ir in the PYN and SON (see Table 3.2 and Figures 3.4 and 3.5). In the 
PYN and SON of the mouse both OT and YP neurones were positive for GP R-ir, with 60-80% of 
OT and YP neurones expressing the receptor (Figures 3.4 and 3.5). Co-localisation of GPER-ir with 





OT I 'Y.. co-Iocalisl'd i VI' % l'o-Iocalisl'd 





50.6 ± lOA 
54.6 ± 8.3 
70 ± 6.5 





59.1 ± 6.3 
62.1±7,4 
70.6 ± 8.2 
64.2 ± 7.8 
Table 3.2. Summary ofGPER co-localisation with OT and VP neurones in the rodent PVN and ON. 
Values represent the total number of OT and VP neurones counted in sections of PVN and ON obtained from 
three male and three female animals, and the average percentage (± D) that also e press GPER-ir. There was 
no apparent difference in the number of co-expressing neurones between the anterior, middle and posterior PVN 
in either rat or mouse. 
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Figure 3.4. GPER is present in rodent OT and VP neurones. 
Double label immunofluorescence for GPER and YP in the adult rat PYN (A-C), SON (D-F) and median 
eminence (G-I), and GPER and OT in the adult mouse PYN (J ,K and L). Immunoreactivities against GPER (A, 
D, G and J; red) and YP (B, E and H; green) or OT (K; green) were merged in each right panel (C, F, I and L; 
overlap yellow), respectively. G-L were captured using a laser confocal microscope. 3Y, third ventricle; OC, 
optic chiasm. Scale bars, ) 00 11m in (A-F); 80 11m in (G-L). 
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Figure 3.5. Double label irnrn unonuore cence for GPER, OT and VP in the ad ult rat 0 and rnou e 
PVN. 
Immunoreactivities against GP R (A, 0 and G; red) and OT (8; green) or VP ( , H; green) were merged in 
each right panel (C, F and I; overlap yellow), re pectively. Arrow indicate OT or VP immunoreactive cell 
bodies that al 0 contain GPER-ir. Note that some GPER-ir cells (arrowhead) do not e pre OT-ir or VP-ir. In 
addition to staining of cell bodie, there al 0 appear to be co-expre ion of GP R-ir and OT-ir in proce es 
(that may be axons or dendrites), suggesting that the receptor may be a o-dendriti ally tran ported, a ha been 
well-established for the neuropeptide (see open arrow). The presence of possible intracellular taining of GPER 
within OT and VP neurones which is consistent with the predominantly cytopla mic di tribution of GPER that 
ha been observed in various cell types in vitro (see di cu ion for detail ). Picture captured at the ame low 
magnification using ala er confocal microscope. cale bar, IOllm in (A-I). 
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3.3.3 Peripheral distribution of GPER 
[n the anterior lobe of the pituitary gland approximately 50% of cells were intensely tained for 
GPER-ir. The majority of cells in the pituitary intermediate lobe stained positively and there was 
prominent staining of fibres in the neural lobe (Figure 3.6A). The adrenal medulla displayed strong 
GPER-ir; occasional GPER-ir cells were also observed in the zona glomerulosa of the cortex. In the 
kidney, G PER-ir was present in the smooth muscle cells of the pelvic region and to a lesser extent the 
medulla, with only a few positive cells in the cortex (Figure 3.68). In the ovary, dense staining was 
found within the granulosa cells with moderate to low staining in the theca cells (Figure 3.6C). 
taining was absent in corpora lutea. There were no species or gender difference ob erved in the 
peripheral distribution of GPER protein expression in the three male and three female rats and mice 
analysed. 
Figure 3.6. Immunohistochemical analysi ofGPER in rodent peripheral ti ue. 
(A) GPER-ir in rat pituitary is prominent in the nerve terminals of the neural (po terior) lobe (NL) and is present 
in most melanotrophs of the intermediate lobe (IL) (e.g. indicated by arrows). GPER-ir i also found in scattered 
(approximately 50%) cells in the anterior pituitary (AP) lobe. Whether these represent endocrine cells (e.g., 
prolactotrophs, corticotrophs) was not determined. (8) High levels of GP R-ir are pre ent in the rat renal pelvis 
(RP), an extension of the ureter, with projections into the renal inner medulla (1M). ( ) In the rat ovary, GPER-
ir is found mainly in the granulosa cells (G), with some staining of theca cells (T) of the developing follicle . 
cale bars, 400llm in (8); 50llm in (A,C). 
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3.3.4 Distribution of GPER mRNA 
We determined the expression of GPER mRNA in tissues that displayed abundant GPER-ir in tissues 
from three male and three female rats and mice. In the rat CNS a hybridisation signal for GPER was 
detected in the PVN and SON particularly in the magnocellular region of the PVN (Figure 3.7A, 
3.7C). In the pituitary gland, the intermediate lobe was intensely labelled (Figure 3.7D-F) and 
scattered cells exhibited a moderate signal in the anterior lobe. The neural lobe was unlabelled. In the 
adrenal glands, high levels of GPER mRNA were present in the adrenal medulla and cells within the 
zona glomerulosa of the adrenal cortex (3.8A,B). In the kidney, intense labelling was present in the 
smooth muscle of the renal pelvis, and to a lesser extent in the medulla, with some sparse labelling in 
the cortex (Figure 3.8C). A few developing follicles of the rat ovary exhibited a hybridisation signal 
(data not shown). A similar distribution of GPER transcripts were observed in mouse tissues - the 
SON, the adrenal medulla and pituitary intermediate lobe expressed the highest amount of GPER 
mRNA compared with kidney, ovary and PVN based on signal intensities observed for the same film 
exposures. Figure 3.8E shows GPER mRNA expression in developing follicles of the mouse ovary, 
with silver grains accumulated mainly in the granulosa and theca cells. No signal was detected in the 
corpora lutea. Rat and mouse sections hybridised with sense GPER riboprobes as controls showed 
only background level oflabelling (Figures 3.7B, 3.8D, 3.SE). 
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Figure 3.7. In situ hybridisation of GPER mRNA in the rodent PVN, ON and pituitary gland: 
Reversed image of emulsion dipped section of the rat PVN the GPER hybridi ation grain appear white in the 
picture (A) (but black on the actual slide); the corresponding sense slide is absent of black GPER hybridisation 
grains (B); low magnification photographs of film autoradiographic images of a lide mounted hypothalamic 
section hybridised with a GPER probe, with signal in the PVN and ON of the rat brain (C), and pituitary 
sections hybridised with a GPER probe in rat (D) and mouse (E) with intense signal in both intermediate lobes; 
emulsion dipped section of the mouse pituitary, hybridisation signal for GPER mRNA appears a black grains 
(F). 3V, Third ventricle; AP, anterior pituitary; IL, intermediate lobe of the pituitary; NL, neural lobe of the 
pituitary. Scale bars, I mm in (C-E); IOOllm in (A, F); 50 Jlm in (B). 
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Figure 3.8. In situ hybridisation of GPER mRNA in the rodent peripheral ti ue: 
Low magnification photograph of a film autoradiographic image of a lide mounted, rat adrenal section 
hybridised with a GPER probe (A); emulsion dipped section of the mouse adrenal medulla - hybridisation signal 
for GPER mRNA appears as black grains on toluidine blue counterstained cells (8); low magnification 
photograph of a film autoradiographic image of a slide mounted, rat kidney section hybridised with a GPER 
probe (C), with an absence of signal in the sense control (D); low magnification photograph of a film 
autoradiographic image of a slide mounted, mouse ovary section hybridised with a GP R probe, with signal 
localised predominantly in the developing follicles (F), with an absence of ignal in the en e control ( ). AM, 
Adrenal Medulla; ZG, Zona glomerulosa; RP, Renal pelvis; 1M, Renal medulla; OF, developing follicle. cale 
bars, I mm in (A, C-F); 251lm in (8). 
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3.4 Discussion 
The GPER gene is widely distributed in human and rat central and peripheral tissues as shown by 
northern blot, and in rat brain by immunohistochemical analyses (Owman et al., 1996; Bonini et al., 
1997; Carmeci et al., 1997; Fung & Gregor, 1997; Kvingedal & Smeland, 1997; Brailoiu et al., 2007). 
These observations have been extended in the present study using IHC and ISHH to obtain the 
cellular context of GPER expression in mouse brain and peripheral tissues. 
3.4.1 Distribution of GPER-ir in the adult mouse brain 
The present study provides the first full comprehensive characterisation of GPER distribution in the 
mouse CNS. Previously the distribution of GPER has been illustrated in the rat brain using the same 
GPER antiserum as described here (Brailoiu et al., 2007). In agreement with our findings in mice 
there are no apparent gender differences in GPER expression in the rat and this appears common to all 
E2 receptors (Laflamme et al., 1998). Brailoiu and coworkers found predominant GPER expression in 
the hypothalamic PVN and SON, hippocampal formation, substantia nigra in the rat brain, and this 
correlates well with our observations in the mouse brain (Brailoiu et al., 2007). However, GPER is 
also highly expressed in the nucleus ambiguus where only low to moderate expression is found in the 
equivalent area in the mouse brain, suggesting some species differences. A comparison of GPER 
mRNA versus protein localisation in both rat and mouse brains may reveal whether receptor 
transcription and translation coincide or whether there are mismatches. 
3.4.2 Comparison of E2 receptor distribution in the adult mouse brain 
There appears to be only a few brain regions that express high levels of GPER and high amounts of 
either ERa or ERP, and even fewer regions that express all three receptors (see Table 3.3) to a high 
degree. For example, GPER is most abundant in the hypothalamus of the mouse, particularly the 
arcuate nucleus, PVN, periventricular nucleus, SON and the dorsomedial, central and ventrolateral 
regions of the ventromedial hypothalamic nucleus. Of these nuclei ERa is highly expressed in the 
arcuate nucleus and in the ventrolateral portion of the ventromedial hypothalamic nucleus (VMH), 
and in rats priming the VMH with E2 over days promotes lordosis, seemingly through ERa (Pfaff & 
Sakuma, 1978). In the rat and mouse hypothalamus ERP is the predominant ER isoform found in the 
PVN (Mitra et al., 2003; Merchenthaler et al., 2004). Interestingly E2 has been shown to activate the 
ERKl/2 pathway in the PVN and SON of the mouse (Abraham et al., 2004). In the PVN this is 
potentially mediated via either ERP and/or GPER (as both are highly expressed in the PVN), and 
presumably GPER in the SON (as GPER appears to be the predominantly expressed receptor in the 
SON). 
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In the forebrain GPER is also highly expressed in the cingulate, motor and somatosensory regions of 
the isocortex, piriform cortex, the hippocampal dentate gyrus hilus, subiculum and entorhinal cortex, 
and the zona incerta where ERa and ER~ expression is either low or absent. Interestingly E2 has been 
shown to induce c-Fos protein expression in some brain regions (e.g., cingulate cortex) of double 
ERaJ~ KO mice. As GPER is abundant in this region it or another E2-binding protein may mediate 
the effects of E2 (Dominguez-Salazar et al., 2006). On the other hand, ERa and ~ are both highly 
expressed in the bed nucleus of the stria terminalis and the medial nucleus of the amygdala, where 
only minimal amounts of GPER can be detected. 
In the midbrain/pons high expression of GPER is found in the pontine nuclei, anterior tegmental 
nucleus, the medioventral periolivary nucleus and superior paraolivary nucleus of the superior olive, 
and the locus coeruleus. Of these only the locus coeruleus contains high levels of the ERs. 
Interestingly in the mouse, noradrenaline neurones of the locus coeruleus have been shown to be 
responsive to E2 stimulation with an upregulation in tyrosine hydroxylase transcription in females, 
and attenuation of transcription in males (Thanky et al., 2002). This gender difference could be 
indicative of the varying roles of all three E2 receptors which are highly expressed in this brain 
region. 
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Dentate gyrus hilus +++ 
Subiculum +++ 
Entorhinal cortex +++ 
Bed nucleus of the stria tenninalis + 
Preoptic area 
Medial Preoptic nucleus ++/+++ 
Amygdala 
Medial nucleus + 
Hypothamalmus 
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Paraventricular nucleus +++ 
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Anterior tegmental nucleus +++ 
Superior Olive 
MedioventraJ periolivary nucleus +++ 
Superior paraolivary nucleus +++ 
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Table 3.3. An overall comparison of tbe distribution of GPER, ERa and ERP, in the mouse brain. 
Results for ERa and ER~ are a summary of the mouse brain atlases from Mitra et al., 2003 and Merchenthaler et 
al., 2004. 
3.4.3 GPER co-localises with OT and VP neurones 
The present study also aimed to clarify the inconsistencies in the literature regarding the distribution 
of GPER in hypothalamic magnocellular neurones. Our findings confirm that in the rat and mouse 
hypothalamus both OT and VP neurones express GPER. This is in agreement with observations of 
Brailoiu and co-workers who found co-localisation of GPER with OT and VP in magnocellular 
neurones of the rat PVN and SON, but contrasts with those of another study that detected GPER only 
in OT neurones of the PVN and SON of the same species (Brailoiu et al., 2007; Sakamoto et al., 
2007). The reasons for these discrepancies are not readily apparent, especially since all three studies 
used the same antiserum directed against the GPER protein (Revankar et al., 2005). To confirm the 
specificity of GPER-ir in the current study we substituted normal rabbit IgG serum for primary 
antibody at the same concentration, and did not observe any staining (Figure 3.1 F). 
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E2 mediates the release of OT and VP in vivo and in vitro. It rapidly stimulates intrahypothalamic OT 
and VP release and rapid peripheral OT and possibly VP release (Wang et al., 1995; Burbach et al., 
2001). In addition, E2 inhibits the release of both peptides from hypothalamo-neurohypophysial 
explants stimulated hyperosmotically via a non-genomic action (Swenson and Sladek, 1997), and 
rapidly alters the electrophysiological properties of OT cells in the SON of lactating, or morphine-
dependent rats (Israel & Poulain, 2000; Brown et al., 2008). There is very little or no ERa in the rat 
and mouse PVN/SON (Merchenthaler et al., 2004; Shughrue et al., 1998b) suggesting that E2 may 
not directly influence OTNP release via this receptor. On the other hand the presence of ERa in many 
central regions that project to the PVN/SON, including the organum vasculosum of the lamina 
terminalis and subfornical organ (regions implicated in blood volume and plasma osmolality 
regulation), and the medial preoptic nuclei and ventromedial hypothalamus (essential areas in 
reproductive behaviour) suggests that E2 may modulate VP/OT secretion indirectly via ERa 
(Merchenthaler et al., 2004; Voisin et al., 1997). ERP is expressed in the magnocellular OT neurones 
of both the rat PVN and SON (Alves et al., 1998; Hrabovszky et al., 2004) and provides a direct route 
for possible E2 manipulation ofVP/OT-expressing neurones. 
The relative contribution of GPER in E2 effects on hypothalamo-neurohypophysial activity is not 
known. However, ERp-ir is absent from the neural lobe suggesting that E2 does not directly mediate 
peripheral release of OT and VP at the level of the pituitary via this receptor (Pelletier et al .. 2000). 
Interestingly in the current study we found high levels of GPER-ir in the neural lobe, indicating that 
E2 could modulate the peripheral release of OT and VP through GPER signalling. As we were unable 
to detect GPER mRNA in the neural lobe, it can be assumed that the receptor had been transported, 
presumably from the magnocellular neurones in the PVN and SON, as we also observed co-
localisation of GPER with OT and VP fibres in the internal zone of the median eminence. It is 
possible that GPER regulates OTNP synthesis in PVN/SON magnocellular cell bodies, and/or 
modulates OTNP release from PVN/SON magnocellular neurone dendrites, or from fibres that 
terminate in the posterior pituitary. Our studies also suggest that GPER could mediate E2 effects on 
the hypothalamic-pituitary-adrenal axis by modulating the release of OT, VP or perhaps CRF into 
portal blood from neurones originating from the parvocellular region of the PVN. 
3.4.4 Peripheral distribution 0/ GPER 
The current study demonstrates high expression of GPER mRNA and protein in the pituitary gland, 
adrenal medulla, renal pelvis, and ovary of the rat and mouse. There is a strong correlation between 
the tissue distribution of both GPER mRNA and protein, apart from in the neural lobe of the pituitary. 
While GPER protein is expressed in all three lobes of the pituitary, the highest mRNA expression was 
observed in the intermediate lobe. ERa and ERP are also expressed in the anterior and intermediate 
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lobes but are absent from the posterior lobe of the pituitary (Mitchner et al., 1998; Pelletier et al., 
2000; Gonzalez et al .. 2008). It is well established that the anterior pituitary is a target tissue for E2, 
regulating gonadotrophin and prolactin secretion from gonadotrophs and lactrotrophs, and this 
response can be rapid, with E2 increasing excitability in prolactin-secreting pituitary cells lines within 
minutes (Dufy et al.. 1979). High expression of GPER mRNA and protein in the intermediate lobe 
and the presence of the traditional E2 receptors, suggests a possible role for E2 in POMC synthesis 
and a-melanocyte stimulating hormone (aMSH) and ACTH-like peptide release. A previous study has 
shown that E2 stimulates the release of aMSH from the intermediate lobe which in tum appears to 
exert a rapid stimulatory effect on prolactin secretion (Ellerkmann et al., 1992). 
In agreement with the current study GPER has been reported to be strongly expressed in the zona 
glomerulosa and the medulla ofthe human adrenal glands (Baquedano et al .. 2007). Fast effects of E2 
have previously been described in primary cultures of bovine adrenal medullary cells with an up-
regulation in catecholamine synthesis within 20 min of E2 stimulation (Yanagihara et al., 2006). This 
suggests a role for GPER in E2 signalling either independently or synergisitically with extranuclear 
ERP which is also expressed in cells of the rat adrenal cortex and medulla (Saunders et al., 1997). 
In the kidney ERaJP are found mainly in the glomeruli and arterioles of the renal cortex where E2 
treatment has been shown to upregulate angiotensin type II receptors that regulate sodium and water 
reabsorption, renal blood flow and glomerular filtration rate (Baiardi et al., 2005; Oestreicher et al., 
2006). We found high expression of GPER mRNA and protein in the contracting muscle of the pelvis 
and to a moderate extent in the medulla. In the renal pelvis the role of E2 is presently unclear but there 
are suggestions that prolonged E2 administration can encourage renal pelvic tumour growth (Oberley 
et al., 1991; Adsay et al., 2000). In other carcinomas (e.g., breast, endometrial) GPER expression has 
been demonstrated (Filardo et al., 2006; Smith et al., 2007). Taken together it is tempting to speculate 
that GPER is an alternative E2 responsive receptor in the production and maintenance of renal pelvic 
tumours. 
E2 has been shown to promote cell division and survival of granulosa cells in developing follicles of 
the ovary (Adashi, 1994). E2 also induces rapid (seconds) increases in cytosolic calcium 
concentration of human granulosa cells in vitro (Younglai et al., 2005). While this could be mediated 
through the ERP which has been shown to be highly expressed within the granulosa cells of 
developing follicles and corpora lutea of the rat (Saunders et al., 1997), our results also indicate a role 
for GPER. GPER mRNA and protein have been found in both granulosa and theca cells of the 
hamster and expression is sensitive to cyclic changes in FSH and LH (Wang et al., 2007). It has also 
been suggested that GPER is required for primordial follicle formation (Wang et al., 200Sc). These 
observations appear to contradict a recent report which concluded that GPER did not mediate E2 
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responses in reproductive organs due to the fertile phenotype of the GPER KO mice (Otto et al., 
2008). In GPER KO animals the normal phenotypes in E2 responsive tissues such as the ovary, uterus 
and mammary gland does not necessarily preclude the possibility that GPER binds E2 in vivo. For 
example, in the KO model ERa and/or ERP may compensate for the loss of GPER especially in 
tissues of co-expression where there is potential for receptor cross-talk (Sirianni et al., 2008). In 
addition it is well known that ERP KOs remain fertile; it is only the deletion of ERa that appears to 
create the infertile phenotype (Walker & Korach, 2004). 
Whilst this manuscript was in preparation, a few papers relevant to the possible function of GPER in 
the brain and adrenal have been published. Isensee and co workers analysed the distribution of GPER 
using GPER-LacZ reporter mice and found predominant expression in subpopulations of cells in the 
cortex and the dentate gyrus of the brain, in the intermediate and anterior lobe of the pituitary gland, 
and in the adrenal medulla (Isensee et al., 2008). As shown in Table 3.1 GPER-ir is also highly 
expressed in regions of the cortex, and in the dentate gyrus of the adult mouse brain. Our results also 
confirm the presence of GPER mRNA in the anterior and intermediate lobes of the pituitary and the 
adrenal medulla. However. in contrast to our data that clearly demonstrate both GPER mRNA and 
protein in the PVN and SON, GPER was only identified in the hypothalamic vasculature and not 
neurones in the GPER-LacZ reporter mice (Isensee et al., 2008). Recently Xu and co-workers 
demonstrated an interaction between GPER and the OT system. Ovariectomised female rats were 
administered a subcutaneous injection of E2, or an icv injection of G-I, a selective GPER agonist (to a 
region directly above the PVN) for 2 consecutive days, and it was found that E2 and G-I were unable 
to alter basal plasma OT levels (Xu et al., 2008). Conversely in rats concomitantly treated with the 5-
HTlA receptor agonist «+)-8-hydroxy-2-dipropylaminotetralin (DPAT)) G-I (albeit a high' dose -
100nM) significantly attenuated a DPAT induced rise in plasma ~T. A similar, although less 
pronounced response was observed with E2 (Xu et al .• 2008). Other studies have also implicated that 
GPER may mediate E2-stimulated GnRH release from primate neurones (Noel et al., 2009) as well as 
from mouse neurones, which may possibly corroborate the expression of GPER in the VMH and/or 
the anterior pituitary gland (Sun et al., 2010). Finally the expression of GPER in the adrenal medulla 
of the rat has been confirmed by Dun et al., with GPER located in tyrosine hydroxylase-positive 
chromaffin cells, further suggesting a likely role for GPER in E2-mediated noradrenaline release from 
the adrenal glands (Dun et al., 2009). 
3.5 Conclusion 
The distribution of GPER in the adult mouse brain appears distinct from ERa. and ERP receptors and 
offers an additional site for E2 action. The expression of GPER in OT and VP neurones in the PVN, 
SON, and in the median eminence, and its presence in the pituitary gland provides a likely means by 
which E2 can modulate fast 'non-genomic' effects on these specific neuropeptide systems. In the 
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periphery, GPER may be involved in multiple functions including hormone release and development. 
Whether E2 initiates responses through GPER alone or in concert with the other E2 receptors (e.g., in 
regions of co-expression) is yet to be fully investigated but the cellular distribution of GPER in the 
brain and peripheral tissues provides a basis for further studies on E2 mediated signalling. 
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Chapter 4: In vitro characterisation of GPER 
4.1 Introduction 
4.1.1 The GPER story so far: recognised mechanisms and possible functions 
GPER (previously known as GPR30, CMKRL2, LyGPR, GPCR-Br, FEG-l, GPR41) first cloned by 
Dr Stephen Lolait and colleagues in 1996 from a human B-cell lymphoblast cDNA library, is a 
member of the class A rhodopsin-like family of GPCRs, and shares closest homology with the 
angiotensin II and chemokine receptors (Owman et al., 1996; Takada et al., 1997). GPER is the first 
official steroid binding GPCR, and has been shown to rapidly activate a variety of transduction 
pathways in response to E2 including the adenylyl cyclase/cAMP, calcium, ERK1I2 and 
phosphoinositide 3-kinase (PI3K) cascades (Maggiolini and Picard, 2010). GPER is also activated by 
the anti-E2s tamoxifen and ICI-182,780, and various environmental E2s e.g., Bisphenol A, genistein, 
nonylphenol, quercetin, and zearalonone (Thomas and Dong, 2006; Maggiolini et al., 2004). It has 
been shown that GPER may couple to more than one family of G proteins e.g., direct GPER-Gas 
binding has been demonstrated in the membranes of HEK293 and SKBR3 cells; and the E2-mediated 
increase in ERK1I2 phosphorylation in Ishikawa, MCF-7, MDA-MB-231 and SKBR3 cells is 
sensitive to pertussis toxin which is indicative of G<lj coupling (Filardo et al., 2000, 2007; Vivacqua et 
al., 2006b; Maggiolini et al., 2004). GPER also transactivates the receptor tyrosine kinase EGFR, 
which activates the ERK pathway, induces calcium mobilisation and stimulates P13K signalling 
(Filardo et al., 2000; Revenkar et al., 2005). Figure 4.1 summaries the diverse range of GPER 
mediated signalling cascades. 
93 










Figure 4.1. Schematic diagram depicting some examples of GPER mediated signalling. 
Activation of GPER by E2 (or G-I, anti-E2s tamoxifen and ICI 182780, and various environmental E2s) causes 
a conformational change in the G protein complex leading to free Ga and GPy subunits that can stimulate a 
number of effectors. GPER appears to couple to at least two different a subunits: Gas and Gai. Many of the 
actions of GPER are dependent on the transactivation of the receptor tyrosine kinase EGFR. Transactivation 
occurs following the dissociation of the GPy subunit which stimulates an increase in Src tyrosine kinase (Src) 
activity and 'membrane impermeable' heparan bound EGF (HB-EGF) - it is HB-EGF that stimulates EGFR to 
activate a variety of pathways including ERKlcalcium/ P 13K (it is worth noting that Revenkar el al., 
demonstrated that GPERIEGFR stimulated calcium mobilisation was not inhibited by the PLC inhibitor 
U73122 - suggesting a PLC independent mechanism of action) (Filardo el al., 2000, 2002; Vivacqua el al., 
2006b; Revenkar et al., 2005). In many instances, the py subunit that activates EGFR appears to be coupled to 
the Gai subunit, as transactivation is inhibited by pertussis toxin, a potent Go, inhibitor (prevents uncoupling). 
However, Revenkar et al., found that pertussis toxin only partially inhibits signalling suggesting an alternative 
mechanism/coupling to a different Ga subunit (Revenkar el al., 2005). Stimulation of GPER when coupled to 
Gas activates adenylyl cyclase leading to an increase in cAMP and in tum protein kinase A (PKA). This 
pathway has negative effects on E2/GPER-mediated increase in ERK I /2 phosphorylation (i.e., E2 via GPER 
stimulates the accumulation of phosphorylated ERKI /2; concurrently, GPER also stimulates an increase in 
cAMP. The rise in cAMP has negative effects on ERKI /2 phosphorylation, and an ERK response is inhibited 30 
mins after the initial activation) (Filardo et aI., 2002). Therefore, E2/GPER can regulate ERKI /2 activation via 
at least two distinct pathways. 
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Various studies have reported over-expression of GPER in a number of cancerous cell lines (e.g., 
ishikawa, MCF-7, MDA-MB-231 and SKBR3 cells) and over expression in tumours e.g., pancreatic 
adenocarcinoma, post-puberal testicular germ cell tumors, and uterine carcinosarcomas (Glass et al., 
2011; Franco et al., 2011; Huang et al., 2010). There is a growing body of evidence to suggest that 
GPER is involved in cancer proliferation, migration, invasion, metastasis, differentiation and 
prognosis (reviewed in Wang et al., 2010). The receptor's affinity for anti-E2s has also provoked 
comments since tamoxifen and ICI-182,780 are often administered to counteract the proliferative 
actions of ERa and ERP in E2-responsive cancers. For example, long term use of anti-E2s in E2 
positive breast carcinomas can lead endometrial hyperplasia (Cano and Hermenegildo, 2000), and 
GPER has been shown to be involved in the development of acquired tamoxifen resistance in breast 
carcinomas - tamoxifen up-regulates the expression of GPER which in turn increases taxoxifen's 
proliferative activity (contradicting its role as an anti-E2) (Ignatov et al., 20 I 0, 20 11). Hence GPER is 
an alternative therapeutic target in the treatment of E2-responsive cancers. 
The development of transgenic GPER models and the GPER-specific agonist and antagonist G-I and 
G-15, respectively, have given insight into the possible general roles of GPER in vivo (Bologa et al., 
2006; Dennis et al., 2009). There are numerous reports indicating that GPER modulates metabolism 
particularly via insulin secretion. For example, female global GPER KO mice are hyperglycaemic, 
have impaired glucose tolerance and reduced serum insulin-like growth factor-I levels (MArtensson et 
a/., 2009). This KO model also indicates that GPER directly modulates insulin release, as isolated 
pancreatic islets from both male and female KO animals are completely devoid of insulin and 
glucagon responses to E2 (MArtens son et al., 2009). In addition, the GPER antagonist G-15 inhibits 
insulin secretion induced by E2 and G-l in the islets isolated from female wild-type mice (MArtensson 
et al., 2009; Sharma and Prossnitz, 2011). Meanwhile in humans, E2 and G-l have anti-diabetic 
actions in islets taken from healthy and type II diabetic female subjects - E2 and G-I improve 
glucose-stimulated insulin release while suppressing glucagon and somatostatin secretion (Kumar et 
al., 20 II). In contrast, there are mixed views on the role of GPER in fat metabolism - some studies 
report both male and female GPER KO mice have increased body weight and visceral adiposity (Haas 
et al., 2009; Ford et al., 2011), whereas others describe no alterations e.g., the body weight and fat 
mass of both male and female GPER-LacZ mice remain unchanged when compared to wildtype 
controls, even if overfed on a high fat diet (Isensee et al., 2009). 
Transgenic animals have also implicated GPERs involvement in other systems including bone 
development. For example, Ford and colleagues found that male GPER KO mice exhibit increased 
skeletal growth, bone mineral density and growth plate proliferation, and Windahl and co-workers 
demonstrated that E2 reduces longitudinal bone growth and growth plate height in ovariectomised 
wildtype but not GPER KO mice (Ford et al., 2011; Windahl et al., 2009). This suggests that GPER is 
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required for a nonnal inhibitory effect of E2 on bone growth and growth plate height in male and 
female mice. Conversely, Martensson and colleagues report that female but not male GPER KO mice 
have reduced skeletal growth characterised by reduced crown-rump and femur length (Martensson et 
01., 2009). Discrepancies between GPER KO models are perhaps indicative of strain differences, age, 
diet (e.g., phytoestrogen content), or technology used to create the colony. 
As GPER was cloned from a human B-celllymphoblast cDNA library, it is perhaps un surprising that 
GPER has been shown to be involved in immune system regulation. Both male and female GPER-
LacZ mice have impaired thymic T cell production with a reduction in CD4+ and CD8+ cells, and a 
decreased expression of CD62L in the T cell compartment (Isensee et 01., 2009). Although, in another 
transgenic model, E2-induced thymic atrophy is attenuated in female GPER KO when compared with 
wildtype controls, and chronic treatment of female wildtype animals with G-I induces significant 
thymic atrophy and thymocyte apoptosis (Wang et 01., 2008a). Together the later points suggest that 
GPER may have immunosuppressive effects. This is further supported by a study which reports that 
G-I inhibits the production of lipopolysaccharide (LPS)-induced cytokines TNF-a, IL-6, and IL-12 in 
human primary macrophages (Blasko et 01., 2009). Moreover, it has been shown that GPER has 
protective actions in experimental models of the autoimmune disease mUltiple sclerosis (experimental 
autoimmune encephalomyelitis (EAE» (Blasko et 01.,2009; Wang et 01., 2009b; Yates et 01.,2010). 
For instance, insertion of an E2 pellet (constant release over 40-60 days) into female wildtype mice 
and GPER KO mice one week prior to the induction ofEAE protects against the development ofEAE 
in wildtype but not GPER KO mice (Wang et 01., 2009b). Furthennore, insertion ofa G-I pellet into 
wildtype mice completely protected against EAE, suggesting that the other ERs may oppose the 
protective (immunosuppressant) actions of GPER (Wang et 01., 2009b). 
GPER is expressed in rat and mouse arteries, in human arteries and veins, and rat and human 
myocardial tissue, suggesting a role for GPER in the cardiovascular system (Isensee et 01., 2009; 
Broughton et 01., 2010; Haas et 01., 2007; Patel et 01., 2010). Indeed, when G-l is infused into 
nonnotensive Sprague-Dawley male rats there is an acute reduction in blood pressure, and both 
pressurised male rat mesenteric resistance arteries, precontracted murine arteries, and human internal 
mammary arteries dilate in response to G-l (Haas et 01., 2009) suggesting that GPER modulates blood 
pressure. Furthennore, it has been demonstrated that G-l elicits a nitric oxide-dependant relaxation of 
the carotid artery endothelium in male and female Sprague-Dawley rats, and decreases vascular 
superoxide production in carotid and intracranial arteries (although the latter is most likely by direct 
inactivation (acting as a scavenger) rather than GPER-mediated enzyme inhibition) (Broughton et 01., 
2010). Therefore, G-l acting via GPER acts as vasodilator in both rodent and human tissues and 
possibly independently acts as an antioxidant - thus G-l may be a potential therapeutic agent during 
vascular diseases such as stroke. Interestingly, chronic G-I treatment reduces infact volume in 
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response to middle cerebral artery occlusion in ovariectomised mice (Zhang et 01 .• 2010); and acute 
G-l administration prior to global ischemialreperfusion improves functional recovery and decreases 
myocardial inflammation in hearts from male and female Sprague-Dawley rats (Deschamps and 
Murphy. 2009; Weil et 01 .• 2010a). 
As shown in Chapter 3. GPER has a wide spread distribution in the brain. and this suggests the 
receptor may have a prominent central role. However. only a few studies have investigated the 
possible central functions of GPER. For example. G-l promotes the release of prolactin release in 
ovariectomised rats (Lebesgue et al .• 2009). stimulates an increase in intracellular calcium oscillations 
in embryonic primate GnRH neurones (Noel et 01 .• 2009). and inhibits 5HT1A-mediated OT and 
ACTH release in ovariectomised females rats (Xu et al .• 2008; Rossi et 01 .• 2010). In addition. chronic 
G-I treatment restores the cognitive performance of ovariectomised rats in the T -maze to that of intact 
controls. suggesting that GPER also has a role in cognition (Hammond et 01 .• 2009). 
4.1.2 GPER and its intracellular localisation 
Unlike many peptidergic GPCR ligands. E2 can freely diffuse through the plasma membrane. This 
has lead to the notion that GPER may be an atypical GPCR and function as an intracellular receptor. 
However. discrepancies surrounding the cellular localisation of GPER have plagued the field for some 
time. In 2005. Thomas and co workers suggested that GPER may be a plasma membrane E2 receptor 
by demonstrating that eH]E2 binds to the plasma membranes of ERalP negative SKBR3 cells that 
endogenously express GPER, and HEK293 cells (ERa-IERp-/GPER-) transiently transfected with 
human GPER (Thomas et 01 .• 2005). Tlte group later confirmed this by visualising the expression of 
HA-tagged GPER in stably transfected HEK293 cells. and found that HA-GPER mainly colocalised 
with lectin concanavalin A. a plasma membrane marker. They also confirmed that the HA-tag in the 
N-terminus of GPER did not compromise receptor functionality - E2 provoked a rapid increase in 
intracellular calcium in cells transfected with HA-GPER but not in control cells transfected with 
empty vector (Filardo et 01 .• 2007). It is important to point out that in these studies the GPER-
expressing HEK293 cells were selected (by flow activated cell sorting) for high plasma membrane 
GPER expression. 
On the contrary. Prossnitz and colleagues reported that transiently transfected GFP-tagged human 
GPER is not found at the plasma membrane of COS-7 cells but instead localises to the endoplasmic 
reticulum and golgi apparatus (Revenkar et 01 .• 2005). The GFP tag was on the C-terminus of GPER, 
immediately following the stop codon. Stimulation of these cells with E2 yields an intracellular 
calcium response suggesting that GFP-tagged GPER is functional. The intracellular localisation of the 
GFP-GPER was verified using primary antibodies generated against the predicted N- and C-terminal 
peptides of GPER. Furthermore, staining of endogenously expressed GPER with the same primary 
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antibodies corroborates this intracellular distribution pattern in several cancer cell lines e.g., MCF7, 
SKBR3, and MDA-MB23I breast cancer cell lines, and a Hec50 uterine carcinoma line (Revenkar et 
al., 2005). Another study also demonstrated that GFP-tagged rat GPER localised to the endoplasmic 
reticulum and cytoplasm in transiently transfected HeLa cells (Funakoshi et al., 2006). Although, 
when the experiment was repeated with a FLAG-tagged rat GPER, the receptor was mainly found on 
the plasma membrane. This suggests that different types of tagging (GFP vs FLAG) may encourage 
alternative intracellular trafficking ofthe receptors (Funakoshi et 01., 2006). 
Studies comparing the ability of impermeable vs permeable E2 ligands to activate GPER have not 
helped clarify the cellular localisation of GPER. One group reports that cell-impermeable E2 
conjugates (e.g., E2-BSA and E2-horseradish peroxidase) are able to activate GPER, suggesting the 
presence of the receptor at the cell membrane (Filardo et al., 2007). Conversely another group 
demonstrated that only permeable E2 derivatives (e.g., 17a-Phenylethynyl-E2 and indium-labelled G-
lanalogues) are able to stimulate GPER - providing evidence that GPER is capable of initiating 
signalling from an intracellular localisation (Revenkar et 01.,2007; Nayak et 01.,20(0). 
4.1.3 Scepticism surrounds the identification of GPER as aputativefast E2 receptor 
A few pUblications have raised concern about the E2-binding capabilities of GPER. In 2006, Levin 
and co-workers were unable to demonstrate E2-activation of ERK, PI3K or adenylyl cyclase in 
SKBR3 cells (Pedram et al., 2006). Even though the group was able to show rapid stimulation of 
these pathways with E2 in MCF-7 cells that express ERa, ERP and GPER, this activation was 
significantly prevented with siRNA directed to ERa (but importantly not prevented with siRNA 
directed to GPER), suggesting a role for ERa but not GPER in the fast E2-signalling in these cells 
(Pedram et 01., 2006). Likewise, Otto and colleagues were unable to show specific E2 binding in 
COS-7 cells transfected with human GPER, GFP-tagged human GPER or mouse GPER. Furthermore, 
these investigators failed to demonstrate that E2 or G-I I) stimulated cAMP in MDA-MB231, MCF-
7, or COS-7 cells transiently transfected with human GPER; or 2) increased intracellular calcium 
levels in MDA-MB231, HECSO, MCF-7 cells, or CHO or COS-7 cells transiently transfected with 
human GPER (Otto et al., 2008). 
One possible explanation for the discrepancies in GPERlE2/G-1 signalling was provided by Kang and 
colleagues who illustrated that E2 and G-I induced stimulation of the ERK pathway in SKBR3 cells 
is not mediated by GPER, but rather ERa-36, an ERa isoform (Kang et 01.,20(0). This relationship is 
plausible considering that (1) ERIl-36 lacks the intrinsic transcriptional activity of ERa; (2) is 
localised to the plasma membrane from which it mediates non-genomic E2 signalling; and (3) is up-
regulated in cells that do not normally express this ERa isoform or ERa, (e.g., HEK293 cells and 
COS-7 cells) following a transient transfection with GPER (Kang et aI., 2010). However, a recent 
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study has added further ambiguity by implicating GPER in ALD signalling: ALD appears to stimulate 
ERK phosphorylation in freshly isolated rat aortic segments via both a MR- and GPER-dependent 
mechanism (Gros et 01.,2011). Collectively, these studies suggest that GPER may have an elusive and 
possibly promiscuous role in steroid signalling. In stark contrast, another study has shown that the 
chemokine CCL 18 directly interacts with GPER, and inhibits an E2/G-l-mediated increase in 
intracellular calcium (Catusse et 01., 2010). This is an intuitive relationship considering GPER's 
homology with the chemokine receptors (Owman et 01., 1996) - although it still indicates a role for 
GPER in E2 signalling. 
The current study was undertaken to try to clarify the controversies surrounding the cellular 
localisation and role of GPER in vitro. Particular interest was paid to the rodent receptors as few 
studies have characterised rat and mouse GPER in vitro, which is surprising considering the vast 
majority of in vivo functional studies have been conducted in these species. To find out the cellular 
localisation of GPER we generated a stable HEK293 cell line expressing an N-tenninus HA-tagged 
rat GPER. The HA tag was preferred as it has previously been used in this lab to detennine the 
cellular distribution pattern of HA-tagged versions of the VIA, VIS and OT receptors (constructed 
using the same PCR protocol), all of which behave similarly to their untagged counterparts (Dr 
Stephen Lolait, unpublished observations). In addition, the HA tag has been used extensively in the 
literature to characterise GPCR internalisation and (sub)cellular localisation, e.g., vasopressin VIA and 
V 2 receptors amongst many others including the GnRH and GPER receptors (Innamorati et 01., 1996, 
1998; Sedgley et 01., 2006; Finch et 01., 2008; Filardo et 01., 2007). For this reason, one would 
anticipate a HA-GPER cellular distribution pattern comparable with that described by Filardo and 
colleagues (Filardo et 01., 2007). 
Next we endeavoured to detennine whether or not E2 activates GPER. As numerous publications 
have demonstrated that E2 rapidly stimulates the ERK 112 pathway and mobilises intracellular calcium 
via GPER, we used an ERK phosphorylation assay and calcium stimulation assay to assess the E2/G-
1 responsiveness of HEK293 cells stably transfected with rodent GPER. If successful, we hoped to 
further characterise E2-GPER signalling in vitro and also expand the current known functions of 
GPER in vivo - notably the possible roles of GPER in the HPA and HNS systems. 
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4.2 Materials and Methods 
4.2.1 Chemicals 
ALD, adenosine 5'-triphosphate (ATP), Carbachol, E2 (water-soluble and ethanol-soluble), EGF, 
ionomycin, PDBU were purchased from Sigma, UK. G-l (Dimethyl sulphoxide (DMSO)-soluble and 
ethanol-soluble) was purchased from Calbiochem (Merck), UK, VP was purchased from Bachem, 
UK, and N-(3-chlorophenyl)-6, 7 -dimethoxy-4-quinazolinamine (AG 1478; EGFR inhibitor) was 
purchased from Cayman Chemical, USA. 
4.2.2 Cell culture and transfections 
Cell lines were obtained from various sources: CHO-Kl and COS-7 cells were purchased from the 
American Type Culture Collection, USA; HeLa and Ishikawa cells were a kind gift from Professor 
Craig McArdle (LINE, DHB); SKBR3 cells were a kind gift from Professor Eric Prossnitz; and 
HEK293 cells were a kind gift from Professor David Murphy. Cells were cultured as described in 
section 2.5.2. 
The epitope-tagged and untagged rat GPER receptors were generated by PCR using approximately 
250ng rat genomic DNA. For the untagged receptor, primers were directed to 5' and 3'-untranslated 
regions of the receptor (upstream: 5'- AGCTTAAGCTIGAAGCCATGGCTGCAACTACT -3'; 
downstream: 5'- AGAGCCTCGAGGTGGTTIGTTAAAGGGCC -3') and corresponded to 
15718643-15720408bp of the rat GPER gene (Genbank Accession numberNC_005111), generating a 
1765bp product. Primers for the tagged receptor were again directed to 5' and 3'-untranslated regions 
of the receptor, but the 5' primer contained an additional 27bp which coded for the Influenza 
hemagglutinin (HA) epitope tag (upstream: 5'-
AAGCTTAAGCTIGAAGCCATGTATCCATATGATGTTCCAGATTATGCTGCTGCAACTAC 
TCCAGC -3' (bold underlined letters highlight the additional HA tag sequence); downstream: 5'-
AGAGCCTCGAGGTGGTTIGTT AAAGGGCC -3 '), and gave rise to a 1793bp product 
corresponding to 15718642-15718643bp of the rat GPER gene. Primers for both taggedluntagged 
receptors contained recognition sequences for the restriction endonucleases HindIII and XhoI 
(represented by underlined italics). The untagged mouse GPER receptor was generated by PCR using 
7.5ng mouse GPER cDNA (cloned from a mouse AtT-20 pituitary tumour cDNA library; Dr Stephen 
Lolait unpublished data) as a template. Primers were directed to 5' and 3'-untranslated regions of the 
receptor (upstream: 5'- ACTGGGATCCGAAGCCATGGATGCGACTACC -3'; downstream: 5'-
GCATCCTCQAGCAGGAAGGCGTTTTGTT A -3 ') and corresponded to 59S-2323bp of the mouse 
GPER gene (Genbank Accession number NM_029771), generating a 1728bp product, and contained 
recognition sequences for the restriction endonucleases BamHI and XhoI (represented by underlined 
italics). Primer restriction endonuclease sites allowed subcloning into the vector pcDNA3.1(+) 
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(containing AMP and neomycin resistance genes) for expression in mammalian cells. The human 
GPER cDNA was a kind gift from Professor Eric Prossnitz; the mouse E2 sulphotransferase cDNA 
clone was purchased from Geneservice, and subcloned into pcDNA3.1(+)Hygro as described in 
section 2.4.2; and the rat VIS receptor cDNA was obtained from Dr Stephen Lolait (Lolait et al., 
1995). 
Rat tagged and untagged GPER, mouse untagged GPER, and mouse E2 sulphotransferase cDNAs 
were introduced into HEK293 cells by calcium phosphate-mediated transfection, and clonal cell lines 
expressing the cDNA was obtained as described in section 2.5.4. In some experiments we used either 
untagged rat or mouse GPER as transcript expression were simiiar. The stable VIB receptor/CHO-KI 
cell line was established by Dr Stephen Lolait as previously described (Lolait et al., 1995). Transient 
transfection experiments were performed 24 hours after seeding COS-7 or HeLa cells in Costar plain 
black-wall 96-well plates using Nanofectin as described in section 2.5.3. It was estimated using the X-
gal staining assay (previously described in section 2.5.3 and Appendix I) that Nanofectin successfully 
transfected 30% of COS-7 and HeLa cells with cDNA. 
4.2.3 Northern 'dot' blot hybridisation 
To determine the endogenous transcript expression of some genes of interest or cDNAs introduced 
into cells by transfection we performed northern 'dot' blot hybridisation. This is a semi-quantitative 
method and it can be used to assess the relative levels of mRNA expression. Cells were cultured in 
clear 96 well plates until 80-90% confluent, and transferred to nitrocellulose membranes using a 96-
well vacuum manifold. The blots were UV -cross-linked, baked for 2 hours at 80°C, and pre-
hybridised at 37°C in pre-hybridisation buffer (see Appendix II) for at least 4 hours. Two 
oligonucleotides were designed against individual target mRNAs (sequences are provided in Table 
4.1) and purchased from Invitrogen. Oligonucleotides were tailed on the 3' end with Terminal 
deoxynucleotidyl transferase and a}2P-ATP. Blots were hybridised with a}2P-ATP-labelled probes in 
hybridisation buffer overnight at 37°C, and washed for 4 x 15 min in lxSSPElO.2% SDS at 56°C. 
Hybridised blots were exposed to Amersham Hyper film MP for 4-10 days at -80°C with intensifying 
screens. 
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5' -GAGGGCCAGAGGGGTG 5' -GAAAGACTGCTTGCAG 91 -138 892-939 
rat GPER CTGTTGGAAGGGGCTG GGAGTGTCCCCTGGCT (variant I) (variant I) NM_133573 (variant I) GCCACACGGGACCTAG-3 ' GCGCCCACTGCAGT AG-3 ' 
69 63 70 68 
mouse E2 I 5' -A TGCTGGAAGGACCT 5' -OAA TGA TTCTGTCCA 433-480 758-805 
sulphotransferase TGGGTGGCAGGTGAGTT CAAGCTCTGCCGAGGG C (variant I) (variant I) NM_023 135 (variant I) TTTACTATTCTGGGAG-3 ' TTTCTCTCCAGGAAC-3 ' 
so 52 63 64 
5' -AGACACGAGGAAACCA 5' -GCCCA TGGTCA TGT AA 1118-1164 1217-1264 human ERa-36 I CTTGTTTCCAAATATT CTGCCTCAAAACAAAA (variant I) (variant I) BX640939 (variant I) TTAGGATGCAAGTTC-3' TGTCCCCACGTCCACA-3 ' 
38 50 57 63 
5' -CGACAGCTGCGGCGGC 5' -GCGTCGA TT A TCTGAA NM_000125 (variant I) 
human ERa GGGTGCAGTAGCATCA TTTGGCCTGTAGAATG 541-588 661-708 NM_OOI 122740 (variant 2) 
GCGGGCTCGGAGACAC-3 ' CCGGCGGGCCGGCCTC-3 ' (variant I) (variant I) NM_001122741(variant 3) NM_001122742(variant 4) 
71 60 71 67 
NM_001437 (variant I) 
5' -CCACAACACA TTTGGG 5' -CCTCTTTGAACCTGGA 661-708 853-900 NM_OO I 040275 (variant 2) human ERP CTTGTGGTCTGCCGAC CCAGTAACAGGGCTGG (variant I) (variant I ) NM_OO I 040276 (variant 3) CAGGCCCACCTTCCAA-3 ' CGCAACGGTTCCCACT -3 ' NM_OO1214902 (variant 4) 
58 58 66 66 
NM_OOI214903 (variant 5) 
5' -AGCCAGCAGCGCCAG 5' -TACGGTTTTCAGAA T NM_OOS228 (variant I ) 
human EGFR GAGCGCTGCCCCGGCC ATCCAGTTCCTGTGGAT 246-293 1393-1499 NM_201282 (variant 2) 
GTCCCGGAGGGTCGCA T -3 ' CCAGAGGAGGAGT A TG-3' (variant I) (variant I) NM_20I 283(variant 3) 
-_. --1284 
77 46 74 61 
Table 4. t. Summary of oligonucleotide sequences and their predicted properties. 
Two oligonucleotides 48bp in length were designed against individual target genes. As some genes code for more than one transcript variant (which may be physiologically active, e.g., 
human ERa has four different mRNA variants all of which code for the same protein) probes were designed against regions of the gene common to all known transcript variants. This also 
included homologues (and variants) from other species (e.g., human, hamster, and monkey) as expression was investigated in a variety of cells lines (human (HEK293/HeLa), hamster 
(CHO-K I), or monkey (COS-7) cells». In instances where the probe was directed to the translated region of the mRNA, maximum effort was made to aim for non-conserved (i.e., limited 
homology to other proteins within a class, or other distinct proteins) regions of the gene. Oligonucleotides were directed as follows: rat GPER (also recognised human and mouse GPER) 
probe I was directed to a sequence in the translated region shortly following the initiating methionine, and probe 2 was directed to a non-conserved region between TM 6 and 7; mouse E2 
sulphotransferase probes I and 2 were directed to non-conserved sequences in the translated regions (in non-cofactor binding regions); human ERa-36 probe I was directed to the final 48bp 
in the coding region of the gene (the final 3bp corresponding to the stop codon), and probe 2 was directed a sequence shortly after the stop codon in the 3' -untranslated region; human ERa 
and ER~ probes I and 2 were both directed to a non-conserved portion of the 5'-translated region which occurs shortly after the initiating methionine; and the human EGFR probe I began at 
the initiating methionine and probe 2 was directed to a non-conserved sequence in the N-terminal translated region. Optimum hybridisation temperature for oligonucleotides is between 37-
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4.2.4 Semi-automated Image Acquisition and Analysis 
Imaging experiments (sections 4.2.5-4.2.7) were performed using a semiautomated system for image 
acquisition (IN CELL Analyser 1000), and validated algorithms for image segmentation and 
quantification (IN CELL Analyser version 1.0 software) as described in sections 2.7-2.9. Digital 
images were acquired, collecting one to four fields per well (each field capturing 0.602mm2 area with 
a lOx objective), in order to obtain images of approximately 50-3000 cells per well. 
4.2.5 Cellular localisation of HA-tagged GPER 
HA-tagged and untagged GPER HEK293 stables were cultured in poly-L-Iysine-coated Costar plain 
black-wall 96-well plates at 15,000 cells per well. If serum starving/treatment was required, cells were 
plated at 10,000 and incubated the next day in 90J.l.I phenol-red free DMEM with PIS, Q, 0.44mM 
calcium chloride dihydrate and 100J.l.g/J.l.1 BSA, with or without treatment (100nM E2 or G-l) 
overnight. For cell surface receptor staining, cells were incubated at 4°C for I hour in mouse 
monoclonal anti-HA.l 1 (diluted 1:200 in 1% BSAllx PBS), washed (ice-cold Ix PBS) and fixed for 
30 min (with 2% PFAllx PBS). Cells were permeabilised (0.1% TX-100/1x PBS 10 mins), washed (3 
x Ix PBS) and non-specific secondary antibody binding blocked with 1% BSAlO.1% TX-100/lx PBS 
for one hour. Cells were incubated in Alexa Fluor 488 goat anti-mouse IgG (H+L) secondary antibody 
(diluted 1:500 in 1% BSAlO.1% TX-100/1x PBS) for 1 hour, washed (3 x), and incubated in 300 nM 
DAPI for 15 min at room temperature. Cells were washed (1 x) prior to imaging. For whole cell 
imaging, cells were washed, fixed, permeabilised, and blocked as previously and incubated at 4°C for 
1 hour in mouse monoclonal anti-HA.ll. Cells were washed (3 x) and incubated in Alexa Fluor 488 
goat anti-mouse IgG (H+L) secondary antibody and then DAPI stained. Cells were washed (l x) prior 
to imaging. Immunofluorescence was detected with excitation filters 475-nm (HA) and 360-nm 
(DAPI), and monitored through emission filters 535-nm (detecting Alexa 488, green fluorescence: 
HA signal) and 460-nm (detecting blue fluorescence: DAPI signal), with a 61002 trichroic mirror (GE 
Healthcare, UK). Analysis of HA-GPER localisation was performed using the IN Cell 1000 Analysis 
Software. Within each cell the software used green channel images (535-nm emission filter) to 
measure HA fluorescence intensity and defined the cytoplasm; while blue channel images (460-nm 
emission filter) measured DAPI intensity and defined the nucleus. Subtraction of background 
fluorescence (measured in wells without primary antibody) gave the average fluorescence intensity in 
AFU per field/well. To calculate the percentage of HA-GPER at the plasma membrane, the average 
AFU value obtained from cell surface receptor staining was calculated as a percentage relative to ·the 
average AFU value from the whole cell receptor staining. 
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4.2.6 Calcium stimulation assay 
Cells were seeded at varying concentrations (10,000 - 20,000 cells per well) into Costar plain black-
wall 96-well plates. The following day, cell types that were to be treated with steroids were serum-
starved overnight (constituents of serum free media are described in section 2.8.1). Prior to treatment 
cells were loaded with 2.5-5).1.M Fluo-4 and 0.5).I.M Hoechst in either serum free media or 
physiological salt solution (PSS) (for CHO-KI cells - see Appendix II for PSS recipe). Cells were 
stimulated and imaged in an environmental control chamber at 37°C in a 5% CO2 humidified 
atmosphere. Fluorescence images of one field per well were acquired every 12000ms ranging from 0 
ms to 72000ms, and immunofluorescence was detected with excitation filters 475-nm (flu0-4) and 
360-nm (Hoechst), and monitored through emission filters 535-nm (detecting green fluorescence; 
fluo-4 signal) and 460-nm (detecting blue fluorescence; Hoechst signal). Analysis was performed 
using the IN Cell 1000 Analysis Software. Within each cell the software used green channel images 
(535-nm emission filter) to measure fluo-4 fluorescence intensity to define staining in the cytoplasm, 
while blue channel images (460-nm emission filter) measured Hoechst intensity to define the nucleus. 
For each field, the average total amount of fluo-4 in the cell cytoplasm was calculated. This value, 
following the subtraction of background florescence (measured in regions of the field absent of cells), 
was expressed as AFU. Data was presented as fold change over time point Oms. 
4.2.7 ERK phosphorylation assay 
Cells were seeded at varying concentrations (10,000 - 20,000 cells per well) into Costar plain black-
wall 96-well plates. The following day (following seeding for CHO, HEK293, Ishikawa or SKBRJ 
cells or transfection for COS-7 and HeLa cells) cells were serum-starved overnight prior to treatment 
(constituents of serum free media are described in section 2.9.1). Cells were stimulated (5-30 min), 
washed (ice-cold Ix PBS for 3-5 min), fixed for 10 min (with 4% PFAllx PBS), and permeabilised 
for 5 min at -20°C with absolute methanol. Cells were washed (Ix PBS) and non-specific antibody 
binding blocked with 5% normal goat serum/Ix PBS for 2 hours. Cells were washed (I x) and 
incubated in mouse anti-ppERK 112 antibody (I :800-1 : 12000) and rabbit anti-ERK 112 (1 :400-1 :3200) 
in 1% normal goat serum/Ix PBS overnight at 4°C. N.B., the titre ofanti-ppERK antibody was greatly 
reduced to 1:6400 for SKBR3 cells (to 1:12000 in some experiments - depending on the antibody 
batch) and still the EGF-induced increase in ppERK fluorescence did not exceed (or even reach) 2-
fold. The following day, cells were washed (3.x), incubated in Alexa Fluor 488 goat anti-mouse IgG 
(H+L) secondary antibody for I hour at room temperature, and further washed (2 x) prior to IS min 
incubation with 300 nM DAPI. Cells were washed (1 x) prior to imaging. Immunofluorescence was 
detected using excitation filters 535-nm (tERK), 475-nm (ppERK) and 360-nm (DAPI), and emission 
filters 620-nm (detecting Alexa 546, red fluorescence: total ERK signal), 535-nm (detecting Alexa 
488, green fluorescence: ppERK signal) and 460-nm (detecting blue fluorescence: DAPI signal) with 
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a 61002 trichroic mirror. Analysis of total ERK and ppERK activity was performed using the IN Cell 
1000 Analysis Software. Within each cell the software used red channel images (620-nm emission 
filter) to measure tERK fluorescence intensity and define the cytoplasm perimeter; green channel 
images (S3S-nm emission filter) to measure ppERK fluorescence intensity and also define the 
cytoplasm perimeter; while the blue channel images (460-nm emission filter) measured OAPI 
intensity and defined the nucleus. For each field the average total amount oftERK and ppERK in the 
whole cell was calculated. These values, following the subtraction of background florescence 
(measured in regions of the field where there were no cells; or in the case of cells that sheath (e.g., 
HEK293) or were confluent (transiently transfected COS-7 and HeLa cells) measured in wells without 
primary antibody as described in section 2.9.2), was expressed as AFU. Data was normalised to 
vehicle to allow pooling of independent experiments. 
Analysis 0/ ppERK values in transiently trans/ected cells. 
ppERK fluorescence intensity values were obtained as above for transiently transfected cells, and the 
data collected was subject to further analysis. As the transient transfection used in this assay is 
approximately 30% efficient (as determined by the X-gal staining assay; for more details see section 
2.5.3), a 'ppERK fluorescence threshold' was introduced for the analyses of fields containing cells 
transiently-transfected with GPCRs, in an attempt to identify transfected cells from unresponsive non-
transfected cells. The 'ppERK fluorescence threshold' was based on V 1B receptor data that 
accompanied each assay. As demonstrated. in Figure 4.2, nuclear and cytoplasmic ppERK 
fluorescence values for control vs. VP treated V 1B receptor transfected cells were plotted against each 
other on a scatter diagram using the new linear discriminant filter tool within the IN CELL Analyser 
version 1.0 software. The cells that had comparatively high levels of ppERK fluorescence in both the 
nucleus and cytoplasm are shown in the upper right quartile (8) as marked with threshold lines on 
Figure 4.2. The vast majority of these cells corresponded with VP responsive V 18 transfected cells. 
Cells that had comparatively low levels of ppERK fluorescence in the nucleus and cytoplasm were 
located in the lower right quartile (C) and were either unresponsive to VP (unsuccessfully transfected) 
or were treated with vehicle. Cells that possessed high ppERK fluorescence values in the nucleus but 
not the cytoplasm (A), or vice versa (0), were considered unstimulated. While in some cells types, the 
rise in ppERK may remain in the cytoplasm or fully translocate to the nucleus, the cells used in this 
assay/thesis demonstrate a concomitant rise in nuclear and cytoplasmic ppERK in response to 
stimulation (at the time points investigated) as shown in Figure 4.2. Hence cells in the (A) or (D) 
quartiles were considered to be either non-specifically activated by agonist or vehicle (i.e., 
mechanically stimulated) or cells possessed intrinsiclbackground ERK activity. The threshold lines in 
Figure 4.2 were positioned so that approximately 30% ofVP responsive cells were located in quartile 
(8) to correspond with the approximate 30% transfection efficiency observed with Nanofectin (the IN 
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CELL Analyser version 1.0 software re-analysed the data each time the threshold lines were adjusted 
to establish the percentage of cells in quartile (B) - this was repeated until (B) contained 
approximately 30% of responsive cells). Therefore, the 'ppERK fluorescence threshold' corresponded 
to the points at which the threshold lines intersected the x- and y-axis, and the cells that emitted AFU 
values below these limits were discarded. Once the 'ppERK fluorescence threshold' had been 
determined it could be applied to ppERK fluorescence data obtained from wells transfected with other 
GPCRs (on the same assay plate; as AFU values val)' between plates, the V 18 receptor transfection 
and subsequent stimulation was performed on each plate). The ppERK fluorescence values for 
agonist- or vehicle- treated GPCR-transfected cells were reanalysed by the IN CELL Analyser version 
1.0 software and the percentage of cells present in quartile (8) was calculated. Thus if a transfected 
receptor was responsive to agonist stimulation it would be expected that significantly more agonist-
treated transfected cells would be found in quartile (8) when compared with vehicle-treated cells. 
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Figure 4.2. Setting the 'ppERK fluorescence threshold' (or transiently translected cells. 
The ppERK fluorescence intensity emitted by HeLa cells either treated with vehicle or lOOnM VP were plotted 
on scatter diagram using the 'new linear discriminant filter' function within the IN CELL Analyser version 1.0 
software. Two threshold lines were implemented into the scatter diagram to separate the data into four quartiles 
(A-D). The threshold lines were adjusted until 30% of cells were in quartile 8 to correspond with the 3()oA, 
transfection efficiency observed with Nanofectin. The 'ppERK fluorescence threshold' corresponded to the 
points which the threshold lines intersected the x and y axis. 
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4.2.8 Statistical analysis 
IN CELL Analyser 1000 experiments were performed in 3-6 replicate wells, and experiments were 
performed at least 2 times. Data is represented in Figures as mean ± standard error of the mean 
(SEM). Statistical analysis was either a Student's I-test, a one-way ANOVA and post hoc test, or two-
way ANOVA and post hoc test (as described in Figure legends) accepting P < 0.05 as significantly 
different. 
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4.3 Results 
4.3.1 Detection of endogenous or 'exogenous' transcript expression in cells by Northem 
blot 'dot' Irybridisation 
Table 4.2 summaries GPER, mouse E2 sulphotransferase, Ra ERP and EGFR tran cript expression 
in cell lines that are frequently used for stable and transient tran fection in our laboratory. GPER 
transcript expression was not detected in untran fected H • K293 cell but wa expre ed in H K293 
cells stably transfected with rat HA-tagged, rat untagged and mou e untagged GPER ( ee Figure 4.3). 
imilarly, mouse E2 sulphotransferase hybridisation signal wa undetected in untran fected H K293 
cell s but was observed in HEK293 cells stably transfected with mou e 2 ulphotran ferase eDNA. 
Endogenous ERa-36, ERa and ERP transcript expression was negligible in the four cell type 
investigated (and ERa-36 mRNA was not expres ed following stable transfection with GP R). On the 
other hand, EGFR hybridisation signal was high in COS-7, H K293 and HeLa cell but wa low-
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Table 4.2. Results from northern 'dot' blot hybridisation. 
(A) Represents endogenous transcript expression of GPER, E2 sulphotransferase, ERn-36, ERn, ERP, - FR in II -K I, 0 -7, HEK293, 
and l-IeLa cells, and also H K293 cells transfected with GPER. As some genes code for more than one tran cript variant (which may be 
physiologically active) probes were designed again t regions of the gene common to all known tran ript variant This also in luded 
homologues (and variants) from other species as expression was investigated in human (H -K2931HeLa), hamster ( II -K I). or monkey 
( 0 -7) cell lines. (8) ' Exogenous' transcript expres ion of rat HA tagged P R, rat untagged P R, m u e GPER, or mou e E2 
ulphotransferase, introduced by single or double tran fection of cDNA into IIEK293 cell . The Iran rected cell line u ed in thi tudy 
were tho e asses ed to have the highest mRNA expression. Oligonucleotides were labelled with n_12P_ATP and designed towards all 
tran cript variants of the gene of interest. This also included homologues (and variants) from other pecle e.g., human, ham ter m nkeyas 
expres ion was investigated in a variety of cells lines (human (IIEK293/HeLa), hamster ( IIO-K I), or m nkey ( 0 -7) cells), +++, high 
expression; ++, moderate expression; +, low expression: -, negligible expre sion (signal n t above ba kground): N/A, e pre ion in the e 
cell line were not investigated. Note that the levels of expression are relative - negligible, low or ab ent mR A expre sion b thi method 


























hapter 4: Characterisation of GPER 
Rat-HA Rat Mouse HEK293 
Mouse GPERIEST 
(A) Endogenous EGFR transcript expression in CHO-KI , COS-7, HEK293 and HeLa cells. (8 ) GPER hybridisation signal was observed in HEK293 clonal lines stably 
transfected with rat HA-tagged GPER (rat-HA), rat untagged GPER (rat), or mouse untagged GPER (mouse), but not in untransfected HEK293 cells (HEK293). (C) 
HEK293 cells were stably transfected with GPER and mouse E2 sulphotransferase and plated into 96 well plates (I celVwell) to create clonal lines. Clones were grown to 
confluency and were then trypsinised and split, with some of the cells transferred to sister 96 well plates. The sister plates were hybridised with oligonucleotides directed 
to GPER mRNA (Ci) or mEST mRNA (Cii). Note the extreme variation in GPERIEST mRNA expression even though all the cells express the cDNA i.e. , all clones have 
G41 8 and Hygro resistance, or some cells were resistant to the antibiotics before transfection. Note that some wells (arrowed) have high GPER and EST gene expression. 
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4.3.2 Rat GPER expressed 'stably' in HEK293 cells is located both on the cell sUrface 
and intracellularly 
To address whether or not GPER is expressed at the cell surface and/or intracellularly, we engineered 
a recombinant rat GPER protein encompassing a HA epitope tag on its N-terminus, and expressed it 
stably in HEK293 cells. At face value, the HEK293 cells are an appropriate model for HA-GPER 
expression as they are devoid of transcript encoding ERa, ERP or GPER as determined by northern 
blot analysis. This is in agreement with Thomas et al., who found that GPER mRNA and protein or 
ERa or ERP mRNA were absent from HEK293 cells (as assessed by RT-PCR and Western blot 
analysis) (Thomas et ai., 2005). The amount of GPER expressed at the cell surface vs intracellularly 
was visualised using the HA-staining protocol, imaged in the IN CELL Analyser 1000, and analysed 
using the In Cell 1000 Analysis Software. In the total population of HEK293 cells maintained in 
normal DMEM growth mediall 0% FCS approximately 24% of HA-GPER (23.898% ± 0.390) was 
expressed at the plasma membrane and 76% (76.102% ± 0.390) expressed intracellularly (Figure 4.4). 
This is in contrast to studies that either report that GPER is predominantly expressed on the plasma 
membrane (observed with HA-tagged GPER), or expressed solely inside the cell (detected with GFP-
tagged GPERlantibodies direct to endogenous GPER) (Filardo et ai., 2007, although it must be 
emphasised that this study used cells selected for high plasma membrane expression; Revenkar et ai., 
2005). One possible explanation for the discrepancies surrounding the localisation of GPER 
(particularly those between studies using the same HA-tag) is that oestrogenic compounds within the 
media may act upon GPER to alter its cellular localisation. With this in mind, HA-GPER expressing 
HEK293 cells were serum starved overnight with or without treatment with either 100nM E2 or 
100nM G-I. Serum-starving did not significantly alter the cell surface expression of HA-GPER 
(22.184% ± 1.339) when compared to cells incubated in normal media. Overnight treatment with 
100nM E2 appeared to slightly increase the cell surface expression of HA-GPER but this was not 
significantly different when compared to the vehicle control (ethanol vehicle: 26.247% ± 2.619 vs E2: 
32.816% ± 4.312). Similarly, there appeared to be a slight increase in plasma membrane expression in 
HA-GPER following overnight treatment with 100nM G-l yet this was not significantly different 
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Figure 4.4. Plasma membrane and intracellular ex pression of HA-GPER in cultured. serum starved. and treated HEK193 cells. 
Characterisation of GPE R 
HEK293 cells stably transfected with HA-tagged rat GPER were cultured in normal media or serum- and phenol-free media, plus or minus IOOnM E2 or IOOnM G-I . Plasma membrane expression of HA-GPER 
was calculated as a percentage of whole cell expression (thus intracellular expression was 100% (whole cell) minus the plasma membrane expression). (A) In HEK293 cells maintained overnight in normal growth 
media (DMEM) HA-GPER fluorescence was expressed at the plasma membrane and intracellularly. Overnight incubation in serum free media (SF) did not significantly alter the cell surface expression of HA-
GPER when compared to cells incubated in normal media. Treatment with E2 did not significantly alter the plasma membrane expression of HA-GPER when compared with the ethanol control, and no significant 
differences were observed following treatment with G-I vs the DMSO control. All values are means ± SEM from 1-2 fields, from 3-6 wells and 3 separate experiments. Statistical analysis was performed using a 
one-way ANOVA and the Bonferroni multiple comparison test. (8 ) Representative images of HA-tagged GPER transfected HEK193 cells stained with anti -HA antibodies. Note that the HA-GPER fluorescence is 
restricted to the plasma membrane of non-permeabilised HEK193 cells, but was expressed by both the plasma membrane and cytoplasm of the permeabilised HEK193 cells. (C) Only background HA staining in 
wells containing HEK293 cells stably transfected with untagged rat GPER, and in wells containing HA-tagged GPER transfected HEK193 cells but are ab.sent of primary antibody. etrl, control. Scale bar, IOOllm. 
111 
Chapter 4: Characteri~atioll of CiPER 
4.3.3 E2 and G-l do not activate rat GPER to increase intracellular calcium 
E2 and G-l reportedly increase intracellular calcium responses in cell lines expressing GPER (see 
section 4.1.1). Calcium mobilisation in response to E2 and G-l in the stable rat HA-GPERlHEK293 
cell line is shown in Figure 4.5. Stimulation with 10nM E2, 100nM E2 or IJ1M E2 (examples of mean 
± SEM at 36000ms (N.B., the data is normalised to the value at time Oms): 10nM E2 0.935 ± 0.078, 
vs 0.001% ethanol 0.867 ± 0.03; 100nM E2 0.785 ± 0.043 vs 0.01% ethanol 0.923 ± 0.171; 1 J1M E2 
1.076 ± 0.080 vs 0.1 % ethanol 0.954 ± 0.028), or 10nM, 100nM or I J1M G-l (examples at 36000ms: 
10nM G-l 1.147 ± 0.196 vs 0.001% DMSO 1.251 ± 0.19; 100nM G-l 0.895 ± 0.076 vs 0.01 DMSO 
1.136 ± 0.177; 1 J1M G-l 0.852 ± 0.16 vs 0.1 % DMSO 0.980 ± 0.038) failed to increase intracellular 
calcium in the HEK293 cells. However, ionomycin induced a 3-fold rise (example at 36000ms: 
ionmycin 3.141 ± 0.027 vs vehicle 0.8525 ± 0.025) in fluo-4 in the HEK293 cells stably transfected 
with rat HA-GPER. 
To assess whether absence in an E2/G-I mediated response was a product of receptor tagging we 
tested the untagged rat GPER in the calcium stimulation assay. Again, neither 100nM and IJ1M E2 
(examples of mean ± SEM at 36000ms (N.B., the data is normalised to the value at time Oms): 100nM 
E2 1.321 ± 0.032 vs 0.01% ethanol 1.132 ± 0.031; 1 JAM E2 1.331 ± 0.044 vs 0.1 % ethanol 1.317 ± 
0.137) or lOOnM and lJAM G-l (examples at 36000ms: 100nM G-l 1.229 ± 0.071 vs 0.01% DMSO 
1.131 ± 0.018; 1 J1M G-l 1.044 ± 0.041 vs 0.1 % DMSO 1.41 ± 0.136) increased intracellular calcium 
(Figure 4.6). In contrast, A TP (which activates endogenous purinergic receptors in HEK293 cells 
(Mundell and Benovic, 2000) and ionomycin induced 2- and 4-fold increases in flu0-4 fluorescence 
when compared to vehicle controls (examples at 36000ms: ATP 2.141 ± 0.125 vs vehicle 1.181 ± 
0.011; ionomycin 4.336 ± 0.395 vs 1.353 ± 0.040). 
As a further method control, CHO-K 1 cells stably transfected with the V 18 receptor previously shown 
to mobilise calcium in response to VP (Lolait et aI., 1995), were treated with lOnM or 100nM VP, 
and 100J1M A TP. All of the treatments significantly increased intracellular calcium (example given 
for lOnM VP at 36000ms: 4.380 ± 0.079) (Figure 4.7). 
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(A) Rat HA-GPER (B) Rat HA-GPER (C) Rat HA-GPER 
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Fluo-4 fluorescence intensity did not increase in HEK293 cells stably transfected with rat HA-tagged GPER in response to 10nM, 100nM or 111M E2 (A) or IOnM, 100nM 
nor 111M G-l (B) when compared to vehicle (N.B. , vehicle or agonist were added to each well at 12000ms). Fluorescence intensity significantly increased in cells treated 
with 211M ionomycin when compared to controls (C). The data shown are normalised to the value at time Oms. Graphs are representative of one field, from triplicate wells 
and three separate experiments (mean ± SEM). Statistical analysis comparing vehicle·treated versus agonist-treated at each time point was performed using a two-way 
ANOV A and the Bonferroni post test. ***, p < 0.00 I. Below each graph are some representative images of cells treated with agonist at Oms and 36000ms. Scale bar, 
100 I1m-
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Figure 4.6. E2 and G-I do not activate calcium mobilisation in HEK293 cell tably tran rected with 
untagged rat GPER. 
Fluo-4 fluorescence intensity did not increase in H 1<293 cells stably tran fected with rat untagged P R in 
response to 100nM or IIlM 2 (A), nor 100nM or IIlM G-I (B) when compared to ehicle (N.B., vehicle or 
agonist were added to each well at 12000ms). Fluorescence intensity significantly increa ed in cell treated with 
211M ionomycin (C) and 100l1M A TP (D) when compared to control . he data hown are normali ed to the 
value at time Oms. Graphs are representative of one field, from triplicate wells and three eparate experiments 
(mean ± S M). Statistical analysis comparing vehicle-treated ver u agoni t-treated at each time point was 
performed using a two-way ANOYA and the Bonferroni post test. ., p < 0.05; •• , P < 0.01 ; ••• , P < 0.001. 
Below each graph are some representative images of cell treated with agoni t at Om and 36000m. cale bar, 
100l1m. 
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Figure 4.7. VP activates calcium mobilisation in CHO-Kl cells stably tran fected with the VIO receptor. 
Fluo-4 fluorescence intensity significantly increased in CHO-K I cells stably transfected with the V IB receptor, 
in response to 10nM and 100nM VP and IOOIlM ATP when compared to control (N.B. , vehicle or agonist were 
added to each well at 12000ms). The data shown are normalised to the value at time Oms. Graphs are 
representative of one field, from triplicate wells and at least two separate experiments (mean ± M). Statistical 
analysis comparing vehicle-treated versus agonist-treated at each time point was perfonned using a two-way 
ANOV A and the Bonferroni post test. ***, p < 0.00 I. Next to the graph are some representative images of cells 
treated with agonist at Oms and 36000ms. Scale bar, 1001lm. 
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4.3.4 E2 and G-I do not activate rodent GPER to induce ERKI12 phosphorylation in 
HEK293 cells 
To ensure that the ERK phosphorylation assay was sensitive enough to detect GPCR-mediated ERK 
responses (at varying ligand concentrations) we perfonned a series of experiments using a CHO-Kl 
line stably transfected with the VP V 18 receptor. VP activates the V 18 receptor to elicit an ERK 
response in a dose-dependent manner (Figure 4.8). We observed a 2-6 fold increase in ppERK with 
varying concentrations ofVP with maximal response occurring between 10 and 15 min: InM (N.B., 
AFU values are nonnalised to vehicle (therefore, values> I are required for an increase): 2.421 ± 
0.596 at 30 min), 3nM (4.210 ± 0.774 at 10 min) 10nM (5.119 ± 0.45 at 10 min), and 100nM (5.747 ± 
0.165 at 10min). In non-transfected CHO-Kl cells, I-I0nM VP did not increase ppERK fluorescence 
levels from that of control (example of 10nM: 1.032 ± 0.062) (Figure 4.9). 
As some GPCRs including GPER elicit an ERK response via transactivating the EGFR, we tested 
whether EGFR is involved in V\B receptor mediated ERK responses. Incubation with the EGFR 
inhibitor, AGl478 (IOOnM for 30 min) did not inhibit the increase ofppERK in response to IOnM or 
100nM VP (10 min) (example of 100nM: VP + AGI478 2.340 ± 0.279 vs VP + AGI478 vehicle 
2.573 ± 0.058) (Figure 4.10). Treatment of VIB transfected CHO-Kl cells with 100nglmi (1.010 ± 
0.008) and 500ng/ml (1.052 ± 0.026) EGF for 10 min did not increase ppERK (Figure 4.10). 
Although northern blot analysis revealed that CHO-Kl cells express moderate levels EGFR mRNA, 
this tyrosine kinase receptor is presumably not functional, and V 18 receptor stimulates ppERK in 
CHO-KI cells through an EGFR independent pathway. Therefore, based on the VIs!ERK results, the 
sensitivity of the assay in our hands, is sufficient to allow observation of E2IO-I/GPER activation of 
the ERK pathway in HEK293 cells (especially as previous studies show maximal GPER-mediated 
ERK response at doses of InM-IJLM E2 and 10nM-IJLM 0-1 occurs within 5-30 min (Filardo et aJ., 
2000; Vivacqua et al., 2006b; Sirianni et al., 2008; Dennis et aJ., 20 II». 
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Figure 4.8. VP stimulated ERK phosphorylation in CHO-Kl cells stably transrected with VIB receptor eDNA. 
CHO-K I cells stably transfected with V IB receptor (V IIJCHO-K I) were stimulated with 10M, 30M, 100M or 100nM for 5, 10, IS or 30 min. All concentrations of VP stimulated a significant increase in ERK 
phosphorylation in the treated V IIJCHO-K I cells. The ERK phosphorylation assay produced sufficient dose response (A) and time course (8) graphs. The data shown are normalised to vehicle and graphs are 
representative of at least two fields , from triplicate wells and at least two separate experiments (mean ± SEM). Statistical analysis was performed using a one-way ANOVA and the Bonferroni multiple comparison 
test . , p < 0.05; •• , P < 0.0 I; ••• , p < 0.00 I. Below each set of graphs are some representative images of eells treated with control (etrl) or agonist and stained with anti-ppERK antibodies. Scale bar, I OO~m . 
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ntran reeted HO- I 
PI 
igure 4.9. Untransfected HO cells are responsive to VP. 
I nM, 3nM, and 10nM VP (10 min) did not activate ERK phosphorylation in untran fected II -K I cells. The data hown arc normali ed to 
vehicle and graphs are representative of at least one field, from triplicate wells and three eparate expenments (mean ± M). tati tical 
analy is was performed using a one-way ANOVA and the Dunnett 's multiple comparison te t Below the graph are s me repre entative 
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Figure 4.10. The V'R receptor doe not activate ERK via EGFR transactivation in 1I0-K I cell . 
(A) Pre-incubation ofCHO-KI cells stably transfected with V,B receptor (Vial II -KI) with the I-R inhibit r A 1478 (IOOnM) for 30 
min did not diminish a VP- ( IOnM or 100nM ~ r 10 min) mediated incre e in ppERK. (B) Treatment of Vial II -K I cell with 100ng/ml 
or SOOng/ml OF for 10 min had no effect on pp RK fluorescence levels. The data h wn are n mlah ed to vehl Ie and graphs are 
repre entative of at least one field, from triplicate well and at least two eparate c pcnment (mean ± EM). tati IIcal anal is was 
perfomled using a one-way ANOVA and the Dunnett 's (A) or B nferroni (B) multiple c mpanson te t Below the graph are some 
rcpresentative images of cells treated with control (ctrl) or agonist/inhibit r and stained with anti-ppERK antibodies. calc bar, 100/lm. 
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It is possible that the E2 and G-l solvents, ethanol and OM 0 re p ctively, may al 0 promote RK 
activation, and mask the effects of E2 and G-l. In fact, both ethanol and OM have previou Iy been 
shown to activate ERK signalling (Reddy and hukla, 2000' Koo and Kim, 2009). In the current 
study, we experienced both ethanol- and OM 0- timulated increa es in RK tluore cence above 
background in HEK293 cells (in some of the experimental plate) although the fluore cence ignal 
was higher following treatment with OMSO (OM 0 60.10 ± 3.90 v thanol 42.00 ± 8.45) (Figure 
4.11). Therefore, it was decided that G-I di solved in ethanol would b u ed in the RK 
phosphorylation assays (Figures 4.12-4.13). 
11£1093 CIIO· KI 
Figure 4.11. Non-specific effects of organic solvent on ERK 1/2 pho phor lation. 
Graphs represent examples of ppERK fluorescence (following subtraction of background fluorescence (AFU» 
in HEK293 and CHO-KI cells treated with solvents. H K293 cells were treated with 0.01 % ethanol or 0.01% 
OM 0 (equivalent dilutions for 100nM of E2 and G-I, respectively) for 10 min . Both olvent induced an 
increase in ppERK fluorescence above background, although the increa e wa higher in OM 0 treated cells. 
HO-K I cells were treated with 10llM acetic acid (VP (I OOnM) vehi Ie) or the organi olvent OM (0.0 I %) 
for 10 min. Acetic acid increased ppERK fluorescence above background (74.67683 ± 16.86284) although the 
increase was greater following treatment with OM (135.23 ± 20.97). Graph are repre entative of AFU 
values from two fields, from triplicate well from one e periment (mean ± M). Adja ent to the graph are 
images of cells treated with solvents and tained with anti-pp RK antibodie . cale bar, 1001lm. 
It has previously been demonstrated by everal group that the timulation f the human P R with 
E2 or G-I activates ERK 1/2 phosphorylation in everal cell line (ee eetion 4.1). To our kn wledge, 
few studies have investigated whether 2 or G-I activate RK 1/2 ignalling pathway in r dent eell 
in vitro. 
H K293 cells stably expre sing rat HA-tagged and untagged GP Rand mou e untagged P R were 
and stimu lated with varying concentrations of 2 or 100nM -I for 5 or 10 min . 100nM 2 and 
100nM G- I (N.B., AFU values are normali ed to vehicle (therefi re, alue > I are required for an 
increase): 100nM E2 0.977 ± 0.027; G-I 0.922 ± 0.085) did not induce RK pho phorylation in 
untransfected H K293 cell at 5 min ( igure 4. 12). imilarly, treatment of 100nM 2 and 100nM G-
119 
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I for 5 min did not increase ppERK fluorescence in HEK293 cells transfected with rat HA-GPER 
(lOOnM E2 0.880 ± 0.064; 100nM G-I 1.232 ± 0.271). 10nM and 100nM E2 and G-I also failed to 
increase ppERK in rat untagged GPER (examples given for 100nM: E2 0.872 ± 0.034; G-I 1.162 ± 
0.035) and mouse GPER (examples of mean ± SEM given for 100nM: E2 1.099 ± 0.029; G-I 0.988 ± 
0.028). 200nM POBu (stimulator of the PKC pathway) (HEK293 1.876 ± 0.370; rat HA-GPER 2.107 
± 0.042; rat GPER 2.546 ± 0.5; mouse GPER 2.493 ± 0.479) and 100ng/ml EGF significantly 
increased ppERK fluorescence in all four cells lines by 2- to 7-fold (Figure 4.12) (HEK293 4.903 ± 
0.301; rat HA-GPER 7.074 ± 0.294; rat GPER 6.0954 ± 0.586; mouse GPER 4.905 ± 0.743). 
Similar results were obtained following 10 min stimulation (Figure 4.13). 100nM E2 and 100nM G-I 
did not increase ppERK expression in untransfected (E2 0.876 ± 0.113; G-I 1.096 ± 0.079) or rat HA-
GPER transfected (E2 1.320 1: 0.263; G-I 1.161 ± 0.194) HEK293 cells. There was no increase in 
ppERK in cells transfected with rat untagged and mouse GPER following incubation with 10nM and 
100nM E2 or 10nM and 100nM G-I for 10 min (examples of mean ± SEM for l00nM: rat GPER, E2 
0.945 ± 0.043; G-I 0.834 ± 0.075. Mouse GPER, E2 0.913 ± 0.036; G-I 0.925 ± 0.075). In all four 
HEK293 cell lines, 200nM POBu (HEK293 2.142 ± 0.326; rat HA-GPER 2.279 ± 0.437; rat GPER 
2.627 ± 0.565; mouse GPER 2.290 ± 0.426) and 100ng/ml EGF (HEK293 3.085 ± 0.425; rat HA-
GPER 7.990 ± 1.329; rat GPER 6.599 ± 0.64; mouse GPER 5.385 ± 0.644) significantly increased 
ppERK fluorescence by 2- to 8- fold (Figure 4.13). 
The levels of total ERK fluorescence (tERK) did not change during this study even after treatment 
with 100ng/ml EGF for 10 min (N.B., AFU values are normalised to vehicle: 1.1 ±,0.078) (example 
given in Figure 4.14). As summarised in Figure 4.14, this was consistent with other cell lines used 
within this thesis - tERK fluorescence did not deviate from control levels, even after treatment with 
EGF for 10 min that significantly increased ppERK fluorescence, in COS-7 (1.361 ± 0.236), HeLa 
(0.934 ± 0.039), Ishikawa (1.040 ± 0.011), SKBR3 cells (0.962 ± 0.103), and CHO-Kl cells 
(expressing the V tB receptor, as CHO-Kl) following VP (100nM) treatment for 10 min (1.035 ± 
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Figure 4.12, S min £2 or G-I treatment (S min) does not stimulate ERK phosphorylation in IIEK293 tabl tran reeted with rodent 
GPER. 
) OOnM E2 and 100nM G-) (5 min) did not increase ppERK flu re cence in untransfected II K29 cells (A), r In II K293 cells tably 
transfected with either HA-tagged rat GP R (B), untagged rat GPER ( ), and untagged m use PER (D). There was a ignificant increase 
in pp RK fluorescence in all of the cell lines (A-D) in response to 200nM PDBu and 100ng/mi GF \\hen compared to control . The data 
hown are normalised to vehicle and graphs are representative of at least two fields, from triplicate well and three cpo rate e periments 
(mean ± EM). Statisti cal analysis comparing vehicle-treated versus agonist-treated (for all treatment apart from EGF and control) was 
performed using a one-way ANOYA and the Bonferroni multiple com pari on te t. Yehi Ie-treated EGF-treatcd data was compared 
separately using a Student's I-test (data sets were split up to avoid a type II fal e negative tallsllcal error at the I wer end f the re ponse 
e.g., a large EGF-mediated increa e in ppERK fluorescence may mask a ubtle re p n induced by the other agoni t ). ' , p < 0.05; " , p < 
0.01 ; and .... p < 0.001 . Below each graph are ome reprcsentallv Images of cells treated with contr I (ctrl) or agoni t and stained with 
anti-ppERK antibodies. Scale bar, I OO~lm . 
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Figure 4.13. 10 min £2 or G-I (10 min) treatment does not stimulate ERK pho phorylation in IIEK29J tably tran reeled with 
rodent GPER. 
100nM E2 and 100nM G- I (10 min) did nol increase ppERK nuorescence in untransfecled II -K293 cell (A), r III II K293 cell tably 
transfected with either HA-tagged rat GPER (B), untagged rat GPER ( ), and untagged m u e GP ' R (D). There was a ignificant increase 
in ppERK nuorescence in all of the cell lines (A-D) in re ponse to 200nM POBu and 100ng/mi E F when c mpared to control . The data 
hown are nonnalised to vehicle and graphs arc repre entative of at least two field , from triplicate well and three eparate experiments 
(mean ± SEM). Statistical analysis comparing vehicle-treated versu agoni t-treated (for all treatments apan from EGF and control) was 
perfonned using a one-way ANOVA and the Bonferroni multiple comparison Ie t. Vehicle·treated v EGF-treated data w compared 
eparately using a Student's '-test (data sets were split up to avoid a type II false negative tatistical error at Ihe lower end of the rc p n e 
e.g., a largc EGF·mcdiated increase in pp -RK nuorescence may mask a ubtle resp nse indu ed by the oth rag nists) . • , p < 0.05: •• , p < 
0.01 : and "., p < 0.001. Below each graph are some repre entative images of cell Ireated w.th control (ctrl) or agoni t and tained with 
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Figure 4.14. tERK levels do not change in response to agonist stimulation (IO min). 
(A) tERK fluorescence levels are not significantly altered in COS-7, HEK293, HeLa, Ishikawa and SKBR3 cells treated with 100ng/ml EGF when compared to vehicle. In 
CHO-KI cells stably transfected VIS receptor (VIIJCHO-KI), tERK fluorescence levels also remain unchanged in response to VP (IOOnM) vs control treated cells. The 
data shown are normalised to vehicle and graphs are representative of at least two fields, from at least three wells and at least two separate experiments (mean ± SEM). 
Statistical analysis comparing vehicle-treated versus agonist-treated was performed using a Student's (-test. (B) Representative images of HEK293, HeLa, and VIIJCHO-
K I cells treated with control (ctrl) or agonist and stained with anti-tERK antibodies. Scale bar, IOOl-lm. 
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To reduce any possible vehicle effects, water-soluble E2 (WS-E2) was also purchased. G-l is not 
water-soluble. As with ethanol-soluble E2, incubation of rat HA-GPER transfected HEK293 cells 
with 10nM or 100nM WS-E2 (example of mean ± SEM given for 100nM (N.B., AFU values are 
nonnalised to vehicle): 1.157 ± 0.075) for 5 min had no effect on ppERK fluorescence (Figure 4.15). 
Similarly 1 nM, 10nM, or 100nM did not activate ERK in HEK293 cells transfected with rat 
(untagged) (1 OOnM: 1.132 ± 0.040) or mouse GPER (1 OOnM: 1.139 ± 0.062). 10nM and 100nM WS-
E2 did not increase ppERK fluorescence in untransfected HEK293 cells (1 OOnM: 0.961 ± 0.051). 
Unexpectedly, stimulation with 1 J.1M WS-E2 for 5 min significantly increased ppERK fluorescence in 
all of the HEK293 lines - including non-transfected cells, suggesting the effect was unrelated to 
GPER and non-specific (HEK293: 2.192 ± 0.044; rat HA-GPER: 3.046 ± 0.252; rat GPER 1.506 ± 
0.079; mouse GPER 1.487 ± 0.169). 
As was observed at 5 min, treatment with 1 nM, 10nM, or 100nM WS-E2 for 10 min did not activate 
ERK in HEK293 cells transfected with untagged rat (example of mean ± SEM given for 100nM: 
0.892 ± 0.045) or mouse GPER (100nM: 0.928 ± 0.1). However, IJ.1M WS-E2 did significantly 
increase ppERK fluorescence in untransfected cells, and HEK293 cells stably transfected with rat 
HA-GPER, untagged rat GPER, and mouse GPER (HEK293: 2.076 ± 0.231; rat HA-GPER: 2.572 ± 
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Figure 4.15. Treatment of HEK293 tably fran feeled with rodent GP R with \ ater oluble 2 for 5 min 
doe not timulate ERK phosphorylation. 
Treatment with either I nM , IOnM, or IOOnM water-soluble 2 for 5 min did not in rea e pp RK fluore cence 
in H K293 cells transfected with un tagged rat GP R (A), and untagged mou e P R (8). Treatm nt with 
IOnM or IOOnM W -E2 for 5 min had no effect on pp RK fluore cence in unrran fected H K293 cell ( ) or 
H K293 cells stably transfected with HA-tagged rat GP R (0). 111M W - 2 non- pe ifically in rea ed pp RK 
fluorescence in all cell lines inve tigated. The data hown are normali ed t vehi Ie and graph are 
repre entative of at lea t two fields, from triplicate well and at lea t two eparate e pcriment (mean ± M). 
tatistical analysis was performed using a one-way AN V A and the Dunnett' multiple om pari on test. •• , p < 
0.0 I; and ..... , p < 0.001. Below each graph are ome repre entative image of treated cell tained with anti-
ppERK antibodies. Scale bar, 100pm. 
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Figure 4.16. Treatment of HEK293 tably transfected with rodent GP R, ith wat r oluble E2 for 10 
min doe not stimulate ERK phosphorylation. 
Treatment with either InM 10nM, or 100nM W - 2 for 10 min did not increa pp RK in H K293 cell 
transfected with untagged rat GP R (A), and untagged mou e PER (B). 111M W - 2 n n- pecifically 
increased ppERK fluorescence in untransfected H K293 cell ( ), H K29 ell tably tran fe ted with HA-
tagged rat GPER (D), and also in untagged rat GP R (A), and untagged mou P R (B). The data hown are 
normalised to vehicle and graphs are representative of at lea t two field , from triplicate well and at lea t two 
separate experiments (mean ± EM). tatistical analysis was performed u ing tuden!' I-te tin ( and D) and a 
one-way ANOY A and the Dunnett's multiple compari on te t in (A and B) .• , P < 0.05; and ••• , p < 0.00 I. 
Below each graph are some representative images of treated cells stained with anti-pp RK anlibodi . cale bar, 
100~lm . 
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4.3.5 E2 and G-l do not increase ERK112 phosphorylation via endogenous GPER in 
human cancer cell lines 
As the vast majority of previous in vitro experiments have been performed on human GPER, we 
speculated that perhaps the rodent forms of GPER do not bind E2IG-I. Human Ishikawa 
(ERa+/ERp+/GPER+) and SKBRJ (ERa-IERp-/GPER+) cells that express endogenous GPER were 
used in these experiments, as ERK activation by E2/GPER has previously been demonstrated in these 
cell lines (Filardo et al., 2000; Vivacqua et al., 2006b). Treatment oflshikawa cells with InM, 10nM, 
and 100nM WS (examples of mean ± SEM for 100nM (N.B., AFU values are normalised to control): 
0.967 ± 0.048) and ethanol-soluble E2 (e.g., 100nM: 1.003 ± 0.026), and InM, 10nM, and 100nM G-
I (e.g., 100nM: 1.087 ± 0.049) for 5 min did not increase ppERK fluorescence when compared to 
vehicle (Figure 4.17). Likewise, 10 min incubation of Ishikawa cells with 10M, 10nM, and 100nM 
WS (e.g., 100nM: 1.107 ± 0.124) and ethanol-soluble E2 (lOOnM: 1.124 ± 0.019), and InM, 10nM, 
and 100nM G-l (e.g., 100nM: 1.55 ± 0.046) did not significantly increase ppERK. In contrast, 
IOOng/mI EGF significantly increased ppERK fluorescence in Ishikawa after 5 and 10 min (Figure 
4.17) (5 min: 4.710 ± 0.334; 10 min 5.501 ± 0.111). 
For SKBRJ cells InM, IOnM, and 100nM WS (e.g., 100nM: 1.077 ± 0.OI7) and ethanol-soluble E2 
(e.g., IOOnM: 1.03 ± 0.065), and InM, 10nM, and 100nM G-I (e.g., 100nM 0.925 ± 0.084) for 5 min 
had no significant effect on ppERK fluorescence when compared to vehicle (Figure 4.17). Similarly, 
InM, 10riM, and 100nM WS (e.g., 100nM: 1.048 ± 0.044), and InM, 100M, and 1000M G-I (e.g., 
1.131 ± 0.09) for 10 min did not alter ppERK levels, although there was a noticeable but not 
significant increase in ppERK following 100nM ethanol-soluble E2 (e.g., lOOnM: 1.257 ± 0.041) 
(Figure 4.17). 100ng/ml EGF significantly increased ppERK fluorescence at S and 10 min (S min: 
1.375 ± 0.108; 10 min: 1.575 ± 0.075), but in contrast to Ishikawa cells, the response was not as 
robust, with a < 2-fold maximal response observed at 10 min. As the pictures in Figure 4.17 depict, 
SKBRJ cells have quite high basal levels of ppERK - even after overnight serum starvation in 
DMEMlFI2 media (absent of serum). 
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Figure 4.1 7. Treatment of human cancer cells that endogenously expres GPER "ith E2 and -I do not I ad to ERKII2 activation. 
I hikawa and KBRJ cell were treated with water- olublc -2 (W -E2; InM-IOOnM). ethanol- oluble F2 (InM-IOOnM) and -I (InM-IOOnM) for 5 
(A and • respectively) and 10 (B and D. respecti ely) min. None of the treatment significantl III re ed ppERK Ou re eence abo e ntrollevels. 
Treatment of both I hikawa and KBR3 cells with EGF for 5 and 10 min significantly IIIcreascd ppERK Ouore cen e when c mpared t c ntrol. The 
data shown are normalised to vehicle and graphs are representative of at least two field . fr m tnpllc te well and three eparale experiment (mean ± 
SEM). tatistical analy is comparing vehicle-treated versus agonist-treated (for all treatmenl in KBR3 cell but not E F and control treated 
I hikawa cell ) was performed using a one-way AN VA and the Bonferroni multiple compan n te t Vehicle-treated F-treated dala wa 
compared eparatcly using a tudent ' He t (data et were plil up to avoid a typc II fal e negallve lall Ileal err r allhe lower end of the respon e 
e.g .• a largc EGF-mcdiated increase in ppERK Ouore cence may mask a ubtle re p n e induced by Ihe other agoOlst ) •• , p < 0.01 ; and •••• p < 
0.001 . Below each graph are ome representative images of cell Irealed with conlr I (elrl) or agolll I and lamed with anll-ppERK anlib die . cale 
bar. I OO~lm . 
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4.3.6 E2 and G-l do not activate human GPER to increase il1tracellular calcium ill 
SKBR3 cells 
Since background levels ppERK levels in KBR3 cell are high compared to the other cell type u ed 
in this study (Figure 4.18) it is possible that E2/G-1 RK re pon e are rna ked . 
Figure 4.18. KBR3 cells have high ba eline level ofppERK. 
Images are of COS-7, HEK293 , HeLa and KBR3 cell treated with water for 10 min. Notice that the pp RK 
fluorescence intensity is higher in SKBR3 cells when compared to the other cell typ (note that the e image 
were captured from different experimental plate , therefore the baseline pp RK AFU valu obtained from the 
difference ce ll types cannot be compared). The high background level ofpp RK in KBR3 cells ould ma k a 
potential 2/G-I response. cale bar, IOOllm. 
We therefore tested whether SKBR3 cell would re p nd to 2 or -I in the cal ium timulation 
a say. Treatment of SKBR3 cell with 100nM W - 2 (e ample at 36000m : 1.009 ± 0.196 v H2 
1.020 ± 0.192), 100nM ethanol-soluble (example at 36000m : 0.979 ± 0.031 0.0 I % ethanol 1.075 
± 0.045), and 100nM G-I (example at 36000m : 1.027 ± 0.026 0.0 I % ethan I 1.075 ± 0.045) did 
not increa e intracellular calcium (Figure 4.19). I OO~lM A P ignificantl increa ed fluo-4 
fluorescence in SKBR3 cells (maximal 4-fold re pon e at 36000m : 4.5181 ± 0.400) ~ h n ompared 
to vehicle control (H20: 1.020 ± 0.192). 
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Figure 4.19. GPER does not increase intracellular calcium in re pon e to E2 or -1 in KBR3 cell . 
(A) 100nM E2 (water- and ethanol-soluble) and 100nM G-I did not increa e fluo-4 fluore cence inten ity in 
KBR3 cells when compared to vehicle (N.B., vehicle or agonist were added 10 ea h well at 12000ms). 
Fluorescence intensity significantly increased in cells treated with 100~tM A P v ontrol. The data hown are 
normalised to the value at time Oms. Graphs are representative of one field, from triplicate well and at lea t two 
separate experiments (mean ± SEM). tatistical analysis comparing vehicle-treated ver u agonist-treated at 
each time point was performed using a two-way ANOVA and the Bonferroni po I te t. u., p < 0.00 I. Below 
each graph are some representative images of cells treated with agoni I at Om and 36000m . cale bar, 100flm. 
4.3.7 E2 and G-J do not activate transiently trallsjected hllmall and rodent GPER to 
stimulate ERKJI2 phosphorylation 
o further corroborate our re ult in cell tably tran fected with or pr umably e pre ing 
endogenous GP R, we tran iently tran fected OS-7 and HeLa cell with human, rat or mou e 
GP R, and stimulated the cells with 2 and G-I for 5 or 10 min in the RK pho ph rylation a ay. In 
parallel, non-transfected cell were treated with 100nglmi F, and V 18 r eptor tran iently-
transfected cells were treated with 100nM VP to en ure that I) the ell had a functional RK 
re ponse; and 2) the as ay wa robu t enough to detect aPR re p n in the 30% of tran fect d 
cells and to set the 'pp RK fluore cence thre hold' (ee ection 4.2.7). 
In non-transfected COS-7 ce lls, 100nglmi EGF treatm nt for 5 min timulat d a 4-fold increa e in 
pp RK fluorescence (N.B., AFU value are normali ed to chicl: 3.914 ± 0.191). In -7 cell 
transfected with V IB receptor cDNA, 100nM VP treatment for 5 min in rea d pp RK b 2-fold 
(1.968 ± 0.088), when compared with vehicle control. In contra t, 10nM and 100nM 2 (Wand 
ethanol so luble) (N.B., value are % of cell above pp RK flu re cence thr h Id ( ample of 100nM 
given): W -E2, 2.982% ± 1.697 v H2 4.112% ± 1.212; ethanol- luble 2: 3.375% ± 0.976 
0.01% ethanol 2.408% ± 0.097) and 10nM and 100nM -I (e.g., 100nM: 2.368% ± 0.544 0.01% 
ethanol 2.408% ± 0.097) failed to ignificantly increa e pp RK flu r en e in -7 c II 
transfected with human GP R (Figure 4.20). Treatment f non-tran ~ ted -7 II with 
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100nglml EGF for 10 min induced a 6-fold increase in ppERK (N.B., AFU values are normalised to 
vehicle: 6.570 ± 0.206). In cells transfected with V IB receptor eDNA, 10 min 100nM VP treatment 
lead to a 2-fold rise in ppERK (2.364 ± 0.076) when compared with vehicle. As with the 5 min 
timepoint, 10 min 10nM and 100nM E2 (WS and ethanol-soluble) {N .B., values are % of cells above 
ppERK fluorescence threshold (example of 100nM given): WS-E2, 2.410% ± 0.357 vs H20; ethanol-
soluble E2: 3.314% ± 1.073 vs 0.01% ethanol 4.176% ± 1.842) and lOnM and 100nM G-l (e.g., 
100nM: 4.301% ± 1.752 vs 0.01% ethanol 4.176% ± 1.842) did not significantly increase ppERK in 
COS-7 cells transfected with human GPER (Figure 4.20). 
In non-transfected HeLa cells, EGF treatment (100nglml) for 5 min activated a robust ERK response 
leading to a 20-fold increase in ppERK (N.B., AFU values are normalised to vehicle: 20.674 ± 0.173). 
In VIB receptor transfected HeLa cells, VP treatment (lOOnM for 5 min) increased ppERK by 7-fold 
(7.749 ± 0.081). As was observed in COS-7 cells,S min treatment of lOnM and 100nM E2 (water-
and ethanol-soluble) {N.B., values are % of cells above ppERK fluorescence threshold (example of 
100nM given): WS-E2 0.970% ± 0.083 vs H20 0.424% ± 0.048; ethanol-soluble E2 0.624% ± 0.202 
vs 0.01% ethanol 0.483% ± 0.105) and 10nM and 100nM G-I (e.g., lOOnM: 0.4% ± 0.043 vs 0.01 % 
ethanol 0.483% ± 0.105) did not increase ppERK in HeLa cells transfected with human GPER (Figure 
4.21). 
Stimulation of non-transfected HeLa cells with 100nglmi EGF for 10 min increased ppERK by 16-
fold (N.B., AFU values are nonnalised to vehicle: 15.760 ± 0.523). In VIB receptor-transfected HeLa 
cells, 100nM VP treatment for 10 min increased ppERK by 5-fold (5.675 ± 0.145). Concomitant with 
the COS-7 cell data, lOnM and 100nM E2 (water- and ethanol-soluble) {N.B., values are % of cells 
above ppERK fluorescence threshold (example of 100nM given): WS-E2 0.147% ± 0.119 vs H20 
0.363% ± 0.175; ethanol-soluble E2 0.354% ± 0.136 vs 0.01% ethanol 0.256% ± 0.042) and 10nM 
and 100nM G-I (for 10 min) (e.g., 100nM: 0.126% ± 0.032 vs 0.01 % ethanol 0.256% ± 0.042) did 
not significantly induce an ERK response in HeLa cells transfected with human GPER (Figure 4.21). 
In COS-7 cells transfected with untagged rat GPER, 10 min treatment with l00nM E2 (e.g., 100nM: 
WS-E2 3.577% ± 1.075 vs H20 4.524% ± 4.366; ethanol-soluble E2 0.747% ± 0.369 vs 0.01% 
ethanol 0.857% ± 0.237) or 100nM G-l (G-I 3.452% ± 0.393 vs 0.01% ethanol 0.857% ± 0.237) did 
not lead to an increase in ppERK (Figure 4.22). As with the rat GPER clone, COS-7 cells transfected 
with mouse GPER did not respond to 100nM E2 (WS-E2 3.312% ± 1772 vs H20 2.574% ± 1.674; 
ethanol soluble E2 0.686% ± 0.217 vs 0.01% ethanol 1.818% ± 0.899) or 100nM G-I (1.73771 ± 1.47 
vs 0.01% ethanol 1.818% ± 0.899) to increase ppERK levels (Figure 4.22). 
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Figure ~.20. Transiently transfected human GPER does not stimulate ERK phosphorylation in COS-7 cells following 5 or 10 min of E2 or G-I treatment. 
In non-transfected cells, IOOnglml EGF stimulated a significant increase in ppERK fluorescence at 5 and 10 min, as represented by an increase in nonnalised ppERK fluorescence (A and C, 
respectively). In COS-7 cells transiently transfected with VIS eDNA, 100nM VP treatment for 5 and 10 min also stimulated a significant increase in ppERK fluorescence when compared with vehicle 
controls (A and C, respectively). The ppERK fluorescence data obtained with the V 18 receptor transfected COS-7 cells was used to set a threshold as described in section 4.2.7. The proportion of cells 
displaying an ERK response (emit ppERK fluorescence above threshold) at 5 (B) or 10 min (D) following 10nM or IOOnM E2 (water- and ethanol-soluble) or 10nM or 100nM G-I treatment was not 
significantly different from vehicle in COS-7 cells transfected with human GPER. Graphs are representative of at least two fields, from triplicate wells and three separate experiments (mean ± SEM). 
Statistical analysis comparing vehicle-treated versus either EGF- or VP-treated (in A-D) was perfonned with a Student's I-test. Statistical analysis comparing vehicle-treated versus either E2-or G-I-
treated (in B and D) was perfonned using one-way ANOVA and the Bonferroni multiple comparison test. .. , p < 0.0 I. Adjacent to each graph are some representative images of cells stained with anti-
ppERK antibodies treated with control (ctrl) or agonist. Scale bar, 100jll1l. 
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Figure 4.21. Transiently transfccted buman GPER does not stimulate ERK pbospborylation in HeLa cells following 5 or 10 min of E2 or G-I treatment. 
In non-transfected cells, lOOnglml EGF stimulated a significant increase in ppERK fluorescence at 5 and 10 min, as represented by an increase in normalised ppERK fluorescence (A and C. 
respectively). In HeLa cells transiently transfected with VI8 cDNA, 100nM VP treatment for 5 and 10 min also stimulated a significant increase in ppERK fluorescence when compared with vehicle 
controls (A and C, respectively). The ppERK fluorescence data obtained with the V 18 receptor transfected HeLa cells was used to set a threshold as described in section 4.2.7. The proportion of cells 
displaying an ERK response (emit ppERK fluorescence above threshold) at 5 (B) or 10 min (D) following 10nM or lOOnM E2 (water- and ethanol-soluble) or 10nM or IOOnM G-I treatment was not 
significantly different from vehicle in HeLa cells transfected with human GPER. Graphs are representative of at least two fields, from triplicate wells and two separate experiments (mean ± SEM). 
Statistical analysis comparing vehicle-treated versus either EGF- or VP-treated (A-D) was performed with a Student's I-test. Statistical analysis comparing vehicle-treated versus either E2-or G-I-
treated (in C and D) was performed using one-way ANOVA and the Bonferroni multiple comparison test. ••. p < 0.0 I; ••• , p<0.005. Adjacent to each graph are some representative images of cells 
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Figure 4.22. Transiently transfected rodent GPER does not stimulate ERK phosphorylation in COS-7 cells following 10 min of E2 or G-I treatment. 
In COS-7 cells transiently transfected with VIB eDNA, 100nM VP treatment for 10 min stimulated a significant increase in ppERK fluorescence when compared with vehicle 
controls (A). The ppERK fluorescence data obtained with the V IB receptor transfected COS-7 cells was used to set a threshold as described in section 4.2.7. The proportion of cells 
displaying an ERK response (emit ppERK fluorescence above threshold) 10 min following 100nM E2 (water- and ethanol-soluble) or 100nM G-I treatment was not significantly 
different from vehicle in COS-7 cells transfected with rat (B) or mouse (C) GPER. Graphs are representative of at least two fields, from triplicate wells and three separate 
experiments (mean ± SEM). Statistical analysis comparing vehicle-treated versus either E2-or G-I-treated (in B and C) was performed using one-way ANOVA and the Bonferroni 
multiple comparison test. Statistical analysis comparing vehicle-treated versus VP-treated (in A-C) was performed with a Student's I-test .• , p < 0.05; •• , p < 0.0 I. Adjacent to 
each graph are some representative images of cells stained with anti-ppERK antibodies treated with control (ctrl) or agonist. Scale bar, IOOflm. 
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4.3.8 Mouse GPER does not increase ERK phosphorylation via an E2 sulphotransJerase 
metabolite 
Given that the data in the previous sections does not reveal that rat, mouse or human GPER are 
activated by E2 or G-I in our ERK assay, we hypothesised that an E2 metabolite rather than E2 may 
bind to and activate GPER. E2 sulphotransferase (SUL Tl E I) is an enzyme that converts E2 to E2-
sulphate, an E2 metabolite that is hydrophilic, has a longer half-life than E2, and is deemed 
biologically inactive as it cannot bind to ERa or ERP (Song, 2006; Pasqualini, 2009). We 
hypothesised that E2-sulphate is in fact the biologically active endogenous ligand for GPER. To test 
this theory, we stably transfected mouse E2 sulphotransferase into HEK293 cells and HEK293 cells 
stably transfected with mouse GPER, and treated them with E2 and/or G-I in the ERK 
phosphorylation assay. As previously shown, 100nM E2 (N.B., AFU values are normalised to vehicle: 
WS-E2 1.012 ± 0.224; ethanol-soluble E2 1.014 ± 0.107) and 100nM G-l (0.904 ± 0.123) treatment 
for 10 min did not significantly increase ppERK in HEK293 cell stably transfected with mouse GPER 
(Figure 4.23). 10 min treatment of 100nM E2 (WS-E2: 0.974 ± 0.115; ethanol-soluble: 0.967 ± 0.049) 
and 100nM G-I (0.955 ± 0.036) did not increase ppERK fluorescence levels in HEK293 cell stably 
transfected with mouse E2 sulphotransferase. In HEK293 cells stably co-transfected with both mouse 
GPER and E2 sulphotransferase, 100nM E2 (WS-E2: 1.116 ± 0.076; ethanol-soluble: 0.964 ± 0.046) 
and 100nM G-I (0.955 ± 0.036) for 10min, did not increase ppERK levels (Figure 4.23). As a further 
experimental control, HEK293 cells (transfected with mouse GPER) were treated with carbachol, a 
muscarinic receptor agonist. Carbachol (500J1M) induced a significant increase ppERK fluorescence 
in the HEK293 cells (1.831 ± 0.190), suggesting that these cells are capable of mediating a GPCR-
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Figure 4.23. 10 min E2 or - I treatment does not stimulate ERK phosphory la tion in II EK293 cell ta bly co-tra nsfccted 
with mou e GPER and mouse E2 sulphotransfera, c. 
Treatment with 100nM E2 (water- and ethanol- oluble) or 100nM G-I Ii riO min did not increase ppERK fluore 
ell tran fected with mouse GP R (A), mouse E2 ulphotransferase (8). r cell co-transfected with bolh mouse P Rand mou e 
E2 ulphotransferase ( ). 500j.lM carbo hoI igni licantly increa ed PP " RK fluore cenee in II K29 ells tran fected with mou e 
P R (D). The data shown are normalised to vehicle and graphs are repre entative of at lea ttwo field. from triplicate wells and at 
least two separate experiment (mean ± . M). tati tical analysi wa performed 1I ing a one-way V and the bonri rr ni (A-
) or Dunnell's multiple compari on test in (D) ... , p < 0.01. Below each graph are orne representati e image of treated ell 
tained with anti-ppERK antibodie . calc bar. 100j.lm. 
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4.3.9 Transiently transfected human and rodent GPER are not activated by aldosterone 
(ALD) to activate ERKll2 phosphorylation 
As mentioned in section 4.1.3 it has been recently reported that low concentrations (e.g., 0.1-1 nM) of 
ALD stimulates ERK phosphorylation in rat aortic vascular endothelial cells via a GPER-dependant 
mechanism (Gros et al., 2011). In COS-7 cells transfected with human GPER, 10 min or 15 min 
treatment with 0.1 nM or 1 nM ALD did not lead to an increase in ppERK when compared to vehicle 
controls (Figure 4.24) (N.B., values are % of cells above ppERK fluorescence threshold. Example of 
1 nM given: 10 min, 3.499% ± 1.856 vs 0.0001% ethanol 4.176% ± 0.651; 15 min, 1.819% ± 0.615 vs 
0.0001% ethanol 1.866% ± 0.752). In addition, O.lnM or InM ALD did not increase ppERK levels in 
HeLa cells transfected with human GPER (Figure 4.25) (example of InM given: 10min, 0.152% ± 
0.091 vs 0.0001% ethanol 0.019% ± 0.019; 15 min, 0.765% ± 0.328 vs 0.0001% ethanol 0.371% ± 
0.077). Furthermore, 100nM ALD did not increase ppERK levels in COS-7 cells transfected with 
either rat or mouse GPER (for 10 min) when compared to vehicle (Figure 4.26) (rat GPER: 5.947% ± 
0.984 vs 0.0001% ethanol 5.598% ± 0.124; mouse GPER: 3.718% ± 1.128 vs 0.0001% ethanol 
3.647% ± 0.965). 
137 
C hap Ie r .f. (h a rae I e r i "a Ii 0 11 tl I (J P I R 










.t: 30 ! 
: : 






.. 10 \.I .. 10 \.I 
• • . • 
0 
Human GPER tr8nsfect d 18 tranf cted Hum n PER tun fected III tr.nfected 
Figure 4.24. Transiently transfected human GPER doe not timulate ERK pho phoryl tion in 0 -7 
cell following 10 or 15 min of ALD treatment. 
As shown in previous figures (Figures 4.20, 4.22), 100nM VP for 10 min timulate a ignificant increa e in ppERK 
fluorescence when compared with vehicle controls in 0 -7 cells tran iently transfected with IB cD A. The ppERK 
fluorescence data obtained with the V IB receptor transfected 0 -7 cell wa u ed to et a thre hold as descri bed in 
section 4.2.7. The proportion of cells displaying an ERK respon e (emit ppERK fluore cence above threshold) 
fo llowing O.lnM, InM or 100nM ALD treatment for 10 min (A), or O.lnM or InM ALD for 15 min (B) was not 
significantly different from vehicle 0 -7 cells transfected with human GP R. Graph ar repre entative of at least 
two fields, from triplicate wells and two separate exp riment (mean ± EM). tatisti al analy i comparing vehicle-
treated versus ALD-treated was performed using a one-way A V and the Bonferroni multiple c mpari on test. 
tatistical analysis comparing vehicle-treated ver u VP-treated (in and B) wa p rformed with a tudent ' I-te t. 
•• , P < 0.0 1. Adjacent to each graph are some representative image of ell tained with anti-pp RK antibodies 
treated with control (ctrl) or agonist. cale bar, 1001lm. 
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Figure 4.25. Transiently transfected human GPER does not timulate ERK pho phorylation in HeLa cell 
following 10 or 15 min of ALD treatment. 
As shown in previous figure (Figure 4.21) in HeLa cells transiently tran fe ted with V 10 cD ,I OOnM VP for 10 
min stimulates a significant increase in ppERK fluorescence when compared with vehicle controls. The pp RK 
fluorescence data obtained with the V 10 receptor transfected HeLa cells wa u ed to et a thre hold as de cribed in 
section 4.2.7. The proportion of cells displaying an ERK respon e (emit pp RK flu re cen e above threshold) 
followi ng O.lnM, InM or 100nM ALD treatment for 10 min (A), or O. lnM or InM ALD for 15 min (8) wa not 
significantly different from vehicle in 0 -7 cells transfected with human GPER. raph are repre entative of at lea t 
two fields, from triplicate wells and two separate experiments (mean M). tati tical analysi comparing vehicle-
treated versus ALD-treated was performed lIsing a one-way A OVA and the Bonferroni multiple com pari on Ie t. 
tatistical analysis comparing vehicle-treated versus VP-treated (in and 8) wa performed with a tudent's I-test. 
•• , p < 0.0 I. Adjacent to each graph are ome representative image of cell tained with anti-pp RK antibodies 
treated with control (ctrl) or agonist. cale bar, IOOllm. 
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Figure 4.26. Transiently transfected rodent GPER doe not timulate ERK pho phor lation in 0-7 
cell following 10 min ALD treatment. 
As shown in previous figures (Figures 4.20, 4.22) in -7 cell tran iently tran fected with V IB 0 A, 100nM VP 
treatment for 10 min stimulates a significant increa e in ppERK fluore c nee when c mpared wilh vehicle controls. 
The ppERK fluorescence data obtained with the VIB receptor tran fe ted -7 ell wa u ed to et a Ihre hold as 
described in section 4.2.7. The proportion of cells di playing an ERK re p n e ( mit pp RK fluorescen e above 
threshold) following 100nM ALD treatment for 10 min was not ignificantly different from vehi Ie in -7 cells 
transiently expressing rat GPER (A) or mou e GP R (8). Graph are repre entati e f at Ie I two field , from 
triplicate wells and two eparate experimenl (mean ± M). tali tical analy i comparing vehicle-treated ersus 
A LD-treated was performed using a one-way A OVA and the 8 nferroni multiple com pari on test. talistical 
analysis comparing vehicle-treated versus VP-treated (in A and B) wa performed with a ludent' I-Iest.· , p < 0.05; 
•• , P < 0.0 I. Adjacent to each graph are some repre entative image of c II tained with anli-pp RK antibodies 
treated with control (ctrl) or agonist. cale bar, JOOflm. 
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4.3.10 Endogenous human and stably transfected rodent GPER are not activated by ALD 
to activate ERK112 phosphorylation 
To confirm that GPER does not increase RK phosphorylation in re pon e to ALD, we timulated 
KBR3 cells that endogenously express GP Rand H K293 cell tably tran fected with rodent 
GPER, with ALD. ppERK levels were not ignificantly altered in KBR3 following 0.1 nM or I nM 
ALD treatment for 5 min or 15 min (N.B., AFU value are normali ed to vehicle (e ample for I nM 
given): 5 min, 0.927 ± 0.076; 15 min, 1.058 ± 0.195) (Figure 4.27). In H " K293 cell tably 
transfected with rat untagged GPER or mou e untagged P R, incubation with 0.1 nM or I nM ALD 
for 5 or 15 min (example of 1 nM given. Rat GP ; R: 5 min 0.830 ± 0.08; 15 min 0.915 ± 0.063. Mou e 
GPER 5 min 0.823 ± 0.148; 15 min 1.066 ± 0.08) did not ignificantl increa RK pho phory1ation 
(Figure 4.28). 
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Figure 4.27. ALD does not timulate ERK activation in KBR3 cell . 
KBR3 15 min 
I 
-
0.1 nM and I nM ALD treatment for 5 (A) or 15 min (B) did not a tivat RK pho ph r lation in KBR3 cell . 
The data shown are normali ed to vehicle and graph are repre entative of at lea t n fi Id. from tripli ate well 
and two separate experiment (mean ± M). tatistical analy i wa performed u ing a one-way AN VA and 
the Bonferroni multiple compari on test. Below each graph are ome repre entati e imag f II treated with 
ethanol control or ALD and stained with anti-pp RK antib die . cale bar, 100llm. 
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Figure 4.28. ALD does not timulate ERK pho phorylation in HEK293 cell tabl tran ~ cted with 
rodent GPER. 
pp RK fluorescence did not alter in H K293 cells tably tran fe ted with rat or m u e P R following 
treatment with IOOnM ALD for 5 (A and , respectively) or 15 min (B and D. re pe tively). The data hown 
are normalised to vehicle and graphs are representative of at lea t one fi eld, from tripli at well and two 
eparate experiments (mean ± M). tatistical analy i wa performed u ing a one-way AN V A and the 
Bonferroni multiple comparison test. Below each graph are ome repre entative image f ell treated with 
ethanol control or ALD and stained with anti-pp RK antibodie. cale bar, IOOllm. 
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4.4 Discussion 
It is well established that E2 provokes rapid non-genomic cell signalling e.g., activation of adenylyl 
cyclase/cAMP, ERK, and P13K transduction cascades (Bjornstrom and Sjoberg, 2005). These actions 
are thought to be attributable to membrane associated forms of the traditional E2 receptors as well as 
the recently identified E2-GPCR, GPER (Levin, 2005; Thomas el 01., 2005; Revankar el 01., 2005). 
However, the GPER field is rife with conflicting results regarding its cellular localisation and 
activation by E2. For this reason, the current study was undertaken to clarify the in vitro 
characterisation of GPER. Our main findings were as follows: (1) the majority of HA-GPER is 
expressed intracellularly in HEK293 cells, a distribution unaffected by overnight E2 or G-I treatment; 
(2) E2 and G-I do not activate the human, rat, or mouse GPER to stimulate ERK phosphorylation or 
mobilise intracellular calcium; (3) the mouse GPER is not activated by an E2 sulphotransferase 
metabolite to stimulate ERK phosphorylation; and (4) the human, rat and mouse GPER are not 
activated by ALD. 
4.4.1 GPER is located at the cell sUrface although the majority is expressed 
intracellularly 
Our observations that the majority of HA-GPER in HEK293 cells is expressed intracellularly, whilst 
only approximately 24% is localised to the plasma membrane, contradicts previous studies that either 
report that the majority of GPER is localised to the plasma membrane (Filardo el 01., 2007; Funakoshi 
el 01., 2006) or GPER is solely. expressed intracellularly (Revenkar el 01., 2005; Otto el 01., 2008). 
Many of the earlier studies used a tagged variant of GPER (HA-, FLAG-, or GFP-tagged) to define 
cellular localisation. Therefore, one explanation for these discrepancies is that tagging of the receptor 
could restrict receptor trafficking to the plasma membrane. In fact, Funakoshi and colleagues 
demonstrated that the rat GPER and another GPCR, GPRI75, are expressed at the plasma membrane 
of He La cells when FLAG-tagged (FLAG tag used in this study was 24 amino acids long), whereas 
their GFP-tagged (GFP tag is 238 amino acids long) counterparts are restricted to the endoplasmic 
reticulum (Funakoshi el 01., 2006). 
In the current study, we decided to combine GPER with a small HA-tag (9 amino acids in length) 
immediately following the initiating methionine that has been shown to have no influence on receptor 
functionality (lnnamorati et aI., 1996, 1998; Sedgley et 01., 2006; Finch et 01., 2008). Filardo and 
colleagues also stably transfected a HA-GPER construct into HEK293 cells and found predominant 
HA-GPER expression at the plasma membrane, in contrast to the distribution pattern to that of the 
current study (Filardo et 01., 2007). These investigators employed a biased selection method to select 
their stable HEK293 lines - they used fluorescence-activated cell sorting (with anti-HA fluorescence 
staining) to isolate cells that highly express HA-GPER at the cell surface, and only used these cells in 
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ub equent experiments (Filardo et al. , 2007). Our clone election procedure wa ba ed on antibiotic 
re istance and GPER transcript expression, and perhap provide a more a curate reflection of the 
endogenous localisation of HA-GPER in HEK293 cell . The tabl cell lin u ed in thi tudy were 
tho e assessed to have the highest transcript expres ion ( ee n 4.3.1), and thi wa table over 
the number of passages used in thi study. It is worth noting there wa e, tr m ariation in GP R or 
2 sulphotransferase mRNA expression between eparate colonie (in the 96 well plate ee ection 
2.5.4) even though all the cells were resistant to G418 and/or H gro. Thi ariable e pre ion may be 
due to the random integration of the GPER or E2 ulphotran fera e con tru t into different site in 
the host genome. 
We have not endeavoured to identify the intracellular tructure in which GP R i found (e.g., using 
ubcellular markers), but a previous study demon trated that non-tagged P R locali e to the 
endoplasmic reticulum in transiently transfected HEK293 cell u ing anti- P ' R antib die (Otto el 
al. 2008). Similarly, Revenkar et al., investigated GP R cellular 10 ali ation with N- or -terminal 
directed antibodies and detected intracellular e pre ion of endogenou P R in the endopla mic 
reticulum and Golgi apparatu of KBR3, MCF-7 and MDA-MB23I cell , and tran i ntlyexpre ed 
GP R in COS-7 cells - with no evidence of GP R at the pia rna membrane (Revankar el al. , 2005). 
The proportion of GPER at the plasma membrane ver e intracellular tm ture rna highlight that 
GPER cellular localisation is cell type-dependant and equalJ it could r flect difference in technique 
u ed. Filardo and colleague investigated the locali ation of endog nou GP R in KBR3 cell by 
we tern blot analysis which revealed GP R in preparati n enriched in either th pia rna membrane 
or endoplasmic reticulum compartments, while a tritiated 2 binding a a nly unma ked 2 binding 
ites at the plasma membrane (Filardo el al. , 2007). In addition, the pia rna membrane form of GP R 
may differ from that found at the endopla mic reticulum I' g Igi apparatu . It i well kn wn that the 
degree of post-translational modification e.g., glyco ylation, palmito lati n or formation of 
oligomeric complexe can influence GP R destination (Tan el al., 2004; hini and Parenti, 2009; 
Wheatley and Hawtin, 1999). 
Cellular GPER localisation may also be influenced by media-born oe trogeni mp und that could 
affect the trafficking of the receptor. Therefore, we inve tigated whether or not 0 ernight incubation 
in serum- and phenol-free media with or without 2 or -I had an effect on P -R urface 
ex pres ion. Neither E2 nor G-I had any ignificant effect on HA- P R di tribution at the time point 
(24 hour) examined. Thi is unexpected con idering the cellular 10 ali ation f aPR i often 
ignificantly altered following agonist treatment, generally leading to r eptor de en iti ation and/or 
degradation (Gainetdinov el al., 2004), but additional time-cour e and d e-re p n e tudie in a 
variety of cell types are neces ary under tand GP R turno er following e po ur to agoni t( ). 
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In this chapter, we did not attempt to determine whether GPER signals from the plasma membrane or 
from inside the cell (since we were unable to identify a viable ligand). As mentioned in the 
introduction, Filardo and colleagues report that cell impermeable E2-conjugates (e.g., E2-BSA and 
E2-horseradish peroxidase) are able to activate GPER (Filardo et al., 2007); while Prossnitz and co-
wor!c.ers demonstrated that only membrane permeable fluorescent E2 or radioactive G-I derivatives 
(e.g., 17a-Phenylethynyl-E2 and indium-labelled G-I analogues) are able to stimulate GPER 
(Revenkar et al., 2007; Nayak et al., 2010). It is possible that GPER can signal from a number of 
cellular compartments, as shown for other GPCRs (Boivin et al., 2008; Calebiro et al., 2010; Re et al., 
2010). However, it should be noted that the use of E2-conjugates such as E2-BSA to prove cell 
surface E2-activation has been queried. Stevis and colleagues demonstrated not only that free E2 can 
leach from E2-BSA compounds which may infuse inside the cell, but E2-BSA also has biological 
activity that is not mimicked by E2 (Stevis et al., 1999). Equally, studying whole cell receptor binding 
with labelled-Iipophillic compounds such as steroids can be misleading. Labelled-Iipophillic 
compounds can rapidly infuse into intracellular organelles and may not be removed with washing (as 
the compound is trapped within the organelle) or not be displaced with excess non-labelled ligand 
(Thomas et al., 2010). 
4.4.2 E2 and 6-1 do not simulate ERK phosphorylation or calcium mobUisation via the 
human or rodent GPER 
In agreement with several other studies, we were unable to demonstrate E2IG-I mediated-ERK 
activation or calcium mobilisation in cells stably transfected with rodent GPER, or transiently 
transfected with rodent GPER (Pedram et al., 2006; Otto et al., 2008). We speculated that there may 
be species differences in the ability of E2 to activate GPER (section 4.3.4) and that rodent GPERs 
may not bind E2/G-I. Sequence alignment of human, rat and mouse GPER (in Figure 4.29) reveals 
that the human GPER and the rodent GPER are highly homologous from the first transmembrane 
domain onwards (amino acids 63-375), but differ substantially in the first extracellular domain (amino 
acids 1-62). This may provide one explanation as to why E2 and G-I do not activate the rOdent 
receptor, as the first extracellular domain corresponds to the amino-terminus which may be involved 
in ligand binding (Kristiansen. 2004). Therefore. E2 and G-I may bind to the human. but not the 
rodent GPER, as a result of a different ligand binding domain. 
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Figure 4.29. Sequence alignment of human, rat and mouse GPER 
60 GPER HUMAN 
60 GPER RAT 
60 GPER MOUSE 
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120 GPER RAT 
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240 GPER RAT 
240 GPER MOUSE 
300 GPER HUMAN 
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300 GPER MOUSE 
360 GPER HUMAN 
360 GPER RAT 
360 GPER MOUSE 
Alignment of the human GPER (top line), rat GPER (middle line) and mouse GPER (bottom line) receptor sequences. 
generated with the aid of the web-based uniprot equence alignment tool ( htln : ,'I\~\,\, . uniprot.org ' uniprotl). To signify exact 
residue matches across al l three receptors, amino acids arc highlighted in dark green and are represented by an asterisk on 
line 4 (*). Light green denotes amino ac id alignment between the rat and mouse GPER only. although amino acids within the 
human GPER sequence that are akin to rat/mouse are indicated on the fourth line \~ith a semi colon (conserved ubstitution) 
or a full top (semi-conserved substitution), All three receptors have similar amino acid sequences (particular the rat and 
mouse receptors), apart from the I Sf extracellular domain (amino acids 1-62), where the human sequence noticeably differs 
from that of the rodent. In addition , the last 18 amino acids of the human receptor arc underlined as the GPER antibody 
(used in Chapter 3) was directed towards those residues (Revankar e/ al., 2005). There is reasonabl) high sequence 
homology between human and rodent in these last 18 amino acids. apart from two conserved sub. titutions in the rat and 
mouse sequences at residues 368 and 370. 
However we could not demonstrate activation of human GPER, whether endogenously expre ed or 
introduced by transfection, in our signal transduction assay. Our result for both rodent and human 
GPER is in disagreement with a large body of evidence that ugge t that 2/G-1 activation of GPER 
stimulates ERK and calcium signalling as well as many other pathway in vitro e.g" the PI3K, cAMP, 
and RhoA/Rho-kinase signalling cascades (Maggiolini et al., 2004; Revankar et al., 2005; Thoma et 
al., 2005; Filardo et aI., 2007; Chavalmane et al., 2010). It i difficult to reconcile all of the tudies 
surrounding GPER's role as an E2/G-1 receptor. 
The unresponsiveness of SKBR3 cells to E2/G-1 is even more baffling considering they were 
obtained from the Prossnitz group - one of the first laboratorie to report E2/GPER ignalling in 
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SKBRJ cells, and those responsible for the identification/synthesis of G-I and G-15 (Revenkar el al., 
2005; Bologa et al., 2006; Dennis el al., 2009). Indeed it is possible (however unlikely) that the E2 
responsiveness of the cells may have been reduced during transit (from New Mexico ~ UK), that we 
were sent an unresponsive subclone, or even subtle differences in culturing (although every care was 
taken to ensure that the SKBRJ cells were appropriately maintained - they were cultured in DMEM 
and DMEMIF 12 as recommended). One caveat pertaining to our studies on SKBRJ cells is that we 
did not measure endogenous GPER expression. However, transfection of human GPER cDNA (also 
obtained from the Prossnitz group) into COS-7 and HeLa cells did not facilitate E2/G-I mediated 
signalling, which has previously been demonstrated in these cells (Revenkar el al., 2005). Together 
this suggests that in our hands the human GPER is not activated by E2 and G-I. 
One possible explanation for the discrepancies surrounding E2/G-I activation of GPER may be that 
studies investigating the effects of GPER on cell signalling do not always employ appropriate vehicle 
controls. For example, Vivacqua and coworkers used I JAM E2 dissolved in ethanol to stimulate GPER 
in ERK and c-Fos assays, but only used untreated cells as their controls (Vivacqua el al., 2006b). 
There are other examples of studies that are devoid of vehicle controls and instead use untreated cells 
or cells transfected with empty vector as controls, or do not mention controls at all (Filardo el al., 
2000; Maggiolini et al., 2004; Revenkar et al., 2005; Brailoiu el al., 2007). While in some instances 
untreated cells and cells transfected with empty vector can be valid controls, in cell stimulation assays 
vehicle controls must be used - even if it means applying water (e.g., for comparison with WS-E2) to 
account for possible mechanical/osmotic stimulation (this is of particular importance when applying a 
ligand for a short time period). As highlighted in the results section 4.3.4, vehicle controls are 
essential when dealing with organic solvents such as ethanol and DMSO that are known to have 
effects on ERK signalling (Reddy and Shukla, 2000; Koo and Kim, 2009). For example, Otto and 
colleagues observed the same time-dependant induction of ERK phosphorylation in transiently 
transfected COS-7 cells after vehicle (e.g., 0.0001% DMSO) and E2 application - independent of the 
presence or absence of GPER (Otto et al., 2008). 
As indicated above, some studies have used I JAM E2 to stimulate GPER (e.g., Vivacqua et al., 2006b; 
Maggiolini el al., 2004). This is disconcerting considering that in the current study we observed non-
specific E2-mediated ERK phosphorylation in untransfected HEK293 cells, following treatment with 
1 JAM E2. It is proposed that high concentrations of steroids may have physicochemical interactions 
with phospholipid membranes e.g., high doses of E2 and tamoxifen (JAM) reduce membrane fluidity in 
MCF7 and MDA-MB-4306 cells, while high levels of progesterone (JAM) decreases the fluidity of 
human and hamster spennatozoa membranes, and also induces aggregation and/or fusion of 
membrane vesicles (Clarke et al., 1990; Shivaji and Jagannadham, 1992). Likewise, high doses of 
glucocorticoids can inhibit calcium and sodium cycling across the plasma membrane and reduce A TP 
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availability in lymphocyte cells (by inhibiting the reactions of substrate oxidation and by increasing 
the leakage of protons across the mitochondrial inner membrane) (Buttgereit and Scheff old, 2002). 
Thus, high concentrations of steroids can non-specifically interact with phospholipid membranes 
which may impact on down-stream signalling cascade such as the ERK pathway. 
In the majority of our cell assays we used E2 and G-I at concentrations between I nM-I OOnM in an 
attempt to elicit a GPER response. While these are a high concentrations with respect to circulating 
levels ofE2 (in women [E2] ranges from 146.8-2IS.lpM in the follicular phase to 734-IS70.8pM in 
the pre-ovulatory peak; in men [E2] ranges from 0.9-IS7.1 pM), it can be assumed that at the tissue 
level the concentration of E2 may be much higher, particularly as E2 can be synthesised locally by 
aromatase activity (Comil et al., 2006). However, the purpose of this study was not to mimic 
physiological E2 concentrations, but to verify that GPER is indeed an E2 receptor - therefore we used 
ligands at concentrations that are pharmacologically relevant. Prossnitz and colleagues have 
previously described that E2 stimulation of GPER activates calcium mobilisation with a half-maximal 
effector concentration (ECSO) of approximately O.SnM, with maximal stimulation observed at 100nM 
(Revenkar et al., 200S). Similarly, the same group report that G-I also activates calcium mobilisation 
with an ECSO of approximately 2nM, with a maximal response between 100-SOOnM (Bologa et al., 
2006). Hence 100nM of E2 and G-I are not only pharmacologically relevant concentrations, but have 
the potential to illicit maximal GPER mediated-responses. 
Another reason for the lack of an E2/G-lIGPER stimulated ERK response in these cells may be that 
the time points were insufficient to observe response. However, many studies have observed a human 
GPER-mediated increase in ppERK in response within a S-1 S min course of E2 treatment (Filardo et 
al., 2000, 2002; Maggiolini et al., 2004). The experimental controls used within this study also 
confirm that the HEK293 cells are able to elicit an ERK response - EGF and PDBu stimulated ERK 
phosphorylation in all of the HEK293 cell lines. Indeed, activation by EGF suggests that these 
HEK293 cells endogenously express the EGFR, which is I) in agreement with the northern 'dot blot' 
analysis which illustrates high levels of EGFR mRNA is expressed by HEK293 cells; and 2) implies 
that E2/G-I via GPER could transactive this receptor to stimulate the ERK pathway. In addition, 
PDBu stimulation of ERK suggests that the ERK pathway is functional downstream of the EGFR 
receptor (Figure 6.1 illustrates how PK.C feeds into the ERK pathway). Together, this indicates that 
ERK signalling is not compromised in these HEK293 cells. 
It has been reported that treatment with serum/phenol-free media downregulates GPER transcript 
expression in HeLa cells, and human endometrial HEC-I-A, KLE and RL-9S-2 cells (Leblanc et al., 
2007). In the current study, cells were serum starved over night prior to ERK phosphorylation and 
calcium stimulation assays, to remove the influence from media borne-oestrogenic compounds, and 
148 
Chapt~r 4: Charact~r'isati()11 nf (iPLR 
also reduce baseline ppERK in the ERK stimulation assay (the latter is a standard procedure and is 
performed for all cell types in this assay) (Caunt el aJ., 2008). As previously described, the absence of 
serum overnight had no significant influence on HA-GPER expression in HEK293 cells when 
compared with media treated controls. This indicates that the receptor was available for activation by 
E2/G-I during the ERK and calcium assays. Moreover, many other studies have demonstrated E2/G-I 
mediated GPER signalling following overnight/48 hour serum starving (e.g., Filardo el aJ., 2002; 
Revenkar et aJ., 2005; Bologa et aJ., 2006). 
4.4.3 Alternative roles for GPER in steroid signalling 
There may be a number of technicaVexperimental differences that could be attributed to the variation 
in GPER signalling. However, one assumes that if GPER is activated by E2/G-I to give ERK and/or 
calcium responses, we would have observed it in this study, especially since we were able to 
demonstrate robust VP activation of the VIB receptor, and other endogenous GPCRs, in both 
signalling assays. It is possible that there is something pivotal to GPER signalling missing from our 
cells lines. For example, Otto and co-workers report a lack of E2IG-lIGPER activation of ERK 
phosphorylation in CHO cells. As GPER appears to stimulate the ERK pathway via EGFR 
transactivation, the lack of signalling may be explained by the fact that EGFR is non-responsive in our 
CHO-K 1 cells. A 'missing' component could be particularly difficult to identify in the other cell types 
(e.g., HEK293, COS-7, and HeLa) used in our studies, especially since the EGFR- and GPCR-
mediated ERK- and calcium-responses appear generally to be intact. If a signal transduction 
component essential to GPCR signalling was absent it may be something extremely subtle such as 
some link between GPER receptor agonist binding and EGFR transactivation. 
Convergence of ERa and GPER signalling? 
In the last few years, a link between ERa and GPER mediated signalling has been reported. In human 
ovarian cancer and mouse spennatogonial cells, both ERa and GPER are required for an E2 and G-l-
induced increase in ERK signalling and c-Fos accumulation (Albanito et 01., 2007; Sirianni et ai., 
2008). As highlighted in Figure 4.30, it has been proposed that GPER collaborates with ERa, 
transfonning early signals from membrane fonns of ERa into downstream signalling cascades (Levin, 
2009). Therefore, it could be possible that the lack of ERa mRNA (as determined with northern 'dot' 
blot hybridisation see section 4.3.1) from our HEK293 and COS-7 cells may hinder E2IGPER 
signalling. However, we observed no E2/G-I response in Ishikawa cells that are reported to express 
ERa. It is known that after long-term culture Ishikawa cells can transfonn into undifferentiated cells, 
and lose their E2 responsiveness - suggesting that our cell line may no longer express ERa (Nishida 
et 01., 2002). Nonetheless, E2- and/or G-I-mediated GPER activation has been demonstrated in 
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several lines that are reported to lack the traditional receptors including HEK293, COS-7 and SKBR3 
cells (Filardo et al., 2000; Revenkar et al., 2005; Bologa et al., 2006). 
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Both ERa and GPER are required for E2- and G-I stimulation of ERK pho phorylation and c-Fo activation in 
ovarian cancer and mouse spermatogonial cells (Albanito el al., 2007; irianni el al., 2008). Membrane bound 
ERa is associated with large protein complexes (signalsome) often con i ting of caffold proteins (e.g., 
caveolin-I (C)), linker proteins (e.g., She), G protein subunit, receptor and non-receptor tyrosine kina es (e.g. 
EGFR and Src, respectively), and serine/threonine kina es (e.g., p8S subunit of PI3K) (Levin el al., 2009). In 
some cell types it is possible that GPER may also be part of the large ignal ome, enabling cros talk between 
the two E2 receptors (Levin et al., 2009). 
151 
Chapt!:r -l: Charactcri~ati()11 or (,JlLR 
GPER may work ;n concert with ERa-36? 
ERa-36 is a truncated isoform of ERa (see Figure 4.31) that is predominately associated with the 
plasma membrane where it appears to transduce E2-, tamoxifen-, and ICI-182,780-dependant 
activation of ERK (Wang et al., 2006). Kang and co-workers have suggested that ERa-36 rather than 
GPER is responsible for E2- and G-I-mediated ERK signalling in SKBRJ cells endogenously 
expressing ERa-36 and in HEK293 cells stably transfected with ERa-36 (Kang el al., 2010). 
Saturation analysis and Scatchard plotting of eH]E2 binding to SKBRJ and HEK293 cells transfected 
with ERa-36 showed the presence of high affinity specific E2-binding sites in both cell lines, and 
competitive binding assays showed that G-I is an effective competitor of E2. Furthermore, eH]E2 
binding was dramatically reduced in SKBRJ cells transfected with shRNA specific for ERa36, or in 
HEK293 cells transfected with empty vector. In an attempt to explain how previous studies have 
observed E2/G-1 activity following transfection with GPER, the group demonstrated that endogenous 
ERa-36 is not expressed basally in HEK293 cells but is upregulated following transfection with 
GPER - they concluded that it was ERa-36 that responded to E2/G-I and not GPER (Kang et al., 
2010). 
In the current study, northern 'dot blot' analysis revealed that basal ERa-36 mRNA expression was 
absent from untransfected HEK293 cells and HEK293 cells stably transfected with rodent GPER. We 
did not investigate the expression of ERa-36 transcript in COS-7 cells following transient transfection 
with GPER, although basally there was no noticeable expression of ERa-36 mRNA. It is worth noting 
that transcript expression does not necessarily equate to translation (or if it does - the protein may not 
be fully functional). However, if gene expression is positively related to translation of a fully 
functional protein, then the lack of expressionlupregulation of ERa-36 may explain the absence of 
E2/G-l-mediated signalling in the cell lines investigated in our studies. It is unclear why ERa-36 
mRNA was not detected in HEK293 cells stably expressing GPER. One possibility is that our 
HEK293 cell subclone does not express ERa-36 under any circumstances. Kang and colleagues 
reported that transient transfection of HEK293 cells with GPER resulted in a 3-fold induction of 
ERa36 promoter activity via a SrclERK I /2/ AP-l pathway (Kang et al., 2010). The mechanism of the 
GPER-mediated upregulation in ERa36 promoter activity was not investigated. It is possible that the 
upregulation of ERa36 is a result of constitutive GPER activity. Alternatively, a media-borne agonist 
(such as E2 or another unidentified compound) may activate the GPER-mediated upregulation in 
ERa36. Therefore, ifthe media used in this study lacks a media-borne agonist. it may explain why, in 
our hands, ERa is not upregulated by HEK293 cells stably expressing GPER. 
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Figure 4.31. Schematic diagrams representing the structural organi ation of ERa and ERa-36 
mRNA and protein. 
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(A) Transcriptional organisation of human ERa and its splice variant ERa-36. ERa mRNA i coded 
by 8 exons, while ERa-36 transcript is coded by I intron and 5 e on from the ERa gene and one 
exon downstream of the ERa coding sequence. tart (AUG) and top codon (UGA or UAA) are 
indicated. The 5'-untranslated region of ERa-36 i identical with the fir t intron (green box) of the 
ERa gene, and the initiation codon for the predicted ERa-36 protein i located in the econd exon of 
the ERa genomic sequence. ERa and ERa-36 transcript hare 100% homology between exon 2-6 
(yellow boxes) of the ERa DNA equence, but the remaining Ra-36 mR A equence i transcribed 
from an exon located 4374bp downstream of the ERa gene (here termed exon 9 (light yellow box», 
and is distinct from the latter part of the Ra gene equence. For thi rea on, the Ra-36 
oligonucleotides used in the northern blot hybridi ation in ection 4.2.3 were directed to the mRNA 
sequence from exon 9. 
(B) Domain structures of ERa and ERa-36. ERa i a embled from 595 amino acid (amino acid 
equence number are shown) and ha a molecular ma of 66kDa while the ER-a36 ariant i 310 
amino acids long and is 36 kDa in mass. ERa and ERa-36 share the ame predicted protein equence 
in domain C (contains the DNA binding domain (DBD», domain D (hinge region) and a portion of 
domain E (contains the ligand binding domain (LBD», although ERa-36 lack the Ra domains A, 
B, F and part of E which also contain the activation function domain (AF-I (ligand-independent 
activation function) and AF-2 (ligand-dependent tran activation function». Ra-36 ha a unique 27 
amino acid domain (represented with a chequered box) in tead of the la t 138 amino acid of ERa 
(corresponding to domain E (part of) and F (encoded by exon 7 and 8 of the Ra gene». Tran cript 
and protein structure of ERa-36 is based on the de cription by Wang and colleague (Wang et al., 
2005). 
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Does E2-sulphate stimulate GPER? 
If E2 is not the endogenous ligand for GPER, we hypothesised that GPER may be activated by an E2 
metabolite. There are a variety of enzymes involved in E2 metabolism e.g., sulfatases, aromatases, 
176-hydroxysteroid dehydrogenases, sulfotransferases, hydroxylases and glucuronidases (Pasqualini, 
2009). E2 sulphotransferase (SUL Tl E 1) has been shown to be highly expressed in breast and 
endometrial tissue, with some evidence to suggest its presence in cancerous forms of these tissues 
(Reich et 01., 2007). Other phenol sulphotranferases with some affinity to E2 (e.g., SUL T I A I and 
SULTlA3) have also been shown to be highly expressed in breast carcinomas (Pasqualini, 2009), In 
the presence of 3'-phospho-adenosine-5'phosphosulfate (PAPS), E2 sulphotransferase catalyses the 
addition of a sulphuryl group to E2 producing estradiol-3-sulfate (E2-sulphate), a soluable 'inactive' 
form of E2 that has no affinity for ERa or ERP (Song, 2006; Pasqualini, 2009). As OPER has been 
reported to be expressed in normal and cancerous breast and uterlne tissue (Prossnitz et 01., 2008; 
Wang el 01.,2010; Huang el 01.,2010) we postulated that perhaps E2-suphate was biologically active 
and stimulated OPER. We tested this theory by introducing mouse E2 sulphotransferase into our 
stable mouse OPER HEK293 cells. However, the presence of E2 sulphotransferase did not provoke 
OPER-mediated ERK phosphorylation in HEK293 cells. This suggests that E2-sulphate does not 
stimulate ERK activation on its own, or concomitantly with OPER following 10 min of E2 treatment. 
It must be emphasised that we do not know whether our E2 sulphotransferase DNA construct directed 
expression of a functional protein. 
Does ALD signal via GPER? 
Finally, we investigated the role of GPER in ALD signalling. Gros and colleagues recently reported 
that ALD exploits both MR and OPER to activate ERK phosphorylation in freshly isolated rat aortic 
segments (Oros el 01., 2011). They also reported that ALD acts solely through OPER to stimulate 
ERK phosphorylation (blocked with the OPER antagonist, G-15) in rat aortic vascular endothelial 
cells that lack MR, but endogenously express GPER (and ERa) (Oros el 01., 2011). However, we 
observed no increase in ppERK in response to ALD in COS-7 or HeLa cells transiently transfected 
with human or rodent OPER. Northern 'dot blot' analysis illustrated that COS-7 and HeLa cells 
express very little or no endogenous MR, ERa, and ERP mRNA (see Chapter 6 (section 6.3.1) for 
details of MR northern 'dot blot' results). Thus, if OPER requires an additional ALDlE2 steroid 
receptor to facilitate ALD-stimulated ERK phosphorylation in COS-7 cells, the lack in these receptors 
may explain an absence of signalling. 
4.4.4 Conclusion 
In summary, our in vitro experiments reveal that OPER is both a cell surface and intracellular protein 
and is not activated by E2 or G-I. One cannot rule out the possibility that E2 and G-l bind and 
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activate GPER in other laboratories (e.g., other cell lines may be more responsive to E2/G-l/GPER 
mediated signalling) particularly when there is such a large body of published evidence (mainly on 
human cells), suggesting this ligand-receptor interaction takes place. However, the reasons for these 
inconstancies are not apparent at this time, and thus we would be reluctant to pursue the GPER story 
any further, especially in vivo. 
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Chapter 5: Distribution of orphan G protein-coupled receptors 
5.1 Introduction 
5.1.1 Glucocorticoids 
As for E2 responses, 'fast', apparently cell surface mediated effects of adrenal steroids have been 
documented. Glucocorticoids (cortisol and corticosterone (CORT) in human and rats, respectively) 
are mainly secreted from the zona fasiculata of the adrenal cortex in pulsatile bursts, that under basal 
conditions are subject to ultradian and circadian rhythms (Lightman and Conway-Campbell, 20 I 0). In 
response to psychological and physical stressors the pulses increase in amplitude (and/or frequency 
over a 24 hour period) (Sarabdjitsingh et 01., 2010; Windle et 01., 2001; Lightman and Conway-
Campbell, 2010). Glucocorticoids are crucial for homeostasis and the adaptation to acute (e.g., 'flight 
and fight' response) and chronic stress (e.g., infection, fasting or cancer), and as a consequence have 
an array of effects on central and peripheral systems. For example, in response to acute stress, 
glucocorticoids mobilise energy and protein stores (by elevating blood glucose and increasing muscle 
catabolism), increase blood pressure and cardiac output, reduce inflammation and dampen the 
(potentially over-active) immune system (Rose et 01.,2010; Vegiopoulos and Herzig, 2007; Sapolsky 
et 01., 2000). In addition, acute and chronic exposure to glucocorticoids modulates appetite, memory 
consolidation and retrieval, and reproduction (Adam and Epsel, 1997; Roozendaal, 2002; Maeda and 
Tsukamura, 2006). 
Much of the effects of glucocorticoids are attributable to the activation of two conventional nuclear 
steroid receptors, the glucocorticoid receptor (GR) and the mineralocorticoid receptor (MR). As with 
all steroid receptors, activation of GR and MR leads to direct regulation of gene transcription and 
subsequent effects are usually observed after 30 min (although transcription and translation of a target 
gene can occur within 15 min) (Haller et 01., 2008). Furthermore, fast non-genomic effects (generally 
less than 15 min) of glucocorticoids have been documented in a variety of tissues. Centrally, 
glucocorticoids have been shown to have immediate effects on behaviour, aggression, HPA axis 
activity and the hypothalamo-neurohypophyseal system; and in the periphery. fast effects have been 
observed in an assortment of respiratory, cardiovascular, metabolic, immune, endocrine, and urinary 
tissues (examples are given in Table 5.1). 
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CORT rapidly increases locomotor a tivity di played by rat in re p n e to a 
novel environment. 
CORT quickly promotes aggression during the resident- intruder te 1. 
CORT enhances glutamate transmission in the hippocampal A I region ( A I 
is implicated in negative regulation of the HPA a i ). 
CORT causes extreme prolongation ofNMDA receptor-mediated elevation in 
intracellular calcium in cultured rat hippocampal neurone , via a non-genomic 
mechani m. 
CORT rapidly inhibits voltage-activated calcium channel urrent in adult 
guinea pig hippocampal A I neurone . 
CORT rapidly facilitates synaptic potentiation in the mou e hippocampal Al 
area. 
An intra-PYN infusion of dexamethasone (D X) a yntheti glu rti oid 
receptor agonist rapidly inhibits restraint-induced A TH and corti terone 
release, by means of cannabinoid B 1 receptor-mediated ignalling. 
Glucocorticoids suppress excitatory glutamatergic synaptic input to rat 
parvocellular PYN and magnocellular PYN/ ON neuron via retrograde 
endocannabinoid release, while facilitating GABAergic input into th N by 
stimulating nitric oxide synthesis. 
CORT rapidly inhibits A VP release from ral hypothalami 
PVN and ON). 
Glucocorticoids rapidly inhibit CRF-induced ACTH release. 
DEX suppresses forskolin-induced increa e in cAMP, A TH and P M 
tran cript in AtT -20 cell . 
Glucocorticoids rapidly suppress histamine-induced mo Ih mu Ie 
contractions in guinea pig trachea. 
DEX quickly activates internucleo omal cleavage of rat lymph yt DNA -
in tigating Iymphocytoly i . 
DEX induces the phosphorylation of the rc kinase, Lck, and the a tivation of 
other downstream mediators, including Rae I, as well a augments in re ting 
signalling in resting human T cell . 
CORT increases the amplitude of L-type cal ium current f i olated guinea 
pig ventricular myo yte . 
Glucocorticoids increase nitric oxide syntha e activity in human end th lial 
cells. 
CORT rapid ly increases Na +/H + exchange a tivil in primary ral aorti 
va cular smooth mu Ie. 
CORT suppresses nicotine-induced cal ium influ in rat P -12 (adr nal 
chromaffin tumour) cells. 
CORT activates ERK via a PK dependent pathwa in P -1 2 11 . 
G1ucocorticoids rapidly increase major pro imal tubu lar Na + fH+ e hang r 
activity in the opos um kidn y. 
Rapidly reduces glycogen content of primary culrur drat hepal yte . 
DEX quickly activates intemucleosomal cleavage of rat lymph yte DNA -
instigating Iymphocytoly is. 
Glucocorticoid rapidly decrea e gluco e timulated P- ell in ulin r Ie 
opposed to chronic glucocorticoid expo ure whi h ha b n rep rt d I 
stimulatory action on in ulin relea e). 
Acute glucocorticoid administration decrea e glu 0 e uptake by rat 
adipocyte . 
ORT reduces mouse . cell cAMP content and te 10 ler ne 
M ikics el al., 2004 
Kar t el al., 2005 




Wiegert el aJ., 2006 
van n el al., 2010 
Di el al., 2003, 
2005,2009 




Hir chelmann, 2000 
Iwa aki el al., 1997 
un el al. , 2006 
ompton and 
idl w ki, 1986 
Gho h et aJ., 2009 
Van el al., 1994 
Hafl zi-Moghadam 
et al., 2002 
Mut el al., 2000 
Qiu el al., 1998 
iu el al., 2001 
Bobule cu el aJ., 
2005 
Zhang el al., 2009 
ompton and 
idlow ki, 1986 
utter-Dub, 2002 
iving ton and 
L kwood,1975 
et al 2004 
able 5.1. Examples of fa t glucocorticoid re pon e in a vari t of brain r gion and p riph ral ti ue. 
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5.1.2 Possible mechanisms of non-genomic action 
The mechanisms that underlie the fast effects of glucocorticoids are not yet clear. Some evidence 
suggests that these fast effects may be mediated by membrane pools of GR and/or MR: GR has been 
shown to be localised to isolated caveolae rafts in the plasma membrane, from which GR could 
interact with signalling proteins e.g., GPCRs, growth factor receptors, non-growth factor tyrosine 
kinases (Jain et al., 2005; Evanson et al., 2010; Hammes and Levin, 2007). Indeed some studies have 
highlighted the indispensable nature of the traditional receptors in non-genomic glucocorticoid 
signalling e.g., CORT rapidly increases Na+/H+ exchange activity in primary rat aortic vascular 
smooth muscle via a non-genomic, protein kinase C dependant-mechanism, which is inhibited in the 
presence of a GR antagonist (Muto et al., 2000). In addition, the fast effects of CORT on glutamate 
transmission in mouse hippocampus CA I region is lost in MR KO mice; and intravenous 
administration of canrenoate (a MR antagonist) rapidly increases plasma ACTH and CORT (Karst el 
al., 2005; Atkinson et al., 2008). However, in other studies the fast effects are not disrupted by 
treatment with GR and MR specific antagonists, suggesting an alternative mechanism of action (Sandi 
el al., 1996; Oi et al., 2005; Sun el al., 2006; Wiegert el al., 2006). 
It has also been postulated that upon ligand binding, and the dissociation of GRlMR from the 
multimeric complex of scaffold and signalling proteins, some cellular components themselves (e.g., 
heat shock proteins, tyrosine kinases, immunophilins etc) rather than the transcription factors, interact 
with cytoplasmic proteins to illicit non-genomic effects (Haller el al., 2008). As discussed in Chapter 
4, high concentrations of steroids can also have non-specific effects on membrane fluidity e.g., 
disrupting ion cycling and A TP use. Alternatively, the fast effects of glucocorticoids could be 
mediated by membrane receptors such as ligand gated ion channel or unidentified GPCRs 
(Falkenstein et al., 2000). Many studies have also shown specific binding of eH]-CORT and/or eH]-
OEX to plasma membranes of a variety of cells and tissues e.g., rat brain and pituitary, AtT -20 mouse 
pituitary tumour cells, rat and mouse liver, human placenta, and rabbit skeletal muscle (Towle and 
Sze, 1983; Koch el al., 1978; Harrison et al., 1979; Suyemitsu and Terayama, 1975; Trueba el al., 
1989; Fant et al., 1979; Savart and Cabillic, 1985). 
In 2005, Maier and colleagues described high affinity binding of OEX to membranes of AtT-20 cells 
using fluorescence correlation spectroscopy. They demonstrated that the binding was sensitive to 
pertussis toxin - a potent inhibitor of GClj alpha family of G protein subunits, thus suggesting the 
coupling of G proteins to the membrane-bound glucocorticoid receptors (Maier el aI., 2005). Other 
labs have also reported sensitivity of fast glucocorticoid effects to pertussis toxin. For example, the 
suppression of a forskolin-induced increase in cAMP, ACTH and POMC transcripts in AtT -20 cells 
by OEX is inhibited by pertussis toxin (Iwasaki el aI., 1997). Furthennore, CORT-mediated rapid 
inhibition of voltage-activated calcium channel currents in adult guinea pig hippocampal CA 1 
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neurones, and its suppression of nicotine-induced calcium influx in PC-12 adrenal chromaffin tumour 
cells, is not only prevented by pertussis toxin, but also diminished by PKC inhibitors (ffrench-Mullen, 
1995; Qiu et al., 1998). In addition, glucocorticoid-induced endocannabinoid-mediated suppression of 
postsynaptic glutamate release in the SON is dependent on activation of Ga., cAMP, and PKA (Di et 
al., 2009) - suggesting that the fast effects of glucocorticoids appear to be mediated by other families 
of Ga proteins. Therefore, the clear involvement of G proteins indicates that the rapid effects of 
glucocorticoids are potentially mediated by a GPCR(s). 
G1ucocorticoids are routinely administered as therapeutics in conditions such as asthma, chronic 
obstructive pulmonary disease, hypersensitivity reactions, autoimmune disorders (e.g., rheumatoid 
arthritis and systemic lupus erythematosus), and in organ transplantation (Ng and Celermajer, 2005). 
Most glucocorticoid treatments target the genomic action of GR and MR to promote the beneficial 
anti-inflammatory and immunosuppressant effects, but genomic actions have also been associated 
with a variety of adverse effects e.g., hyperglycaemia, hypertension, central obesity, diabetes mellitus, 
skin atrophy, osteoporosis, and depression (Ng and Celermajer, 2005; Haller el al., 2008). Therefore, 
the possible existence of a membrane-bound glucocorticoid receptor distinct from GR and MR. but 
encompassing some of the beneficial actions of these receptors, has huge therapeutic potential. Its 
discovery may help eliminate some of the adverse effects associated with the current long-term 
glucocorticoid use (that targets the nuclear receptors), as drugs targeting a fast glucocorticoid receptor 
could be administered for shorter periods of time (and perhaps have fewer detrimental effects). 
5.1.3 . A G protein-coupled glucocorticoid receptor1 
In this chapter, we attempted to identify a putative glucocorticoid receptor from the non-
chemosensory orphan GPCRs in the mammalian genome. We endeavoured to identify candidate 
GPCRs by firstly comparing their tissue distribution with tissues which exhibit fast glucocorticoid 
effects such as: brain (SON, PVN and hippocampus), pituitary gland, trachea, thymus gland, heart, 
adrenal gland, kidney, liver, spleen, pancreas, adipose tissue, and testis. As the distribution of many 
orphan GPCRs has yet to be published, we began by searching the expression sequence tag (EST) 
profiles of orphan GPCRs commonly expressed in both human and rodent tissues (EST profiles: 
http://www.ncbi.nlm.nih.gov/unigene). ESTs are short sequences of DNA (approximately 200-600bp) 
usually produced from a single sequencing read from one or both ends of a cDNA clone, that has been 
selected at random from a tissue specific cDNA library (Pontius et aI., 2003; EST sequence data base: 
http://www.ncbi.nlm.nih.gov/dbESTD. An EST sequence can be compared with known sequences in 
BLAST to identify the corresponding full-length cDNA clone. The frequency at which an identified 
cDNA clone is picked from each tissue specific library is recorded and summarised in EST profiles. 
This gives a rudimentary indication to the density of gene expression within each tissue. 
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However, it must be noted that EST profiles are not without limitations. For example, sequencing of 
ESTs is relatively inaccurate with approximately 2 % error; and the random selection of cDNAs from 
the library favours common transcripts masking those of lower abundance (normalisation and 
subtraction techniques can be introduced to reduce/remove frequently expressed cDNAs to 
accommodate rarer transcripts - but NCBI EST profiles do not include counts from any biased 
libraries) (Schuler, 1997). Detection sensitivity is a particular issue when attempting to document 
GPCR gene expression (particularly in the brain) because GPCR mRNA is not as abundant compared 
to other receptor (such as ionotropic receptors) mRNA e.g., according to the V IB receptor NCBI EST 
profile the mouse VIB receptor gene is not expressed in the brain (zero EST transcripts out of 459991 
cDNA clones) when V IB receptor mRNA and protein have been detected in the mouse brain by ISHH 
and RT-PCR (Young et al., 2006), ARG (Dr. James Roper and Dr. Stephen Lolait, personal 
communication), and VP is known to have a central role mediated by the VIB receptor (Wersinger el 
al., 2002). On the other hand, the cannabinoid CBI receptor which is abundantly expressed in rat brain 
(as shown by ISHH, IHC, and ARG (Matsuda el al., 1993; Pettit et al., 1993; Herkenham el al., 
1991» has an EST expression profile of 3/61377. To give some perspective, we can compare the gene 
expression of these receptors with some of the most abundant glutamate ionotrophic receptor subunits 
in the rat brain (ionotropic receptors tend to be more abundant than GPCRs): expression patterns of 
the AMPA receptor subunit GluA2 and the NMDA receptor subunit GluNI are 31161377 and 
18/61377, respectively. The most abundant kainate receptor subunit GluK2 has a brain expression 
pattern of 4/61377 (according to NCBI EST profiles), a value similar to that ofCBI. It is important to 
point out that EST profiles are not yet available for all genes and/or species e.g., VIB receptor and 
GPER profiles are not available for rat tissues. 
Notwithstanding the limitations of EST profiles, they still remain an excellent and dynamic directory 
with which to examine gene expression in tissues· from various species (ranging from zebrafish to 
human). We searched the EST profiles of approximately 125 orphan GPCRs common to humans 
(number based on lists in the on-line IUPHAR Database of Receptors and Ion Channels (Hannar et 
al., 2009) and rodents and located 9 orphans with gene expression (according to EST profiles) in 
some or all of the tissues known to exhibit fast glucocorticoid effects: GPRC5B, GPR48, GPRS6, 
GPR65, GPRI08, GPRI25, GPR146, GPRI53, TMEM878 (Tables 5.2 and 5.3 summaries the human 
and rat EST profiles of these orphans). To verify gene expression distributions, riboprobes were 
designed against the 3 'UTR of each candidate transcript and a series of ISHH experiments were 
performed to determine the anatomical expression of the orphan GPCRs in target brain regions and 
peripheral tissues. 
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21 465 32 
0 0 I 
0 I 3 
I I I 
I 4 4 
2 I 0 
2 29 32 
2 I 18 
0 2 I 
0 2 6 
0 0 0 
0 47 24 
Table 5.2. Human orphan GPCR EST profiles. 
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No. of receptor clones picked from tissue specific cDNA library 
669 0 14 50 
I 0 I 2 
55 0 0 3 
41 I I 0 
I 0 I 6 
0 0 0 2 
42 3 17 8 
6 0 I II 
I 3 0 0 
37 I 6 5 
0 I I 0 






































N .B., NCBI EST profiles are continually updated. These values are correct as of May 20 II . GPER is included as the GPER probe acted as a positive method control for the orphan GPCR probes. 
18 0 21 0 6 0 0 0 3 61,377 
I I 0 I 4 0 0 0 0 17,007 
0 0 3 I 2 0 0 0 0 8,186 
0/52131 I I 2 0 0 I 3 2 0 30,798 
02044 0 0 0 0 I 0 0 0 0 6,921 
1/122453 I 3 10 0 2 0 0 0 0 22,578 
0/108957 0 2 I 0 I 0 0 0 0 77,670 
0/94430 0 0 0 I 3 0 2 I 2 16,370 
0105756 7 0 4 0 0 0 0 0 4 34,468 
0/1564 I 0 0 0 2 0 0 0 I 6,038 
3/113759 0 0 2 0 4 0 0 I 0 12,189 
Table 5.3. Rat orphan GPCR receptor EST profiles. 
As the rat GPER EST profile is unavailable on the NCBI database. the mouse profile is shown instead. Trachea profiles are not available for either rat or mouse. Values are correct as of May 20 II. 
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5.2 Materials and methods 
5.2.1 Animals 
Three adult male Sprague-Dawley rats, weighing 200-250g (Harlan) were used in this study. Animals 
were sacrificed by decapitation and tissues frozen on dry ice as described in section 2.1.2. 
5.2.2 ISHH 
Coronal cryostat sections (12Jl111) were cut, thaw mounted onto polylysine-coated slides, and stored at 
-80°C until use. Each orphan probe was generated by peR using approximately 125ng rat genomic 
DNA extracted from rat testis. The GPER probe was generated from l50ng rat genomic DNA 
purchased from Promega#G3l3A, UK. The primers, the primer restriction endonuclease sites, and the 
size of each riboprobe are described in Table 5.4. Primer restriction endonuclease sites allowed 
subcloning into the RNA generating vector pGEM4Z, and sense and antisense probes were generated 
using T7 and SP6 polymerases with 35S_UTP and the MAXI script in vitro transcription kit 
(summarised in Table 5.5). The integrity of each probe was verified by DNA sequencing. All ISHH 
experiments were performed as outlined in section 2.2, although the hybridisation and the high 
stringency wash temperatures were modified depending on the G+C content of each probe, as 
summarised in Table 5.6. Hybridised sections were exposed to film (Amersham HyperfilmTM MP) 
for 6 weeks, or emulsion dipped (Ilford K5) for 18 weeks and counterstained with toluidine blue. 
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GPRC58 5' -GGGACGAA ITCCA TGGCACCTGTIT AAGT -3 ' 5' -ITGGCGGATCCAAAAGACAACTCITCCCC-3 ' 1274-1773 NM_00 1106304 EcoRI-Hindlll 430 
GPER 5' -GAGAGGA TCCfCCf AGAGGAAAACGGA-3 ' 5' -AAACAAGCTITGTGAGAGGAGCA TC-3' 15718722-15718072 NM_ 133573! BamHl- Hindlll 637 NC_0051II 
GPR48 5' -TAATAGAAITCCACAGITGTCCTGTAITG-3' 5' -ITITCAAGCTTCATITATITAGAATAGAG-3 ' 2667-3160 NM_ 173328 EcoRI-HindllI 477 
GPR56 5' -CCfCfGAA TTCGGGGTGCACA TGCA TGGC-3' 5' -CAGACAAGCTTGGAAGA TGCTCAGCTCCT A- 2376-2834 NM_152242 EcoRl-HindJll 454 3 ' 
GPR65 5' -TGACGGAAITCGGGAGATCCGATATGTGG-3' 5' -ACCA T AAGCTTGAA TGGCCCCCGATGTAC-3 ' 878-1310 XM_00 1063813 EcoRI-Hindlll 417 
GPR108 5' -ACITCCCCGAGITCAGAGA TCCGCCITC-3 ' 5' -AA TCAAAGCTIT A TGAAGCCCAGGCTCT -3' 1752-3005 NM_I99399 AvaI-HindHl 329 
G PR125 5'-CCAAGGAAITCAGCTGCAGCTGA CCITGA-3' 5'- ITTITAAGCTITGGGGAAGGGCAATITAG -3 ' 4198-4549 XM_223485 EcoRI-HindllI 326 
GPR146 5 ' -GGGCCGAA ITCCAAGGAGAGGGCCfGACCA- 5' -TCCTCAAGCTIT AACACTGGTA TITGCGA-3 ' 1202-1719 XM_573364 EcoRI-Hindlll 501 3 ' 
G PR153 5' -CCCCAGAA ITCA TGCAGACGGAAGAGGC-3 ' 5' -AAGGAGGACITGCTCAATAGAACITGIT-3 ' 2059-2521 NM_ 001034855 EcoRI-HindllI 447 
n1EM878 5' -CCAGTGAA ITCAGTGTGCA TGGGAGCGCG-3 ' 5' -TITCf AAGCTITGAGGCAGGGTCfCACf A-3 ' 1998-2452 XM_342515 EcoR1-Hindlll 439 
Table 5.4. Summary of riboprobe primers. 
The riboprobe DNA templates were generated by peR using 125ng rat genomic DNA (see section 2.2.2 for peR protocol and Appendix I for the varying peR conditions). 
Primers contained restriction endonuclease linkers to allow subcloning into a pGEM4z vector 
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. K\ \ Iwl, 111"1'11'" ""," 10 !!"III'l'IIh' 111'0111' 
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I
lh,'lrirliOIl "11/\ III" ""," 10 IIIH'ari", I 
IWwprolH' --- - ----- - - 1 - - - - - - --
\lIli"'II'" ""'11'" \lIli"'II'" I ""'11'" 
GPR SB EcoRI lIindlll T7 P6 
GPER BamHI Hindlll T7 P6 
GPR48 coRI lIindlll T7 1'6 
GPRS6 EcoRI Hindlll T7 P6 
GPR6S EcoRI lIindlll T7 P6 
GPRI08 Aval Hindlll T7 P6 
GPRI25 EcoRI lIindlll T7 P6 
GPRI46 EcoRJ Hindlll T7 P6 
GPRIS3 EcoRI lIindlll T7 P6 
TMEM87B EcoRI Hindlll T7 P6 
Table 5.5. Generation of the orphan riboprobe . 
ach vector was linearised using a restriction endonuclea cite in orp rat d in the primer u ed to P R the 
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, ' 
GPRCSB 50 4 0 78 
GPER 53.06 637 80 
GPR48 46.75 477 76 
GPRS6 56.83 454 83 
GPR6S 38.37 417 70 
GPRI08 54.1 329 80 
GPRI2S 44.04 327 73 
GPRI46 43 .9 501 74 
GPRISJ 55.48 447 82 
TMEM87B 48.75 439 77 
Table 5.6. Calculating the hybridi ation temperature and high 











rature for the 
he hybridisation temperature and high tringency wa h temp ratur were b ed n the m for ea h pr b 
calculated using the formula, Optimum hybridi ation t mp rature i appro imat I 15-25° b I w m, while 
the high stringency wash temperature i approximately 5_15° blow m (Wilkin n, 1999). 
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5.3 Results 
5.3.1 Distribution of orphan GPCR mRNA in a collection of brain regions and 
peripheral tissues 
The mRNA distributions of nine orphan GPCRs were mapped in brain regions and peripheral tissues 
that have been reported to exhibit putative fast glucocorticoid receptors: the brain (at the levels of the 
PVN, SON and hippocampus), pituitary gland, thymus, trachea, heart, liver, spleen, pancreas, kidney, 
adrenal, adipose tissue and testis. The mRNA distributions for each probe (based on results from both 
film and emulsion dipped sections) are summarised in Table 5.7 and film images of hybridised 
sections are shown in Figure 5.1. As the localisation of the rat GPER mRNA (and protein) has been 
characterised in Chapter 3, and the GPER gene is expressed at low-moderate levels in the PVN and 
SON, the GPER probe acted as a positive method control for the orphan GPCR probes. Unless 
otherwise stated, sections hybridised with control sense riboprobes (directed against antisense 
sequences of all of the GPCR mRNAs) showed only background/or were absent of hybridisation 
signal (examples given in Figure 5.6Cii, ,5.7Cii and 5.8C). 
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u :-n I (,I'IUS I (,I'W5h I (,I'Kh:- I (,I'I{ II 
++ ++/+++ -/+ ++/+++ -/+ +++ + + +++ +++ 
++ +/++ ++ ++/+++ -/+ + +/++ +++ 
(mPVN, pPVN) (mPVN, pPVN) (mPVN, pPVN) (mPVN, pPVN) (mPVN, pPVN) (mPVN, pPVN) (mPVN, pPVN) (mPVN, pPVN) 
-/+ ++ -/+ ++ +++ +/++ + +++ 
(CAI -3, DG) (mainly in DG) (CAI-3, DG) (DG>CAI-3) (CAI-3, DG) (CA3, DG) (CAI-2, DG) + (CAI -3 , DG) 
-NL +++NL +++NL +++NL ++NL +/++NL +/++NL -/+ NL +NL 
++[L -lL +lL +++ IL +++ IL +/++ IL ++/+++IL -/+ IL +++IL 
+/++AL +/++AL ++AL +/++AL +++AL ++/+++AL ++/+++AL +AL +++AL 
-/+ +/++ +/++ ++ ++ +/++ ++ 
(connective ( connective + (connective (connective ++ (connective (connective ( connective (connective ( connective tissue, hyaline tissue, hyaline 
tissue) tissue, hyaline tissue, hyaline tissue) tissue, hyaline tissue, hyaline tissue, hyaline 
cartilage) cartilage) cartilage) cartilage) cartilage) cartilage) cartilage) 
+ -/+ +++ +++ ++/+++ +++ + +/++ + +++ 
(cortex, medulla) (capsule) (cortex, medulla) (cortex, medulla) (cortex, (cortex, medulla) (cortex, medulla) (medulla) (medulla) (cortex, medulla) 
medulla) 
++ 
-/+ I ++ I -/+ I + I +/++ + (myocytes, +/++ +/++ (m}OC}1cs) (m}OC}1cs) (myocytcs) (m}OC}1cs) - (myOC}1es) (myOC}1es) particularly in (myocytes (myocytes) 
atria) 
h I +/++ + + -/+ +++ +++ ++ +/++ +++ G, medulla) (mainly in ZG) (cortex) (ZG, medulla) (ZG) (cortex, medulla) (cortex) (cortex, medulla) (ZG, medulla) (cortex, medulla) 
++1+++ ++/+++ 
++/+++ 
I (RP, thlC!.. +++ +++ -/+ ++/+++ (RP, proximal 
++ 
+/++ +1++ (labelling of all (labelling of all (RM.RP) ascendmg 11mb (OM,IM,RP) (OM.lM,RP) (lSOM) (RP, 1M, ISO\1) tubules oflM and (IM,OM) 
of 1M and OM) 0\1) la}ers) layers) 
++ -/+ + +/++ ++ -/+ 
(hepatoc>1CS) (hepatocytes ) - (hepat0C}1cs ) (hepatocytes) (hepatOCytcs) - (hepatocytcs) 
++,+++ +++ -+ +++ ++ 
I (red PUI;, PALS) I +1++ (red and ~hlle +++ (~hlle pulp > red (red and ~hlle (red and ~hlle +++ (red pulp) (MZ. PALS) (MZ. PALS) (red and wh Ite (~hite pulp) pulp) pulp) pulp) pulp) pulp) 
+ -1+ -/+ -/+ 
ml and islets) - - - (acini and islets) (acini and islets) - (acini and islets) 
++ - '+ 
I 
+++ ++1+++ 
++/+++ ++ (stroma, (stroma. + (stroma. (stroma. (stroma) I (stroma) I vasculature. (stroma) (stroma. vasculature. (stroma) vasculature. (stroma, 
adiJ>OC>lcs) vasculature) vasculature) adi»O<..,tcs) adlJ>OC>lcs) vasculature) 
++ 
++/+++ +++ (sertoll cells, ++ 
+++ 
+++ (sertoll cells, + ++ ++ 
-
(sertoll cells, (spennatogonia (a1lla}ers of the spennatogonla, (sertoli cells, (sertoll cells, (developmg (sertol! cells, spennatogonla, 
spennatogonia) spennatogonla, spennatogonla) spennat0C}1cs) and seminiferous spennatogonia) developing developing le:rdlg cells) spennatocytcs) tubulcs) 
spennatocytcs) spennallds and 
• 
Table 5.7. Summary of ISIIII result. from emulsion/film. 
The celll}pe/reglOn ~here the maJonl} of receptor transcnptls e'\prcssed IS mdlcated for each tissue N B. pancreas signal IS based pnmanl} on emulSIOn dipped sections due to low Signal on film -, Negligible 
Signal. +, low Signal. ++ moderate Signal. +++, high Signal AL, antenor lobe, CA 1-3. hippocampal regions 1-3, DG, dentate g:rrus of the hippocampus. IL, mtennedlate lobe, 1M, renal lOner medulla; ISOM, renal 
lOner stnpe of the outer medulla. MZ. spleniC margmal zone; mPVN. magnocellular PVN; NL. neural lobe. 0\>1. renal outer medulla. PALS, spleniC penarteriolar l}mphOld sheath. pPVN. parvocellular PVN, RM. 
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GPER GPRC5B 
Figure 5.1. Orpba n GPCR gene ex pression in brain a nd peripberal tissues. 
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GPR48 GPR56 GPR65 
Low magnification photographs of film autoradiographical images of brain (at the level of the SON, PVN and dorsal hippocampus (CA I·CAJ), pituitary gland and trachea (T) hybridised with either GPER, 
GPRCSB, GPR48, GPR56, or GPR65 riboprobes. For some orphans, transcript expression was also observed in other regions of the brain (e.g., suprachiasmatic nucleus (SCN), membranes lining the lateral and 
dorsal ventricles (LVID3V», and/or peripheral tissues (e.g., oesophagus (0) and blood vessels (bv». The GPER probe acted as a positive method control for the orphan GPCR probes in all studies. 3V, third 


























Figure 5.1. Continued. Orpban GPCR gene expression in brain and peripheral tissues. 
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GPRl46 GPRl5J TMEM87B 
Low magnification photographs of film autoradiographical images of brain (at the level of the SON, PVN and dorsal hippocampus (CA I-CAJ ), pituitary gland and trachea (T) hybridised with either GPR I 08, 
GPR 125, GPR 146, GPRI53, or TMEM87B riboprobes. For some orphans, transcript expression was also observed in other regions of the brain (e.g., SCN (open arrows), membranes lining the lateral and dorsal 




























Figure 5.1. Continued. Orphan GPCR gene expression in peripheral tissues. 
Chapt~r 5: Distribution of orphan GPCR~ 
GPR48 GPR56 GPR65 
Low magnification photographs of film autoradiographicallmages of thymus, heart, adrenal gland, kidney and liver hybridised with either GPER, GPRCSB, GPR48, GPR56, or GPR65 riboprobes. Ca, Capsule; Tc, 
Thymic cortex; Tm, Thymic medulla; V, heart ventricle; ZG, rona glomerulosa; AC, adrenal cortex; AM, adrenal medulla; RC, renal cortex; OS, outer stripe or the renal outer medulla; [S, inner stripe of the renal 
outer medulla; 1M, renal lOner medulla; RP, Renal pelvis Scale bars, I mm. 
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GPRl08 GPRl25 GPRl46 GPRl53 TMEM87B 
Figure S.l. Continued. Orphan GPCR gene expression in peripberal tissues. 
Low magnification photographs of film autoradiographical images of thymus, heart, adrenal gland, kidney and liver hybridised with either GPRJ08, GPRI25, GPRI46, GPRl53, or TMEM87B riboprobes. Tc, 
Thymic cortex; Tm, Thymic medulla; V, heart ventricle; ZG, zona glomerulosa; AC, adrenal cortex; AM, adrenal medulla; RC, renal cortex; OS, outer stripe of the renal outer medulla; IS , inner stripe of the renal 
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Figure 5.1. Continued. Orpban GPCR gene npression in peripberal tissues. 
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GPR48 GPR56 GPR65 
Low magJ1lficalion photographs of film autoradlographlcaJ Images of spleen. pancreas. adipose tissue and tesliS hybndlsed "itb either GPER. GPRC5B. GPR48. GPR56. or GPR65 riboprobes WP. "bite pulp: RP. 








Figure 5.1. Continued. Orphan GPC R gene u pression in peripheral tissues. 
Chapter) Distribution of orphan GPCRs 
GPRl.t6 GPRl5J r\IE~187B 
Low magnificallon photographs of film autoradiographlcallmages of spleen, pancreas, adIpose tissue and testIS h:rbridised with either aPR I 08, OPRI25, aPR 146, aPR 153, or TMEM878 nboprobes. WP, white 
pulp; RP, red pulp; Tr, trabeculae ; SFT, seminiferous tubules . Scale bars, I mm. 
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GPRC5B 
Radiolabelled GPRCSB receptor transcript appeared to be ubiquitously expressed throughout the 
selected brain regions as shown in the x-ray film images Figure 5.1. Closer inspection of emulsion 
dipped sections confirmed high GPRCSB gene expression in the SON and optic chiasm/tract, the 
hippocampus (in particular the dentate gyrus). and to lesser extent the PVN. Brains regions of intense 
GPRCSB transcript expression (at the levels of bregma investigated) included the external globus 
pallidus. anterodorsal and reticular thalamic nuclei (Figure S.2.1A). layer 3 and 5 of the cerebral 
cortex. and the corpus callosum. Other tissues that contained moderatelhigh GPRCSB expression 
included the pituitary. heart, kidney. and adipose tissue. In the pituitary gland, high levels ofGPRCSB 
transcripts were found throughout the neural lobe. and low-moderate expression in the anterior lobe 
with dense patches of silver grains concentrated in an unknown cell type (Figure 5.2.2 CilCii). There 
was an absence of signal above background in the intermediate lobe. In the kidney. GPRC5B was 
highly expressed in the pelvis. and the medulla, with cells expressing mRNA radiating from the inner 
medulla through to the inner stripe of the outer medulla, and to a lesser extent to the outer stripe of the 
outer medulla (Figure S.50i). Signal in the outer stripe of the outer medulla was consistent with 
labelling of the thick ascending limb (Figure S.50ii). The labelling in the cortex had a speckled-like 
appearance associated with an unidentified tubular structure. Signal was moderately diffuse among 
myocytes of the heart (Figure S.4C), and stroma of the adipose tissue (with light labelling of 
adipocytes). There was low transcript expression throughout the adrenal medulla and most of the 
adrenal cortex, although moderate mRNA expression was observed in the zona glomerulosa. 
Labelling was barely above background in the thymus, and negligible or no signal was observed in the 
liver. pancreas or testis. 
GPR48 
In the brain, there was a noticeably high expression of GPR48 receptor mRNA in the subfornical 
organ (Figure 5.2.1 B) and to a lesser extent in the SCN. In the hypothalamus. GPR48 transcripts were 
weakly expressed in the SON. and appeared not to be expressed in the PVN. The pituitary gland was 
highly labelled with the GPR48 probe with intense, moderate, and low signal in the neural, anterior 
and intermediate lobes, respectively (Figure 5.2.20). GPR48 gene expression was found throughout 
the cortex and medulla of the thymus gland. In the kidney, intense labelling was dispersed throughout 
tubular structures in the inner medulla and in tubules of both stripes of the outer medulla some of 
which may be proximal tubules (Figure S.5C), with some light labelling of glomeruli and unidentified 
tubular structures in the cortex. There was also moderate of expression of GPR48 mRNA in cells and 
vasculature/connective tissue of adipose tissue, and hepatocytes of the liver. Low hybridisation signal 
was observed in the exocrine (acini) and endocrine (islets of langerhans) pancreas (Figure 5.6Ci) 
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which was negligible in sections treated with sense probe (Figure 5.6Cii). Low transcript expression 
was found in the trachea, pancreas and adrenal cortex. There was a low-negligible GPR48 signal in 
the cardiac muscle, and an absence of detectable expression in the adrenal medulla. 
GPR56 
As with GPRC5B mRNA, GPR56 receptor transcripts were highly expressed in brain regions such as 
the SON, lateral ventricles, paraventricular nucleus and intermediodorsal thalamic nucleus of the 
thalamus, and the medial habenular. Moderate expression was observed in the CA 1-3 of the 
hippocampus, SCN and PVN (Figure 5.2.IC). The intermediate and neural lobes of the pituitary were 
also intensely labelled, while the anterior pituitary was moderately labelled (Figure 5.2.2E). GPR56 
mRNA is distributed throughout the cortex and medulla of the thymus (cortex> medulla) with 
distinct labelling of an unknown cell type/structure in the medulla (Figure 5.3C). GPR56 labelling 
was throughout the red and white pulp of the spleen, although it appeared to be a higher in the 
germinal centres of the white pulp. Intense labelling was evident in the blood vessels and stroma 
within the adipose tissue, with some labelling of adipocytes. A high level of GPR56 mRNA was also 
dispersed throughout the cortex, medulla and pelvis of the kidney. GPR56 gene expression appeared 
to be in the proximal tubules in the outer strip of the outer medulla (Figure 5.58), while signal 
accumulated over both the collecting tubules and the thick ascending limbs in the inner stripe of the 
outer medulla, and possibly in the thin (descending and ascending) limbs of the inner medulla. In the 
testis, GPR56 transcripts were present in both the seminiferous tubules and leydig cells. Highest 
expression was found mainly around the outer layer of the seminiferous tubules (containing sertoli 
cells and spermatogonia), as well as in the developing spermatocytes. High levels of GPR56 
transcripts were also identified in the oesophagus (Figure 5.1. I) (where it appeared to be localised 
within the lamina propria). A moderate-low level of GPR56 mRNA expression was found in the 
trachea, and low expression in the heart and adrenal. A low-negligible GPRS6 signal was observed in 
the liver. 
GPR65 
Apart from an extremely faint signal in the SON, the brain sections were virtually absent of GPR65 
receptor mRNA. In the periphery, the white pulp of the spleen was intensely labelled with the GPR65 
probe, particularly in the marginal zone and periarteriolar lymphoid sheath (PALS) of the white pulp 
(5.60). Moderate-high signal was found in the thymus gland with slightly more labelling in the 
medulla when compared with the cortex. In the testis, moderate expression of GPR6S mRNA was also 
in the developing spermatocytes (Figure 5.7E). Low labelling was observed in adipose tissue, and 
low-negligible labelling was in the adrenal and kidney. GPR6S hybridisation signal was not above 
background in liver, heart, pituitary gland, and pancreas. 
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GPRI08 
GPRI08 receptor transcripts were highly expressed in the SCN, SON, PVN, CAI-3 (and dentate 
gyrus (Figure 5.2.1 D» of the hippocampus, dorsal third and lateral ventricles, and all three lobes 
(anterior and intermediate lobe> neural lobe) of the pituitary gland. GPR108 mRNA was equally as 
prevalent in the periphery. Intense expression ofGPRl08 mRNA was observed in the both the cortex 
and medulla of the thymus gland, although expression was highest within an unidentified cell 
type/region within the medulla (Figure 5.3D). Dense labelling was found in the spleen (particularly 
the white pulp), all layers of the adrenal gland, while moderate labelling was observed in the 
connective tissue and vasculature of the adipose tissue (Figure 5.78). In the testis, GPR I 08 mRNA 
expression was localised to the outer perimeter (containing sertoli cells and spermatogonia) and 
developing spermatocytes of the seminiferous tubules, with some labelling of leydig cells. Moderate 
to high levels of transcripts were found in the kidney, with diffuse labelling of possible tubular 
structures extending from the inner medulla to the inner stripe of the outer medulla, and moderate 
labelling of tubular structures in the outer stripe of the 'outer medulla and cortex. Interestingly, the 
GPR 108 sense probe also hybridised to the kidney with a distinct pattern compared to that of the 
antisense (Figure 5.8A). High sense probe labelling was found in the outer stripe of the outer medulla 
consistent with proximal tubules which radiated into the cortex (Figure 5.5E), while the inner medulla 
and pelvis appeared conspicuously devoid of any signal. Moderate GPR 108 expression was observed 
in the connective tissue and hyaline cartilage of the trachea, low-moderate expression was found in 
heart myocytes, and low expression in the liver. There was no discernible GPRI08 probe labelling in 
the pancreas. 
GPR125 
GPR125 receptor mRNA expression was observed in the dentate gyrus and CA3 of the hippocampus, 
and the dorsal third and lateral ventricles, with faint expression in the PVN and SON. The anterior 
lobe of the pituitary was strongly labelled with GPRl25 probe with a faint, diffuse signal in the 
intermediate and neural lobes. High levels of transcript were found in the adrenal cortex but not 
medulla (Figure 5.3E). In the testis, moderate-high expression was observed in the seminiferous 
tubules with light labelling of leydig cells (Figure 5.7DilDii). However, the seminiferous tubules had 
varying patterns of expression - in some instances spennatids were strongly labelled, in others 
labelling was not prevalent in the developing spermatocytes, and/or the outer perimeter of the tubules 
(Figure 5.7 Dii). In the kidney, signal was diffuse throughout the pelvis, and inner and outer medulla. 
Labelling appears to concentrate to a tubular structure that radiated from the medulla into the cortex 
such as the proximal tubules. Moderate GPR 125 mRNA expression was observed in the trachea, 
particularly in the mucosa and submucosa but also the hyaline cartilage with faint expression in the 
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fibroelastic tissue (Figure S.3A) (N.8., hyaline cartilage is the most abundant cartilage in the body, 
which acts to support tissues such as the trachea, and also cover. the articular surfaces of bones in 
synovial joints). Moderate-low GPR125 transcript expression was found in the hepatocytes of the 
liver. Low hybridisation signal was observed in the heart and thymus, and low-negligible signal was 
found in the pancreas and spleen. 
GPR146 
GPRI46 mRNA was present in the PVN, SON and hippocampus, and highly expressed in the dorsal 
third and lateral ventricles (Figure 5.2.28) and anterior lobes of the pituitary, with moderate/faint 
expression found in intennediate and neural lobes. In the spleen, transcript expression was particularly 
high in the red pulp trabeculae. In the white pulp, signal appeared to be concentrated around the 
perimeter of the germinal centres, presumably in the marginal sinus, although the genninal centres 
themselves were absent of labelling (Figure 5.6E). In some splenic areas there was slightly denser 
labelling of the PALS compared with the rest of the white pulp. Transcript was predominantly 
expressed by stroma of the adipose tissue, with some expression in vessels and adipocytes. In the 
heart, G PR 146 signal was generally well distributed over the myocytes of the ventricular walls, but 
GPR146 gene expression was higher in myocytes of the atrial muscle (Figure 5.4A). Moderate 
labelling was seen throughout the liver (Figure 5.68), over hyaline cartilage (Figure 5.38), 
submucosa, and fibroelastic tissue of the trachea, in the outer layer of cells in the seminiferous tubules 
of the testis, and all layers of the adrenal glands. Labelling of the inner medulla and pelvis of the 
kidney was unifonn, although labelling appeared to branch out from the inner medulla through to the 
inner and outer stripes of the outer medulla. Punctuate labelling in the renal cortex appeared to label 
the glomeruli. Low-negligible GPRl46 transcript expression was observed in the pancreas. 
GPR153 
GPR 153 labelling was striking throughout the thalamus, in the medial habenular nucleus (Figure 5.1.2 
and 5.2.1 E), SCN (Figure 5.2.2A), and cortical layers 2, 3 and 5. Moderate signal was observed in the 
PVN and SON, with weak expression in CAI-3 of the hippocampus and anterior pituitary. In the 
periphery, GPRI53 transcript was highly expressed in the testis. Expression varied between 
seminiferous tubules, with transcript confined to the developing spennatocytes in some but also the 
outer layer of the seminiferous tubules in others (Figure 5.7F). Low levels ofmRNA were also found 
in the leydig cells. In the kidney, faint to moderate labelling in the inner medulla radiated out into the 
inner stripe of the outer medulla and also dispersed into the outer medulla. Faint labelling was 
observed in the renal cortex whereas there was no absence of labelling in the pelvis. In the spleen, 
moderate transcript expression was mainly found in the red pulp, although there was some labelling in 
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the PALS surrounding central arterioles of the white pulp. Moderate-low hybridisation signal was 
observed in the heart and trachea, and there was an absence of signal in the liver and pancreas. 
TMEM87B 
TMEM87B receptor transcripts were highly expressed in all the brain regions of interest: PVN, SON 
(Figure 5.2.IF) and CAl-3 and dentate gyrus ofthe hippocampus. Intense signal was also found in the 
medial habenular and dorsal third and lateral ventricles. In the pituitary, TMEM87B mRNA was 
highly expressed in the anterior and intennediate lobes. and weakly expressed in the neural lobe. 
Intense labelling was ubiquitous throughout the lobes of the thymus and all layers of the adrenal gland 
(Figure 5.3F). In the spleen. there was a high level of transcript in the white pulp, and to a lesser 
extent in the red pulp. TMEM87B transcripts were highly expressed in the renal pelvis and medulla. 
The labelling in the pelvis. and inner medulla and inner stripe of the outer stripe was diffuse, while the 
signal in the outer stripe of the outer medulla appeared to radiate out to the cortex, labelling tubular 
structures such as the proximal tubules. Signal was found over the glomeruli and tubules in the renal 
cortex (Figure 5.5A). There was labelling dispersed throughout the adipose tissue stroma and lightly 
scattered over the adipocytes (Figure 5.7Ci) - an example of section labelled with sense probe is 
shown in Figure 5.7Cii. A moderate level of transcripts were found throughout the heart muscle, and 
was also in the testis - in the latter tissue labelling was mainly in the perimeter of the seminiferous 
tubules and in occasional spennatids and supporting leydig cells. 
GPER 
The hybridised GPER probe is usually exposed to film for at least 2 months (particularly in the brain) 
(see Chapter 3) nevertheless it clearly labels the SON. PVN, and anterior and intennediate lobes of 
the pituitary gland, but not the neural lobe after a 6 week exposure. An extremely faint signal is also 
observed in the SCN. and CAt/CA2 and CA3 hippocampal regions. In agreement with Chapter 3, 
moderate expression of GPER was also found in the adrenal medulla (with faint expression in the 
zona glomerulosa) and renal medulla and pelvis (pelvis> medulla). In addition to the data reported in 
Chapter 3. faint labelling was also observed in the spleen (mainly in the red pulp). Interestingly, the 
GPER sense probe labelled the spleen. with a pattern distinct from that of the antisense probe 
labelling. Sense signal was confined to the white pulp, largely is labelling genninal centres and PALS 
(5.8B). 
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Figure 5.2. Examples of orphan gene expres ion in the brain - image from cmul ion-dipped cetion. 
(A) GPRC5B mRNA is ubiquitously expressed throughout the brain secti n inve ligated, although it is 
particularly evident in anterodorsal and reticular thalamic nuclei (AD and Rt, re pecli ely). (B) Labelling of the 
ubfomical organ (SFO) with GPR48 probe. (C) As wilh GPR 5B, GPR56 tran cripl i highly expre ed 
throughout the brain levels investigated, including the PYN, (D) GPRI08 h bridi at ion ignal in the dentate 
gyrus of hippocampus. (E) Intense GPR 153 probe labelling in the medial habenular nucleu (MHb) and 
thalamus (Th). (F) TMEM87B mRNA in the ON. D3Y, dor al third ventricle; 3Y, third ventricle; GrOG, 
granular dentate gyrus; PoDG, polymorph layer of the dentate gyru ; opt, 0plic Ira t. cale bar, 400!lm in (A); 
IOO!lm in (B-F). 
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Figure 5.2. Continued. Examples of orphan gene expression in the brain and pituitary gland - image 
from emulsion-dipped sections. 
(A) GPR 153 hybridisation signal in the CN. (B) GPR 146 tran cripl e, pres ion in the h roid plexu (Chp) of 
the lateral ventricle (LV). (C-E) Different expre sion pattern of orphan mR in the pituitar gland: (Ci) high 
levels of GPRC5B mRNA in the neural lobe (NL), low-moderate expre ion in an unidentified cell type in the 
anterior pituitary (AP) (arrows), and an absence of expre ion in the intermediate lobe (IL); ( ii) higher 
magnification of GPRC5B labelling of an unknown cell type in the anterior pituitary (arrow); (D) intense 
GPR48 probe signal in the neural lobe, moderate signal in the anterior lobe, and low ignal in the intennediate 
lobe; (E) High levels of GPR56 transcript in the neural and intermediate lobe , \! ith moderate expre ion in 
anterior lobe. 3V, third ventric le; OC, optic chiasm; cc, corpus callo um; fi, fimbria of the hippocampus. cale 
bars, 100l1m in (A, Ci, 0 and E); 50l1m in (B and Cii). 
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Figure 5.3. Examples of orphan gene expression in trachea, th ym us and adrena l gland - image from ern ul ion-
di pped ections. 
Trachea: (A) GPR 125 hybridisation signal in the mucosa (m) and ubmuco a (s). with ome labelling of the hyaline 
cartilage (H) and faint labelling in the fibroelastic tissue (t). (B) GPR 146 tran cript in the perichondrium and in 
hyaline cartilage chondrocytes (c), although ome chondrocyte have been 10 t during proce ing leaving empty 
lacuna (L). The probe has also bound non-specifically around the ti ue. Thymus labelling of the cortex (T ) and 
medulla (TM) by GPR56 (C) and GPR I 08 (0) probes, with signal concentrating ar und an unidentified cell type( ) in 
the medulla (arrows). Picture (0) is a reversed image of the thymu ection (re er ing highlighted the labelling of the 
unidentified cell types(s) in the medu lla) - GPR 108 probe hybridi ation grains appear" hite in the picture (but black 
on the actual slide). Adrenal gland: (E) GPR 125 transcript wa highlyexpre ed in the adrenal cortex (zona reticulari 
(ZR) layer shown here) but not in the adrenal medulla (AM). (F) T lEM87B mR wa highlyexpres ed throughout 
the entire adrenal gland - only examples of labelling in the capsule (c) and the zona glomerulo a (ZG) and zona 
fasiculata (ZF) of the cortex are shown here. ilc, intralobular connective ti ue. ale bar. 200l-lm in ( ); 100pm in 
(0); 50pm in (A, B, E and F). 
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Figure 5.4. Examples of orphan gene expression in heart tissue. 
(A) low-magnification photograph ofa film autoradiographic image ofa heart section hybridised with GPRI46 
probe. Labelling was quite prevalent in the atrial wall (a). (8) Emulsion dipped heart section hybridised again 
with G PR 146 probe. G PR 146 labelling was also observed in myocytes (open arrows point towards myocyte 
nuclei) in the ventricular walls. (C) Emulsion-dipped heart section demonstrating GPRC58 mRNA expression 
in myocytes and a blood vessel (bv). Scale bars, I mm (A); 50~m in (8 and C). 
Figure 5.5. Orphan gene expression in the kidney - images from emulsion-dipped sections. 
(A) TMEM878 mRNA expression in glomeruli (G) and tubules (T) of the cortex. (8) GPR56 hybridisation 
signal in proximal tubules (small arrows) of a medullary ray. (C) Labelling by GPR48 probe in tubules of the 
outer stripe of the outer medulla (OSOM), some of which appear to be proximal tubules. (Oi). GPRC58 
transcript expression in the inner stripe of the outer medulla (IS0M), inner medulla (1M), and pelvis (RP). (Oii) 
Higher magnification image of GPRCRB mRNA in the ISOM, and possibly the thick ascending limb (open 
arrows). (E) GPR 108 sense probe binding in the OSOM - perhaps localised in the proximal tubules. RC, renal 
cortex. Scale bars, 400~m in (Oi); I OO~m in (8, C, Oii, E); 50~m in (A). 
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Figure 5.6. Examples of orphan gene expression in liver, pancreas and spleen - images from emulsion-
dipped sections. 
Liver: labelling ofhepatocytes by GPR48 (A) and GPRI46 (8) probes. Pancreas: (Ci) Low GPR48 transcript 
expression in cells of the islets of langerhans (i) and acinar cells (a). (Cii) GPR48 sense probe binding in islets 
of langerhans and acinar cells - only a few grains are visible when compared to the antisense probe sense 
labelling. Spleen: reverse images of emulsion-dipped spleen sections hybridised with GPR65 (D) and GPRI46 
(E) probes - silver grains appear white. In (D), note that GPR6S mRNA is expressed in the germinal centre 
(abbreviated to G), periarteriolar lymphoid sheath (PALS) and marginal zone (MZ), but is absent from the 
marginal sinus (MS). (E) GPR 146 transcript expression in the red pulp (RP) and marginal sinus, and is absent 
from the germinal centre and marginal zone. cv, central vein . Scale bars, IOOl1m in (A, D, and E); SOl1m in (8, 
Ci and Cii) . 
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Figure 5.7. Examples of orphan gene expression in adipose tissue and testis - images from emulsion-dipped sections. 
Adipose tissue: (A) Intense GPRC5B mRNA expression observed in stroma (S), with some mRNA found on the perimeter of unilocular 
adipocytes (U). (B) Labelling of stroma with GPRI08 probe, and low labelling of unilocular adipocytes . (Ci) Grains of hybridised 
TMEM87B probe on adipocytes, which are absent in a section hybridised with sense probe (Cii) . Testis .· (Oi) High GPRI25 transcript 
expression in the perimeter of the seminiferous tubules (containing sertoli cells and spermatogonia) (arrows), low-moderate levels of 
transcript also found in developing spemlatocytes (dashed arrows) and spemlatids (open arrows). (Oii) Inverted lower magnification image 
of GPR 125 mRNA expression in the testis (black grains appear white) . Note that the location of transcript varies in each seminiferous tubule 
(although the functional significance of this is currently unknown). Faint hybridisation is also observed in leydig cells (arrow heads). (E) 
Labelling of developing spemlatocytes with GPR65 probe. (F) Inverted image of GPRI53 probe binding (appears white) in the perimeter of 
seminiferous tubules and developing spermatocytes. Scale bars, 200llm in (F); 100llm in (A, B, Oii, and E); 50llm in (Ci, Cii, and Oil. 
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Figure 5.8. Examples of sense binding - low magnification photographs of film autoradiographic images. 
(A) GPR I 08 sense probe binding in the renal cortex (RC) and outer stripe of the outer medulla (OS). Inverted 
image of GPR I 08 mRNA expression in the renal cortex (hybridisation signal appears white) . (C) GPER sense 
probe binding in the white pulp (WP) of the spleen. (D) Absence of GPR65 sense binding in the spleen. RP, red 
pulp. Scale bars, I mm. 
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Discussion 
5.4.1 Narrowing the search for a fast glucocorticoid receptor to four orphan GPCRs 
The aim of the present study was to find a candidate orphan GPCR for 'fast' glucocorticoid responses. 
To accomplish this, we screened a number of orphan GPCRs to determine their expression in brain 
regions/peripheral tissues that exhibit fast glucocorticoid responses; namely brain (SON, PVN and 
hippocampus), pituitary gland, trachea, thymus gland, heart, adrenal gland, kidney, liver, spleen, 
pancreas, adipose tissue, and testis. The validity of such an approach is not without precedent. For 
example, the cannabinoid CB I receptor was deorphanised principally on the basis of its expression in 
cells and brain regions known to show responses to tetra-hydrocannabis and cannabinoid derivatives 
(Matsuda et 01., 1990). As summarised in schematic Figure 5.9, out of the 9 orphan GPCRs, at least 4 
(GPRI08, GPRI46, GPR56, TMEM87B) have a gene expression profile that closely maps to the 
regions/tissues of interest. However, the ISHH gene expression profiles in this study are by no means 
defmitive; for example negligible gene expression in the some tissues may be due to low transcript 
expression - the 6 week film exposure (18 week emulsion exposure) used here may not be enough 
time to develop sufficient signal i.e., GPER hybridised probe is normally exposed to film for 8 weeks. 
The pancreas exhibited low-negligible expression for most of the orphan transcripts - of all the 
orphans GPR48 had the highest gene expression in the pancreas and even this was very low. This may 
imply that pancreatic orphan gene expression is low, or that the pancreas is a difficult target to 
hybridise with these probes. Indeed the pancreas is the major source of digestive ribonucleases 
(RNases) and thus it is possible that some endogenous RNA was degraded by pancreatic RNases after 
tissue removal (the pancreas was frozen about 10-15 min following animal sacrifice) (Bernard, 1969). 
In future studies it may be prudent to prioritise freezing the pancreas following sacrifice. 
Alternatively, immediately submerging the pancreas in 4% PF A would fix and in turn inactivate 
RNAses. It is assumed that the orphan transcripts in this study translate into fully functional and 
active proteins. There are examples of mRNA and protein mismatches in the literature e.g., GLP-l . 
mRNA is highly expressed in the PVN, but only weak autoradiographic binding is observed (Tauchi 
et 01.,2008) and in Chapter 3, GPER protein but not transcript is located in the posterior pituitary. The 
questions of technique sensitivity and gene verses protein expression has been addressed in Chapter 1. 
185 
C hap t c r 5 : Dis t rib 1I t ion 0 r 0 r p han () peR s 
Hippocampus: GPRC5B, GPR56, GPRI08, 
GPRI25, GPRI46, GPRI53, T\1EM87b 
PVN: GPRC58, GPR56, 
GPR 108, GPRI46, 
GPR153, T\1EM87b 
Trachea: GPRC5B, GPR48, 
GPR56, GPR I 08 , GPRI25, _-H~:?---i 
GPRI46, GPRI53, T\1EM87b 
Adrenal gland: GPRC5B, 
GPR48, GPR56, GPRI08, 
GPR125, GPRI46, GPR153, 
TMEM87b 
Kidney: GPRC5B, GPR48, 
GPR56, GPRI08, GPR125, 
GPRI46, GPRI53, TME:'187b 
Liver: GPR48, GPRI08, 
GPRI25, GPR146 
Testis: GPR48, 
GPR56, GPR65, GPRI08, GPR125, 
GPRI46, GPRI53, TM~M87b 
SON: GPRC5b, GPR56, 




GPR56, GPRI08, GPR125, 
GPRI46, GPR153, TMEM87b 
Thymus gland: GPR48, 
GPR56, GPR65, GPRI08, 
GPRI46, GPRI53, TMEM87b 
Heart: GPRC5B, GPR56, 
GPRI08, GPRI25, GPRI46, 
GPR153, lMl:.M87b 
Spleen: GPRC5B, GPR48, 
GPR56, GPR65, GPRI08, 
GPRI46, GPRI53, TMEM87b 
Pancreas: GPR48 
Adipose tissue: GPRC5B, GPR48, 
GPR56, GPR65, GPRI08, GPRI25, 
GPRI46, I'Ml:.M87b 
Figure 5.9. Schematic illustration demonstrating orphan GPCR gene expression in some rat tissues known to exhibit fast 
glucocorticoids responses. 
N.B. , only high-low transcript-expressing tissues are shown. Of the fourteen brain regions/peripheral tissues investigated low-high levels of 
GPR I 08 and GPR 146 mRNA were expressed in all brain regions/peripheral tissues investigated, except the pancreas (although GPR 146 was 
expressed at low-negligible levels) . GPR56 and TMEM87B gene expression was also found in all brain regions and tissues, but not in li ver 
and pancreas (TMEM87B mRNA was expressed at low-negligible levels in the liver); GPR 125 in all areas/tissues apart from PVN, spleen 
and pancreas; GPR 153 in all areas/tissues except liver, pancreas and adipose tissue; GPRC5B in all areas but not thymus, liver, pancreas, 
and testis ; GPR48 transcripts were not observed in any of the brain regions of interest but were found in all peripheral tissues apart from the 
heart ; and finally GPR65 transcripts were only expressed by the thymus, spleen, adipose tissue and testis. 
Even though the gene expression pattern shown here is not definitive (e .g., longer exposure of hybridised sections to film/emulsion may 
further reveal low expression of some of the orphan GPCRs currently considered low-negligible/negligible; ISHH needs to be optimised for 
pancreas) , it indicates that many of the orphan GPCRs are in the tissues of interest. As summarised in the text (5.4.1), GPR I 08 GPR 146 and 
TMEM87B have been chosen as preferred candidates based on the high correlation between their transcript expression in tissues that exhibit 
rapid glucocorticoid responses (even though GPR56 transcript has a wide distribution profile like TMEM87B - it's possible role in cell 
adhesion (and reports it binds tissue transglutaminase, TG2 (Xu el at., 2006) makes it an unlikely candidate). Rat diagram adapted from an 
illustration by Chris McKee (hltp:l/ratguide.comihealthlbasies/rat anatomy.php). 
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We have identified GPR108, GPRI46, GPR56, and TMEM87B as candidate GPCRs that could be 
activated by glucocorticoids, and that the biology of these receptors is conserved between mammals. 
A review of the literature reveals that little is known about the biological properties of three of these 
candidate glucocorticoid GPCRs. Human GPRl46 is a class A (rhodopsin-like) receptor with 
orthologues in many species including fish (suggesting that the receptor arose early in vertebrate 
evolution at least 450 million years ago) (Gloriam et al., 2005). Conservation of receptor homology 
between species may suggest an important biological role for GPRI46. GPRI08 and TMEM87B are 
atypical GPCRs with low sequence homology with any other family of GPCR. They belong to the 
lung 7TM receptor (LUSTR) family which have a common predicted structure of an amino-terminal 
hydrophobic signal peptide sequence (docking domain), large N-terminus, and depending on the 
algorithms used between 6 and 7 transmembrane domains (known as the LUSTR domain) (Edgar, 
2007; Li et al., 2008). It has been suggested that TMEM87B interacts with the high-risk human 
papillomavirus oncoprotein 18 E6 (HPV 18 E6), but its endogenous ligand remains unknown (Li et al., 
2008). 
GPR56, the remaining candidate glucocorticoid GPCR, has a more defined biological role. It belongs 
to the adhesion receptor subfamily of the class B of GPCRs. Humans that harbour mutations in 
GPR56 have bilateral frontoparietal polymicrogyria (BFPP), an autosomal recessively inherited 
condition characterised by the development of small gyri (Piao et al., 2005). GPR56 KO mice exhibit 
brain defects similar to that in BFPP, which are attributed to a loss in cell adhesion between neurones 
and the extracellular molecules of the pial basement membrane (Li et al., 2008; Koirala et al., 2009). 
GPR56 has also been implicated in modulating tumour growth and metastasis (Kausar et aI., 2011; Xu 
et al., 2006). It is therefore unsurprising that Xu and colleagues reported that the N-terminal of 
GPR56 binds tissue transglutaminase, TG2, an ubiquitously expressed cross-linking enzyme in the 
extracellular matrix that is also involved in cell adhesion and tumour progression (Xu et al., 2006; Xu 
et al., 2007). However, there are no major developmental abnormalities in TG2 KO mice, suggesting 
that TG2 may not be the only candidate agonist of GPR56 (De Laurenzi and Melino, 2001). 
Nevertheless, the pervasive nature of GPR56 transcript expression throughout many of the tissues in 
this study, particularly the brain (at the levels of the SONIPVNI and dorsal hippocampus), together 
with its clear involvement in cell adhesion (as its family name suggests) and its close interaction with 
TG2, suggests that it is an unlikely candidate for a fast glucocorticoid receptor. 
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5.4.2 The other five orphan GPRCRs - could they still be candidates for a fast 
glucocorticoid receptor? 
GPR125 
Like GPR56, GPR125 is also a member of the adhesion family (Bjarnad6ttir et 01., 2004). GPRl25 
was found in all of the tissues in the study (but at almost negligible levels in the PVN, spleen and 
pancreas), and as such may be a good candidate for a fast glucocorticoid receptor. Centrally, high 
GPR125 mRNA was observed in the choroid plexus of the dorsal and lateral ventricles, and the 
dentate gyrus and CA3 region of the hippocampus, which is consistent with reports that suggest 
mouse GPR125 gene expression increases two fold (as shown by qPCR) in the choroid plexus and 
hippocampus in response to traumatic brain injury (Pickering et 01., 2008). In addition, an association 
study has identified GPR125 as a possible gene involved in bipolar disorder and schizophrenia, 
diseases that are linked to dysfunction in limbic-related regions such as the hippocampus 
(Christoforou et 01.,2007). However, much of the literature surrounding GPR125 concerns its role as 
a marker for human and mouse spermatogonial stem cells (He et 01., 20 I 0; Seandel et 01., 2007). In 
the current study, we located GPRl25 transcript in all stages of rat sperm development and not simply 
restricted to spermatogonia - this may indicate possible species differences between rats, mice and 
humans. On the other hand, as described in Table 5.1 fast glucocorticoid responses have been 
observed in mouse leydig cells - but according to Seandel et 01., (2007) GPR125 is confined to mouse 
spermatogonia (Seandel et 01., 2007). Fast glucocorticoid responses have been reported in the 
hippocampal CAl region which is devoid of GPR125 mRNA (Wigert et 01., 2006). Taken together 
this suggests that perhaps GPR125 may not be a high-priority candidate as a fast glucocorticoid 
receptor. 
GPR153 
GPR153 mRNA was also found in many of the tissues in this study, excluding the liver and pancreas. 
Of all the orphans investigated GPR153 has the most striking transcript distribution in the brain at the 
levels investigated, with intense expression in the cortex and thalamus. It is somewhat surprising that 
little, if anything is known about the receptor's role in the brain. Intriguingly, the pattern ofGPR153 
gene expression in the cortex and thalamus is similar to that of the alB-adrenoceptor (see Figure 5.10) 
(Day et 01., 1999). Interestingly, as a class A (rhodopsin-like) receptor, GPR153 has closest sequence 
homology to the biogenic amine subfamily of receptors (Gloriam et 01., 2005). Given this, one would 
speculate that GPR153 would more likely bind a biogenic amine rather than a glucocorticoid. This 
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could be tested by expressing this receptor in heterologous cells and examining signal transduction 
parameters in response to amines such as noradrenaline, adrenaline, serotonin, and dopamine. 
Figure 5.10. Similarities between ulB-adrenoceptor and GPRI53 transcript distributions in the rat brain. 
A) Autographical film image of ul B-adrenoceptor riboprobe binding in the brain (at the level of the PVN) -
picture taken from Day et al., (1999). B) Central expression ofGPRI53 (at the level of the PVN, but slightly 
caudal when compared with (A)) . 
GPRC5B 
GPRC5B (previously known as retinoic acid-induced gene 2 (RAIG 2) or bride of sevenle s) is a 
member of the class C (metabotropic glutamate-like) family of receptors (Brauner-Osborne and 
Krogsgaard-Larsen, 2000). Unlike most of the orphans in this study the distribution of GPRC5B has 
previously been investigated in human and rat tissue. For example, northern blot analysis of human 
tissues revealed that GPCR5B mRNA is highly expressed in brain (e.g., corpus callosum, triatum, 
substantia nigra, thalamus, hippocampus, and spinal cord), and low relatively weakly expressed in the 
heart, kidney, lung, pancreas, testis and stomach (Robbins et al. , 2000). A northern blot analysis of rat 
tissues revealed that GPRC5B gene expression was also high in brain (e.g. , neocortex, striatum, 
substantia nigra, thalamus, amygdala and cerebellum) and pituitary, and low in heart, adipose tissue, 
kidney, lung, mammary gland, testis and ovary (Robbins et al. , 2002). These reports are broadly in 
agreement with the current study, where we found ubiquitous di tribution of GPRC5B transcript 
throughout the brain levels investigated (notably the SON, external globus pallidus, anterodorsal and 
reticular thalamic nuclei , cerebral cortex, and the corpus callosum), the pituitary gland, kidney, heart 
and adipose tissue (but not testis, pancreas and liver). Therefore, based solely on it distribution across 
three different species GPRC5B may contender for a fast glucocorticoid receptor. However, 
functional studies indicate that GPCR5B may have a different role. 
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As its previous name RAIG2 suggests, GPRC5B is upregulated in a variety of cell lines following 
treatment with all-trans-retinoic acid, a synthetic form of retinoic acid (Robbins et al., 2000). Retinoic 
acid is a metabolite of vitamin A and plays a key role in embryonic cell and tissue differentiation. 
Therefore, the upregulation of GPRC5B by retinoic acid may indicate a role for GPCR5B in 
embryonic development (Mark et aJ., 2009). This has been demonstrated in Drosophila - GPRC5B 
has been identified as the ligand for sevenless tyrosine kinase (sevenless; hence GPRC5B's alternative 
name 'bride of sevenless'), a receptor involved in photoreceptor neuron R7 development in the 
embryonic eye (Hart et aJ., 1990; Cagan et aJ., 1992). GPRC5B and sevenless are expressed by 
Drosophila photoreceptor neurones R8 and R7, respectively, and GPCRC5b expression by R8 
neurones is required for normal R7 cell development. Surprisingly, communication between R8 and 
R7 neurones occurs via a receptor-mediated transfer of GPRC5B from cell to cell. Upon binding to 
sevenless GPCR5B is internalised by the opposite R7 neurone (Cagan et aJ., 1992). Kohyama-
Koganeya and co-workers have subsequently identified the endogenous ligand for GPRC5B in 
Drosophila as glucose, and shown that it is required for homeostatic metabolism of glucose and lipids 
(Kohyama-Koganeya et aJ., 2008). Whether glucose is the endogenous ligand of the mammalian 
GPRCSB has not been substantiated. However, a recent association study further indicates a role for 
human GPCR5B in metabolism by suggesting the receptor is involved in body weight regulation 
(Speliotes et aJ., 2010). 
GPR48 
GPR48 (also known as LGR4) is a class A receptor in the leucine-rich, G protein~oupled receptor 
(LGR) subfamily (otherwise known as glycoprotein hormone receptor subfamily) (Loh et aJ., 2001). 
As with GPRC5B, the distribution of GPR48 has been investigated using northern blot analysis and 
GPR48-LacZ reporter mice, but differences exists between species and techniques. In human tissue, 
GPR48 transcript was highly expressed in pancreas, while only moderate expressed in placenta, 
kidney, brain, heart and muscle (Loh et al., 2001). Northern blot analysis of mouse tissue revealed a 
species difference in GPR48 mRNA distribution between human and mouse with high transcript 
expression in liver and kidney, moderate expression in muscle, and low expression in brain, heart and 
testis (Loh et al., 200 I). This is in contrast to GPR48-LacZ reporter mice which showed highest 
GPR48 transcript expression in kidney, adrenal gland, and testis, medium expression in eye, trachea, 
cartilage, and cerebellum, and weak expression in brain, with no expression in spleen and pancreas 
(Van Schoore et al., 2005). Overall, our rat GPR48 ISHH revealed transcript expression similar to that 
of the mouse but with some species differences. We observed highest mRNA expression in pituitary, 
thymus and kidney, moderate expression in liver and adipose tissue, low-moderate expression in 
spleen and testis, and low expression in pancreas and adrenal. Since GPR48 is widely expressed it 
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may still be a valid candidate to be a fast glucocorticoid receptor. GPR48 transgenic animals have 
given some insight into the receptor's role in vivo. In the uterus, GPR48 KO embryos display eye lid 
and bone growth retardation characterised by delayed bone formation and decreased osteoblast 
differentiation and mineralisation, while foetuses display transient anaemia and abnormal definitive 
erythropoiesis (Jin et al., 2008; Luo et al., 2009; Song et al., 2008). Post gestation, only 40 % of 
GPR48 KOs survive (with some reports that none reach weaning age), and those that do are born with 
anterior segment dysgenesis (symptoms include small eyes and cataracts), severely compro~ised 
kidney function, and males have a deformed reproductive tract (Luo et al., 2009; Van Schoore et al., 
2005; Weng et al., 2008; Kato et al., 2006; Mendive et 01., 2006). In addition, ERa is down regulated 
in male reproductive tissues lacking GPR48 (Li et al., 20 I 0). 
Glucocorticoids produced by the foetal adrenals or from the mother via the placenta act as potent 
differentiation factors close to term. Glucocorticoids promote the maturation of foetal lungs, heart, 
kidney, gastrointestinal tract and CNS (Ng et al., 2000). Therefore, one would expect that if GPR48 
was a fast glucocorticoid receptor, a GPR48 mutant phenotype may possibly have some form of 
dysfunctional/undeveloped lungs, heart, or gastrointestinal tract, or even be functionally intact due to 
the presence of GRIMR. This is in contrast to the devastating effects the absence of GPR48 has on 
embryonic and foetal eye, bone, red blood cells, and male reproductive organ development. GPR48 
clearly has an indispensible role in development, and we consider it unlikely to be a prominent 
candidate for a glucocorticoid receptor. Since the complet.ion of this study, the apparent 
deorphanisation of the mouse GPR48 has been reported. Carmon and colleagues demonstrated that 
mouse GPR48 binds the novel extracellular molecules R-spondins 1-4 with high affinity, and 
mediates R-spondinlWntip-catenin signalling in HEK293 cells (Carmon el al., 20 II). , 
GPR65 
The final orphan, GPR65, is a class A receptor previously known as T-cell death-associated gene 8 
(TDAG8) (Kyaw et al., 1998). We find GPR65 gene expression predominately in rat thymus, spleen 
and testis. This is in agreement with a previous northern blot analysis of ~uman tissue which located 
GPR48 mRNA mainly in lymphoid tissues, including peripheral blood leukocytes, spleen, lymph 
nodes, and thymus (Kyaw et al., 1998). The prominent expression of GPR65 in lymphoid tissues 
suggests a role for GPR65 in the immune system. In fact, GPR65 is upregulated in thymocytes during 
T cell receptor or glucocorticoid-induced apoptosis (Choi et 01., 1996). In addition, it has also been 
suggested that GPR65 binds psychosine (o-galactosyl-P-I,l'sphingosine), a glycosphingolipid that 
accumulates in the condition Globoid cell leukodystrophy (OLD, also known as Krabbe's disease) 
(1m et al., 2001). It is proposed that psychosine acts via a GPR65-dependant mechanism to increase 
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the formation of multinuclear globoid cells from macrophages in the brain (1m et al., 200 I). GPR65 
has also been identified as a proton-sensing GPCR - extracellular acidic pH stimulates GPR65 to 
activate cAMP formation in CHO-S cells, inhibits proinflammatory cytokine production via a 
cAMPIPKA signalling pathway in mouse macrophages, and enhances the tumour development by 
Lewis lung carcinoma (LLC) cells (Ishii et al., 2005; Mogi et al., 2009; Ihara et al., 2010). Therefore 
it appears more likely that GPR65 is a photon and/or psychosine receptor rather than a glucocorticoid 
receptor. 
5.4.3 Is this targeted approach the best way to identify a candidate 'fast' glucocorticoid 
receptor? 
After assessing the EST distribution profiles of all known orphan GPCRs (common to human and 
rodent), determining the tissue expression of nine orphan GPCRs, and reviewing the literature 
surrounding their potential biological roles, we have deemed three orphans as suitable candidates for a 
fast glucocorticoid receptor: GPRI08, GPR146 and TMEM87B. It should be noted that in some cases 
where orphan GPCRs have been assigned ligands in the literature, IUPHAR may still acknowledge 
them as orphans. This is due to I) prospective ligands have not been confirmed in more than one 
study; 2) deorphanising has yet to be confirmed in humans; and 3) the lack of evidence that ligand 
stimulation results in the activation of signalling pathways. Therefore, it is possible that some of the 
other orphan GPCRs in this study remain glucocorticoid receptor candidates, even if a different 
candidate ligand has already been proposed. 
It is also feasible that a fast glucocorticoid receptor is actually a GPCR with a known validated ligand 
e.g., CORT may bind the same or a different binding pocket to another ligand. As such, the 
alternative ligand may have a similar or dissimilar structure to CaRT. For example, some reports 
indicate that progesterone at high concentrations binds the aT receptor, and inhibits OT -induced 
signalling (Burger et al., 1999). In addition, the CB I cannabinoid receptor binds 'endocannabinoids' 
(e.g., derivatives of arachidonic acid), tetrahydrocannabis derivatives as well as a protein called 
hemopressin (Heinmann el al., 2007). In this study, we have also made an assumption that a 
glucocorticoid-binding GPCR is not a chemosensory receptor, yet these receptors are not restricted to 
sensory tissues and hence may have non-chemosensory ligands (Feldmesser et al., 2006). Moreover, 
Neuhaus el al., reported that an odorant GPCR, prostate-specific G protein-coupled receptor (PSGR), 
is activated not only by the odorant i3-ionone but also by testosterone metabolites (although specific 
binding has yet to be shown) (Neuhaus el al., 2009). Similarly, we have assumed that a single GPCR 
will evoke the fast glucocorticoid response rather than working in concert with, for example, 
additional proteins (e.g., the pharmacological specificity of the family of calcitonin receptors and 
calcitonin receptor-like receptors are dictated by additional proteins known as receptor activity-
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modifying proteins (RAMPs) (Sexton et al., 2006), or fonning a heterodimer with another GPCR 
(e.g., GABABI and GABAB2 heterodimerise to fonn the functional GABAB receptor (Marshall el al., 
2010», or a different family of receptor such as ion channel subunit (e.g., dimerisation between 
dopamine Os and GABAA y2 ligand-gated ion channel subunit reduces Ds mediated cAMP signalling 
(Liu et al., 2000». In addition, by initially searching ESTs profiles for candidate GPCRs based on 
their gene expression in the tissues of interest, we may have possibly discarded some good candidates 
because of their relatively low abundance. For example, if we were looking for a mouse vasopressin 
receptor in the same way, we would have missed the V IB receptor due to its general low gene 
expression (e.g., in the mouse pituitary there was 0 EST transcript out of 16965 cDNA clones), 
according to the EST profile. 
An alternative to the targeted approach of this study would be to test all chemosensory/non-
chemosensory orphan GPCRs in unbiased, high-throughput screening assays that could detect 
glucocorticoid-mediated second messenger responses. This would involve screening approximately 
125 mammalian non-chemosensory orphans (common to human and rat) and approximately 418 
human chemosensory orphans (which there are approximately 1,474 in rodents) (Gloriam el al., 2007; 
Harmar et al., 2009). Expression- or functional-based screens may miss unidentified splice variants 
which may also have a biological role - a GPCR splice variant could behave as a fast glucocorticoid 
receptor alone or in concert with another receptor (GPCRlsteroid receptor/ion channel). Sequencing 
RNA from all tissues that exhibit fast glucocorticoid responses would likely detect most, if not all 
GPCRs and their splice variants, and deep (transcriptome) sequencing can achieve this quickly and 
efficiently (e.g., Roche 454 GS FLX instrument can sequence 500 megabases in 10 hourS 
(Voelkerding el al., 2009). However, these approches are expensive and high throughput assays 
demand cloning of all receptors for screening. In an attempt to deorphanise our three candidate 
receptors (see Chapter 6) we used the only high through-put assay available in the laboratory, the IN 
CELL Analyser 1000. The 96 well plate fonnat of the IN CELL is on a much smaller scale than that 
of some high throughput assays (with plate formats ranging from 384 to 3456 wells), but is adequate 
considering we are only testing three orphans in the first instance. 
5.4.4 Sense transcript expression? 
An interesting observation from the current study was specific GPER and GPRI08 sense probe 
binding in the spleen and kidney, respectively. Although the sense probe is nonnally used to control 
the specificity of antisense probe binding, on occasions it highlights the presence of antisense 
transcript (Foletta el al., 2002). However, according to NCBI/Gene the sequence on the opposing 
strand to the GPER gene does not code for an obvious protein (i.e., NCBI have tenned the sequence 
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hypothetical protein LOC498154). Intriguingly, the next identified gene upstream of human, rat and 
mouse GPER encodes GPR 146 - whether this has any functional relevance remains to be seen. 
GPRI08 sense probe binding in the kidney was quite distinct, with binding restricted to the cortex and 
outer stripe of the outer medulla, possibly labelling the proximal tubules. Referring to NCBI database 
(e.g., Gene) it appears that the sequence on the opposite strand to GPRI08 does not code for a 
recognised protein, although the gene downstream of this sequence codes for thyroid hormone 
receptor interactor 10 (Trip I 0), a protein that has been shown to localise to proximal tubules (Tsuji et 
al., 1998). It is possible that the sense probe is in fact binding a transcript variant of Trip I 0 - a variant 
which shares part of the coding region of Trip 10 with a sequence that lays adjacent to the 
3'untranslated region of GPR 108 (where the riboprobes were directed). This hypothesis could be 
tested by screening a rat kidney eDNA library with the radiolabelled sense probe and sequencing any 
cDNA clones obtained. These clones may correspond to a variation of Trip 1 0, or may express a 
cDNA that has high homology to GPR 108. It is highly unlikely that the probe is cross-reacting with 
another mRNA from a known gene as all of our probes are subject to a BLAST search . The BLAST 
search with the GPR 108 probe obtained sequence matches with a maximum of 20 contiguous bp, 
which is extremely low considering the GPR I 08 probe is 329bp long. In any case, hybridisation 
between 20bp and a target gene is unlikely to remain following the stringent washes within the ISHH 
protocol (2 x 30 min wash in 0.1 x SSPE at 65°C). 
Genomic context 
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Figure 5.1 J. Genomic context of the rat GPRI 08 gene. 
Schematic diagram taken from the NCB I database (http://www.ncbi.nlm.nih.gov/gene/316136) depicting the 
genomic context of the rat GPR 108 gene. The sequence on the opposite strand to GPR I 08 does not code for a 
recognised protein, while the gene downstream of this sequence codes for Trip lOa protein that has been shown 
to localise to proximal tubules (Tsuji et aI. , 1998). It is possible that the sense GPRI 08 probe binding observed 
in the kidney is in fact binding a transcript variant of Trip I 0 - a variant which shares part of the coding region 
ofTriplO with a sequence that lays adjacent to the 3'untranslated region ofGPRI08 (where the riboprobes were 
directed). 
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5.4.5 Conclusion 
Deorphanising receptors based on their distribution profile is not a novel approch - for example, as 
mentioned previously Matsuda and colleagues deorphanised the CBI receptor based partly on 
similarities between its central transcript distribution and that of a previous binding study with eH]CP 
55,940, a radiolabelled synthetic cannabinoid (Matsuda et 01., 1990; Herkenham et 01., 1990). Using 
this same principle we have narrowed down our search for a fast glucocorticoid receptor to three 
candidates: GPRI08, GPR146, and TMEM87B. In the next chapter, we attempt to determine whether 
the three orphans respond to glucocorticoids via activating the ERK signalling pathway. 
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Chapter 6: A fast G protein-coupled glucocorticoid receptor? 
6.1 Introduction 
6.1.1 History of orphan GPCR receptors: discovery and methods of deorphanisation. 
In 1986, after exhaustive efforts to biochemically purify adrenergic receptors, Dixon and colleagues 
cloned the mammalian p2-adrenergic receptor from a hamster genomic library (Dixon et al., 1986). 
This was a fortunate find, facilitated by the fact that the p2-adrenergic receptor was intronless. It was 
also a significant discovery - the group not only recognised that the receptor shared sequence 
homology with bovine opsin but also shared similarities in function: both receptors were involved in 
G protein-mediated signal transduction (Lefkowitz, 2007). This invigorated research into, and 
commenced the cloning era of, the GPCRs. 
In an attempt to clone related GPCRs, the cDNA for the coding region of the p2-adrenergic receptor 
gene was radioactively labelled and used to screen genomic libraries under low-stringency 
hybridisation conditions. In this manner, the rat D2 receptor (Bunzow et al., 1988), rat 5-HTIA (Albert 
et al., 1990) and the rat PI-adrenoceptor were cloned (Machida et al., 1990). Development of 
increasingly complex cDNA libraries (i.e., libraries containing larger and more cDNA inserts) and the 
PCR fuelled further GPCR discovery. For example, degenerate primers corresponding to conserved 
TM regions of known GPCRs were used to amplify fragments from cDNA and genomic templates. 
Clone fragments were sequenced to check for homology to existing GPCRs, and if novel, used to 
screen cDNA libraries. Libert and coworkers were one of the first to publish this technique, and 
identified four orphan GPCRs, ROCl, ROC4, ROC7, and ROC8 from a dog thyroid cDNA library 
(Libert et al., 1989). The orphans have subsequently been identified as the chemokine CXCR7, 
serotonin 5-HT\O, adenosine AI and A2A receptors, respectively. Numerous other receptors were 
cloned using this approach including the rat cannabinoid CBI (Matsuda et al., 1990), rat vasopressin 
V2 (Lolait et al., 1992), rat somatostatin ssts (O'Carroll et al., 1992), and human GPER receptors 
(although GPER remained an orphan until 2005) (Owrnan et al., 1996). Sequencing of the genome in 
the late 90's (finally completed in 2003) paved the way for bioinformatic homology screening which 
predicted the existence of many more orphan (particularly chemosensory) GPCRs, and thus increased 
the number of known human GPCRs to about 800 (Chung et al., 2008). 
In the absence of GPCR sequence homology that may assist in predicting ligand classes - e.g., usually 
greater than 30% amino acid homology can place a GPCR in a particular subclass - reverse 
pharmacological techniques have been employed by many laboratories in an effort to deorphanise 
newly described GPCRs. Often mammalian cells are transfected with orphan GPCRs and screened 
with a plethora of ligands in the hope of obtaining a functional response. However, the bank of known 
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potential GPCR ligands is not vast enough to accommodate the growing number of GPCRs. As many 
of the orphan GPCRs are expressed in the CNS, it seemed intuitively obvious that brain tissue may be 
the source of novel GPCR ligands. For example, peptidergic brain extracts have been purified and 
fractionated, and the fractions tested for their ability to stimulate cells expressing orphan GPCRs 
(Chung et al., 2008). This lead to the discovery of the novel peptides nociceptin, orexins-A and -B, 
prolactin-releasing peptide, and apelin, the endogenous ligands for the orphan receptors NOP, OXI 
and OX2, PRRP, and APJ, respectively (Meunier et al., 1995; Sakurai et al., 1998; Hinuma et al., 
1998; Tatemoto et al., 1998). The prospect of deorphanising a receptor at the same time as 
discovering a new ligand, and in tum unveiling a new biological system, has been an attractive 
proposition to the pharmaceutical industry. High throughput assays were developed, and a multitude 
of candidate ligands were screened against orphan receptors expressed in mammalian cells, yeast, or 
xenopus melanophores. The compiled sets of ligands included known GPCR ligands, possible lipid, 
peptide, and protein ligands, candidate ligands from other organisms, those predicted from the 
structure of known GPCR ligands using bioinformatics, and synthetic ligands (Wise et al., 2004). 
Within a few years 40 receptors were deorphanised (Chung et al., 2008). Unfortunately, in the last 10 
years interest has dwindled, and the rate of receptor deorphanisation has declined (Chung et al., 
2008). Consequently, the endogenous ligands for about one hundred mammalian orphan GPCRs 
common to human and rat remain to be identified, although ligands (usually small-molecule, non-
peptidergic) from pharmaceutical platforms have been identified in some cases (e.g., Omeros 
Corporation, press release, 2011 ). 
6.1.2 Are GPR108, GPR146 or TMEM87Bfast glucocorticoid receptors? 
Numerous lines of evidence suggest the existence of a glucocorticoid binding GPCR (e.g., the binding 
of eH]-CORT to amphibian neuronal membranes is inhibited by nonhydrolysable guanyl nucleotides 
(Orchinik et al., 1992)). In Chapter 5, we hypothesised that one of the remaining mammalian orphan 
GPCRs may be a fast glucocorticoid receptor, and narrowed the search down to three candidates: 
GPRI08, GPRI46, TMEM87B. In this Chapter, we tested this hypothesis by transiently transfecting 
mammalian cells with each orphan GPCR and determining whether any of the receptors provoked a 
cellular signalling cascade in response to glucocorticoid treatment. As it is difficult to predict the 
likely G protein-coupling of each receptor it was imperative that we use a cell signalling assay that 
would best reflect the stimulation of all of the main G protein-coupling systems. A growing body of 
evidence has revealed that most GPCR signalling can feed into the ERK1I2 cascade (summarised in 
Figure 6.1) (Osmond et al., 2005; Gutkind, 2000; Werry et al., 2005; Rozengurt, 2007; Marinissen 
and Gutkind, 2001; New and Wong, 2007). In addition, glucocorticoids have been shown to activate 
ERK e.g., DEX augments ERK phosphorylation in the mouse amygdala in response to fear 
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conditioning, via a non-genomic mechanism (Lee et al., 2011). For these reasons we used the IN 
CELL AnalyserlERK phosphorylation assay as previously described in chapter 4. 
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Figure 6.1 Many G protein-coupled signalling pathways converge to stimulate ERK activation. 
ERK 1/2 is a member of the mitogen-activated protein kinase (MAPK) family of proteins, and has a prominent role in cell differentiation and proliferation (Johnson and Lapadat, 2002). Classically, ERK is activated 
following the sequential activation of Ras G proteins (Ras), Raf kinases (Rat) and MAPKIERK kinase I and 2 (MEK) (Roux and Blenis, 2004). GPCRs can feed into this pathway via a variety of different G 
protein-mediated signalling cascades (reviewed in Gutkind, 2000; Werry el 01. , 2005 ; Rozengurt, 2007; Marinissen and Gutkind, 2001; New and Wong, 2007) which can be cell context-dependent. The diagram 
highlights a few examples: (I) the Ga, subfamily of G proteins activate adenylyl cyclases to increase adenosine 3 ' ,5' -monophosphate (cAMP). Increasing cellular concentrations of cAMP stimulates protein kinase 
A (PKA), and this can directly activate (and in some instances inhibit) Raf. Ga, may also form a complex with Src tyrosine kinase (Src) leading to receptor tyrosine kinase transactivation (e.g., EGFR). (2) Ga, is 
well known for its inhibition of cAMP production, but it can also interact with Src. Src can directly influence the ERK pathway by activating Ras and also via the stimulation of phosphoinositide 3-kinases (P 13K) 
and/or receptor tyrosine kinases. Ga, can also directly stimulate MEK 1-2 via Raf kinases. (3) GClqJII activates the phospholipase C isoform ~ (PLC~) which catalyses the hydrolyses of phosphatidylinosilol 4,5-
bisphosphate (PIPl) into diacylglycerol (DAG) and IP,. IP, subsequently stimulates the release of calcium from intracellular stores. DAG and calcium synergistically act to stimulate protein kinase C (PKC). PKC 
activates the ERK pathway by direct phosphorylation of Raf (and can also activate Ras). DAG can also stimulate protein kinase D (PKD) and this leads to further activation of Raf. (4) G[3y subunits (often 
associated with Ga,) have been shown to interact with the ERK cascade in many ways. G~y can directly stimulate Ras, activate Src, and interact with PI3K isoforms which can in tum stimulate Src as well as 
directly enhance Raf activity. (5) Ga l2l lJ can also activate the ERK pathway. Gallil1 stimulates Rho which infiltrates the PLC/calcium pathway by stimulating DAG - this in tum activates ERK as per point (3). 
Gal ld ' can also stimulate Src. (6) It is worth noting that GPCRs can activate ERK phosphorylation independently of G proteins (Sun el 01., 2007; Luttrell and Gesty-Palmer, 20 I 0) . For example, the binding of 
arrestins to activated receptors can either directly stimulate ERK signalling or via the recruitment ofSrc. GPCRs can also directly couple to Src - activation of which induces ERK signalling. 
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6.2 Materials and Methods 
6.2.1 Chemicals, eDNA, and cell culture 
Hydrocortisone (ethanol soluble), DEX (water soluble) and EGF were purchased from Sigma, UK, 
and VP was purchased from Bachem, UK. GPRI08, GPR146 and TMEM87B receptor cDNA clones 
were purchased from Geneservice and the rat V IB receptor cDNA was obtained from Dr Stephen 
Lolait. COS-7 cells were purchased from the American Type Culture Collection and HeLa cells were 
a kind gift from Professor Craig McArdle. Cells were cultured as described in section 2.5.2. 
6.2.2 Northern blot hybridisation 
To determine the endogenous transcript expression of some genes of interest in commonly used cell 
lines we performed northern 'dot' blot hybridisation. This is a semi-quantitative method and it can be 
used to assess the relative levels of mRNA expression. Cells were cultured in clear 96 well plates until . 
80-90% confluent, and transferred to nitrocellulose membranes using a 96-well vacuum manifold. 
The blots were UV-cross-linked, baked for 2 hours at 80°C, and pre-hybridised at 37°C in pre-
hybridisation buffer (see Appendix II) for at least 4 hours. Two receptor specific oligonucleotides 
were designed against individual target mRNAs (sequences are provided in Table 6.1) and purchased 
from Invitrogen. Oligonucleotides were tailed on the 3' end with terminal deoxynucleotidyl 
transferase and a)2P-ATP. Blots were hybridised with a)2P-ATP-Iabelled probes in hybridisation 
buffer overnight at 37°C, and washed for 4 x 15 min in Ix SSPE/O.2% SDS at 54°C. Hybridised blots 
were exposed to Amersham Hyper film MP for 4-10 days at -80°C with intensifying screens. 
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1 ) 
NM_OO1018074 (variant 2) 
5' -CACACTGCTGGGGTlT 5'CAGTCCCA TTGAGAGT 1001-1048 1211-1258 NM_OO1018075 (variant 3) human GR TCTTCTCTACCAGGAG GAAACTGCTlTGGACA (variant I) (variant I) NM_OO 101 8076 (variant 4) 44 54 60 64 TT AA TGA TTCTlTGGA-3 ' GATCTGGCTGCTGCGC-3 ' NM_000176 (variant 5) 
NM_OO 1 020825 (variant 6) 
NM_OO 1 024094 (variant 7) 
5' -CTGA T AAA TCTT AGCT 5' -CTTCTCTTCA TT AAG 721-768 2833-2880 NM_OO0901 (variant I) human MR I GGACTCATGCTTCCT ACTAGGTCTGGTGCAA 46 38 61 58 
TGTTGGTTCTGCTGCTC-3' AA TAGAGAAA TTGGCT -3' (variant I) (variant I) NM_OO1166104 (variant 2) 
5' -A TT ACTTGCTCCA TCT 5' -TCA T AACAGTTCCCGC 1561-1608 1631-1678 NM _001080452 (variant I) human GPRI08 GAACATCCTCCTCGTCC CCGCTGGCTGTTTTGT 56 54 65 64 
TCCTGGGGCAGCTGC-3 ' TGACTTTGGAGAGGCC-3 ' (variant I) (variant I) NM_020171 (variant 2) 
5' -CAGGGCAGCTTTlTCA 5' -CT ACGCCAGCACCTGC 
human GPRI46 TCAGCCGTTGGAGCTTGC TGCACCCCCATGTGGT 911-958 966-1013 NM_138445 58 71 66 71 
TGGGGAAGCTCTGG-3 ' CCGGGGAGCAGTGCCG-3 ' 
human I 5' -ATCCACTAACACTGGA 5' -CTGAAGAGAACA TTlT 
TMEM87B AGAGCT ACA TCTGTGA TTCAGCCATlTCAGAT 1921-1968 1976-2023 NM_032824 40 38 59 58 ATGAAGAGGGAATATT-3 ' CTGGTCA TGA TTTCCT -3 ' 
Table 6.1. Summary of oligonucleotide sequences and their predicted properties. 
Two oligonucleotides approximately 48bp in length were designed against individual target genes. As some genes code for more than one transcript variant (which may be 
physiologically active) e.g., human GR has seven different mRNA variants: 1-5 codes for the same protein isoform GRa; 6 codes the protein isoform GR~; and 7 codes 
for the protein isoform GRy, probes were designed against regions of the gene common to all known transcript variants. This also included homologues (and variants) 
from other species (e.g., human, hamster, and monkey) as expression was investigated in a variety of cells lines (human (HEK293/HeLa), hamster (CHO-K 1), or monkey 
(COS-7) cells». In instances where the probe was directed to the translated region of the mRNA, maximum effort was made to aim for non-conserved regions of the gene. 
Oligonucleotides were directed as follows: human GR probes I and 2 were both directed to non-conserved portions of the translated region which occurred shortly after 
the initiating methionine; human MR probe I was directed to a sequence in the translated region shortly following the initiating methionine, and probe 2 was directed to a 
non-conserved translated sequence in the steroid binding region; GPRI08, GPRI46, and TMEM878 probes 1 and 2 were directed to non-conserved sequences in the 
translated region just prior to the stop codon. Optimum hybridisation temperature for oligonucleotides is between 37-45°C in a hybridisation solution containing 50% 
formam ide, while the high stringency wash temperature is approximately 5-20°C below Tm (Wilkinson, 1999). As the (% G+C) of the second human MR and TMEM87B 
probes were low, we reduced the high stringency wash temperature to 54°C (as opposed to 56°C in Chapter 4), even for probes (e.g., GPRI46) that could potentially 
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6.2.3 Transient transfections and ERK phosphorylation assay 
Cells were seeded (COS-7 cells at 10,000 cells and HeLa cells 15,000 cells per well) into Costar plain 
black-wall 96-well plates so that the cells were 50% confluent the following day. Transient 
transfection experiments were performed 24 h after seeding COS-7 or HeLa cells in Costar plain 
black-wall 96-well plates using Nanofectin as described in section 2.5.3. It was estimated using the x-
gal staining assay (previously described in section 2.5.3 and Appendix I) that Nanofectin successfully 
transfected approximately 30% of COS-7 and HeLa cells with eDNA. The following day cells were 
serum-starved overnight prior to treatment (constituents of serum-free media are described in section 
2.9.1). Cells were stimulated (5-10 min), and processed for the IN CELL ERK assay as previously 
described in Chapter 4, section 4.2.7. 
For wells treated with VP and control or EGF and control, the total amount of ppERK in the whole 
cell was calculated for each field. These values, following the subtraction of background florescence 
measured in wells absent of primary antibody (the background was difficult to detect in individual 
wells due to the high density of cells required for transient transfection), was expressed as AFU. The 
data obtained from VP and vehicle treated wells was used· to calculate a 'ppERK fluorescence 
threshold' previously described in detail in section 4.2.7. The 'ppERK fluorescence threshold' was 
applied to ppERK fluorescence data from the glucocorticoid treated or vehicle treated cells transfected 
with orphan GPCRs. Cells which emitted ppERK fluorescence above that threshold were deemed 
responsive to agonist stimulation. 
6.2.4 Statistical analysis 
IN CELL Analyser 1000 experiments were performed in 3-6 replicate wells, and experiments were 
performed at least 2 times. Data is represented in Figures as mean ± standard error of the mean 
(SEM). Statistical analysis was a one- way ANOV A and Bonferroni multiple comparison test 
accepting P < 0.05 as significantly different. 
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6.3 Results 
6.3.1. Expression of endogenous transcript expression in cells by Northern blot 'dot' 
hybridisation. 
The endogenous transcript expression levels of the orphan GPCRs and glucocorticoid receptors (GR 
and MR) were investigated in cell lines that are frequently used for stable and transient transfections 
in our laboratory, and is summarised in Table 6.2. Notably, low-moderate GR transcript expression 
was observed in He La cells, and low-negligible GR expression was found in CHO-K I, COS-7 and 
HEK293 cells. Low-negligible MR mRNA expression was observed in all of the four cell types. The 
CHO-K I and COS-7 cells exhibited moderate GPR 108 hybridisation signal, while low-negligible signal 
was detected in HEK293 and He La cells. Low-negligible levels ofGPRI46 transcript was observed in 
HeLa cells, but no GPR 146 mRNA was detected in CHO-K I, COS-7 and HEK293 cells. Low-negl igible 
TEMEM87B hybridisation signal was found in CHO-KI , COS-? and HeLa cells, and no TMEM878 was 
detected in HEK293 cells. 
GR -/+ -/+ -/+ +/++ 
MR -/+ -/+ -/+ -/+ 
GPRI08 ++ ++ -/+ -/+ 
GPR146 -/+ 
TMEM87B -/+ -/+ -/+ 
Table 6.2. Results from northern 'dot' blot hybridisation. 
The table is a summary of the endogenous transcript expression levels of human GR, MR, GPRI08, GPRI46, 
TMEM8?8 receptors in CHO-K I , COS-7, HEK293 and HeLa cells. Oligonucleotides were labelled with a_32p_ 
ATP and designed towards all transcript variants of the gene of interest. This also included homologues (and 
variants) from other species e.g., human, hamster monkey as expression was investigated in a variety of cells 
lines (human (HEK293/HeLa), hamster (CHO-KI), or monkey (COS-7) cells». +++, high expression; ++, 
moderate expression; +, low expression; -, negligible expression (signal not above background); N/ A, 
expression in these cell lines were not investigated. Note that the levels of expression are relative - negligible, 
low or absent mRNA expression by this method does not imply that the cells do not express any mRNA, or that 




















Figure 6.2. Examples of northern 'dot' blot hybridisation film images. 
Endogenous GPRI 08 and GR transcript expression in CHO-K I, COS-7, HEK293 and HeLa cells, (A) Moderate 
GPRI08 hybridisation signal was observed in CHO-KI and COS-7 cells while low-negligible signal was 
detected in HEK293 and HeLa cells. (8) Low-moderate levels of GR mRNA was expressed in HeLa cells, 
whereas low-negligible GR transcript expression was found in the other cell types. 
With the exception of GPR 108, the endogenous GPCR orphan transcript expression are low or absent 
in the cell types investigated . Assuming that GPRI 08 mRNA translated to protein, CHO-K I or COS-
7 cells would appear suitable for use in the ERK assay without transfection of the GPR 108 eDNA i.e. , 
endogenous GPR 108 expression in these cell lines may be sufficient to expres the orphan receptor. 
The transfection of additional GPRI08 receptor into CHO-K 1 or COS-7 cells could even amplify a 
glucocorticoid response beyond that attributable to endogenous GPR 108. The cell types tested are 
commonly used in deorphanising assays (Irelan and Morgon, 20 I 0; Lecca and Abbacchio, 2008). 
However, if the orphan GPCRs require the transactivation of EGFR to mediate the glucocorticoid 
response, then the CHO-K 1 line would likely be inappropriate. As described in ection 4.3.4 EGF 
does not stimulate an ERK response in CHO-K I cells in our hands. The HEK293 cell line used in this 
thesis is also not the best cell type for transient transfections, since no more than 5% of HEK293 cells 
were transfected with control vector in the X-gal assay as described in Chapter 2 (see Figure 2.1 in 
section 2.5.3). On the other hand, at least 30% of COS-7 and HeLa cells were con istently tran fected 
using Nanofectin (see Figure 2.1). Hence COS-7 and HeLa cells were con idered the preferable cell 
types for the deorphanising assay in this Chapter. It is possible that the low-moderate expression of 
GR in HeLa cells may influence the glucocorticoid signalling in these cells. 
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6.3.2. The orphan receptors GPR108, GPR146 and TMEM87B do not stimulate ERK 
phosphorylation in COS-7 or BeLa cellsfollowing 5 or 10 min of glucocorticoid treatment 
To determine whether the orphan GPCRs responded to glucocorticoids, we transiently transfected the 
receptors into COS-7 and HeLa cells and used the IN CELL AnalyserlERK. phosphorylation assay. 
Each transfected cell type was treated with glucocorticoids (CORT or DEX) for 5 or 10 mins. In 
parallel, non-transfected cell were treated with 100ng/ml EGF, and V IS receptor transfected cells were 
treated with 100nM VP to ensure that 1) the cells had a functional ERK. response; and 2) the assay 
was robust enough to detect a GPCR response in the 30% of transfected cells, and to set the 'ppERK 
fluorescence threshold' (see section 4.2.7). 
In non-transfected COS-7 cells, 100ng/ml EGF treatment for 5 min stimulated almost a 4-fold 
increase in ppERK fluorescence (N.B., AFU values are normalised to vehicle (therefore, values> 1 
are required for an increase): 3.871 ± 0.168). In COS-7 cells transfected with VIS receptor eDNA, 
100nM VP treatment for 5 min increased ppERK by approximately 2-fold when compared with 
vehicle controls (1.837 ± 0.039). However, none of the glucocorticoid treatments (lOnM CORT, 
100nM CORT, or 100nM DEX) significantly increased ppERK fluorescence in COS-7 cells 
transfected with GPRlO8, GPRI46, or TMEM87B (Figure 6.3) (N.B., values are % of cells above 
ppERK fluorescence threshold (example of 100nM given): GPRI08, CORT 3.771 ± 0.6074 vs 
0.001% ethanol 4.722 ± 1.358, DEX 3.027 ± 0.218 vs vehicle (H20) 4.298 ± 0.207; GPRI46, CORT 
9.910 ± 1.773 vs 0.001% ethanol 10.155 ± 1.669, DEX 7.571 ± 0.045 vehicle 8.144 ± 0.374; 
TMEM87B, CORT 5.354 ± 0.715 vs 0.001% ethanol 7.312 ± 0.057, DEX 4.573 ± 0.441 vs vehicle 
3.958 ± 0.301). 
Treatment of non-transfected COS-7 cells with 100ng/ml EGF for 10 min induced a 6-fold increase in 
ppERK (N.B., AFU values are normaHsed to vehicle: 6.525 ± 0.328). In cells transfected with VIS 
receptor cDNA, 10 min 100nM VP treatment lead to a 2-fold rise in ppERK when compared with 
vehicle (2.398 ± 0.033). As with 5 min, 10 min glucocorticoid treatment (lOnM CORT, lOOnM 
CORT, or 100nM DEX) did not significantly increase ppERK in COS-7 cells transfected with 
GPR 108, GPR 146 or TMEM87B (Figure 6.4) (N .B., values are % of cells above ppERK fluorescence 
threshold (example of 100nM given): GPRI08, CORT 4.963 ± 0.607 vs 0.001% ethanol 1.561 ± 
0.163, DEX 1.389 ± 0.161 vs vehicle 1.558 ± 0.336; GPRI46, CORT 4.440 ± 0.547 vs 0.001% 
ethanol 1.327 ± 0.081, DEX 2.121 ± 1.057 vs vehicle 0.910 ± 0.036; TMEM87B, CORT 1.838 ± 
0.626 vs 0.001% ethanol 0.906 ± 0.418, DEX 0.665 ± 0.129 vs vehicle 1.407 ± 0.466). 
It is worth noting that background levels of ppERK were elevated in COS-7 cells following 5 min 
agonist- or vehicle-treatment when compared with respective 10 min treatments. Thus there was a 
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higher percentage of vehicle- or agonist-treated cells emitting ppERK fluorescence above threshold at 
5 min when compared with 10 min. Mechanical stimulation during agonist loading may have lead to a 
the increase in baseline ppERK which was apparent at 5 min, but not at 10 min - 10 min was perhaps 
long enough to diminish the non-specific loading effects on ERK activation in this case. 
In non-transfected HeLa cells, EGF treatment (IOOnglml for 5 min) activated a robust ERK response 
leading to a 16-fold increase in ppERK (N.B., AFU values are normalised to vehicle: 16.690 ± 0.474). 
In VIB receptor transfected HeLa cells, VP treatment (lOOnM for 5 min) increased ppERK by almost 
5-fold (4.919 ± 0.251). As was observed in COS-7 cells, glucocorticoid treatment (lOnM CORT, 
100nM CORT, or 100nM DEX for 5 min) did not increase ppERK in HeLa cells transfected with 
GPRI08, GPRI46, or TMEM87B (Figure 6.5) (N.B., values are % of cells above ppERK 
fluorescence threshold (example of 100nM given): GPRI08, CORT 0.176 ± 0.09 vs 0.001% ethanol 
0.105 ± 0.038, DEX 0.057 ± 0.057 vs vehicle 0.019 ± 0.019; GPRI46, CORT 0.064 ± 0.064 vs 
0.001% ethanol 0.138 ± 0.083, DEX 0.135 ± 0.083 vs vehicle 0.022 ± 0.022; TMEM87B, CORT 
0.021 ± 0.021 vs 0.00 I % ethanol 0.141 ± 0.071, DEX 0.039 ± 0.039 vs vehicle 0.0 ± 0.0). 
Stimulation of non-transfected HeLa cells with 100nglml EGF for 10 min increased ppERK by 14-
fold (N.B., AFU values are normalised to vehicle: 14.343 ± 0.704) . In VIB receptor-transfected HeLa 
cells, 100nM VP treatment for 10 min increased ppERK by 3-fold (3.339 ± 0.083). Concomitant with 
the COS-7 cell data, glucocorticoid treatment (lOnM CORT, 100nM CORT, or 100nM DEX for 10 
min) did not significantly induce an ERK response in HeLa cells transfected with GPRI08, GPRI46, 
TMEM87B (Figure 6.6) (N.B., values are % of cells above ppERK fluorescence threshold (example 
of 100nM given): GPRI08, CORT 0.040 ± 0.020 vs 0.001% ethanol 0.097 ± 0.052, DEX 0.764 ± 
0.418 vs vehicle 0.252 ± 0.087; GPRI46, CORT 0 ± 0 vs 0.001% ethanol 0.17 ± 0.17, DEX 1.653 ± 
0.393 vs vehicle 1.673 ± 0.402; TMEM87B, CORT 0.188 ± 0.053 vs 0.001% ethanol 0.142 ± 0.057, 
DEX 1.962 ± 0.642 vs vehicle 1.718 ± 0.191). 
While the mechanical element of agonist loading appeared to have non-specific effects on ppERK 
levels in COS-7 cells, it showed little effect on HeLa cells. The background ppERK levels were 
noticeably lower in HeLa cells when compared with COS-7 cells (as depicted by the % of cells 
expressing ppERK above threshold in the graphs of Figures 6.3-6.6), which meant that there were far 
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Figure 6.3. The orphan receptors GPRI08, GPR146 and TMEM87B do not stimulate ERK phosphorylation in COS-7 cells following 5 min of glucocorticoid treatment. 
(A) [n non-transfected cells, IOOng/ml EGF stimulated a highly significant increase in ppERK fluorescence, as represented by an increase in ppERK fluorescence. In COS-7 cells transiently 
transfected with V IB cDNA, 100nM VP treatment for 5 min also stimulated a significant increase in ppERK fluorescence when compared with vehicle controls. The AFU data obtained with 
the VIB receptor transfected COS-7 cells was used to set a threshold as described in section 4.2.7. The proportion of cells displaying an ERK response (emit ppERK fluorescence above 
threshold) following glucocorticoid treatment ( IOnM or 100nM CORT, or IOOnM DEX for 5 min) was not significantly different from vehicle in GPRI08 transfected (8), GPRI46 
transfected (C), or TMEM878 transfected (D) COS-7 cells. Graphs are representative of at least two fields, from triplicate wells and two separate experiments (mean ± SEM. n=2). Statistical 
analysis comparing vehicle-treated vs either EGF- or VP-treated (A-D) was performed using a students I-test. Statistical analysis comparing vehicle-treated versus glucocorticoid-treated was 
performed using one-way ANOVA and the 80nferroni multiple comparison test. •• , p < 0.0 1; ... , P < 0.001. Adjacent to each graph are some representative images or cells stained with 
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Figure 6.4. The orphan receptors GPRI08, GPRI46 and TMEM878 do not stimulate ERK phosphorylation in COS-7 cells following 10 min of glucocorticoid treatment. 
In non-transfected cells, 100ng/ml EGF stimulated a highly significant increase in ppERK fluorescence. as represented by an increase in ppERK fluorescence. In COS-7 cells transiently 
transfected with V IB eDNA, 100nM VP treatment for 10 min also stimulated a highly significant increase in ppERK fluorescence when compared with vehicle controls. The AFU data 
obtained with the VIB receptor transfected COS-7 cells was used to set a threshold as described in section 4.2.7. The proportion of cells displaying an ERK response (emit ppERK 
fluorescence above threshold) following glucocorticoid treatment ( I OnM or 100nM CORT, or 100nM OEX for 10 min) was not significantly different from vehicle in GPR I 08 transfected 
(B), GPR 146 transfected (C), or TMEM87B transfected (0) COS-7 cells. Graphs are representative of at least two fields, from triplicate wells and two separate experiments (mean ± SEM, 
n=2). Statistical analysis comparing vehicle-treated vs either EGF- or VP-treated (A-D) was performed using a students t-test. Statistical analysis comparing vehicle-treated versus 
glucocorticoid-treated was performed using one-way ANOYA and the Bonferroni multiple comparison test. **, p < 0.0 I; ***, P < 0.00 1. Adjacent to each graph are some representative 
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Figure 6.5. The orphan receptors GPRI08, GPRI46 and TMEM878 do not stimulate ERK phosphorylation in HeLa cells following 5 min of glucocorticoid treatment. 
(A) [n non-transfected ce[[s, 100nglmi EGF stimulated a highly significant increase in ppERK fluorescence, as represented by an increase in ppERK fluorescence. [n HeLa ce[[s transiently 
transfected with V 18 eDNA, 100nM VP treatment for 5 min also stimulated a highly significant increase in ppERK fluorescence when compared with vehicle controls. The AFU data 
obtained with the V 18 receptor transfected HeLa ce[[s was used to set a threshold as described in section 4.2.7. The proportion of ce[[s displaying an ERK response (emit ppERK fluorescence 
above threshold) fo[[owing glucocorticoid treatment ( I OnM or IOOnM CORT, or 100nM DEX for 5 min) was not significantly different from vehicle in GPR I 08 transfected (B), GPR 146 
transfected (C), or TMEM87B transfected (D) HeLa cells. Graphs are representative of at least two fields, from triplicate wells and two separate experiments (mean ± SEM, n=2). Statistical 
analysis comparing vehicle-treated vs either EGF- or YP-treated (A-D) was performed using a students (-test. Statistical analysis comparing vehicle-treated versus glucocorticoid-treated was 
performed using one-way ANOYA and the Bonferroni multiple comparison test. •• , p < 0.0 1; •• ., P < 0.001. Adjacent to each graph are some representative images of cells stained with 
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Figure 6.6 The orphan receptors GPRI08, GPRI46 and TMEM87B do not stimulate ERK phosphorylation in HeLa cells following 10 min of glucocorticoid treatment. 
(A) In non-transfected cells, 100ng/ml EGF stimulated a highly significant increase in ppERK fluorescence, as represented by an increase in ppERK fluorescence. In HeLa cells transiently 
transfected with VIB cDNA, 100nM VP treatment for 10 min also stimulated a highly significant increase in ppERK fluorescence when compared with vehicle controls. The AFU data 
obtained with the V 18 receptor transfected HeLa cells was used to set a threshold as described in section 4.2.7. The proportion of cells displaying an ERK response (emit ppERK fluorescence 
above threshold) following glucocorticoid treatment (IOnM or 100nM CORT, or 100nM DEX for 10 min) was not significantly different from vehicle in GPRIOS ·transfected (8), GPRl46 
transfected (C), or TMEMS7B transfected (D) HeLa cells. Graphs are representative of at least two fields, from triplicate wells and two separate experiments (mean ± SEM, n=2). Statistical 
analysis comparing vehicle-treated vs either EGF- or VP-treated (A-D) was performed using a students (-test Statistical analysis comparing vehicle-treated versus glucocorticoid-treated was 
performed using one-way ANOV A and the Bonferroni multiple comparison test. **, p < 0.0 I; ***, p < 0.00 I. Adjacent to each graph are some representative images of cells stained with 
anti-ppERK antibodies treated with control (ctrl) or agonist Scale bar, 1001lm. 
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6.4 Discussion 
As with many steroids, glucocorticoids are known to elicit fast non-genomic and genomic effects that 
are not always attributable to the traditional glucocorticoid receptors (Sandi et al., 1996; Oi et al., 
2005; Sun et ai., 2006; Wiegert et ai., 2006). Various lines of evidence suggest the existence of a G 
protein-coupled glucocorticoid receptor e.g., specific CH]-CORT and/or CH]-OEX binding to plasma 
membranes of a variety of cells and tissues, and the fast effects of glucocorticoids often appear to be 
mediated by G protein signalling (Towle and Sze, 1983; Koch et ai., 1978; Harrison et al., 1979, 
ffrench-Mullen, 1995; Qiu et ai., 1998, Oi et al., 2009). We hypothesised that 'fast' glucocorticoid 
responses may be via an orphan non-chemosensory GPCR receptor (or receptors). In Chapter 5, we 
began the search for a candidate fast glucocorticoid GPCR by comparing the EST distribution profiles 
of all orphan GPCRs common to human and rodents, with tissues known to exhibit non-genomic 
effects of glucocorticoids. Of the 125 mammalian orphan GPCRs, only 9 had EST distribution 
profiles that correlated with the tissues of interest. Transcript distribution profiles of the 9 orphan 
GPCRs were corroborated using ISHH - this revealed only three receptors (GPR 108, GPR 146 and 
TMEM87B) were expressed in many of the tissues that show evidence of non-genomic glucocorticoid 
signalling. In the current study, we tested this hypothesis using a basic ' rever e pharmacological ' 
approach - COS-7 and HeLa cells were transiently transfected with GPRI08, GPRI46, or 
TMEM87B, to establish whether these receptors elicited an ERK response in response to 
glucocorticoid treatment. In the cell lines and assay we chose, none of the orphan GPCR candidates 
stimulated ERK signalling in response to glucocorticoids. 
6.4.1. GPRI08, GPR146 and TMEM87B are not glucocorticoid receptors? 
Agonist concentrations and incubation time 
One possible reason why we did not observe a glucocorticoid-induced activation of the orphan 
GPCRs may simply be due to inadequate glucocorticoid concentrations and/or (agonist) incubation 
times. Obviously, it is difficult to predict the glucocorticoids concentrations that would activate an 
unknown receptor. Instead we can only make assumptions based on physiological levels and also the 
concentrations which have been used in previous publications to elicit a fast non-genomic response 
(via a putative receptor). Rat plasma CORT levels fluctuate throughout the day in the unstressed 
animal, and as such basal concentrations can range from 1-350 nmol/ I (although this i sex- and 
species-dependent), while exposure to severe stress can cause CORT levels to rise to 1500 nmolll 
(Haller et al., 2008; Lightman and Conway-Campbell, 20 10). At the tissue level, for example in the 
rat brain, basal glucocorticoid concentrations are approximately 10-1 OOnM, and can increase 
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anywhere from I J.lM to 10J.LM during stressful periods (Haller et al., 2008). Studies which have 
observed non-genomic effects of glucocorticoids in the brain have done so with locally delivered 
concentrations ranging from IOpM to 500J.LM (ffrench-Mullen, 1995; Evanson et al., 2010; Oi et al., 
2005; Liu et al., 1995; Takahashi et al., 2002; Wiegert et al., 2006). For example, CORT 
concentrations from 10pM to I J.LM rapidly inhibits voltage-activated calcium channel currents in adult 
guinea pig hippocampal CAl neurones, and CORT concentrations between 100nM and 500J.LM 
prolong NMOA receptor-mediated elevations in intracellular calcium in cultured rat hippocampal 
neurones (ffrench-Mullen, 1995; Takahashi et al., 2002). 
ERK 112 are activated in minutes to a large range of stimuli e.g., for many GPCRs (e.g., acetylcholine 
MJ and M3, neurotensin NTS), cholecystokinin CCK2, and gherlin receptors) the maximal ERK1I2 
response occurs somewhere between 5 and 10 minutes after agonist activation (Ebisuya et al., 2005; 
Osmond et al., 2005; Mousseaux et al., 2006). The duration and magnitude of an ERK response is 
controlled by many other regulators in the cell, including scaffold proteins, GTPases, and other 
signalling pathways (Ebisuya et al., 2005). For this reason, it cannot be assumed that the putative 
glucocorticoid receptor will have an ERK response comparable to other GPCRs - although previous 
studies have indicated that an ERK response to glucocorticoids occurs rapidly and is maintained for 
periods well within the scope of this study. For example, OEX (lOOnM) rapidly induces ERK 1/2 
phosphorylation in rat preovulatory granulosa GSP53-10 cells (within 1 min), with a maximal ERK 
response appearing between 10 and 20 min (Sasson et al., 2003). 
Therefore, the CORTIDEX concentrations and ligand incubation times used within this Chapter are 
comparable with other studies that have observed fast effects of glucocorticoids. This suggests that 
GPRI08, GPRI46 or TMEM87B are not glucocorticoid receptors. Nevertheless, we cannot rule out 
the possibility that the orphan receptors may well be activated by glucocorticoids in a different 
experimental paradigm e.g., in an alternative cell type or using another cell signalling assay. 
COS-7 and HeLa Cells 
It is possible that COS-7 and HeLa cells lack a component vital for GPCRlglucocorticoid signalling. 
However, this is unlikely considering that 1) COS-7 and HeLa cells are very common cell types used 
in GPCR mediated-cell signalling assays involving many types of GPCR subfamilies that couple to 
similar and different G-proteins; 2) COS-7 cells in particular are often used in deorphanisation assays; 
and 3) the activation of ERK 112 in COS-7 cells has been shown to be possible from a variety of 
GPCR signalling inputs (Irelan and Morgon, 2010; Lecca and Abbacchio, 2008; Osmond et al., 2005). 
Besides, the VPN 1B receptor activation of ERK provides evidence that these cell lines in our hands 
are not devoid of GPCR- and G protein-mediated signalling. 
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As mentioned in Chapter 5, the orphans may also require the expression of an additional protein to 
conduct glucocorticoid-mediated signalling. For example, the receptor may rely on a modifying 
protein (e.g., RAMPS), or is only functionally active on forming a heterodimer (or oligomer/ 
signalsome) with another receptor (or a multitude of receptors and/or proteins) - possibly another 
GPCR (e.g., dopamine receptor O2 and the somatostatin receptor SSTR5 heterodimer has greater 
affinity for both dopamine and SST agonists and enhanced G protein and effector coupling to 
adenylyl cyclase (Rocheville et 01.,2000», a non-related receptor such as an ion channel (e.g., direct 
interaction between dopamine 01 receptors and NMOA glutamate receptor subunits GluNI and 
GluN2A inhibits NMOA receptor-gated currents (Lee et 01.,2002», or even a steroid receptor such 
as GR and/or MR. As stated in Chapter 4, it is suspected that in some instances GPER may work in 
concert with ERa (Levin, 2009). Transfection of orphan GPCRs into cell lines that endogenously 
express other receptor(s) or interacting protein(s) has the potential to affect receptor trafficking and 
signalling as well as ligand binding (Prinster et 01., 2005). For instance, a\D-adrenoceptor requires 
heterodimerisation with (lIB- or ~2-adrenoceptors to enhance cell surface expression and functional 
activity (Uberti et 01., 2003, 2005). Thus if activation of the putative glucocorticoid-binding GPCR is 
dependent on oligomer formation then perhaps GPCRlglucocorticoid signalling is limited to cell types 
which express the correct proteins - which mayor may not be present in COS-7 or HeLa cells. 
If the putative receptor requires the expression of GR or MR to elicit a response, the low expression or 
possible absence of these receptors from COS-7 and HeLa (as indicated with Northern 'blot' 
hybridisation) may explain why there was an absence of glucocorticoid activation. On the other hand, 
there are studies that indicate that the traditional receptors are not always involved in fast 
glucocorticoid signalling suggesting they do not always need to be present. For instance, high doses of 
CORT (2.5 or 5mglkg that mimic plasma concentrations produced by substantial stress) rapidly 
increase the locomotor response displayed by rats in a novel environment, which is not prevented with 
administration of GR and MR antagonists (Sandi et aI., 1996); BSA-CORT (presumptive cell 
membrane-impermeable CORT) increases ERKII2 phosphorylation in rat embryonic hippocampal 
neurones independently of GR and MR (Xiao et 01., 2005); and OEX (via PKA and ERKII2 
signalling pathways) accelerates intracellular pH recovery after acid load in human bronchial 
epithelial (l6HBE 140-) cells which is unaffected by treatment with classical GR or MR antagonists 
(Verriere et 01., 2005). 
Alternative deorphflnisation IlSSays 
It is difficult to predict which G proteins the orphan GPCRs are likely to couple to, particularly as 
GPCRs often have promiscuous relationships with these proteins. For instance, the coupling of 
GPCRs to G proteins can change depending the nature of the ligands, e.g., the recently deorphanised 
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GPCR, LPAR6, is stimulated by the endogenous ligands lysophosphatidic acid (LPA) and farnesyl 
pyrophosphate (FPP), and following activation by LPA, LPAR6 can couple to both Go, and/or Gal2l13 
family of proteins to initiate the ERK and Rho signalling pathways, respectively, whereas FPP 
activates Gal2/\3 but not Ga.; (Pasternack et al., 2008; Lee et al., 2009). For this reason, we used an 
ERK signalling assay, since many GPCRlG protein-mediated signalling cascades converge into this 
pathway (see Figure 6.1) and of all the GPCR-mediated signalling pathways it is considered one of 
the most 'universal'. On the other hand, if activation of the orphan GPCRs by glucocorticoids 
stimulated an alternative (or even 'unknown') signalling pathway in COS-7 and He La cells types 
which does not stimulate ERK phosphorylation, then deorphanisation would likely be impossible 
using our IN CELL assay. Other deorphanising protocols have also addressed this issue, by using for 
example, fSS]GTPyS binding assays and cell lines engineered to express promiscuous G proteins. 
The eSS]GTPyS binding assay relies solely on the stimulation of G proteins to determine receptor 
activation. As described in Chapter 1, GPCR-Iigand interaction results in guanine nucleotide 
exchange (the replacement of GOP for .GTP) on the a-subunit, leading to the dissociation of the a-
subunit from the Jty complex. Hence, ligand induced-GPCR stimulation can be monitored by 
measuring the binding of fSS]GTPyS. While this assay appears attractive at face value, it is often 
restricted to Ga.; family of proteins (unless the assay is combined with immuno-capture techniques 
e.g., immunoprecipitation of Ga-subunits, and/or over expression of GPCR-Ga fusion proteins), as 
they have substantially higher rates of guanine nucleotide exchange compared to other G proteins 
(Milligan, 2003; Seifert et al., 1999). 
Murine GalS, and its human counterpart Ga16, are members of the Ga.q family of G proteins and are 
only expressed in a subset of haematopoietic cells. Their promiscuous nature was first identified by 
Offermanns and Simon, who noticed that Gals and Gal6 are able to couple to a wide variety of 
GPCRs that would otherwise associate with a different family of Ga protein (i.e., Gas, Ga;, Gal2l13) -
upon ligand mediated-stimulation these GPCRs (via Gals or Ga16) activate calcium mobilisation 
(Offermanns and Simon, 1995). Therefore, in terms of deorphanisation, cONAs encoding orphan 
GPCRs and GalSI16 can be co-transfected into cell lines (e.g., COS-7) and stimulated with an array of 
putative ligands in the hope of eliciting a calcium response (Offermanns and Simon, 1995). However, 
GalS and Gal6 do not recognise all GPCRs e.g., several Ga;-Iinked receptors are incapable of 
activating phospholipase C via Ga16. Attempts to construct 'universal' G protein adapters have 
uncovered two highly promiscuous chimeras: 16z2s or 16z.u - hybrids between the G proteins Gal6 
and Gaz (member of the Gai family). 16z2s and 16z.u have the back bone Gal6 protein and also 25 or 
44 amino acids from the C-terminal domain of of Gaz, respectively (Mody et al., 2000). They are said 
to be superior in sensitivity and efficiency when mediating ligand-induced PLCP activity for Go,-
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linked receptors when compared with the parental Ga)6, but their interactions with Gas-linked 
receptors are slightly impaired (Mody et al., 2000; Liu et al., 2003). 
The above techniques are examples of deorphanising strategies that are not reliant on prior knowledge 
of GPCR signalling. However, both techniques appear to show a certain level of bias towards 
different GPCRs i.e., receptors that would normally couple to Gi (binding assay) and/or Gaq 
(promiscuous G proteins) (Lecca and Abbracchio, 2008; Mody et al., 2000). The ERK 
phosphorylation assay used in this Chapter has the potential to incorporate signalling from all of the 
major G protein families (Gas, G<lj, Gaq and Gal2l13), as well as G protein-independent pathways i.e., 
GPCRs are also involved in G protein-independent (possibly arrestin and/or Tyrosine kinase Src 
dependent) activation ofERK1I2 (see Figure 6.1) (Sun etal., 2007; Luttrell and Gesty-Palmer, 2010). 
Therefore, even if GPR 108, GPR 146 and TMEM87B signal in the absence of G proteins, they may 
still activate the ERK pathway. Moreover, glucocorticoids have been reported to activate ERK in a 
variety of cell types e.g., rat PC-12 (adrenal chromaffin tumour) (Liu et al., 2001), rat preovulatory 
granulosa (Sasson et al., 2003), rat embryonic hippocampal neurones (Xiao et al., 2005), human 
bronchial epithelial (Verriere et al., 2005), and bovine lens epithelial cells (Samadi and Cenedella, 
2003) suggesting that responsiveness may be less rather than more 'tissue-specific.' 
It is conceivable that GPRI08, GPRI46 and TMEM87B do not have endogenous ligands, or even 
biological roles. Some calculations suggest that approximately 17% of non-olfactory GPCRs have 
become redundant during evolution (Schoneberg et al., 2004) - although this is based on identified 
pseudogenes, of which non-functionality is disputable (Pink et al., 2011). In the absence of known 
ligands it is difficult to demonstrate that GPRI08, GPRI46 and TMEM87B are functionally active. 
To address this issue, one could induce constitutive receptor activity with the view to activate second 
messenger signalling. Constitutive activity can be induced by a number of means including receptor 
overexpression, site-directed mutagenesis (e.g., alteration of the ionic lock between TM3 and TM6, 
by charge-neutralisation mutation of DIE residue in TM6 or mutation of DIE in TM3 to either A or N) 
or even by G protein overexpression (Le., overexpression of Gaq in HEK293 cells upregulates 
constitutive activity of angiotensin II AT) receptors) (Scragg et al., 2005; Smit et al., 2007). Inducing 
constitutive activity in functional receptors may give insight into possible G protein-coupling, and 
providing the GPCR couples to the same G proteins during ligand-dependant and -constitutive 
signalling, indicate the most appropriate cell signalling assay for deorphanisation. Drug discovery 
programmes have benefited from screening approaches that use constitutively active GPCRs, for 
example constitutively activating receptor technology (CART) screens constitutive active non-orphan 
and orphan GPCRs to identify reagents that regulate ligand-independent receptor activity, such as 
.a1losteric modulators and inverse agonists (Chalmers and Behan, 2002). This is of particular 
importance in diseases where the eitology relates to gain or loss in GPCR constitutively activity e.g., 
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constitutively active mutants in the thyroid-stimulating hormone TSH receptor gene causes 
autonomous secretion ofthyroid hormones, and constitutively active mutations ofthe calcium sensing 
CaS receptor results in hypoparathyroidism; while that loss of constitutive activity in mutant 
melanocortin MC4 receptors is one cause of obesity (reviewed in Smit et al., 2007 and Tao, 2008). 
Thus, CART can identify potential antagonists and inverse agonists of GPCRs that lack known 
. endogenous/exogenous ligands, which are subsequently used in vitro/in vivo to elucidate biological 
roles of the orphan receptors (reducing the need for transgenic animals) (Chalmers and Behan, 2002). 
6.4.2. Other potential candidotes? 
Since the orphan candidates within this Chapter are unlikely glucocorticoid receptors, the identity of 
the putative fast glucocorticoid receptor still remains to be discovered. As emphasised in Chapter 5, 
we restricted out pursuit for a fast glucocorticoid receptor to orphan non-olfactory GPCRs. Of course 
it is possible that the initial EST distribution profile search of the 125 orphan GPCRs overlooked 
some potential candidates i.e., EST profiles did not accurately reflect orphan receptor expression in 
the tissues of interest, and thus some orphans would inevitably be disregarded. Equally, it is possible 
that other non-orphan or even olfactory GPCRs may remain candidates. Furthermore, one cannot rule 
out the possibility that the fast-glucocorticoid receptor is in fact a membrane-bound nuclear receptor, 
distinct from GR and MR. 
A different orphan GPCR? 
With approximately 360 human non-chemosensory GPCRs of which approximately 125 are orphans 
(Chung et al., 2008; Harmar et al., 2009), it seemed intuitive to begin the search for a fast 
glucocorticoid receptor with receptors yet to be assigned a ligand. Our initial search of human and 
rodent EST distribution profiles of the 125 orphan GPCRs gave rise to 9 potential candidates - but the 
fast glucocorticoid receptor could conceivably be any of the other 91. Whether any of the other 
orphans are activated by glucocorticoids could be investigated in the deorphanising assay used in this 
study - although all 91 receptors would have to be cloned and expressed in cells which would be quite 
daunting given the time it would take, materials consumed, and the possibility of 'failure'. 
As highlighted in Chapter 1 and in Supplementary Table 8, there are instances in the literature of 
agonist-mediated regulation in GPCR transcript expression. For example, noradrenaline treatment (6 
hours) increases (lIB adrenoceptor transcripts (6-fold) in cultured pineal glands via a cAMP-dependent 
mechanism (Coon et al., 1997), while noradrenaline (4 hours) greatly reduces (75%) (lIB adrenoceptor 
mRNA in rabbit aorta vascular smooth muscle cells (Izzo et al., 1990). In the PVN, chronic (4 week) 
subcutaneous infusions of angiotensin II increases ATI receptor mRNA expression (1.5-2 fold), while 
an acute O.lJ1g CRF intra-PVN microinjection increases CRFI transcript (-3 fold) (Wei et al., 2009; 
Konishi et al., 2003). Therefore, it may be possible to determine which of the orphan GPCRs are most 
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likely to be a fast glucocorticoid receptor by observing changes in transcript expression (possibly up-
or down-regulation) following treatment with CORT or DEX or in response to an acute stressor 
(although this would likely activate non-glucocorticoid pathways as well). This global approach may 
be achieved by employing DNA microarray-based transcriptional analysis: rats would be exposed to 
acute or chronic glucocorticoids, sacrificed, and then RNA extracted from tissues known to exert fast 
glucocorticoid effects (listed in Chapter 5). The RNA extractions from control vs treated tissue would 
be exposed to rat genome cDNA arrays, in the hope of identifying regulated orphan GPCR transcripts. 
The existence of a GPCR-specific and correctly annotated array (currently not commercially 
available) covering all GPCRs would obviously be highly beneficial to such an enterprise. As 
highlighted in Chapter 1, there are limitations to DNA microarrays - not all GPCRs (including 
orphans) are included on the chips, some lowly expressed transcripts may escape detection, and some 
RNAs may cross-hybridise with a cDNA probe designed against a different gene. Obviously, results 
from an array would have to be verified with another technique such as ISHH and qPCR (and also 
verify protein expression in a westernlIHC if an antibody is available). 
Hindmarch and colleagues used microarrays to investigate transcript expression in the PVN and SON, 
the data from which is presented in-part in Chapter 1 and the Supplementary data (Hindmarch et al., 
2006). Indeed, the array data in Chapter 1 demonstrates gene expression of many GPCRs in the rat 
PVN and SON, some of which are orphans. Of the 9 candidate orphan GPCRs in Chapter 5, the 
transcripts of GPRC5b, GPR48, GPR56, GPRI08, GPRI46 and GPRI53 were detected in both the 
PVN and SON with Affymetrix 230 2.0 rat genome chips, while GPRI25 mRNA was only detected 
in the PVN (see Supplementary Tables 5 and 6). This is in general agreement with our ISHH results 
from Chapter 5, although we observed high expression of TMEM87B mRNA in the PVN and SON 
(absent from arrays), low-negligible levels of GPR65 transcript in the SON (absent from arrays), low 
expression GPRI25 mRNA in the SON (absent from arrays), and found no expression of GPR48 
transcript in the PVN (detected by arrays), following the exposure of 3sS-UTP orphan GPCR-specific 
riboprobes to 6 week film/IS week emulsion exposure. Therefore, microarrays as with many other 
global techniques have sensitivity issues (Murphy, 2002a). But arrays are undoubtedly a refined 
alternative to EST distribution profiles, and can potentially detect changes in gene expression - which 
may allude towards a fast glucocorticoid receptor. A downside of this semi-targeted DNA array 
approach would be that we would also detect changes in glucocorticoid-regulated genes (dependent 
on e.g., the transcriptional activity of GR) which may also include the up- or down-regulation of 
orphan GPCR transcript - an effect that may be unrelated to direct orphan receptor occupancy by 
glucocorticoids. 
Other orphan GPCRs detected in the PVN and SON by arrays include GPR19, GPR34, GPR37, 
GPR37L1, GPR61, GPR68, GPR83, GPR85, GPR88, GPR98, GPRI07, GPRl16, GPR123, GPR149, 
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GPRIS8, GPRI62, and GPRI76. Anyone ofthese receptors could possibly be a fast glucocorticoid 
receptor (particularly as they are expressed in two of the target tissues). Interestingly, of the listed 
orphans, the gene expression of GPR83 is upregulated in murine thymoma WEHI-7TG cells 
following treatment with glucocorticoids and forskolin (hence its unofficial name glucocorticoid-
induced receptor); while acute DEX administration has been reported to down regulate GPR83 
transcript in various mouse brain regions (Harrigan et al., 1991; Adams et al., 2003). However, in 
disagreement with the array data, Sah and collegues found no expression of GPR83 transcript in the 
rat PVN or SON using ISHH - although others have observed GPR83 mRNA expressed in the human 
PVN and SON (by ISHH) (Sah et al., 200S; Blizillon et al., 2001). As GPR83 has highest sequence 
homology with the NPY family of receptors, much emphasis has been placed on GPR83 belonging to 
the NPY receptor subfamily (Parker et al., 2000). A recently study has shown that the rat GPR83 
binds NPY compounds with high affinity, but has low affinity for NPY (13nM) when compared with 
the other NPY receptors (sub-nanomolar). The authors concluded that central levels of NPY were 
sufficient to activate GPR83, but that there may be an alternative endogenous ligand that binds 
GPR83 with higher affinity (Sah et al., 2007). To our knowledge, whether GPR83 has any affinity for 
glucocorticoids has yet to be determined. 
Of course, while glucocorticoid treatment may regulate the expression of many genes, some of which 
may be orphan GPCRs (such as GPR83), it is not certain that receptor occupancy will result in 
transcriptional or translational changes in a putative fast glucocorticoid receptor. 
A non-orphan GPCR? 
The idea that fast glucocorticoid receptor may be a GPCR with a known endogenous ligand is not 
inconceivable. There are examples of GPCRs that bind related peptides i.e., the chemokine CCRI 
receptor is activated by the chemokines CCL3, CCLS, CCL7, CCL8, CCL13-16 and CCL23 (Murphy 
et al., 2002b), and the associated peptides cholecystokinin and gastrin are the physiological agonists 
of the cholecystokinin CCK2 receptor (Rehfeld et al., 2007). Non-related endogenous compounds, 
such as steroids and proteins, would seem less likely to bind the same GPCR. However, Berger and 
colleagues demonstrated that high concentrations of progesterone (J,LM range) directly inhibits 
agonist-stimulated signalling of the OT receptor (Berger et al., 1999), suggesting that GPCRs can 
bind both peptides and steroids. Yet, it is worth noting that while the same group also describe the 
same progesterone mediated-inhibition of agonist-stimulated signalling for several other GPCRs e.g., 
bradykinin B2 and histamine H\ receptors they do not show specific binding of progesterone to any 
receptors other than the OT receptor (Berger et al., 1999). This along with the J,LM concentrations of 
steroid used in the study may suggest the effects of progesterone were non-specific. Therefore, the 
competitive nature of progesterone on eH]OT/OT receptor binding affmity could be attributed to the 
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fact that high J.lM levels of steroids can affect membrane fluidity and as such cause conformational 
changes within the GPCR that could alter ligand binding (Clarke et al., 1990). 
Olfactory receptors? 
Olfactory receptors are the largest group of chemosensory GPCRs, and there are at least 388 human, 
1234 rat and 1081 mouse olfactory receptors (Gloriam et al., 2007). Mammalian olfactory receptors 
share the structural features common to all GPCRs (particularly those of the rhodopsin subgroup) 
including 7TMs, a potential disulfide bond between highly conserved cysteines in the first and second 
extracellular loops (EL), a conserved (NXSrr consensus) glycosylation site in the N-terminus, several 
potential phosphorylation sites in intracellular regions, and numerous conserved short sequences 
(Gaillard et al., 2004). Characteristics that are unique to olfactory receptors include an extremely long 
second EL which contains two cysteines, and five conserved amino acid motifs -sequence homology 
to which is enough to classify a GPCR as an olfactory receptor (LHTPMY in the first intracellular 
loopl, MA YDRYV AIC at the end ofTM3 and the beginning of the second intracellular loop 2, SYat 
the end of TM5, and FSTCSSH at the beginning of TM6 and PMLNPF in TM7) (Mombaerts, 1999; 
Gaillard et al., 2004). These receptors are classed as olfactory receptors based on a general: 1) high 
prevalence of receptors in olfactory tissue; 2) evolution divergence - high number of receptors in 
mammals with renowned sense of smell; 3) some evidence of activation by known odorants (Foord, 
2002). We precluded olfactory GPCRs as candidate fast glucocorticoid receptors since the vast 
majority of the fast effects of glucocorticoids have been observed in non-olfactory tissues (reviewed 
in Chapter 5). However, it is now coming to light that olfactory GPCRs are not restricted to tissues 
associated with olfaction, for example the olfactory receptor HT2 (NCBI gene name OR7E24) 
transcript is expressed in human embryonic primordial germ cells (Goto et 01.,2001). In addition, the 
odorant receptor PSGR (NCBI gene name DRS 1 E2) abundantly expressed in the prostate, has been 
reported to be activated by testosterone metabolites as well as its conventional ligand the odorant P-
ionone (Neuhaus et al., 2009). The premise that an olfactory receptor may bind a steroid is feasible 
considering that many olfactory receptors bind other organic compounds (made up of various 
alcohols, aldehydes, ketones and esters; and chemicals with aromatic, non-aromatic, or polycyclic 
ring structures) (Gaillard el al., 2004): 
Another steroid receptor? 
The fast effects of glucocorticoids may also be associated with an unknown splice variant of GR 
and/or MR. As addressed in Chapter 4, it has been suggested that a membrane-bound splice variant of 
ERa, ERa-36, mediates some of the fast effects of E2; and is also activated by the anti-E2s tamoxifen 
and ICI-182,780. This suggests that if there is are alternative forms of GR and MR they may have a 
distinct pharmacological profile i.e., the GR and MR antagonists, mifepristone and spironolactone, 
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respectively, do not inhibit the rapid glucocorticoid-mediated suppression of glutamate synaptic 
inputs to OT and VP magnocellular neurones of the PVN and SON (Di el al., 2005). 
Alternatively, the fast effects may be attributable to an orphan steroid receptor. There are currently 23 
orphan nuclear receptors (out of 49 known nuclear receptors; numbers from the IUPHAR database) 
with unidentified endogenous ligands. Since their initial discovery, it has become evident that the 
orphan receptors themselves form a highly diverse group (Benoit el al., 2006). They are not linked 
functionally or evolutionarily, have varied structures (e.g., receptor domains range in size, and 
receptors may only contain one of the two distinguishing domains (DBD or LBD) of the NR 
superfamily), and bind to DNA in a manner of ways (e.g., most bind DNA as h~modimers, while 
others form DNA-binding heterodimers (e.g., with retinoid X receptors) or even oligomers) (Benoit et 
al., 2006). Of the orphan receptors that have been shown to interact with ligands (e.g., pregnane X 
receptor (PXR; NR1I2» it is understood that their ligand-binding pockets are larger than classical 
NRs and can bind to a large diversity of molecules with lower affinity (Mukherjee and Mani, 2010). 
Therefore, orphan nuclear receptors are functionally and structurally different from the classical 
steroid receptors - and thus could be the potential mediators of fast steroid effects. For example, the 
once orphan (now termed 'adopted' orphans) liver X receptors LXRa (NRIH3) and LXR~ (NRIH2) 
are activated by a subgroup of steroids, the oxysterols (Lu et al., 2001; Germain et al., 2006). 
6.4.3. Conclusion 
The ERK phosphorylation assay offers a universal receptor signalling platform for deorphanising 
GPCRs. Therefore, the lack of ERK phosphorylation in response to CORTIDEX strongly suggests 
that the orphan GPCRs, GPRI08, GPRl46 and TMEM87B are not fast glucocorticoid receptors. 
Whether or not the fast glucocorticoid receptor is another orphan GPCR remains to be seen. There is 
technology available to exten.d the search for possible candidates to non-orphan and chemosensory 
GPCRs, as well as steroid receptor splice-variants and orphans which may (directly or indirectly) 
couple to G proteins. 
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Chapter 7: General Discussion 
The PVN and SON are important mediators in homeostatic control, and influence an array of 
processes including appetite, labour and lactation, reproductive behaviour, the cardiovascular system, 
and the stress response. Thus the receptors within these nuclei interpret and translate a plethora of 
incoming signals (e.g., from higher brain regionslbrain stem/humoral signals) and ultimately regulate 
the output of various honnones and/or neurotransmitters (e.g., the release ofCRF, VP and OT into the 
peripheral blood or other brain regions). As GPCRs are the largest family of transmembrane receptors 
in the genome, it is un surprising that GPCRs are known to interpret many of the inputs arriving at the 
PVN/SON. The rat genome codes for at least 224 non-chemosensory GPCRs (with known 
endogenous ligands) and another 132 orphan GPCRs. Approximately 134 GPCRs have been located 
in the rat PVN, 26 of which are orphans, and 110 GPCRs have been found in the SON, of which 30 
that are orphans (values from Table 1.1). However, only a few studies have investigated the 
distribution of orphan receptors in the PVN and SON (numbers are mainly based on array data), and 
so the true value is likely even higher. The presence of orphan GPCRs in the PVN/SON raises 
questions with regards to their role in these nuclei. Are these receptors artefacts of evolution, inherited 
from ancestral creatures, and the functions of which have become functionally redundant? Do they 
lack an endogenous ligand, and are instead constitutively active, and serve to regulate the expression 
and function of other GPCRs and/or other proteins? Are the ligands for these orphans co-expressed in 
the PVN and SON e.g., peptides yet to be assigned receptors such as NERPS-1I2 or neuronostatin 
(Toshinai and Nakazato, 2009; Samson et al., 2008). Or alternatively, their ligands may be derived 
from other regions of the brain and/or are blood-borne factors that can cross the blood-brain barrier 
such as steroids. With relation to the latter point, the concept of GPCRs as steroid receptors has been 
deliberated for some time. Fast effects of steroids have been observed in numerous tissues including 
the PVN and SON. In 2005, the 'apparent' discovery of a G protein-coupled E2 receptor, the once 
orphan GPER, implied there may be other steroid-binding GPCRs. GPER proved to be of particular 
interest (especially in our laboratory) as it was shown to be expressed in the PVN and SON, 
suggesting that it may mediate the fast effects of E2 in neuroendocrine systems. 
The studies within this thesis were undertaken to further explore the concept of GPCRs as steroid 
receptors. The first experimental Chapter (Chapter 3) investigated the rodent distribution of the 
putative E2 receptor, to gain insight into its possible physiological roles. We found high expression of 
GPER in tissues associated with neuroendocrine and endocrine systems such as the PVN/SON, the 
pituitary and adrenal glands, and the ovary. Chapter 4 attempted to clarify the discrepancies 
surrounding the activation of GPER by E2. In agreement with various other published studies we 
were unable to demonstrate that GPER was indeed a bona fide E2 receptor, and as a consequence 
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GPER (at least in our hands) may still remain an orphan. Given there is a large amount of evidence to 
suggest the existence of other fast steroid receptors that act via G protein-dependent pathways, and are 
different from the traditional nuclear receptors, we postulated there may be other steroid binding 
GPCRs. Undeterred by the GPER story, in Chapter 5 we began to search for a fast glucocorticoid 
receptor. With distribution profiling, we narrowed the search to just three orphan GPCR candidates: 
GPRI08, GPRl46 and TMEM87B. A universal ERK deorphanising assay in Chapter 6 revealed that 
none of the orphans were a G protein-coupled glucocorticoid receptor. 
7.1.1. GPER - an E2 receptor? Inherent problems associated with steroid assays. 
It is unclear why some laboratories are able to obtain an E2-/G-I-mediated GPER response whilst 
others cannot. One explanation is that not all studies have employed satisfactory vehicle controls. 
Steroids are often dissolved in lipophillic vehicles (e.g., ethanol or DMSO) that can have non-specific 
effects on cellular activity (Otto et al., 2008). In our own experiments we experienced an above 
baseline increase in phosphorylated ERK in HEK293 cells in response to organic vehicles 
(particularly DMSO). In a very recent study, Prossnitz and colleagues performed an ERK 
phosphorylation assay on SKBRJ cells and demonstrated that E2 (I OnM) and G-I (I OnM) treatment 
(for an unspecified period of time) activated ERK. A close inspection of the representative Western 
blot (Figure 8 of Dennis et al., 2011), reveals that DMSO (0.1%) also induced a slight ERK response 
(Dennis et al., 20 11). This indicates that if adequate controls are not in place then a vehicle response 
may be misinterpreted as an E2/G-I response. Nonetheless, in the same study, the E2/G-1 induced 
activation of ERK was 5 times that of the DMSO control, which was comparable with the EGF-
mediated ERK response, indicating that in the current thesis, the magnitude of an E2 and G-I 
stimulated ERK response should have been sufficient to be observed above any non-specific vehicle 
effects. In Chapter 4 (section 4.3.6), we investigated the E2/G-1 activation of ERKI/2 in the same 
SKBRJ cells (kindly provided by Professor Eric Prossnitz). Not only were we unable to demonstrate 
E2/G-1 induction of ERK phosphorylation, but we were only able to show relatively modest increases 
in ppERK following EGF treatment « 2-fold at 10 min). Admittedly, it is difficult to compare the two 
experiments directly, as Dennis and co-workers failed to specify the stimulation times (Dennis et al., 
2011). 
The same study also showed that E2 (200nM) and 0-1 (200nM) rapidly increased calcium 
mobilisation in SKBRJ cells (Dennis et al., 2011). However, it is difficult to understand why 200nM 
of E2 and G-I was used in the calcium mobilisation assay considering this group have observed 
maximal calcium responses with concentrations of E2/0-1 between 1 nM and 100nM, in previous 
publications (Revenkar et aI., 2005; Bologa et al., 2006). Equally, the group have changed the SKBR3 
culture media from that used previously (DMEM or DMEMJFI2) to RPMI1640. The reasons for the 
change in media are not explained, but it may be indicative of the fickle nature of GPER signalling 
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i.e., GPER signalling may be reliant on the presence of certain media-borne chemicals, the 
concentration of which may be enhanced in RPMI 1640 media - for example, the media-borne factors 
may upregulate other GPCRs that form a functional heterodimer with GPER. 
The inconstancies between laboratories associated with E2/GPER binding and/or signalling emulate 
. the situation previously observed with the putative membrane bound progesterone receptors. In 2003, 
Zhu and colleagues cloned and characterised a new family of G protein-coupled, membrane bound 
progesterone receptors (mPR) consisting of the three isoforms mPRa, mPRp, or mPRy (Zhu et al., 
2003a). Binding assays revealed that the mouse mPRp and human mPRa and mPRy receptors bound 
progesterone with high affinity, and progesterone rapidly reduced cAMP production and activated 
ERKl/2 in MDA-MB-231 breast cancer cells transfected with fish mPRa (Zhu et al., 2003a; Zhu et 
al., 2003b). Conversely, Krietsch and co-workers found that the human mPRa, mPRp and mPRy 
localised to the endoplasmic reticulum and did not bind progesterone. They also observed no evidence 
that the fish mPRa or the three human mPR isoforms regulate cAMP or ERK signalling following 
progesterone administration (Krietsch et al., 2006). Like that observed with GPER, these two groups 
had two opposing results with regards to the binding and activation of the G protein-coupled steroid 
receptors. 
There are clear inherent problems with regard to GPCRlsteroid assays - the reasons for which remain 
unidentified. Inconsistencies may be attributable to the varying non-specific effects that steroids or 
their vehicles can have on cell membranes. Similarly, cellular binding with labelled-steroids can be 
misleading: these compounds can infuse into internal compartments, become entrapped, and in turn 
are not displaced with non-labelled ligand - thus conveying a false impression of specific steroid 
binding (Thomas et al., 20 I 0). However, some studies in the GPER field have shown robust 
activation of the receptor by E2 or G-l with various dose-response curves, appropriate controls, and 
inhibition with antagonists, which would usually be indicative of an authentic receptor. 
However, the recent 'discovery' of another steroid-binding GPCR is an encouraging sign in the search 
for other possible fast steroid receptors. GPRC6 is an amino acid, calcium and osteocalcin-sensing 
GPCR that has also been implicated in testosterone signalling. A recent study has demonstrated that 
transfection of the orphan GPRC6 into HEK293 cells renders the cells responsive to testosterone (and 
also certain concentrations of the testosterone metabolites dihydrotestosterone (200nM-400nM) and 
E2 (60-80nM), but is inhibited with progesterone (concentrations ~ 80nM), and increases specific 
eH]-testosterone binding sites on the plasma membrane (Pi et al., 2010). In addition, the fast effects 
of testosterone on ERK phosphorylation are abolished in bone marrow stromal cells derived from 
GPRC6 KO mice (Pi et al., 2010). The same study also used computational modelling to provide a 
preliminary hypothesis regarding which residues on GPRC6 would be responsible for testosterone 
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binding. The modelling predicted that testosterone would dock under EL2 (see Figure 7.1 for GPRC6 
sequence). While more studies are required to determine the credibility of this androgen (and 
potentially E2) binding GPCR, the possible discovery of another fast steroid receptor provides 
encouragements for attempts to find the fast glucocorticoid receptor. 
7.1.2. The search for the fast glucocorticoid receptor continues. 
As addressed in Chapter 6, there is an abundance of orphan GPCRs that are potential candidates for 
the fast glucocorticoid receptor (not forgetting the numerous other non-orphan or olfactory GPCRs 
and orphan steroid receptors). Therefore, a high-throughput universal assay is essential to provide 
quick and efficient screening of many receptors. Whilst it is generic, the ERK phosphorylation assay 
within this thesis is long-winded - the immunocytochemistry requires two days to process (which 
follows 3 days of cell culture). A potential alternative is Surface Plasmon Resonance (SPR) - a 'label-
free' analysis method that detects molecular interactions. SPR-based instruments use polarized laser 
light to measure the change in the refractive index of a solvent that occurs near a sensor chip surface 
during complex formation or dissociation. In brief, sensor chips are coated with a 'ligand', while its 
binding partner (the analyte) is dissolved in a running buffer which is continuously infused over the 
sensor surface. A Iigand-analyte interaction is indicated by an increase in the refractive index - a 
'SPR response' (van der Merwe, 2000). Many attempts have been made to adapt SPR into a new 
GPCR-deorphanising screening strategy. Protocols have been developed that immobilise ligands to 
sensor chips which are then treated with a detergent-solubilised GPCR perfusate (Harding et at., 
2000; Navratilova et ai., 2011). This technique is an excellent way to screen large ligand catalogues 
with one GPCR - and if testing steroid ligands it would hopefully bi-pass the non-specific actions of 
steroids or their organic buffers. However, to perform this method for numerous GPCRs would prove 
awkward and time consuming as GPCRs are notoriously difficult to dissolve in detergents due to their 
inherent hydrophobicity. 
Reversing the technique (fusing the GPCR to the chip and infusing the ligand) is equally as difficult 
as SPR is unsuitable for investigating small analytes (molecular weight <1000 Da), or analytes that 
are extremely small when compared with the molecules attached to the chip (such as GPCRs and their 
respective ligands) (van der Merwe, 2000). Furthermore, removing GPCRs from a cellular context 
will remove native proteins that may be imperative for receptor activation. Recently, Chen and 
colleagues adapted the SPR protocol in the hope of eventually developing a SPR GPCR 
deorphanising screening method (Chen et ai., 2010). CHO-Kl cells stably expressing (non-orphan) 
GPCRs are cultured directly onto SPR sensor chips and stimulated with respective ligands. In this 
instance a SPR response is not based on direct molecular interactions but instead represents a GPCR-
mediated alteration in cell shape (which is indicative of overall cytoskeletal actin rearrangements). 
Although, the authors concluded that although the sensitivity of SPR was comparable to calcium or 
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cAMP assays, the activation of actin rearrangement is restricted to GQj and Ga\2l13 coupled-receptors 
(Chen et al., 2010). Moreover, the cells require stable transfection of the receptors of interest, which is 
a laborious procedure in itself (especially for lots of receptors!). 
It is clear that deorphanising GPCRs is a long and arduous process - it requires cloning of many 
receptors and the selection of an assay that is efficient, inexpensive, non-bias towards certain receptor 
Oa protein-coupling, and is not sensitive to non-specific effects of vehicle solvents. Even then, it is 
difficult to predict the necessary conditions for ligand-receptor activation. Mapping the central and 
peripheral distribution of an orphan gene or protein expression (as demonstrated within Chapter 5 of 
this thesis) will undoubtedly give insight into 1) the identity of a possible endogenous Jigand(s); 2) the 
function of the receptor; and/or 3) the possible interacting proteins or receptors that may accentuate 
ligand binding. As for uncovering a fast steroid receptor, it is perhaps reasonable to continue, but 
refine, the strategies of the current thesis. One could continue to use distribution profiling such as 
array and ISHH (and deep transcriptome sequencing - see section 5.4.3) to narrow down possible 
candidates (whether it be orphan, non-orphans, or chemosensory GPCRs, or even orphan steroid 
receptors). This could be used in conjunction with bioinformatics - potential targets could be screened 
for homology with known steroid binding OPCRs e.g., search for hydrophobicity in EL2 (see Figure 
7.1). 
As it is one of the only assays to provide an excellent universal platform with which to deorphanise 
receptors, it may be advisable to continue to test the potential candidates in the ERK phosphorylation 
assay. However, the assay may be improved by utilising a fast acting ppERK directed primary 
antibody that requires only a short incubation period (e.g., 1 hour - as opposed to overnight, this 
would likely require an antibody with higher affinity than ones currently used, so that signal-noise 
ratios are maximised at shorter incubation times). Also the steroids used for stimulation should be 
dissolved in a variety of different solvents (e.g., water and ethanol) to counteract non-specific, vehicle 
effects. In addition, other steroids should be tested alongside the steroid of interest, to check that 
increases in ppERK are steroid-specific e.g., if many steroid hormones activate the same receptor then 
it is indicative of non-specific activity (such as non-specific interactions with the 
membranelhydrophobic regions on the receptor). Finally it would be advantageous for any orphan 
responses to be validated in animal models in which the GPCR has either been knocked out or 
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Figure 7.1. Sequence alignment of human GPER, PSGR, and GPRC,. 
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(A) Sequence alignment of the human GPER (top line), human odorant receptor PSGR (middle line), and human GPRC6 (bottom line) receptors, generated with the aid of the web-based uniprot sequence alignment 
tool (http ://ww\\ .. uniprot.org/uniprotJ ). Exactresiduematchesacrossallthreereceptorsarerepresentedbyanasteriskonline4(*). Amino acids that have similar properties are indicated on the fourth line with a semi 
colon (conserved substitution) or a full stop (semi-conserved substitution). Residues that fom1 the predicted transmembrane domains (TMs; as designated by uniprot) are boxed. All three of the GPCRs thought to be 
activated by steroids (GPER, putative E2 receptor (Revenkar et aI. , 2005); PSGR, reported to be activated by testosterone metabolites (Neuhaus et aI. , 2009); GPRC6, though to bind testosterone (Pi et aI. , 20 I 0» . 
Studying the sequences of the GPCRs may reveal certain sequence motifs that are indicative of steroid binding, and thus may be used to find other such receptors using a bioinformatic search engine. For example, Pi 
and colleagues used computational modelling to indicate which residues on GPRC6 would be responsible for testosterone binding. The modelling predicted that testosterone would dock under EL2 surrounded by 
common hydrophobic residues (the amino acids that Pi el aI. , deemed as EL2 are highlighted in yellow). Note that GPRC6 has a longer N-tenninal than the other receptors - as such GPRC6's TMs do not line up with 
the TMs of the other receptors. (B) Re-alignment of the last 375 amino acids ofGPRC6 with PSGR and GPER to enable a sequence comparison between the extracellular domains, particularly EL2. For each receptor, 
the hydrophobic residues within the EL2 are highlighted in red (these amino acids may interact with the steroid ligand). The EL2s of PSGR and GPER are much longer than GPRC6, and share no obvious sequence 
motifs with the putative testosterone receptor. It remains to be seen whether hydrophobicity within the EL2 holds the key to steroid binding. 
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7.1.3. Why are fast steroid receptors required? 
One wanders, if steroids mainly exhibit prolonged genomic effects, why is there a biological need for 
rapid steroid signalling? One theory is that non-genomic signalling primes the cell ready for steroid-
mediated alterations in transcription. For example, E2 can stimulate ERK, PI3K, or PKA activation 
which in tum can phosphorylate key residues on ERa, and augment the transcriptional activity of the 
nuclear receptor (Hammes and Levin, 2007). Likewise, the rapid activation of kinases by E2 can 
recruit co-activators (e.g., steroid receptor coactivator 3) to the nuclear receptor complex and thereby 
accelerate the transcriptional effects of E2 (Zheng et al., 2005). In addition, steroids can modulate 
transcriptional activity independent of the nuclear receptors e.g., E2 can rapidly upregulate the 
expression of the transcription factor c-Fos via an ERK-dependent pathway (Alban ito et al., 2007). 
Therefore, steroids can alter the transcription of a range of genes via transcription factors such as c-
Fos, and can even modulate the transcription of the their target nuclear receptors e.g., c-Fos 
upregulates GR transcript and protein expression in mouse fibroblast NIH3T3 cells, via an AP-I site 
present in the promoter region of the GR gene (Wei and Vedeckis, 1997). Therefore, steroids can 
rapidly prime cells in anticipation of their own genomic actions by increasing the activity and 
expression of the nuclear receptors and recruiting their co-activators. 
However, not all of the effects of steroids are dependent on the direct or indirect activation of 
traditional nuclear receptor signalling. For instance, rapid E2 signalling promotes the survival and 
differentiation of bone osteoblasts, limits neuronal cell damage and death, and modulates endothelial 
and vascular smooth muscle cell migration and proliferation (Hammes and Levin, 2007). Similarly, 
CORT rapidly inhibits the HPA axis, amplifies the responses to other neurotransmitters in the CNS 
(Le., during a stressful episode), and prevents testosterone production from the testis (Groeneweg et 
al., 2011; Hu et al., 2008). Furthermore, non-genomic activation of signal-transduction pathways 
(such as ERK1I2) can lead to epigenetic regulation of gene expression e.g., activation of ERKII2 
increases histone H3 phosphorylation in the rat hippocampal CA I area (Chwang et al., 2006). 
Therefore, it is a combination of non-genomic and genomic signalling that mediates the fundamental 
effects of steroids. 
It is clear that both fast and genomic steroid effects can be mediated in part by the traditional nuclear 
receptors, but there are numerous lines of evidence (examples given in sections 1.6.2 and 5.1.2) that 
suggest there are other 'unknown' receptors that also mediate rapid actions. Only when these putative 
receptors are identified, or their mechanism of action established, can the true nature of steroid 
signalling be understood. 
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Appendix I: Extra Protocols 
Molecular biology techniques 
PCR conditions for riboprobes 
1'1 I ,he I i( 1< I ~ 1<. .. 1 II \) 1 1111 \ I '( I~ ", III I1111 'II , 
Sill lOx HotStar buffer; Sill dNTPs; 0.51l1 2.5U 9Soe I min; 94°C 4Ss, S2.5°e I min, 72°C 30s 
rat GPReSB amplitaq polymerase; 2111 10llM primers; distilled for 40 cycles; 72°C 10 min; 4°C soak H20 to SOIlI 
Sill 10 x HotStar buffer; Sill dNTPs; O.SIlI 2.SU 9soe I min; 94°C I min, ssoe I min, 72°C 1 
rat GPER amplitaq polymerase; 2111 IOIlM primers; distilled 
min for 40 cycles; 72°C 10 min; 4°C soak H20 to SO/.11 
S/.11 lOx HotStar buffer; 8111 dNTPs; 0.SIl12.SU 9Soe I min; 94°C 45s, 4Soe I min, 72°C 30s for 
rat GPR48 amplitaq polymerase; 21l110llM primers; distilled 40 cycles; 72°C 10 min; 4°C soak H20 to SO/.11 
5111 10 x HotStar buffer; Sill dNTPs; 0.51l12.5U 95°C I min; 94°C 4Ss, sooe I min, 72°C 30s for 
rat GPR56 amplitaq polymerase; 2111 10/.1M primers; distilled 40 cycles; 72°C 10 min; 4°C soak H20 to 50/.11 
Sill 10 x HotStar buffer; 8111 dNTPs; 0.51l12.5U 9Soe I min; 94°C 4Ss, 52.Soe I min, 72°C 30s 
rat GPR65 ampJitaq polymerase; 2111 IOIlM primers; distilled for 40 cycles; 72°C 10 min; 4°C soak H20 to SOIlI 
5111 10 x HotStar buffer; Sill dNTPs; 0.5/.112.5U 95°C I min; 94°C 45s, 47.5°e I min, 72°C 30s 
rat GPRI08 amplitaq polymerase; 2111 10J.lM primers; distilled for 40 cycles; 72°C 10 min; 4°C soak H20 to SOul 
5111 10 x HotStar buffer; Sill dNTPs; 0.51l12.SU 95°C I min; 94°C 4Ss, 50°C I min, 72°C 30s for 
rat GPRI2S amplitaq polymerase; 2111 10llM primers; distilled 40 cycles; 72°C 10 min; 4°C soak H20 to SO/.11 
Sill 10 x HotStar buffer; 8111 dNT~s; 0.51l~ 2:SU 9soe I min; 94°C 45s, 50°C I min, 72°C 30s for 
rat GPRI46 amplitaq polymerase; 2111 10llM pnmers; distIlled 40 cycles; 72°C 10 min; 4°C soak H20 to SOIlI 
Sill 10 x HotStar buffer; Sill dN~s; 0.51l~ 2:5U 9Soe I min; 94°C 4Ss, sooe I min, 72°C 30s for 
rat GPRI53 ampJitaq polymerase; 2111 10llM pnmers; distilled 40 cycles; 72°C 10 min; 4°e soak H20 to SOIlI 
rat Sill lOx HotStar buffer; 8111 dN~s; O.SIl~ 2:SU 95°C I min; 94°e 45s, 500 e I min, 72°e 30s for 
TMEM87B ampJitaq polymerase; 2111 10llM pnmers; distIlled 40 cycles; 72°C 10 min; 4°C soak H20 to SOIlI 
Sill lOx HotStar buffer; 8111 dN~s; 0.51l~ 2:5U 95°e I min; 94°C I min, 55°C 1 min,72°e 1 
mouse GPER ampJitaq polymerase; 2111 10llM pnmers; distIlled 
min for 40 cycles; 72°C 10 min; 4°e soak H20 to SOIlI 
Filling-in DNA. 
The process of filling in uses T 4 DNA Polymerase to catalyze the synthesis o~ DNA in the 5'-+ 3' 
direction to create blunt ends. This is used to ensure there is complete extension of PCR products, 
particularly if subsequent steps require unmitigated restriction enzyme recognition sites. 
I) PCR product is made up to 300111 with TE or H20 and DNA precipitated overnight at -20°C 
with 24111 5N NaCI and 990111 absolute ethanol. 
2) Solution was centrifuged (16,000xg) and pellet washed with 70% ethanol and resuspended in 




3) Added to the 21fll DNA were 25fll dNTPs, 6fll BSA, 6fll T4 polymerase buffer (New England 
BioLabs, UK) and 2fll T4 polymerase (3U/fll; New England BioLabs, UK). 
4) The reaction mix was incubated at 12°e for 45 min and then at room temperature for 15 min. 
5) 140fll TE was added to the product and phenol/chloroform/isoamyl alcohol (p/ell) extracted 
(with 200fli p/ell; see Appendix II) and then chloroform/isoamyl alcohol (ell) extracted 
(with 200fll ell; see Appendix II). 
6) DNA was precipitated with SOfll 7.SN ammonium acetate, 600fll ethanol and 2fll tRNA on 
dry ice for 15 min, and centrifuged (16,000xg) for 10 min. DNA was resuspended in TE. 
Gel electrophoresis 
Gel electrophoresis was used to separate, and identify, different sized strands of DNA. To perform 
electrophoresis an ethidium bromide agarose gel (see Appendix II on how to make a gel) was placed 
into a gel tank (VWR, UK) filled with Ix TAE buffer/IOOfll and 5fll 10mg/ml ethidium bromide (see 
Appendix II). DNA premixed with 10% stop buffer (Appendix II) was loaded into the gel lanes, 
leaving one lane for a DNA marker (Appendix II). An electric current (between 50-SOY) was run 
through the tank for approximately 2 hours. 
Gel extraction 
Agarose gel is extracted from DNA using the Qiaex II gel extraction kit and protocol (Qiagen, UK). 
I) Bands of interest were cut out of agarose gel and weighed. 
2) QXl buffer was added to agarose (DNA fragments < 100bp add 6 volumes QX1; DNA 
fragments 100bp-4kb add 3 volumes of buffer QX t; DNA fragments> 4kb add 3 volumes of 
buffer QX 1 and 2 volumes distilled H20; agarose gels> 2% add 6 volumes of buffer QX 1), 
followed by Qiaex II beads (~ 2flg DNA add 10fll; 2-1 Oflg DNA add 30fll). 
3) Bands were incubated at 500 e for 10 min, vortexing every 2 min. 
4) Solution was centrifuged at (16,000xg) for 30s and supernatant removed leaving DNA pellet. 
5) DNA pellet washed with 500 fll QX 1 buffer. 
6) 2x wash with buffer PE. 
7) DNA was left to air dry for 5.-15 min, and resuspended in 20 fll TE, ph S and incubated for 5-
10 min (DNA fragments < 4kb for 5 min at room temperature; DNA fragments 4-10 kb at 
500 e for 5 min; DNA fragments> 10 kb at sooe for to min). 
8) Solution was centrifuged (16,000xg) for 30s and supernatant collected. 
Vector-Insert ligations 
Vectors were digested with the same restriction endonucleases used to digest the insert, and run on a 
0.8% ethidium bromide gel. Linearised vectors were removed from the ethidium bromide agarose gel 
(over a UV light box) and the DNA extracted using the Qiaex II gel extraction kit and protocol. To 
ligate insert into a vector, 4fll Vector (SO-IOOng), was added to tOfll insert DNA (approximately 3x 
vector concentration), plus 4fll Sx DNA ligase buffer (Invitrogen, UK), 1 fll 100mM ATP (Sigma, UK) 
and Ifll T4 DNA ligase (Invitrogen, UK) and incubated at 14°C overnight. 
Transforming recombinant plasmids into E.coli cells 
The recombinant vectors were introduced into DH5a E.coli via a heat shock protocol: 
262 
;\ p p ~ 11 d i" I 
1) Vector added to SO-100J,11 DHSa and placed on ice for 30 min. 
2) E.coli heat shocked with 20s at 37°C and 2 min on ice. 
3) Bacteria were rocked (22Srpm) for 1 hour at 37°C in 9S0fll SOC medium (Sigma, UK), 
centrifuged (16,000xg) for lOs, and resuspended in 100J,1l SOC medium. 
4) Using an aseptic technique, the bacteria were spread on to an LB-agar plate (containing 
antibiotics that corresponds to the antibiotics resistance gene within the vector), and left to 
grow overnight at 37°C. 
DNA miniprep 
1) Single colonies were picked from the LB-agar plate and put into 5ml LB (plus antibiotic) and 
grown overnight (placed at 37°C and rocked (225rpm». 
2) S00J,11 of bacteria culture was centrifuged (l6,000xg) for 5 min and supernatant discarded. 
The bacterial pellet was resuspended in 100fli of lysosome solution (see Appendix II) and 
incubated on ice for 30 min. 
3) 0.2N sodium hydroxide/l% SOS was added and incubated on ice for 5 min to continue lysis, 
followed by the addition of 150J,11 3M sodium acetate and incubated on ice for a further 30 
min to precipitate the bacterial DNA. 
4) The lysis was centrifuged (l6,000xg) for 10 min, supernatant collected. 900J,11 of absolute 
ethanol was added to the supernatant and DNA precipitated out for 10 min on dry ice. This 
was followed by a 10 min centrifuge (16,000xg), and supernatant removed. 
5) Pellet was washed with 70% ethanol for 3-5 min, allowed to air dry for 3-5 min, and 
dissolved in 40,,11 TE. 
6) 10JlI DNA was digested with appropriate restriction endonucleases and ran on a low 
percentage agarose gel to check the vector contained the correct insert. 
Qiagen plasmid maxiprep protocol 
Plasmid DNA was retrieved from E.coli using the Qiagen plasmid maxiprep kit (Qiagen, UK). The kit 
contained Qiagen tips that purified the DNA. 
1) Colonies that contained the correct insert were cultured overnight in 100ml LB (and 
antibiotics). 
2) Bacteria were centrifuged (-2,500xg) for 10 min and LB removed. Pellet was resuspended in 
10ml of the supplied Qiagen resuspension buffer PI, then 10ml of lysis buffer P2, and 
incubated at room temp for 5 min. 
3) 10ml neutralization buffer 3 was added and solution incubated on ice for 20 min and then at -
20°C for 20 min, inverting every 5 min. The suspension was then centrifuged (20,000xg) at 
4°C for 30 min. 
4) Supernatant was removed and applied to a Qiagen tip. 
S) Qiagen tip was washed wi,th wash buffer QC x 2. 
6) DNA was eluted from tip with elution buffer QF, precipitated with 10.Sml isopropanol, and 
centrifuged (l5,OOOxg) for 30 min at 4°C. 
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7) Supernatant was removed and pellet washed with 70% ethanol, and centrifuged (15,OOOxg) 
for 10 min at 4°C. 
8) Ethanol was removed and pellet' was air-dried for 5-10 min, and dissolved in 200,,11 TE, pH 
8.0. 
Further to the Qiagen protocol, the vector was precipitated and cleaned up by PfCII extraction as 
follows: 
I) DNA precipitated with 4,,11 5 N NaCI and 400J.l.I absolute ethanol at -20°C overnight. 
2) Centrifuged (l6,OOOxg) for 5-10 min and DNA pellet washed with I ml 70% ethanol. 
3) Pellet resuspended in 500J.l.I (lOmM Tris-HCI, pH 7.5, ImM ethylenediaminetetraacetic acid 
(EDTA), OAM NaCI, 0.5% SDS). If pellet did not dissolve straight away the solution was 
incubated at 60°C for 10 min. 
4) DNA was cleaned by PfCII extraction (500J.l.I PfCII; see Appendix II) and upper phase 
collected. 
5) DNA was precipitated overnight at -20°C with 10J.l.I 5N NaCI and Iml absolute ethanol. 
6) Solution was centrifuged (16,OOOxg) and DNA pellet washed in 70% ethanol, and dissolved 
in 100-200J.l.I TE. 
ISHH techniques 
Linearising vectors that generate riboprobes 
To 10-20J.l.g vector DNA, IOJ.l.I lOx CORE (see Appendix II for CORE recipe), 5J.l.I I N NaCl, 5J.l.I 
restriction endonucJeases, was added and made up to 100J.l.I with distilled H20, and placed at 37°C for 
2 hours. Another 2J.l.I of enzyme was added and incubated for another 2 hours at 37°C. 
5-10J.l.I digested vector was run on a 0.8-1 % ethidium bromide agarose gel to check the DNA had 
linearised. Remaining DNA was cleaned-up by PfCII (200J.l.1 PfCII; see Appendix II) and CII (200J.l.1; 
see Appendix II) extraction. DNA was reprecipitated overnight with 80J.l.1 7.5N sodium acetate and 
560J.l.1 absolute ethanol at -20°C. Following a 10-15 min spin the DNA pellet was washed in 70% 
ethanol, and resuspended in 21 J.l.I TE. I J.l.1 was taken and DNA concentration calculated using an 
spectrophotometer (at a 260nm wavelength). 
AmbioD MAXlscript® transcription prot04:ol. 
Added to each SOOng of DNA starting template: 
1) IJ.l.1 10 x reaction buffer (from Ambion kit), 1.5J.l.I 10mM ATP/CTPfGTP (0.5J.l.I of each 
nucleotide; from Ambion kit), 2.5J.l.I 3sS_UTP (PerkinElmerQD, UK), 0.5J.l.I SP6 or T7 (from 
Ambion kit), and incubated at 37°C for 30 min. 
2) An additional 0.5J.l.1 SP6 or T7 and further incubated at 37°C for 30 min. 




4) Finally 190111 TE, pH 8, 2111 tRNA (Invitrogen, UK), 80111 7.SN ammonium acetate and 700lli 
ethanol. 
Emulsion dipping 
Perfonned in a dark room: 
1) A solution containing 30f,l1 glycerol and 6ml distilled H20, was make up to 10ml with 
emulsion (Ilford KS, UK), and heated to 43-4SoC to melt emulsion for IS-20 min. This 
was inverted and left for another IS-20 min. 
2) Slides were dipped in emulsion, and left to dry for approximately 2 hours. 
3) Once dry, slides were put into a slide holder with 1-2 sachets of silica gel, and sealed to 
prevent light penetration. 
4) Slides were stored at 4°C until developing (slides stay in emulsion for 3 x the duration of 
film exposure). 
S) To develop dipped slides were placed in a slide rack (still in dark room), and immersed in 
D19 developer (Sigma, UK) for 3.S min, indicator stop (Sigma, UK) for O.S min, fixer 
(Sigma, UK) for 3.5 min and washed in H20 for S-30 min. 
6) Slides were counterstained in 0.1-0.S% toluidine blue (dissolved in 70% ethanoVdistilled 
H20) 20-30s, and rinsed in running H20 and leave to air dry. 
7) Slides were coverslipped with Cytoseal (Richard Allen Scientific, UK). 
Cell culture techniques 
Media Change 
Media was removed by aspiration and cells washed with Ix PBS (approximately Sml was used for a 
small petri dish, 1 ml for each well of a 6 well plate, and IOOIlI for each well of a 96 well plate) for up 
to S mins, with occasional agitation of the plate. Ix PBS was discarded and fresh media replaced 
(approximately IOml for a small petri dish, 2ml for each well of a 6 well plate, and 100-200lli for each 
well of a 96 well plate). 
Passaging cells 
For a small petri dish, media was removed by aspiration and washed with Sml 1 x PBS. The PBS was 
aspirated and 2.Sml trypsin was applied and the plate incubated at 37°C/S% CO2 until the cells no 
longer adhered to the plate (the cells looked rounded up under the microscope). 2.Sml of media was 
added to the plate to deactivate the trypsin. The cells were then split into a new plate or frozen down. 
Freezing down cells 
Following trypsinisation and the addition of media, cells were moved to a I5ml falcon tube and 
centrifuged (-2,500xg) for 5 min. The supernatant was aspirated and cells resuspended in 2-3ml 
freezing down media (Appendix II) and transferred to 2-3 Cryotube vials. Cryotube vials were 
immediately placed on ice and moved to -20°C freezer. After a couple of hours the vials were placed 
over night at -80°C and then transferred to liquid nitrogen stores for long-tenn storage. 
Thawing cells from liquid nitrogen stocks 
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Cells were removed from liquid nitrogen stores and placed 011 dried ice for transportation. Cells were 
defrosted very quickly in 37°C water with constant agitation. Once thawed, cells were placed in a 
small petri dish with 10mi media and left OIN at 37°C/5% CO2• Media was changed the following 
day to remove any residual DMSO. 
Poly-I-Iysine coating coversJips and plates 
Poly-I-Iysine coating greatly increases cell adherence and thereby reduces the amount of cells lost 
during processing. This is of particular use when dealing with cells that adhere less well to cell culture 
apparatus or during a procedure with multiple wash steps. 
A working solution of 0.1 mg/ml poly-I-Iysine was made by dissolving Smg of poly-I-Iysine (Sigma, 
UK) into SOml distilled H20 or Ix PBS and stored at -20°C. The poly-I-Iysine was defrosted in a 37°C 
water bath when required. 
To poly-I-lysine coat coverslips: 2-3 coverslips were placed in a well of a 6 well plate. Enough poly-I-
lysine solution was applied to each well until the cover slips were completely submerged and left for 
30 min. The poly-I-Iysine was removed and washed S x with 100J,l1 Ix PBS for 10 min. For a 96 well 
plate 100J,l1 of poly-I-lysine was applied to each well for 30 min. Again the poly-I-Iysine was removed 
and washed 5 x with 100J,l1 Ix PBS for 10 min. The poly-I-lysine can be re-frozen and thawed up to 6 
times. 
X-Gal staining for expression of LacZ in cultured cells 
Control cells were transfected with a pSV mammalian vector (pSV-p-Galactosidase control vector; 
Promega, UK) containing the LacZ gene. LacZ encodes for the p-galactosidase (p-Gal) enzyme that 
catalyses the hydrolysis of p-galactosides. This assay relies on the cleavage of S-bromo-4-chloro-3-
indolyl-~-D-galactopyranoside (X-Gal) by ~-Gal into galactose and S-bromo-4-chloro-3-
hydroxyindole. The latter is oxidised into S,S'-di-bromo-4,4'-dichloro-indigo (the reaction is 
facilitated by ferric and ferrous ions), an insoluble dark blue product. 
Transfection efficiency = Amount of cells that express the dark blue product x 100 
Total number of cells 
The protocol below was used to test for p-gal activity (the volumes stated are for a 6 well plate, but 
when performed on a 96 well plate, the volumes were reduced approximately 1: 10 e.g., I ml ~ 100J,l1) 
1) 24-48 hours after transfection media was removed from cells and washed with I x PBS for 5 
min at room temperature. 
2) Cells were fixed in Im14% PFA in I x PFA for IS min on ice. 
3) 3 x washes with 2mllx PBS for S min at room temperature. 
4) Cells were permeabilised in Iml 0.1% TX-IOO in I x PBS for 10 min at room temperature. 
S) 3 x washes with 2mllx PBS for S min at room temperature. 
6) Cells were incubated for 3-20 hours in the dark at 37°C in Iml X-gal staining solution (see 
Appendix II) containing Imglml X-gal. 
7) Once the dark blue colour had sufficiently developed, cells were washed 3 times with 2ml I x 




Northern Blot hybridization techniques 
Roche Terminal Transferase tailing protocol. 
The addition ofnucleotides to the 3' terminus of DNA is catalysed by the DNA pol~erase terminal 
deoxynucleotidyl transferase (TdT) - in this instance TdT catalyses the addition of a- 2p_ATP to the 3' 
end of an oligonucleotide. 
Oligonucleotides were reconstituted with 100J.11 TE ph8.0 and diluted to form a 35J.1M solution. Added 
to each 3.5J.1M oligonucleotide (on ice) was IJ.115x reaction buffer (Invitrogen, UK), O.5J.11 a)2P-ATP 
(PerkinElmer~, UK), O.625J.11 TdT (Roche, UK) and made up to 2.375J.11 dH20 (not DEPC treated), 
and incubated at 37°C for 15 mins. 
267 
/\.ppl'lldi:x II 
Appendix II: Buffers and Solutions 
Microbiological media 
1 litre LB 
109 Tryptone (Appleton Woods Ltd., UK), Sg Yeast extract (Appleton Woods Ltd., UK), 109 NaCl, 
made up to I litre with distilled H20, autoclaved and stored at 4°C. The correct antibiotics (SOJ.lglml 
AMP; or 30J.lglml kanamycin sulphate; or 34J.lglml chloraphenicol) are added prior to use. 
1 litre LBlagar 
109 Tryptone, Sg Yeast extract, 109 NaCl, ISg agar, made up to 1 litre with distilled H20 and 
autoclaved. LB-agar was cooled following autoclaving and the correct antibody added (SOJ.lglmI 
AMP; or 30J.lglml kanamycin sulphate; or 34J.lg/ml chloraphenicol). SOml of LB-agar was added to a 
large Petri dish and left to set prior to storing at 4°C until use. 
Antibiotics. 
AMP was dissolved in distilled H20 (concentration of SOmg/ml), divided into aliquots and kept at -
80°C. When required, AMP was thawed on ice and added I: I 000 to LB or LB/agar. 
Kanamycin sulphate was dissolved in distilled H20 (concentration of 30mglml) divided into aliquots 
and kept at -80°C. When required, kanamycin sulphate was thawed on ice and added 1: I 000 to LB or 
LB/agar. 
Choloramphenicol was dissolved in ethanol at a concentration of 34mglml. When required, 
chloramphenicol was and dissolved 1: 1000 in LB or LB/agar. 
Molecular biology buffers and solutions 
Tris- ethylenediaminetetraaceticacid (Tris-EDTAIfE) 
500J.lI Tris-EDTA (I OOx pH 8, Sigma, UK) in 49.5ml distilled H20. 
lOx Core 
SOOmM Tris, pH 7.6, 100mM MgCh. SOOmM NaCI, 100J.lg/ml BSA (New England Biolabs, UK), 
lOmM DTT in distilled H20. 
Phenol/chloroformlisoamyl alcohol (P/CII) 
25ml tris-saturated phenol, 23ml chloroform and 2ml isoamyl alcohol. Ix volume P/CII was added to 
solution, vortexed and centrifuged (I6,OOOxg) for 5 min. Upper phase containing DNA was collected. 
ChlorofonnflSOamyl alcohol (CII) 
23ml chloroform and 2ml isoamyl alcohol. lx volume e/I was added to solution, vortexed and 




Smglmllysozyme (Sigma, UK) in 2SmM Tris-HCL, pH7.9, 10mM sodium-EDTA (pH adjusted to pH 
7) and 9mglml glucose added. 
Agarose gel 
E.g., to make a 1% gel 1.2g of agarose was dissolved in Ix TAE (see below) to a total volume of 
120J11. To dissolve the agarose, the solution was heated in a microwave on full power for 1-5 min with 
frequent agitation. Once cool SJ11 10mglml ethidium bromide was added to the gel, and the gel poured 
into a mould containing a 15 tooth comb, and allowed to set. 
Ultra Pure™ agarose (Invitrogen, UK) was used to make an agarose gel, whereas low gel agarose 
(Severn Biotech Ltd, UK) was used to make a microsieve gel. 
SOx TAE buffer solution 
484g Tris, 272g sodium acetate • 3H20, 37g disodium EDTA, - 200m I glacial acetic acid (pH 
adjusted to 7.5-8.0), and made up to 2 litres with distilled H20. 
Ethidium bromide 
1 g ethidium bromide (Sigma, UK) was dissolved in 100ml distilled H20 (final concentration 
10mglml). Stored at room temperature in a foil-covered bottle. 
DNA markers 
40J1g HaeIII-cpX digest (NEB, UK), 40JLg A-HindIII digest (NEB, UK), 100J11 STOP-dye (lacking 
RNase A, see below), 780J11 TE, pH7.6, heated at 60°C for 10-15 mins. 
Restriction stop buffer 
0.4% Bromophenol blue, 10% FicoIl400, 0.2M EDTA (pH8.0), 100Jill0mg/ml RNase A, made up to 
Iml with distilled H20. 
ISHH buffers and solutions 
DEPC-H10 
4ml of DEPC (Sigma, UK) to 4 litres distilled H20. Incubated overnight at 37°C with occasional 
shaking. Autoclaved. 
lOx PBS 
90g NaCI, 1.22 g potassium dihydrogen phosphate, 8.1Sg disodium hydrogen phosphate, made up to 1 
litre with DEPC-H20. Diluted in DEPC H20 1: 1 0 to acquire 1 x PBS. 
Ribonucleic acid solution 
100Jig/ml Sperm DNA (Sigma, UK); 2S0Jig/ml Yeast total RNA (Sigma, UK); 2S0fl8t'ml Yeast 
tRNA (Invitrogen, UK) made up in DEPC-H20. 
SOml Hybridisation buft'er 
23.8ml formamide (50%); 0.9Sml 1M Tris-HCL (25mM), ph 7.5; O.l9ml 2S0mM EDTA (1mM), pH 
8.0; 3.7Sml 4M NaCI (lOOmM); 9.52ml dextran sulphate (10%) (Sigma, UK); 0.9Sml SOx denhardts 
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solutionlll (IX); 0.84ml DEPC-H20 (1.7%). Brackets indicate the percentage or concentration of 
reagent when made up to total volume of hybridisation solution. 
IllSOX Denhardt's solution 
Ig ficoll400 (Sigma, UK), Ig polyvinylpyrrolidone-360 (Sigma, UK), Ig BSA (Sigma, UK), DEPC-
H20 up to 100ml. 
RNase solution 
SOml NaCl, Sml Tris-HCI, pH 8.0, 0.2Sm1500ml EDTA, pH 8.0 and 444.7Sml DEPC-H20. 
IHCI immunocytochemistry buffers and solutions 
lOx PBS 
Same recipe as lOx PBS in the ISHH buffers and solutions section, although made up with distilled 
H20 (not DEPC treated). . 
4°"- PFA in Ix PBS 
To make 100mi 4g PFA (Sigma, UK) was dissolved in 10m I lOx PBS and 80ml distilled H20 
(preheated to S8°C) by incubating at 58°C for about 30min. To ensure all of the PF A dissolved, the 
solution was placed on a stirrer and IN sodium hydroxide was added dropwise until all PF A had 
dissolved. It was then made up to a total volume of 100ml with distilled H20 and then pH was 
adjusted to approximately 7.4. It was then cooled to room temperature, filtered (to remove any 
polymers formed during heating) and stored at 4°C. 2% PFA in Ix PBS was make up with 2g PFA 
rather than 4g and made up to 100mi with Ix PBS (or dilute 4% PFAllx PBS 1:2). If the PFA was 
intended for use during perfusion fixation, the PF A was made up fresh (could be used the next day 
providing it had been stored overnight at 4°C). For immunocytochemistry 10ml aliquots of 2%/4% 
PF A in I x PBS were placed at _20DC and defrosted when required. 
Cell culture media and solutions 
Trypsin 
lOx Trypsin (Trypsin-EDTA solution; Sigma, UK) was stored at -20°C in 5ml aliquots. Aliquots were 
defrosted in a 37°C when required and diluted 1: lOin 1 x PBS (Sml lOx trypsin into 45ml 1 x PBS). 
Freezing down media 
All cells apart from CHO-K 1: 10% DMSO in DMEM, supplemented with 20% FCS, 500 unitslml 
Penicillin, 0.5mglml Streptomycin, and 2mM L-glutamate. 
CHO-K 1: 10% DMSO in aMEM, supplemented with 20% FCS, 500 unitslml Penicillin and 0.5mglml 
. Streptomycin. 
X-gal staining solution 
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SmM potassium ferrocyanide (Sigma, UK), SmM potassium ferrocyanide (Sigma, UK), 2mM 
magnesium chloride hexahydrate (Sigma, UK), and 1mglml X-gal made up in Ix PBS. 
O.2SM calcium chloride dihydrate 
2.SM CaCh·2H20 stock and filtered through a 0.2J.U1l filter. 2.5M CaCh·2H20 stock was split into 
Sml aliquots and stored at -20°C. Aliquots were defrosted at 37°C when required, and diluted 1: 10 
with sterile H20 for 0.25M CaCh·2H20 solution. 
2xBES 
2x BES: SOmM N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid, N,N-Bis(2 hydroxyethyl) 
taurine (BES; Sigma, UK), 280mM NaCl, 1.SmM Na2HP04. 
1.07 g BES, 1.6g NaCI and 0.0213g Na2HP04 was dissolved in a total volume of 90ml H20. pH was 
adjusted to 6.96 with HCl and volume made up to 100ml with distilled H20. Solution was sterilised 
through a O.2J.U1l filter and stored in Sml aliquots at -20°C. 
Physiological salt solution (PSS) for calcium imaging 
For 1 litre of PSS: 127nM NaCl, O.SmM NaH2P04·H20, 1.8mM CaCh"2H20, 2mM MgCh, SmM 
KCh, 5mM NaHC03, 10mM Hepes in dH20 (not quite 1 litre-allow for displacement by BSA and 
glucose) and pH adjusted to 7.4. An additional 0.1% BSA and 10mM glucose was added (and more 
dH20 to 1 litre if needed). PSS was sterile-filtered with a O.4S~m filter in a cell culture hood. SOml 
aliquots were frozen immediately at -20°C. On day of use PSS was defrosted at 37°C. 
NOl1hern blot buffers and solutions 
SOml Prelhybridisation buffer 
10ml 20x SSPE, Sml SOX Denhardt's, 2.5ml ssDNA (10mg/ml), SOOJiI yeast tRNA (25mg/ml), 500Jil 
10% SDS, 2Sml formamide, and 6.5ml DEPC-H20. 
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2806 Calmodulin 2 226.7 Protein kinase C, zeta 
2731 Calmodulin I 221.8 Guanine nucleotide binding protein 12 
2265 Dynamin I 203 .6 Mitogen activated protein kinase 3 (Mapk3) 
1745 Clathrin, heavy polypeptide 197.5 Adenylate cyclase 5 
1447 Guanine nucleotide binding protein, beta 2-like I (Gnb211) 188.2 Adenylate cyclase 6 
1277 Protein kinase, cAMP dependant regulatory, type I, alpha 162.6 Guanine nucleotide binding protein, alpha z (Gnaz) 
1235 Clathrin, light polypeptide 16\.2 Mitogen activated protein kinase kinase 5 (Map2k5) 
1071 Calmodulin 3 150.1 Regulator of G protein signalling 19 
1045 Guanine nucleotide binding protein, beta I (Gnb I) 141 Dynamin 3 
794 Mitogen activated protein kinase kinase I (Map2kl) 134.7 G protein-coupled receptor kinase 6 
794 Guanine nucleotide binding protein, gamma 10 (GnglO) 127.5 Phospholipase C, delta 4 
734.2 Protein kinase C, beta I 118 Regulator ofG protein signalling 2 
679. 1 Guanine nucleotide binding protein, alpha 12 (Gnal2) 116 MAP kinase-activated protein kinase 2 (Mapkapk2) 
616.4 Regulator ofG protein signalling 4 111.9 Protein kinase, cAMP-dependent, regulatory, type 2, alpha 
613 .2 Guanine nucleotide binding protein, beta 5 (Gnb5) 105.5 Arrestin, beta 2 
530.4 Calcium/calmodulin-dependent protein kinase II, delta 103.3 Protein kinase C, gamma 
494.5 Calcium/calmodulin-dependent protein kinase II , beta 102.2 Guanine nucleotide binding protein, alpha II (Gnall) 
471.8 Regulator of G protein signalling 2 102.2 Regulator ofG protein signalling 9 
454 Phospholipase A2, gamma 90. 1 Phospholipase D2 
430.3 Adenylate cyclase 2 81.02 Guanine nucleotide binding protein, beta 4 (Gnb4) 
406.6 Guanine nucleotide binding protein, beta 2 (Gnb2) 79.78 Regulator of G protein signalling 5 
400.8 Calcium/calmodulin-dependent protein kinase n, gamma 77.96 Mitogen activated protein kinase 12 (Mapkl2) 
396.7 Protein kinase C, lambda 75.9 Regulator ofG protein signalling 12 
387 Protein kinase C, epsilon 70.46 Guanine nucleotide binding protein, gamma II (Gngll) 
386.1 Mitogen activated protein kinase kinase 2 (Map2k2) 67.14 Phospholipase C, delta I 
382.4 Phospholipase C, gamma I 65 .22 Protein kinase C, delta 
381.3 Regulator ofG protein signalling 7 63.5 Calcium/calmodulin-dependent serine protein kinase 
367.8 Guanine nucleotide binding protein, alpha 0 (Gnao) 62.06 Phospholipase DI 
367.6 Phospholipase C, beta 4 60.54 Guanine nucleotide binding protein, gamma 12 (Gng 12) 
350.1 Mitogen activated protein kinase kinase kinase 12 (Map3kl2) 50.62 Guanine nucleotide binding protein, beta 3 (Gnb3) 
330.4 Regulator ofG protein signalling 17 41.7 Phospholipase A2, group IVA (cytosolic, calcium-dependent) 
307.8 Mitogen activated protein kinase 10 (MapklO) 41.4 Calcium/calmodulin-dependent protein kinase kinase 2,beta 
282.5 G protein-coupled receptor kinase 5 40.6 Phospholipase A2, group VI 
264.3 Regulator ofG protein signalling 10 38.24- - Regulator ofG protein signalling 14 
261.7 Mitogen activated protein kinase 6 (Mapk6) 34.06 Regulator ofG protein signalling 8 
257 .7 Calcium/calmodulin-dependent protein kinase II, alpha 32.08 Protein kinase C, eta 
251.6 Mitogen activated protein kinase 14 (MapkI4) 27.2 Protein kinase C, alpha 
235.3 Adenylate cyclase 3 23.24 Phospholipase C, epsilon I 
230.2 Mitogen activated protein kinase I (Mapk I) 21.38 Regulator of G protein signalling 3 
-Supplem entary Table 1. GPCR signal transduction components detected in tlte PVN by DNA microarrays Comparative levels (arbitary units) of genes listed as present in 
the PVN on AflYmetrix 230 2.0 rat genome chips as in [115]. The chips contain 31,099 individual probe sets covering about 30,000 transcripts encoded by 28,000 genes. Selected intracellular Signalling compone t 
transcripts on the DNA microarray were isolated using specific wildcard operator terms such as ' calmodulin ', ' protein kinase ', 'guanine nucleotide' , ' phospholipase ', 'G protein ' and ' adenylate cyclase ' . The list ~s 
not a comprehensive coverage of all signalling molecule transcripts in the PYN - many kinases and potential splice variants, for example, have not been included. Apart from differences in relative gene expressio 
levels, all genes in the PYN are present in the SON except RGSI4 (asterisk). Signalling molecule data sets such as those presented here can be searched in general gene/protein databases such as the Nation~ 
Center for Biotechnology Information (NCBI - http://www.ncbi .nlm.nih.govl) and the European Bioinformatics Institute (http://www.ebi.ac.u!0, and/or some specific online databases (e.g., http://www.afcs.orgl 
http://www.signaling-gateway.orgl; http://dip.doe-mbi .ucla.eduldiplMain.cgi) that provide resources for the analysis of core signalling components and signalling clusters, including the importance of individuai 
components such as calcium and cAMP. There are also a number of useful Web resources that deal with various aspects of cell signalling listed at http://www.cellsignal com/reference/webResources.html. 
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2652 Calmodulin 2 196.9 Adenylate cyclase 6 
2545 Calmodulin I 188.4 Adenylate cyclase 3 
1879 Clathrin, heavy polypeptide 187.6 Protein kinase C, zeta 
1779 Dynamin I 186.5 Mitogen activated protein kinase 3 (Mapk3) 
1759 Guanine nucleotide binding protein, beta 2-like I (Gnb211) 183.5 Regulator of G protein signalling 17 
1427 Protein kinase C, beta I 163.3 Dynamin 3 
1220 Clathrin, light polypeptide 145.4 MAP kinase-activated protein kinase 2 (Mapkap2) 
1164 Protein kinase, cAMP dependent regulatory, type I, alpha 138.1 Protein kinase C, delta 
922.6 Guanine nucleotide binding protein, beta I (Gnb I) 137.7 Mitogen activated protein kinase kinase 5 (Map2k5) 
832.3 Calmodulin 3 132.2 Phospholipase C, delta 4 
807 .9 Guanine nucleotide binding protein, gamma 10 (GngIO) 105.1 Regulator of G protein signalling 2 
77L1 Calcium/calmodulin-dependent protein kinase II, gamma 104.1 G protein- coupled receptor kinase 6 
767 .3 Guanine nucleotide binding protein, alpha 12 (GnaI2) 101.3 Regulator ofG protein signalling 5 
691.6 Mitogen activated protein kinase kinase I (Map2k I) 100.9 Guanine nucleotide binding protein, alpha II (Gnall) 
588 .5 Regulator of G protein signalling 4 98.74 Guanine nucleotide binding protein, alpha z (Gnaz) 
523 .5 Guanine nucleotide binding protein, gamma II (Gngll) 97.54 Regulator ofG protein signalling 9 
499.8 Guanine nucleotide binding protein, beta 5 (Gnb5) 97.28 Phospholipase 02 
488 .4 Calcium/calmodulin-dependent protein kinase II , delta 94.14 Guanine nucleotide binding protein, beta 4 (Gnb4) 
423 .6 Adenylate cyclase 2 93 .24 Calcium/calmodulin-dependent protein kinase II , alpha 
410.4 Phospholipase A2, gamma 91.5 Phospholipase 01 
386.1 Phospholipase C, gamma I 83 .12 Arrestin, beta 2 
382.7 Phospholipase C, beta 4 82.4 Regulator ofG protein signalling 12 
380.6 Protein kinase C, lambda 82.36 Guanine nucleotide binding protein, gamma 12 (GngI2) 
379.3 Guanine nucleotide binding protein, beta 2 (Gnb2) 82.18 Regulator ofG protein signalling 4 
364.9 Mitogen activated protein kinase kinase 2 (Map2k2) 79.5 Phospholipase C, delta I 
332.9 Regulator of G protein signalling 2 74.12 Mitogen activated protein kinase 12 (MapkI2) 
299.8 Calcium/calmodulin-dependent protein kinase II , beta 72.18 Phospholipase A2, group IVA (cytosolic, calcium-dependent) 
293 .8 Mitogen activated protein kinase kinase kinase 12 (Map3kI2) 64.34 Regulator ofG protein signalling 19 
290.5 Regulator of G protein signalling 7 61.42 Protein kinase C, gamma 
281.5 Guanine nucleotide binding protein, alpha 0 (Gnao) 60.08 Calcium/calmodulin-dependent serine protein kinase 
271 Regulator ofG protein signalling 10 58.16 Phospholipase C, delta 4 
267.5 Protein kinase C, epsilon 54.46 Guanine nucleotide binding protein, beta 3 (Gnb3) 
245 .1 Mitogen activated protein kinase 10 (MapkIO) 46.92 Protein kinase C, eta 
238 Guanine nucleotide binding protein, beta 12 (GnbI2) 44.9 Phospholipase A2, group VI 
224.3 G protein-coupled receptor kinase 5 40.36 Calcium/calmodulin-dependent protein kinase kinase 2, beta 
209.2 Mitogen activated protein kinase I (Mapkl) 34.64 Protein kinase C, alpha 
208.4 Mitogen activated protein kinase 14 (MapkI4) 30.72· • Adenylate cyclase 4 
202.8 Adenylate cyclase 5 29.6 Protein kinase, cAMP-dependent, regulatory, type 2, alpha 
199.3 Mitogen activated protein kinase 6 (Mapk6) 25 .68 Regulator ofG protein signalling 3 
Supplementary Table 2. GPCR signal transduction components detected in the SON by DNA microarrays 
Comparative levels (arbitary units) of genes listed as present in the SON on Affymetrix 230 2_0 rat genome chips as in [115]. The intracellular signalling component 
transcripts were isolated as in Tab[e 1_ All gene transcripts in the SON are present in the PVN except Adeny[ate cyclase 4 (asterisk). 
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5-Hydroxytryptamine 5-HTIA and S-HT2 (subtype unknown) PVN [28 1 ,8,181] 
" 5-HT7 PVN- [101] 
Acetylcholine muscarinic subtype unknown rVN and SON [153] 
Adrenoceptor UI I2 (subtype unknown) pPVN [56] 
" U2 (subtype unknown) PVN and ON [133] 
~2 SON [164] 
Angiotensin ATI PVN and SON [279] 
Apelin APJ PVN and SON G. Pope and A-M. O'Carroll 
unpublished data 
Bombesin BB2 PVN and SON [1 63] 
Calcitonin CT PVN [114] 
Cannabinoid CBI PVN and SON [III] 
Cholecystokinin CCKI and CCK2 PVN and SON-- [116] 
Corticotropin-releasing factor subtype unknown PVN [63] 
Endothelin subtype unknown PVN and SON [155] 
GABAB GABABI or subtype unknown PVN and SON [24] 
Galan in subtype unknown PVN and SON [35] 
Ghrelin Ghrelin PVN [104] 
Glucagon GLP-\ PVN [94] 
Histamine HI PVN and SON [184] 
H3 PVN and SON [249] 
Melanocortin subtype unknown PVN and SON [300,183] 
Neuropeptide FF/AF NPFFI PVN [96] 
Neuropeptide Y YI or unknown sUbtype PVN and SON [70,194] 
" Y2 PVN and SON [81] 
Y~ pPVN [81] 
Neurotensin subtype unknown PVN [226] 
Opioid K PVN and SON [20 1] 
NOP PVN and SON [223] 
Relaxin RXFP3 PVN and SON [296] 
Somatostatin subtype unknown pPVN and SON [176] 
Tachykinin NKI PVN and SON [258] 
" NK3 PVN and SON [258,72] 
VIP and PACAP VPAC I PVN and ON [311 ,205] 
subtype unknown SON [2081 
Supplementary Table 3. GPCRs detected ill the rat PVN and SON by receptor ARG 
For receptor ARG, typically 8-301lm sections from frozen adult male rat brain are incubated with eH]- or [1 251]_ 
labelled GPCR ligands (with/without enzyme inhibitors to reduce protelolytic degradation of radio labeled 
peptides), washed in cold buffer, and exposed to X-ray film for weeks-months depending on factors such as 
GPCR abundance, ligand specific activity and signal-noise ratios. pPVN, parvocellular region of the 
paraventricular nucleus; * receptor subtype discriminated by presence after displacement with other 5-HT 
ligands; ** receptors discriminated by displacement with CCK 1 or CCK2 ligands. 
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5-
Hydroxytryptamine 
5-HT1A ". ./ ./ - [339,327] - ./ - [327] 
5-HTIB iii ./ - - [198,262] ./ - - [198] 
5-HTIO -
-
- - - -
5-HTI< 
- - - - - -
5-HTIF - - - - - -
5-HT2A i ./ - - [339,337] - - -




- [110] - ./ - [22 1] 
5-HT. 
- - - - - -
5-HTs. - - - - - -
5-HT", 
5-HT6 
- - - - - -
5-HT7" - - ./ [115] - - ./ [1 151 
Acetylcholine 
(muscarinic) 
MI' - - - - - -
M2ill - - - - - -
MI' - - ./ [115] - - -
M. - - - - - -
Ms - - - - - -
Adenosine 
A 1111 ./ 
-
./ [179, 115] ./ - ./ [259. 115J 
A2A " ./ - - [263] ./ - - [263] 
AlB " - - ./ [115] - - ./ [115] 





- [68] - ./ - [68] 
aIB-adrenoceptor' ./ ./ ./ [321 ,59, 115] - - ./ [ 115] 
alD-adrenoceptof - ./ - [275] - - -
a 2A -adrenoceptor''' ./ - - [7] ./ - - [71 
a2s-adrenoceptor - - - - - -
a2c-adrenoceptor - - - - - -
~I-adrenoceptor - - - - - -
~2-adrenoceptor" - - - - - ./ [1 15] 
~)-adrenoceptor - - - - - -
Ana phyla tox in 
C3a 
-




C5L2 - - - - - -
Angiotensin 
ATIA I,ui ./ ./ ./ [248,319,279, 11 5] ./ - - [248] 
ATIB - - - - - -
AT2•JJ ./ - - [ 10] ./ - - [10] 
Apelin 
APJ·H ./ ./ 
- [2 16,233] ./ ./ - [302,233] 
Bile Acid 
GPBA 
- - - -
- -
Bombesin 
BBI - - - - - -
BB2' - ./ - [313] - ./ - [313] 
BB)' ./ 
-
- [130] ./ - - [130] 
Bra dykin in 









CT' ./ ./ ./ [22,280, I 15] ./ - ./ [22, 11 5] 
AMYl - - - - - -
AMY2 - - - - - -
AMY) 
- - - - - -
Calcitonin receptor-
- -
./ [1 15] - - ./ [11 5] 
like 
CGRP - - - - - -
AMI -
-
- - - -
AMl - - - - - -
Calcium-sensing 







GPRC6 - - - - - -
Cannabinoid 
CBI'" ./ ./ ./ [39,209, 115] - - ./ [ 11 5] 
CB2 - - - - - -
Supplementary Table 4. GPCRs in the para ventricular nucleus (PVN) and supraoptic nucleus 
(SON) of the rat hypothalamus: a summary of the literature (page 1 of 5). 
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Chemokine 
CCRI 
- - - - - -
CCR2m 
'" 
- - [15) 
'" 
- - [15) 
CCR3 
- - - - - -
CCR4 - - - - - -
CCR5 - - - - - -
CCR6 - - - - - -
CCR7 
- - - - - -
CCR8 - - - - - -
CCR9 - - - - - -





















- - - - - -






- - S.T. Yao et al., - - -
unpublished data 
XCRI - - - - - -
Cholecystokinin 
































- [320] - - -
0 3 -
'" 
- [30] - - -
0,,111 
'" 




























- - - -




Free fatty acid 
FFAI (GPR40) - - - - - -
FFA2 - - - - - -









[115] - - -
Fl03 - - - - - -
FlO. - - - - - -
FZOl - - - - - -
Fl06 - - - - - -
FZOg 
- -
- - - -
Fl09 - - - - - -
SMO 
- -
- - - -
GABAB 
GABA B, 
'" '" '" 
[203,257,24, 115] 




- [257,7 1] 






























GHRH - - - - - -
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FSH - - - - - -
LH - - - - - -
TSH - - - - - -
Gonadotrophin-
releasing hormone 
GnRH - - -
- - -
Histamine 
III ' - ,/ - [184] - ,/ - [1841 
Hz' - - - - - -
H 11II 
-
,/ ,/ [249, 115] - ,/ - [249] 
H. - - - - - -
Hydroxycarboxy1ic 
acid 
HCAI - - - - - -
HCAz - - - - - -
Kis peptin 
kisspeptin - - - - - -
Leukotriene 
BLTI - - - - - -
BLTz - - - - - -
CysLTI - - - - - -
CysLTz - - - - - -
FPR2/ALX - - - - - -
Lysophospholipid 
LPA I'·111 - - ../ [115] - - ,/ [ 115] 
LPAz - - - - - -
LPA, 






,/ [115] - - ../ [115] 
SIPz - - - - - -
SIP) - - - - - -
SIP. - - - - - -




MCHIlii.iii ../ ../ 




- - - -
MCz - - - - - -
MC) 
- -
- - - -
MCl' - ,/ - [151] - ../ - (151] 





MTz - - - - - -
Metabotropic 
glutamate 
mG1uI ' ,/ ,/ ,/ [154,284,115] ,/ ,/ ../ [154,284,6,115] 
mGluz - - - - - -
mGlu, '" 
-




,/ [115] - - ../ [ 115] 
mG1us' ../ ../ - [74] - - -
mGllI6 - - - - - -
mG1ui " ,/ ,/ ../ [149, 150, 115] ,/ ../ ../ [149,150,115] 
mG1ushi - - ../ [115] - - -
Motilin 
motilini - - - - - -
Neuromedin 
NMU1 - - - - - -
NMU2' - ../ - [98] - ,/ - [981 
Neuropeptide 
FF/Neuropeptide AF 
NPFF1'" - ../ - [185] - - -
NPFF2 - - - - - -
Neuropeptide S 
NPSi,u ../ ../ 













Vi"i ,/ ,/ 




- [323] - ,/ - [323] 






y j lll ,/ ,/ ,/ [323,245,81 , 115] ,/ ,/ ../ [245,81 ,1151 
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Neuroten in 
TSi - ,/ - (3) ,/ ,/ - [3,75) 





- [200] - ,/ - [200] 
1(111 ,/ ,/ ,/ [11 ,88,115] ,/ ,/ ,/ [11 ,88,115] 
Il'" ,/ ,/ - [200,199) ,/ ,/ - [88,199] 
NOP'" 
-
,/ ,/ [223, 115] - ,/ ,/ [223 ,115] 
Orexin 
OX!""' ,/ - - [113] ,/ ,/ - [ 113,202] 
OXl ' ,/ ,/ ,/ [113,50,303,115] ,/ ,/ - [50,202] 
P2Y 
P2Y I ' ,/ - - [289] ,/ - - [289] 
PlY2 - - - - - -
P2Y. - - - - - -
P2Y6 - - - - - -
P2Y12"' - - - - - ,/ [115] 
P2Y IlIII - - ,/ [ 115] - - ,/ [115] 
P2Y I • - - - - - -
Parathyroid hormone 
PTHI" - ,/ ,/ [318,115] - ,/ ,/ [3 18, 115] 
PTH2" ,/ ,/ - [314] ,/ - - [314] 
Peptide PSI8 
QRFP I '.111 
-
,/ 
- [841 - - -





- - - -
Prokineticin 










- [261] - - -
Prostanoid 
DP I - - - - - -
DP2 - - - - - -
EP I ; ,/ ,/ - [212,236] - - -
EP2 - - - - - -
EP)ii' ,/ 
- -




- [236,340] - ,/ - [340] 
FP 
-
- - - - -
!PI - - - - - -





,/ [115] - - ,/ [115] 
PAR2 - - - - - -
PAR3 - - - - - -






- (195) - ,/ - [195] 




- [296] - ,/ - [296] 
Somato tatin 
ssti" ,/ ,/ - [160,2 1) - - ,/ (11 5] 
sst 2"' ,/ ,/ ,/ [160,21,115] - - -
sst , 111 ,/ 
-
,/ [160,115] - - ,/ (11 5] 







,/ ,/ [197,115] - - ,/ (11 5] 
NK2 - - - - - -
NK,' ,/ ,/ - [67,102,72] ,/ ,/ ,/ [67,102,72, 11 5] 
Thyrotropin-
releasing hormone 
TRH, ' - ,/ ,/ [234,11 5] - - ,/ [115] 
TRH2' - ,/ - (234) - - -
Trace amine 
TA l ii - - - - - -
Urotensin 
tIT - ,/ - [129] - ,/ - [129] 
VIP and PAC P 
PAC," ,/ ,/ 
-
[136,229) ,/ ,/ - [136,229) 
VPAC," ,/ 
- -
[136] ,/ - - [136] 
VPAC2" ,/ ,/ 
-
[136,1921 ,/ ,/ - rt36,192] 
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Vasopressin and 
oxytocin 
VIA' ".. ".. 
-
[122,121] ".. ".. - [122,121] 
VIB' ".. ".. - [122,121] ".. ".. - [1 22,121] 
V2 - - - - - -
OT' ".. ".. - [204,2 141 ".. ".. - [204,2 141 
Supplementary Table 4. GPCRs in tlte para ventricular nucleus (PVN) and supraoptic nucleus 
(SON) of the rat hypothalamus: a summary of the literature 
Detection of GPCR expression by immunohistochemistry (IHC), in situ hybridisation histochemistry (ISHH) 
and DNA microarrays (arrays). Receptor nomenclature is based on the official family receptor names given in 
the on-line IUPHAR Database of Receptors and Ion Channels (www.iuphar-db.orgl) excluding chemosensory 
GPCRs (e.g., olfactory, vomeronasal and taste receptors), and only includes receptors known to be in the rat 
genome. For some GPCR sub-families, e.g., calcitonin, pharmacological responses are dictated by additional 
proteins (e.g., RAMPS: receptor activity-modifying proteins), whereas in others e.g. , GABAB, 
heterodimerization of two GPCR subunits is required for a functional response. In some instances only 
functional GPCRs have been documented (see Supplementary Table 9) - examples of these include responses to 
anaphylatoxins (C5a), formyl peptides, kisspetin, leukotrienes, platelet-activating factor and trace amines in the 
PVN, and responses to melatonin and motilin in both the PVN and SON. For the GPCRs expressed (or where 
functional responses of known or unknown subtypes are indicated), the major Ga protein involved in signal 
transduction (as per www.iuphar-db.orgl) is provided: i, coupled to the Gq/l l: downstream signal increases 
intracellular Ca2+ and stimulates phosphatidyl inositol phosphorylation (also activates phospholipase C, and 
sometimes phospholipase A2 and D); ii, coupled to Gs: downstream signal increases cAMP; iii, coupled to Gi/o: 
downstream signal decreases cAMP. (,() indicates the presence of either receptor mRNA or protein in the PVN 
or SON, and (-) denotes either an absence ofmRNA or protein in the PVN or SON, or a localisation study for 
that GPCR has not been undertaken or reported to our knowledge. Known or possible splice variants for the rat 
GPCRs have not been indicated but for some GPCRs (e.g., metabotropic glutamate mGlul receptors [228]) 
splice variants have been detected in the PVN and SON. 
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GABAB, * ( I 
1,197 NTS2 neurotensinSON 79.05 GPRI23soN 
1,046 GABAB,. (Ij)SON 77.38 FZD2 frizzled 
900 ETB endothelin SON 76.42 CXCR7soN 
853 S,P, lysophospholipidsoN 75.98 NK, tachykininSON 
830.6 GABAB2soN 71.42 GABAB,· (Ia) 
703.1 GPR37-likel soN 69.52 OX2orexin 
596.2 GPRC5b*so 68.82 CK, cholecystokinin 
504.3 GPRC5b*SON 62.44 GPRI4IJ"DN 
428.2 GPR56soN 61.88 GPR34soN 
390.9 CB, cannabinoidsoN 60.14 M3 muscarinic 
378.8 mGlu, metabotropic glutamateSON 60.08 T2 somatostatin 
375.5 GPR3fiON 59.86 5-HT7 serotoninSON 
362.8 GPR15sSON 58.26 FZD, frizzledsoN 
355.8 GPRI6~ 58.06 AT, angiotensin II 
351 .3 PAR I protease-activated SON 53.94 SST, omatostatin ON 
286.2 CT calcitoninsoN 50.62 GAL2 galanin* 
228.7 LPA, lysophospholipidsoN 49.44 mGlu. metabotropic glutamateSON 
190.6 GPR4sSON 49.38 Y, neuropeptide ySON 
179.3 H, histamine 42.74 CXCR4 chemokineoSON 
156.5 GPR123soN 40.7 GPRIJ6·SON 
152.3 GPR9sSON 40.62 mGlus metabotro~c glutamate* 
148.8 TRH, thyrotrophin releasing facto~N 39.96 P2YS N 
136.9 GPR8SSON 36.94 GPRI25 
129.6 Calcitonin receptor-likesoN 34.58 GAL2 galanin* 
128.8 K opioid*so 33.78 GPR8sSON 
121.7 mGlu3 metabotropic glutamateSON 33.08 GPR6lsoN 
120.6 GPRI16*SON 31 .38 P2 y " purinergicSON 
114.2 GPRI08soN 31.02 CXCR4 chemokine*SON 
11 3.5 GPRI76soN 30.7 PTlI , parathyroid hormone. SON 
111 .8 GPR6sS0N 29.34 K opioid*SON 
109.1 NOP nociceptin·SON 28.36 ETA endothelin·so 
104.5 SST, somatostatinSON 27.42 GPRIS3soN 
104.3 GPR146soN 26.66 ETA endothelin·soN 
102.9 GPRIIJ"DN 25.66 mGlu7 metabotropic glutamateSON 
102.8 GPRlOfiON 23 .82 PTH, parathyroid homlone·SON 
85.54 mGlus metabotropic glutamate· 20.36 NOP nociceptin·SON 
85.24 A2B adenosine 17.82 A, adenosine 
83.78 A, adenosineSON 15.96 CXCR3 chemokineSON 
82.24 
Supplementary Table 5. GPCRs noted as present in rat PVN arrays 
Comparative levels (arbitary units) of GPCR genes listed as present in the PVN on Affymetrix 230 2.0 rat 
genome chips as in [115] . Lists of genes that are represented on the Affymetrix array were isolated using the 
wildcard operator terms ' receptor', 'GPCR', 'GPR' and 'G protein-coupled receptor' and hand-finished. The 
Tas I r2 (taste R, type I) and Vom2r44 vomeronasal 2 receptors were also detected in the PVN (expression levels 
of 175 and 18.72, respectively) . The pharmacological specificity of the family of calcitonin (CT) receptors and 
calcitonin receptor-like receptors are dictated by additional proteins known as receptor activity-modifying 
proteins (RAMPs). These are integral parts of the receptor complex and were detected in the PVN (expression 
levels of 333 .2 and 324 for Ramp I and Ramp2, respectively). GPCRs also found in the SON (superscript) are 
indicated. GPRI07 and GPRI08 appear to have a 7TM structure but show little homology to other GPCRs. 
Orphan GPCRs are in bold italics. For comparison, OT, VP, p-actin, TRH and CRF were detected at expression 
levels of 4,090, 3,531 , 280 1, 614.7 and 282, respectively. * denotes GPCRs with possible spliced transcripts. 
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1,312 NTS2 neurotensin 70.88 A, adenosine 
1,096 ET B endothelin 70.24 CXCR4 chemokine* 
1,006 GABAB'· (I f) 68.3 P1Y5 
857.5 GABAB,* (Ij) 67.94 a'B adrenoceptor 
750.1 S,P, Iysophospholipid 61.3 GPR149 
734.9 GPR37-1ike I 60.96 FZD, frizzled 
574.5 GPRC5b 59.86 NK, tachykinin 
521.3 LPA,lysophospholipid* 59.24 ETA endothelin* 
499.2 GABAB2 56.22 GPR34 
351 mGlul metabotropic glutamate 56.1 SST, somatostatin 
337.8 PAR I protease-activated 55.26 GPR1I6* 
331.4 GPR37 54.58 STl somatostatin 
308.5 GPRI58 53 .72 XCR4 chemokine* 
285 .6 CB , cannabinoid 51.7 GPR88 
249.4 GPR56 51.14 PTH , parathyroid homlOne 
246.2 GPRI62 47.82 GPR83 
191.3 GPRII6* 42.92 GPR84 
168 GPR48 41.26 GPR126 
165.3 Calcitonin receptor-like 40.52 P2Y 12 purinergic 
159.2 mGlul metabotropic glutamate 37.54 5-HT7 serotonin 
147.9 GPRI07 34.72 GPRI82 
145.8 GPR123* 33.4 GPR61 
136.3 CXCR7 30.62 GABA BI " (Ig) 
129.3 GPR85 30.22 CXCR4 chemokine* 
126 GPR108 29.92 mGlu. metabotropic glutamate 
122.7 GPR123* 29.68 GPRl16" 
118.4 GPRI76 28.82 ETA endothelin* 
117.1 GPRJ9 27.34 PTH , parathyroid hormone" 
114.7 GPR98 26.64 P2Y 11 purinergic 
113.8 GPR146 25.76 1C opioid* 
104.3 A2B adenosine 21.76 Ys neuropeptide Y 
97.52 1C opioid* 20.18 GPR153 
94.66 CT calcitonin 19.78 mGlu7 metabotropic glutamate 
94.36 GPR68 19.22 LPA, Iysophospholipid* 
89.88 TRH, thyrotrophin releasing factor 19.22 GPR16 
74.46 NK, tachykinin 18.32 CXCR3 chemokine 
72.92 NOP nocicejJlin 15.88 P2 adrcnoceptor 
Supplementary Table 6. GPCRs noted as present in rat SON arrays 
Comparative levels (arbitary units) of GPCR genes listed as present in the SON on Affymetrix 230 2.0 rat 
genome chips as in [115]. The GPCR transcripts were isolated as in Supplementary Table 5. Tas 1 r2 (taste R, 
type I) and olfactory receptor Olr414 were also detected at expression levels of 188.2 and 29.4, respectively. 
Ramps 1 and 2 were detected at expression levels of 358.7 and 388.5, respectively. GPRI07 and GPRI08 
appear to have a 7TM structure but show little homology to other GPCRs. Orphan GPCRs are in bold italics. 
For comparison, VP, OT and p-actin were detected at expression levels of 4,996,4,588 and 3014, respectively. 
* denotes GPCRs with possible spliced transcripts. 
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v" ' (PV " -SON) 
v"'(PVNISON) 
v"'(PVNISON) 
Supplementary Table 7, Orpltan GPCRs in tlte rat PVN & SON 





see figure 1 
[165] 
see figure 1 
see figure I 
see figure 1 
There are 30 orphan GPCR genes expressed in the PVN and/or SON with 26 common to each nuclei. 
Expression was detected by DNA microarray profiling [115] with the exception of GPR I 0 I ('I'). Orphan GPCR 
expression has been con finned by ISHH in this study (*) or previously published work. x = present in 
periventricular PVN, and not detected in pPVN, mPYN or SON by ISHH. (-) denotes that orphan GPCR mRNA 
has not been reported present in the PYN/SON as assayed by ISHH to our knowledge. There are some 
interesting features of a number of these orphans, e.g., G PR84 is proposed to be a free fatty acid receptor in one 
study [124] and GPRI26 appears to be preferentially expressed in glia [156,276] . GPRI07 and GPRI08 appear 
to have a 7TM structure but show little homology to other GPCRs. Orphan GPCR mRNA is clearly expressed in 
the mouse PVN and/or SON in some instances, e.g. , GPR88, 98, 116, 123, 162, 165 and 176 - see Allen Brain 
Atlas; htto://www.brain-map.org/. GPRI 0 I and GPR 165 are not represented by probe sets on the Affymetix 230 
2.0 rat genome chip u ed to derive this list [115]. Potential orphan GPCR splice variants are not included in the 
table. 
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Daily ip injections of paroxetine, 
5-HT'A a 5-HT uptake inhibitor (1-14 No effect on S-HT IA expression (ARG in PVN) [181] 
days). 
5-HT 'B Gastric bypass on obese male 1 39% (ir in PVN) [262] 
rats ( 10 days) . 
Daily ip injections of (-)-1-(2,5- ! - 50% (ARG in PVN); i 167% (4 days) or i 191% (7 dimethoxy-4-iodophenyl)-2-5-HT2A aminopropane HCI (DOl; 4 or 7 days) (Westerns on PVN tissue); no effect on mRNA (q- [281] 
day treatment). PCR on PVN mRNA). 
a ,- and a2- Salt loading (10 days) or alt loading! in a, (43%) and a2 (50%), while 
adrenoceptors adrenalectomy (sacrificed after adrenalectomy ! (45 %) U2 but has no effect on a, (ARG in [56] 14 days). PVN) 
Adrenalectomy (sacrificed 1, 3, i mRNA 7 (173%·) or 14 (193%·) days following 
a'B -adrenoceptor 7 or 14 days), some received sc adrenalectomy; 10 mg CORT prevented adrenalectomy- [59] 
CORT pellets (sc for 7 days). induced i in mRNA, and 50 mg further! (42%·) mRNA 
expression (ISHH in PVN). • compared to sham controls. 
24 hour isolation stress or sc 
Angiotensin AT, infusion of candesartan, a non- Isolation stress i (- 2-fold) receptor binding, an effect [10] 
competitive AT, receptor inhibited by candesartan pretreatment (ARG in PVN). 
antagonist, for 14 days. 
2 week sc administration of i mRNA (- 10%) and protein (40-60%) (ISHH and ARG in PDI23319 aAT2 [196] 
receptor antagonist. PVN). 
4 week sc infusion of Angiotensin 111 (- 1.5-2-fold) mRNA and protein (- 1.5-2-
Angiotensin II (with or without fold), an effect blocked by losartan, the p44/42 MAPK 
concomitant 4 week icv inhibitor PD-98059, and the JNK inhibitor P-600 125, but [319] infu ions ofMAPK inhibitors or 
losartan (AT I receptor not p38 MAPK inhibitor SB-203580 (q-PCR, and Westerns 
antagonist)) . on PVN tissue). 
- 20% ! mRNA and protein following adrenalectomy 
(reversed with CORT or dexamethasone); - 20% i mRNA 
Adrenalectomy, CORT (in and protein following dexamethasone injection in intact 
drinking water), dexamethasone rats ; immobilization stress 1 mR A (49-66%) and protein (- 30%) in intact animals; ip salt injection, water deprivation [I] injection (SC), and various stress 
and salt loading also i mRNA and protein in intact animals; paradigms. 
stress! (30"10) mRNA in adrenalectomized animals (a stres 
induced CORT surge is required to i mRNA)(ISHH and 
ARG in PVN). 
Coronary artery ligation-induced AT I protein 1 in PVN (Western blots of dissected PVN) [142] heart failure 
Pharmacological model of acute Furosemide induces a rapid and long-lasting i (estimated 
Na+ depletion (furosemide - 3-4-fold) in pPVN AT'A mRNA (ISHH) and angiotensin [42] 
injections). \I binding sites (ARG). 
Acute/chronic restraint i mRNA (1 240% acute, 195% 
chronic) in pPVN of intact rats ; adrenalectomy i mRNA in 
Apelin APJ Acute/chronic restraint stress pPVN (by 301%); re traint in adrenalectomized rats could [231] 
and/or adrenalectomy. not 1 mRNA above that of adrenalectomized controls in 
pPVN; stress had no cffect on mRNA in mPVN although 
adrenalectomy 1 111% mRNA (lSI III in PVN). 
Salt-loading and dehydration 1 APJ mRNA (salt loading 1 
mRNA by 101% in mPVN, 75% in SON; dehydration i 
24-48 hour salt-loading (2% mRNA by 874% in mPVN, 455% in SON); salt-loading i 
NaCI in drinking water) or colocalisation of APJ mRNA in VP mRNA- containing [232] 
dehydration. neurons (by - 12%) within SON but not mPVN, dehydration 
had no effect on colocalisation in either mPVN or ON 
(ISHH). 
Chronic treatment (15 days) with 
Cannabinoid CB, SR 141716A(ip)aselective CB, 1 10 % (ARG in PYN) [39J 
receptor antagonist 
Chemokine CXCR4 Long Evans and Brattleboro ir-CXCR4! 60% in the PVN/ ON of Brattleboro rats, when [37] (VP-deficient) rats compared to Long Evans control rats. 
S.T. Yao el 
Chemokine CX,CRI Induced chronic heart failure i - 34 % in pPVN and - 28% in mPVN (ir in PVN) 0/., 
unpubli hed 
data 
Cholecystokinin Large i (- 8-1 O-fold) CCK2 mRNA and protein in PVN and 
alt-Ioading (various durations) SON; smaller i CCK, mRNA (PVN i - 169%; SON 1 [116,217] CCK, and CCK2 
- 355%)/ protein (PVN 126%; SON i 50%)(ISHHlARG). 
Supplementary Table 8. Examples of GPCR regulation in tlte PVN/SON 
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Immobilization stress, 
dehydration, salt-loading (2% 
aCI in drinking water for 12 
days), adrenalectomy. 
Leptin infusions into third 
ventricle (5 days) and/or running 
stress (60 min) 
0.1 ~g CRF microinjection into 
the PVN. 
Restraint stress (60 min) on 
virgin, pregnant or lactating 
female rats 
4 day salt-loading (2% aCI in 
drinking water), dehydration and 
food-deprivation . 
48 hour fasting. 
Female virgin v pregnant or 
lactating rats 
tage 5 amygdala kindling 
(induction of seizures) 
Salt-loading (2% NaCI in 
drinking water for 24-72 hours) 
or dehydration (48 hours) 
Comparison of young (8-10 
months), presenescent (27-30 
months) vs. senescent (27-33 
months) Fischer rats 
iv LPSflL-1 p, icv PGEl (SOOng), 
im injection of 
turpentine. 
Salt-loading (2% NaCI in 
drinking water for 5 days) 
I week of reduced or high water 
intake. 
Female virgin vs pregnant or 
ovariectomised (with 
progesterone or E2 replacement) 
rats. 
r (50-76%) mRNA in PVN following acute and chronic 
immobilization stress; dehydration (24 or 60 hours) and salt-
loading r mRNA in PVN and SON; transient r mRNA (4-5-
fold) in PVN 18 hours after adrenalectomy in PVN but no 1 
following long-term adrenalectomy (4-6 days)( ISHH ). 
Running stress i mRNA in PVN (1--4-5-fold) and SON (i 
--4-5-fold), an effect blunted by leptin (lSHH). 
1 (- 3-fold) mRNA (lSHH in PVN). 
CRFI mRNA 1 in PVN in response to restraint; restraint 
response is augmented (estimated - 1.2-fold) in lactation 
when compared with parturition (lSHH). 
Salt-loading and dehydration 1 GALl I11RNA in mainly 
mPVN and SON (e.g., ON mRNA: 1 - 143% in salt-
loading, and i - 180% in dehydration)(ISHH» and 1 total 
GAL-binding si tes (e.g., ON protein 1 - 120-130% in salt-
loading and water deprivation (ARG); food deprivation ! 
GALl mRNA (- 30-45%)(ISHH) but not protein (ARG) in 
the SON. GALl 111 RNA express ion in pPVN or SON did not 
change following salt-loading, dehydration or food 
deprivation (I HH). 
No effect on receptor protein (ARG in PVN) 
i mRNA at the end of gestation 0 - 75%) and during 
lactation (1 - 125%) in SON and throughout lactation in 
pPVN 0 - 200%) (I HI I). 
i I11GluR I and mGluR3 mRNA (28-61 %), but only i 
I11GluRI protein (i - 30%)(ISHH and ir in SON). 
- 2-fold 1 number ofir-Y I positive cells protein in SON 
following salt-loading or dehydration (IH ); - 2-3-fold 1 in 
Y I mRNA in SO after salt-loading (ISH H). 
Y I and Y, mRNA - 2-4-fold higher in young versus older 
animals; no difference in YI and Y, mRNA between 
presenescent and senses cent (q-PCR in PVN), although 
number ofir-YI-expressing PVN neurons i in presenescent 
compared with young and senescent rats . 
- 2-fold 1 EP, mRNA in pPVN following LP ; IL- IP i EP, 
mRNA in pPVN (but not ON) --4-6-fold ; PGEl 1 pPVN 
EP, mRNA - 2-3-fold; turpentine 1 EP, I11RNA - 2-4-fold in 
pPVN (I HH). 
1 protein (ir in SON) 
High water intake! (59%), while reduced water intake i 
(26%) mRNA (I HI-I in the SO ). Reduced water intake 
significantly 1 (35%) protein levels (i r in the ON). 
OTR mRNA expression i - 1.5 fold in ON (but not PVN) 
at parturition (ISHH); OTR binding i mid-late gestation in 
the PVN/SON (0.5-2.5 fold) ; E2 (but not progesterone) i 
binding in SON (but not PVN) - 2-2.5 fold in 















Supplementary Table 8. Examples of GPCR regulation in the PVN and SON 
* Change in GPCR protein (ARG), immunoreactivity (ir/Western), or mRNA (ISHHIRT-PCRlquantitative (q)-
PCR). All studies were performed on male rats unless otherwise stated. icv, intracerebroventricular injection; 
im, intramuscular; ip, intraperitoneal injection; iv, intravenous injection; mPYN, magnocellular PVN; pPVN, 
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5-HT'A inhibits water intake; .J.. GABA synaptic transmission in presympathetic PYN neurons; and i plasma OT and ACTH 
levels. The 5-HTlA/2Creceptor agonist, DOl «±)1-(2,5-dimethoxy-4-iodophenyl)-2 aminopropane), t c-Fos in PYNneurons 
and plasma OT, prolactin, ACTH and CORT levels. Administration (sc) of 5-HT'A agonist t expression of phosphorylated 
ERKs in the PVN. 
lntra-PVN injection of the muscarinic receptor antagonist, or nicotinic receptor antagonist, blocks saline-stimulated t in plasma 
VP levels . Icv administration of carbachol (muscarinic and nicotinic rcceptor agonist) stimulates VP release. Muscarine 
(muscarinic receptor agonist) t the frequency of phasic bursts by VP neurons in the ON in vitro. Iv muscarinic agonist 
arecoline stimulates ACTH and CORT release in vivo, and arecoline t CRF secretion in hypothalamic cells in vitro (blocked by 
atropine). Cholinergic stimulation ofPVN..!. body temperature and t water intake, whereas cholinergic stimulation of ON t 
body temperature (blocked by muscarinic antagonist). 
Application of the selective adenosine A2A receptor agonist depolarizes SON neurons. Adenosine inhibits SON neurons via 
presynaptic AI receptors. Activation of A I i firing activity and hyperpolarizes PVN presympathetic neurons . 
a r adrenoceptor agonist (ip) t c-Fos expression in OT but not VP neurons. a,-adrenoceptoragonist (icv) t CRF mRNA in PVN 
and plasma ACTH release. Noradrenaline excites both phasic and non-phasic firing SON neurons (putative VP and OT cell s, 
respectively). oradrenaline microinjected into the PVN t pain threshold via local a-adrenoceptors and NM DA receptors. 
Noradrenaline t frequency of spontaneous glutamatergic excitatory postsynaptic currents (EPSCs) in PVN and SON 
magnocellular neurons via presynaptic a,-adrenoceptors > a 2-adrenoceptors. Hypoxia t noradrenaline and CRF release in the 
PVN and median eminence: Hypoxia-stimulated release ofCRF from median eminence is blocked by a,-adrenoceptor 
antagonist but facilitated by a 2-adrenoceptor antagonist. a,-adrenoceptor agonist t the firing rate of spinally projecting PYN 
neurons (but not in the presence ofGABAA or ionotropic glutamate receptor antagonists), and also t the frequency of 
spontaneous EPSCs and .l. the frequency of spontaneous inhibitory postsynaptic currents ( IPSCs). Icv noradrenaline augments 
TRH release from the PVN and median eminence in re ponse to acute hypoxia, via a 2-adrenoceptors. a2-adrenoceptor agonist i 
the amplitude of evoked GABAergic IP Cs and..!. the frequency ofGABAerglc miniature IP Cs (blocked bya2-adrenoceptor 
antagonist) in spinally-projecting PVN neurons. VP release from HNS explants t following exposure to a a,-adrenoceptor 
agonist, while simultaneous exposure to A TP and a,-adrenoceptor agonist induces a synergistic stimulation of sustained VP and 
OT release, through activation of multiple ai-subtypes (aI A.B.O). Stimulations of a,-adrenoceptors t intracellular Ca2+ in isolated 
ON explants . lImulation ofal /a2 receptors modulate spontaneous IP Cs in mPVN and pPVN neurons: a 2A i spontaneous 
IPSCs whereas a, (subtype unknown) t spontaneous IP s. 
Ip administration of a C5a antagonist..!. LP -induced c-Fos in CRF neurons. 
Angiotensin 11 (ATII) activates the intracellular MAPK and JNK signalling pathways in PVN neurons via AT,. ATII stimulates 
VP, OT, ACTH secretion (some effects may be indirect via SFO). Activation of central AT, receptors is necessary to mount a 
full HPA axis response to isolation stress: subcutaneous infusion of an AT, antagonist inhibits isolated stress mediatcd t in 
pitUitary ACTH and adrenal CORT content, an effective glucocorticoid feedback inhibition (a i in PVN CRF mRNA and 
protein), and an t in AT, binding (ARG) in pPVN. All excites SON OT and VP neurons in ex vil'o preparations. All 
microlnJected Into the PYN t blood pressure, which is blocked by systemic administration of an ATI receptor antagonist. All 
depolarizes mPV neurons and t frequency of EPSCs/excitatory postsynaptic potentials via glutamate release. All depolarizes 
and t frequency of action potential discharge of PVN neurons that innervate In the rostral ventrolateral medulla Via AT, . All 
intra-PVN t renal sympathetic nerve activity responses to electrical stimulation: blocked by intra-PVN AT, antagonist. AT, 
antisense oligonucleotides into PVN .l. resting renal sympathetic nerve activity and normalizes enhanced cardiac sympathetic 
afferent reflex in males rats with chronic heart failure. All t intracellular a2+ in ON neurons. 
Apelin depolarizes and t axonal action potential firing in VP (but not OT) SON neurons, while"!' somatodendritic VP release. 
APJ KO mouse studies suggest apelin stimulates HPA axis activity via both CRF, and VP VIB receptors. 
lev (but not iv) gastrin-releasing peptide (BB2 agonist) t 5-HT in PVN and plasma A TH and CORT levels. Gastrin-releasing 
peptide also t CRF release from isolated hypothalamI. 
Bradykinin regulates release of noradrenaline from rat hypothalamic slices. 
Icv adrenomedullin-5 t c-Fos mRNA in PVN & SON OT neurons and t plasma OT levels through central GRP or AM 
receptors. Adrenomedullin excites OT but not VP neurons in SON. ICV adrenomeduilln 2 and adrenomedullin t plasma OT 
levels (adrenomeduJlin 2 > adrenomedullin). 
Endocannabinoids mediate fast-feedback action of glucocorticoids on PVN CRF release; presynaptic action mediates -MSH-
induced inhibition of OT cells . Endocannabinoids released from ON magnoceJlular soma/dendrites .l. glutamate release and 
postsynaptic spiking. 
Chemokine stromal cell derived factor I SDF-I /CXCL 12 (activates CXCR4) icv blocks plasma VP relcase induced by ,cv 
angiotensin or ip injection ofNaCl , but has no effect on basal plasma VP levels . Electrophysiologlcal recordings demonstrate 
that endogenous SDF-I has no effect on basal plasma VP levels (basal activity not inhibited by a CXCR4 antagonist), though 
administration ofSDF-1 can blunt the autoregulation ofVP neurons 
CCK tOT neuronal activity and OT release, and i VP neuronal activity and VP release. 
tress induces CRF, expression in pPVN and ON. Urocortin I (binds RF2 With higher affinity than CRF,) Injected Into the 
SO alters behaviour In open-field test (blocked by CRF2 antagonists). CRF injection into PVN t RF, mRNA expressIOn in 
pPVN (blocked by CRF antagonist). CRF t CRF I mRNA levels in primary hypothalamiC neuron cultures. CRF ICV i plasma 
OT, with no effect on plasma VP levels Urocortin 2 and 3 (CRF2 agonists) mto lateral ventricle t RF and VP hnRNA in 
pPYN and plasma CORT levels ; effect attenuated by CRF2 antagonist. Urocortln 3 into PVN t blood pressure, heart rate and 
renal sympathetic nerve activity (blocked by CRF2 antagonist) CRF (icv) i c-Fos and RF mRNA in the pPVN, an effect 
blocked by a CRF, antagonist. CRF, antagonist Intra-PVN potentiates the feeding Induced by Intra-PVN PY ( RF systems In 
the PVN exert Inhibitory control over NPY-induced food intake) 
Dopamine acts mainly on D2 and D. to tOT-stimulated penile erection. Dopamine i magnocellular neuron excitability: 
activation ofD. i the frequency of miniature IPSCs; D. activation reduces GABA release in ON - dopamine facilitation of 
neurohypophysial hormone release partly results from distribution of magnocellular neurons; presynaptic D. activation Inhibits 
glutamate neurotransmission onto SON magnocellular neurons (N.B. when deviating from base line a tivity the modification of 
both glutamatergic and GABAergic input is essential to allow for phasic or spontaneous firing ofVP or OT neurons, 
respectively). Dopamine D2 activation t TRH release. D. receptor activation t ERK phosphorylation and c-Fos expression in 
the PVN. 
ETA agoDists t , while ET B agonists i basal VP release. 
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E2 E2 .j. 5-HT-stimulated ACTH release via GPER, independent ofER~. ER amplifies the naloxone-induced t in OT neuron firing [330,266,32] 
rate in morphine-dependent female rats. 
Formylpeptide Formylpeptide works concomitantly with annexin to .j, VP and CRF release. [135] 
GABAs Activation ofGABAa.j, the frequency of spontaneous and miniature [PSCs in pPVN. [187] 
Galanin .j, evoked EPSCs and .j, eEPSC frequency in VP/OT neurons. Administration of galanin (icv) .j, hypothalamic and 
Galanin neurohypophys ial OT, but has no effect on plasma OT or VP levels in euhydrated rats; icv ga lanin in salt-loaded rats t VP and [159,49,162] OT levels within the hypothalamus and neural lobe and .j, plasma VP and OT levels. Intra·PVN microinjection of galanin t 
food intake. 
Ghrelin injected into PVN t food intake (inhibited by MC. agonists). lev and iv administration of ghrelin t VP plasma levels. 
Knockdown ofGhsrla in the PVN .j, body weight and plasma ghrelin levels. Ghrelin icv t c-Fos in magnocellular and [285,128,28 
Ghrelin parvocellular PVN OT neurons. Ghrelin (via Ghsrl a) potentiates miniature EPSCs in approximately 80% of SON 6,239,335,1 
magnocellular neurons tested. Ghrelin (IOOnM) t CRF and VP mRNA levels 2-3 fold (maximum response at 6 hours) in 39] 
hypothalamic 46 cell line. 
Glucagon Secretin t VP release from hypothalamus. Icv glucagon-like peptide-I-(7-36)amide (GLP-I) t VP (though nol OT) and CORT [47,167] 
release, and t c-Fos expression mainly in CRF neurons of the pPVN and OT neurons of the mPVN/SON. 
Histamine t PVN and plasma OT levels and modulates OT neuronal activity in the SON via Hl receptors . In HNS explants [18,107,287, Histamine histamine depolarizes VP neurons via HI receptors. Histamine Hl receptor activation t TRH release from hypothalamic slices. 
Histamine HI and H2 antagonists prevents suckling-induced OT release in PVN. 41 ,19] 
Kisspeptin K isspeptin injected into PVN augments plasma L1-1 and testosterone levels. [247] 
Leukotriene Leukotriene B4 (LTB.) t CRF release from hypothalamic explants in vitro. Icv LTB. (via BLTI) t PVN CRF mRNNprotein [23,338) 
and plasma ACTHICORT levels in ovalbumin-sensitized animals. 
Melanin- MCH icv or directly into the PVN t ACTH release; MCH t CRF release from hypothalamic explants; intra-PVN injection of 
concentrating MCH t food intake. MCH .j, basal ACTH release at end of lights-on period. [ 146,265,26] hormone 
Icv melanocortin agonist t CRF transcription in PVN and plasma CORT levels. alpha-melanocyte-stimulating hormone (a-
MSH) t OT release from SON dendrites and.j, OT release from neurohypophysial terminals (via MC4). a-M H t intracellular [188,270,87, Melanocortin Cal+ in isolated SON neurons. Adrenoviral shRNA-MC. into PVN .j, food intake and body mass. a-MSH infused over SON in 
vivo, t c-Fos mRNA expression, though has no effect on VP hnRNA or mRNA. MC. agonist into PVN .j, food intake. 145,92,148] 
Melanocortin MC. activation t TRH release from hypothalamic slices. 
Melatonin Melatonin significantly .j, VP secretion in HNS explants; .j, substance P-stimulated OT and VP release in vil/'O: and .j, VP and [137,138,33 OT (but not eRF) release from the hypothalamus in vilro. 3] 
Activation of presynaptic group III mGluRs (includes mGlu •. mGllI6. mGlu7.and mGlu8 although distribution studies suggest that 
Metabolropic only mGlu4and mGlu 7 may be present in the SON) .j, frequency of miniature EP Cs in SON neurons, and .j, glutamate/GABA 
release onto SON neurons. Activation of group I mGluRs (mGlul and mGlu,: however only mGlu I has been shown to be in the [29,277,182] glutamate SON) t glutamate/GABA release onto SON neurons. Group I mGlu agonist injected into PVN t lumbar sympathetic nerve 
activity (blocked by mGlulI' antagonists). 
MOlilin Icv motilin t c-Fos in PVN and SON. [328] 
IOOnM neuromedin U (NMU) binding of NMU2 depolarizes 31 % of pPVN neurons, but not magnocellular neurons, via 
Neuromedin U enhancement of hyperpolarization-activated inward current; Neuromedin S (icv), an endogenous ligand for NMU2, t c-Fos in [255,256,27 OT neurons in PVN and SON, and OT release. Intra-PVN NMU .j, food intake and t plasma ACTH and CORT levels. NMU t 3,326] 
CRF and VP release from hypothalamic explants. 
Neuropeptide FF (NPFF) facilitates inhibitory input to mPVN via GABAergic interneurons. Hypervolemia or hyperosmolality-
europeptide induced t in plasma levels ofVP are blunted by NPFF (injected into the lateral ventncle), and hyperosrnolality-induced plasma [ 132,9,334,1 
FF/neuropeptide AF VP is significantly augmented by icv NPFF antibodies. Icv NPFF t c-Fos expression mainly in brainstem-projecting pPVN OT 34] 
neurons, and a few VP and CRF neurons. 
Neuropeptide S 
Icv or intra-PVN neuropeptide S .j, palatable food intake. Intra-PVN injection ofneuropeptide S t plasma ACTI-I and CORT [77,288] levels, and neuropeptide S t CRF and VP release from HNS explants. 
Neuropeptide 
Neuropeptide B (icv) induced increase in ACTH is completely blocked by anti-CRF antibodies with no effect on plasma VP/OT 
levels. Neuropeptide W (icv) stimulated-rise in plasma CORT is prevented by eRF antagonist without effect on plasma VP/OT [274,301] W/neuropeptide B levels. Neuropeptide W depolarizes and t spike frequency of PVN neurons. 
Stimulation of HNS explants with NPY potentiates the VP and OT response to phenylephrine, but has no effect on basal VP and 
OT release; however the YI-agonist, [Leu3I ,Pro34]-NPY stimulates OT and VP under resting conditions, with no effect on 
phenylephrine stimulated release, suggesting alternative roles for the neuropeptide receptors . In vivo intra-PVN injections of [144,174,32 
Neuropeptide Y 
NPY t feeding, and plasma VP and CORT levels in males. Intra- SON administration ofNPV t plasma OT levels in lactating 2,244,78,14 
females via YI and also t the OT secretory response to ai-adrenergic receptor stimulation. lev NPY.J.. PVN pro-TRH mRNA 0,79,304,29 
expression. NPY-induced c-Fos in mPVN blocked by VI and V, antagonists; both VI and V, antagonists required to block 4] 
feeding. Yl and Y5 agonists delivered in the cerebrospinal fluid .j, PVN pro-TRH mRNA expression. NPY t CRF release from 
hypothalamic explants, and t CRF mRNA in the PVN. 
eurotensin 
Neurotensin (icv) t plasma ACTH and CORT levels (attenuated by CRF antagonist); icv neurotensin t VI' but not eRF in [267] 
median eminence. 
Opioids have complex (and contradictory) effects on ACTI-I and CORT release: acute dose of morphine (ip) t plasma ACTI-I 
and CORT levels; chronic morphine administration (ip) .j, plasma ACTH and CORT levels; and endomorphin I and 2 have no 
effect on the CORT levels. Sc injection of IC or 11 agonists (but not B) strongly inhibit the release of OT and VP, however only 11 [312,52,308, 
Opioid agonists .j, release when given icv. Icv nociceptin t plasma ACTHICORT levels and t pPVN CRF mRNA (no effect on VP 173,16,241 , 
, mRNA), an effect blocked by a nociceptin antagonist. Microinjection of 15 agonist into the PVN t ethanol intake, while IC 95] 
agonist .j, alcohol intake. Il-agonist DAMGO ([d-Ala2,N-Me-Phe",Gly -ol]-enkephalin).j, K+-induced OT> VP release. Intra-
PVN injection of dynorphin t food intake via IC opioid receptor. 
Icv orexin-A t pPVN CRF and VP mRNA levels and plasma ACTH and CORT levels. Orexin A t CRF and NPY release, but 
[268,82,2] Orexin not VP from isolated hypothalamic explants, an effect blocked by a neuropeptide Y I antagonist Orexm-A depolarizes m PV 
I and pPVN neurons. 
ATP t CaH in SON neurons. P2YI activation t ea2+ in HNS SON explants (response blocked by P2Y\-selective antagonist); [73,292] P2Y Responses to UTP (most potent at P2V ~4 receptors) and UDP (most potent agonist for P2Y6) occurred in fewer SON neurons 
and produced smaller peak amplitude when compared to a P2YI stimulated response. 
Platelet-activating 
Platelet-activating factor t CRF release from hypothalamic explants. [69] factor 
Parathyroid Icv tuberoinfundibular peptide of 39 residues (TIP39) (the endogenous PTH2 ligand) .j, VP release in response to dehydration. [295,316] 













VIP and PACAP 
Vasopressin and 
oxytocin 
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Prokineticin 2 (PK2) depolarizes the majority of magnocellular neurons, an effect blocked by kynurenic acid (glutamate 
antagonist), which suggests involvement of glutamate intemeurons. On the other hand, PK2 depolarizes the pre-autonomic and 
neuroendocnne parvocellular neurons through MAPK signalling. 
Icv prolactin-releasing peptide t plasma ACTH levels (inhibited by CRF antagonist), t c-Fos expression in neurons of the 
pPVN and mPVN, and t plasma OT and VP levels in female rats, but only plasma OT levels in male rats. 
Prostaglandin E2 (PGE2) t the firing rate of rat SON neurons an effect mimicked by an EP~ agonist (but not by EPI, EP2, or P1 
agonists). PGE2 and EP1 .!. the frequency of spontaneous IPSCs in the rat SON (EPI, EP2, EP2 or FP agonists had no significant 
effects on IPSCs). PGE2 effects on phasic and non-phasic neurons in SON mostly excitatory. EP, levels in the PVN are t 
following iv IL- I p. Icv PG E2 t plasma CORT levels . 
Icv relaxin t c-Fos expression in VP and OT neurons of PVN and SON, as well as many pPVN neurons. Relaxin-3 t food 
intake (via RXFP3) when administered intra-PVN or -SON, and water intake when administered icv (via RXFPI ?). Relaxin-3 
intra-PVN t plasma luteinizing hormone levels. 
Icv somatostatin (SST) t plasma OT levels in virgin and pregnant rats. lev SST tOT and VP neuron firing rates and c-Fos 
expression in SON and PVN (which may be mediated in part by SST2). Retrodialys is of SST onto ventrally exposed SON t VP 
neuron firing rate but'!' OT neuron fi ring rate - this may indicate that the direct effect of SST on SON OT neurons is inhibitory, 
and may not contribute to enhanced OT release. 
Hydralazine induced hypotension activates NK3 signalling in magnocellular neurons to release VP and OT. Icv NKI antagonist 
attenuates the duration of plasma ACTH and CORT response to acute restraint stress. Icv NK I antagonists .!. the activation of c-
Fos in the PVN, and the cardiovascular (t in mean arterial pressure and heart rate) and behavioural reactions (hind limb 
groominglbiting) in response to noxious stimuli (sc formalin). NK3 agonist intra-PVN causes hypertension which is blocked by 
a VP VI antagonist. NK3 agonist t VP release and substance P t VP and OT release from HNS explants. 
Iv TRH appears to t hypothalamic VP content in young male rats, and '!' hypothalamic OT content in mature male rats. 
Chronic 10 day delivery ofp-phenylethylamine (ip) t CRF mRNA in the PVN, CRF immunoreactivity in the median eminence, 
and plasma ACTH and CORT levels in response to stress. 
lev urotensin li t c-Fos immunoreactivity in the PVN, heart rate, and plasma glucose and CORT levels. 
Pituitary adenylate cyclise activating polypeptide (PACAP) excites and t firing rate of both phasic and non-phasic neurons; 
PACAP stimulates local somatodendritic VP release in SON and.!. basal glutamate and aspartate release. Icv PACAP t c-Fos in 
rat PVN and SON. PACAP t VP/OT release from isolated neural lobe. lntra-PVN injection of vasoactive intestinal peptide 
(VIP) t plasma ACTH and CORT levels, an effect attenuated by pre-treatment with the CRF I and/or V I receptor antagonists. 
Peptide histidine isoleucine (PHI) via VIP/PACAP receptors t % c-Fos staining neurons in PVN. PHI icv or intra-PVN .!. food 
consumption in overnight food-deprived rats. PACAP t intracellular Ca2+ in isolated SON neurons. 
VP effects depend on activity of VP neurons; VP neurons with weak phasic or irregular activity are exc ited by VP, whereas VP 
neurons with robust phaSIC activity or continuous activity are inhibited by VP (N.B. most VP neurons do not display phasic 
activity under basal conditions). OT excites OT and VP neurons but only OT neurons show spike frequency reduct ion. 
lonotropic glutamate receplor antagonists./. the effects ofOTon firing rate (consistent with presynaptic loci ofOT action) . VI A 
antagonists (concomitantly with CRF antagoni sts) deli vered into the PVN t plasma ACTH levels - thus PVN VI A has an 
inhibitory effect of on VP-mduced HPA actiVity. V IA/V 2 antagonists'/' osmotically-stimulated intra- ON VP release. OT and 
VP stimulate the release ofOT and VP, respectively from SON in vitro. Infusion of lysine VP intra-SON t basal VP release 
into extracellular nuid. Intra-PVN OT administration '!' anxiety-related behaviour in male rats , and t ERK phosphorylation in 
PVN and SON neurons (some express ing VP) which may be linked to the anxiolytic actions ofOT. OT and VI A t intracellular 





















Supplementary Table 9. Some functions of GPCRs in tile rat PVNISON 
Abbreviations: ACTH, adrenocorticotropic hormone; CORT, corticosterone; CRF, corticotropin-releasing 
factor; EPSCs, excitatory postsynaptic currents; HPA, hypothalamic-pituitary-adrenal; HNS, hypothalamo-
neurohypophysial system; IPSCs, inhibitory postsynaptic currents; icy, intracerebroventricular injection; ip, 
intraperitoneal injection; iv, intravenous injection; pPVN, parvocellular region of the paraventricular nucleus; 
mPVN, magnocellular region of the paraventricu)ar nucleus; OT, oxytocin; sc, subcutaneous injection ; VP, 
vasopressin; TRH, thyrotropin-releasing hormone. 
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